



EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

Noticias en la Web

FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

Aug 1. Health Secretary Robert F Kennedy Jr. has long questioned the value of mRNA vaccine technology. And soon the Food and Drug Administration will decide whether to approve a new kind of flu shot built on mRNA.

How the agency rules on the experimental vaccine made by Moderna has big implications for the future of mRNA research.

In February, Moderna received a letter from the FDA informing them that it would not review its application for the mRNA flu vaccine, effectively rejecting it.

The company had held prior discussions with the FDA at every stage of the process, even before submitting the application, and the FDA responded that they could proceed with the application and it would remain pending review.

An FDA decision that reverberated

Moderna went public with what happened. The news shook the pharmaceutical industry. There was an outcry over the FDA's backtracking.

A little over a week later, the agency reconsidered and agreed to review the vaccine after Moderna promised to add a confirmatory study of the vaccine if it makes it to market. In June, a panel of advisers to the FDA recommended that the agency approve the vaccine.

The agency has a Wednesday deadline to make a decision. If the FDA gives it the green light, the Moderna vaccine would be the first mRNA-based flu shot to make it to market. But the FDA's flip-flop in February has already had a chilling effect.

Rena Conti, a health economist at Boston University, says the industry and its investors will be watching closely because the U.S. market is where they make most of their money. They depend on the FDA to be consistent and fair.

"They don't want to spend money if they don't think there's going to be a way to actually make money on the other end," she says.

What's more, the Department of Health and Human Services canceled nearly \$500 million in mRNA vaccine research funding last summer.

In response to NPR's questions about the administration's actions on experimental mRNA vaccines, an HHS spokesman provided the following statement: "Under Secretary Kennedy's leadership, HHS is advancing President Trump's commitment to strengthen public health through gold-standard science, and FDA will continue applying rigorous, evidence-based standards to every product it reviews while supporting innovation that meets those standards."



Investors in mRNA research are wary

But Hoge says Moderna is holding off on some planned mRNA research until the company knows how things will shake out.

In the world of mRNA, Moderna is a big fish and most of the rest are tiny biotechs with 20 or 30 employees, says Jeff Collier, a professor at Johns Hopkins University who has studied mRNA technology for decades.

"When you see the FDA rejecting a product that comes from Moderna, why is it that my little company would be able to push through?" he says.

Collier says the FDA's actions combined with the HHS funding cuts spooked the venture capital firms that backed many of the smaller biotechs working on mRNA therapies for conditions ranging from Lyme disease to rare cancers.

Fuente: NPR Illinois. Disponible en <https://n9.cl/n2578>

AI-Designed Vaccine Tested in Groundbreaking Trial by Cambridge Scientists

Aug 1. In a pioneering development in medical technology, scientists from Cambridge have announced the first successful testing of a vaccine designed entirely by artificial intelligence. This groundbreaking trial marks a significant milestone in the use of AI for medical innovation, potentially redefining how vaccines are developed globally. The Cambridge team employed sophisticated AI algorithms to analyze vast datasets, identifying the optimal vaccine composition to combat specific pathogens. This method promises to expedite the vaccine development process, a crucial advantage during global health crises.

Dr. Emily Shaw, the lead researcher from the Cambridge team, emphasized the transformative potential of AI in vaccine development. "By leveraging AI, we can significantly reduce the time it takes to develop effective vaccines, potentially saving millions of lives during pandemics," she stated. This AI-designed vaccine has undergone rigorous testing, with initial results indicating promising efficacy and safety for human use.

The AI-driven approach addresses several traditional challenges in vaccine development, such as predicting the virus's evolution and optimizing the immune response. This technology could be particularly beneficial for developing nations with limited resources, as it offers a cost-effective method to produce vaccines tailored to regional disease profiles. Analysts predict that AI could revolutionize healthcare in these regions, enhancing disease prevention capabilities.



The World Health Organization (WHO) has expressed interest in the potential of AI-driven vaccines. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, remarked on the importance of innovation in tackling global health challenges. "The integration of AI in vaccine development is a leap forward in our fight against infectious diseases," he commented. "We look forward to supporting further research in this area to ensure equitable access to these advancements worldwide."

With the successful testing of this AI-designed vaccine, researchers are optimistic about the broader applications of AI in medical science. The technology's ability to process and analyze complex biological data at unprecedented speeds could lead to breakthroughs in treatments for various diseases, including cancer and autoimmune disorders. However, experts caution that regulatory frameworks must evolve to address ethical considerations and ensure the responsible use of AI in healthcare.

Looking ahead, the Cambridge team plans to conduct more extensive clinical trials to validate the vaccine's efficacy across diverse populations. This next phase will be critical in determining the vaccine's global applicability and its potential to become a standard tool in the fight against infectious diseases. As AI continues to advance, its integration into medical research and public health strategies will be a key area of focus for scientists and policymakers alike.

Fuente: MWAKILISHI. Disponible en <https://n9.cl/if19wp>

Advancing Strep A vaccine development: Insights from India

Aug 4. For one mother in Chandigarh, India, the impact of Strep A has shaped her life for almost a decade. What began as an infection progressed to rheumatic heart disease (RHD), one of the most serious complications of Strep A, leaving her with a chronic condition that can damage the heart valves and requires ongoing medical care.

Over time, she stopped her regular penicillin injections as her symptoms improved and concerns about side effects grew. It was only after enrolling at a local research site established by the Strep A Vaccine Global Consortium (SAVAC) that she gained a clearer understanding of her condition and agreed to restart treatment after a multi-year pause.

Her story highlights the urgent need for a Strep A vaccine to prevent avoidable suffering and serious disease, as well as the human impact behind SAVAC's work. In India, IVI and its partners are building the foundation for future vaccine trials through hospital- and community-based surveillance—revealing the long-term burden of Strep A while directly connecting affected families with care.

During a recent visit to the Chandigarh sentinel site, International Vaccine Institute (IVI) Director General Dr. Jerome Kim and Dr. Annette Kraus, IVI's SAVAC project lead and Senior Research Scientist, met with her and other families to hear their experiences firsthand.

"Visits like this remind us why this work matters," says Dr. Kim.

"The surveillance program is not only generating important scientific evidence, it also creates connections between healthcare teams and the communities they serve."



Preparing the world for a Strep A vaccine

Since SAVAC 2.0 launched in 2023, all four sentinel surveillance sites have become operational, conducting standardized hospital- and community-based surveillance. Additional workstreams are assessing the global Strep A vaccine pipeline, strengthening engagement with vaccine manufacturers, developing the business case for future vaccines, and supporting WHO efforts related to Strep A vaccine research and development.

Surveillance activities at all four SAVAC sentinel sites will continue through 2028, generating the epidemiological evidence needed to advance future vaccine development. At the same time, these sites are being prepared for potential clinical trials through investments in laboratory capacity, research systems, and clinical trial readiness.

For Dr. Kim, the visit highlighted the critical role of SAVAC's sentinel sites in generating the evidence needed to advance Strep A vaccine research.

“By generating high-quality epidemiological data and strengthening clinical trial capacity, these efforts are helping to advance our understanding of Strep A and bring us closer to effective vaccines that could prevent disease in millions of people worldwide,” he adds.

Fuente: International Vaccine Institute IVI. Disponible en <https://n9.cl/1ixft>

African Institutions' Readiness to Conduct Phase 1 Bundibugyo Vaccine Trials

Aug 5. The speed at which clinical trials can be activated in an outbreak is essential to an efficient outbreak R&D response. That's why, together with the Africa Centres for Disease Control and Prevention (Africa CDC), the Coalition for Epidemic Preparedness Innovations (CEPI) has published a database of comprehensive information on 45 African clinical trial units across 17 African countries' capability to conduct Phase 1 trials to accelerate development of safe, effective Bundibugyo ebolavirus vaccines.

The publicly accessible resource will help to connect leading African research institutions with Bundibugyo vaccine developers seeking to conduct early-stage clinical trials on the continent. Data were gathered through a Request for Information, which invited institutions across the continent to submit information.

Details on each site, including self-reported prior experience, facilities, regulatory track record and operational capabilities, are available here.

“Africa has the scientific expertise, infrastructure and leadership to drive vaccine research on the continent. This database gives developers a clear pathway to experienced African clinical trial sites and enables faster action when every day matters. Africa CDC is committed to building a research ecosystem that protects our people, strengthens health security and places African institutions at the centre of solutions to Africa's health emergencies,” said H.E. Dr Jean Kaseya, Director-General of Africa CDC.

Well-established research networks, as well as emerging centres of excellence across the continent, submitted detailed responses to the Request for Information. All of these sites reported experience in conducting Phase 1 vaccine trials, and in many cases these institutions also bring:

- ♦ Extensive experience conducting clinical research on epidemic pathogens including Ebola, mpox, Marburg, Lassa and Rift Valley fever.
- ♦ Standardised electronic data management systems compatible with sponsor requirements.
- ♦ Mature quality assurance systems.
- ♦ Established ethical and regulatory review processes as well as Data Safety Monitoring Board oversight.
- ♦ Community engagement infrastructure essential for rapid, ethical recruitment and retention of participants during an outbreak response.

"In an outbreak, every day counts. Rapid vaccine development depends on clinical trial systems that are ready to activate. Improving the visibility of Phase 1 trial-ready sites across Africa will help connect vaccine developers with capable sites faster, meaning vaccines can be tested in Africa for African populations, while also enabling studies to start quickly and strengthening the overall effectiveness of outbreak response," said Dr Nicole Lurie, Executive Director, Preparedness and Response at CEPI.

Clinical trials capacity in Africa has been built over time, collectively, through partnerships between African research institutions, governments and partners in the clinical research ecosystem. However, while Africa is home to nearly 20 percent of the world's population, less than five percent of clinical trials take place in Africa. Continued investment in clinical trials strengthening is needed to increase the volume of clinical trials conducted on the continent and ensure robust data can be generated to support efficient outbreak R&D responses, like the current Bundibugyo ebolavirus.

The Bundibugyo epidemic unfolding in the Democratic Republic of the Congo and Uganda is already the second largest Ebola outbreak in recorded history. CEPI, Africa CDC and partners are coordinating an urgent R&D response to develop vaccines and other medical countermeasures that could help curtail the outbreak, save lives, and ensure the world is better prepared if Bundibugyo emerges again in the future. Phase 1 trials underpin vaccine development; they are the foundational first step for human testing, determining whether a promising lab concept can safely proceed to broader clinical evaluation. By publishing this information openly, CEPI and Africa CDC are enabling vaccine developers with candidates ready for Phase 1 testing to rapidly identify and activate partnerships with African sites, according to their requirements.

The analysis was undertaken through a structured Request for Information which captured self-reported, standardised information on core domains including prior Phase 1 experience, geographic reach and community engagement, facilities and infrastructure, quality systems, regulatory and ethics compliance, clinical and scientific expertise, participant safety and risk management and Material Transfer Agreement processes. This database enables developers to conduct rapid, informed screening of which sites best match their trial needs.


The complete Request for Information responses and summary of the 45 sites' capabilities are publicly available [here](#).

Vaccine developers and sponsors interested in partnering with any of the institutions are encouraged to carefully review the site information package before engaging directly with sites on trial design, timelines and ethics and regulatory requirements.

Fuente: CEPI. Disponible en <https://n9.cl/5g5kg>

New vaccine strategy protects against chikungunya and could become a platform for combating other diseases

Aug 5. An international team of researchers has developed an innovative strategy for producing new vaccines. They created a genetically modified version of the Chikungunya virus that replicates only once, yet still trains the immune system to defend itself without causing disease. In tests conducted on mice, a single dose of the formulation containing the modified immature virus was sufficient to generate antibodies and protect the rodents against lethal infection.



Anatomy of the Chikungunya virus, with a cross-section showing its genetic material (ssRNA), membrane, capsid, and the E1 and E2 proteins — the latter responsible for allowing the virus to enter the cell (image: Victor Padilla-Sanchez)

The study was published in May in the journal NPJ Vaccines and was conducted by scientists from the University of São Paulo (USP) in Brazil and the University of Bonn in Germany. It paves the way for a new vaccine platform. In addition to protecting against chikungunya, the technology developed by the researchers can be adapted to combat other diseases.

“The idea was to create a virus that enters the cell and activates the immune system but is physically incapable of becoming infectious. Thus, the vaccinated individual doesn’t experience symptoms nor are they at risk of developing the disease. That’s important because it allows for robust protection without the risk of side effects, expanding its use to include immunocompromised individuals and older adults,” explains Danilo Lucas Alves Esposito, a researcher at the Ribeirão Preto School of Pharmaceutical Sciences at the University of São Paulo (FCFRP-USP) and author of the study. Esposito is supported by FAPESP through a Young Investigator Grant.

Traditionally, vaccines are produced to train the immune system using attenuated viruses, which are weakened through genetic mutations, or inactivated viruses, which are unable to replicate. “In this study, we sought to combine the efficacy of attenuated-virus vaccines with the safety of inactivated vaccines,” Esposito says.

In addition to attenuated and inactivated virus vaccines, more recent platforms include protein subunit, recombinant, conjugate, viral vector, DNA, and RNA vaccines. Rather than using the entire virus, these vaccines use fragments, proteins, or genetic instructions to induce an immune response.

The new platform proposed by the international team uses a unique strategy involving the inoculation of viruses that cannot mature within the host cell. As a result, the viruses do not become infectious but still provide protection against future infections.

“That’s important because we currently have an attenuated virus vaccine against chikungunya that was reapproved by the FDA [the U.S. agency that regulates drugs] in 2025, albeit with restrictions, after a period of suspension.

It isn't recommended for very young children, older adults, immunocompromised individuals, or those with certain comorbidities because it may cause adverse effects," he says.

Non-virulent, but with an immune response

The researcher explains that almost all viruses undergo a maturation process that is essential for them to become infectious. In the case of arboviruses, such as Chikungunya, Zika, dengue, and yellow fever, this maturation occurs at the end of the replication cycle within the host cell.

"Specifically, in the case of Chikungunya, maturation depends on the removal of a surface protein [E3], which covers the protein [E2] responsible for allowing the virus to enter the cell. When E3 isn't removed, E2 remains hidden, and the virus can't infect the cell," the researcher explains to Agência FAPESP.

In the natural life cycle of the Chikungunya virus, furin, a host enzyme, plays the role of removing the E3 protein and allowing E2 to act as the key to invading the next cell. To develop the vaccine using immature viruses, therefore, the scientists used human cells derived from colon cancer tissue (LoVo), which lack the furin enzyme.

Tips for editing the genome

Esposito explains that the virus must replicate at least once inside the cell to generate an immune response. For this reason, the researchers modified the viral genome by replacing the region recognized by furin with a sequence identified by an enzyme from a plant-infecting virus, the tobacco mosaic virus, which does not affect humans or mosquitoes.

"Thus, the virus is artificially 'activated' before vaccination. However, since this enzyme isn't present in the human body, the virus can't cause new infections," says Esposito.

After this initial, controlled replication, all the resulting viruses are immature and incapable of infecting other cells. "They function solely as antigens, serving as a model for the immune system," Esposito adds.

Another interesting finding from the study was that the immunized animals demonstrated the ability to neutralize the Mayaro virus in addition to being protected against Chikungunya, suggesting broader protective potential. "Since several arboviruses rely on furin to become infectious, the platform can be adapted for Zika, yellow fever, and even variants of SARS-CoV-2, for example" he says.

"It's an interesting platform. Now, in addition to moving forward with clinical trials, we're interested in using this vaccine platform for other arboviruses," he states.

Fuente: Agencia FAPESP. Disponible en <https://n9.cl/ggng9>

FDA Approves First mRNA Flu Vaccine

Aug 7. The FDA has approved Moderna's influenza vaccine, mFlusiva, for use in adults aged 50 years and older after positive Phase III results in a trial of more than 40,000 people in this age group.

This makes Moderna the first company to get an approval for an mRNA flu vaccine from the U.S. regulator, although others are in development. This adds to the company's two FDA approved COVID vaccines, Spikevax and mNextspike, and mResvia, an approved vaccine against lower-respiratory-tract disease caused by respiratory syncytial virus.

"The FDA approval of mFlusiva, our fourth approved product in the United States and the first mRNA-

based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform,” said Stéphane Bancel, chief executive officer of Moderna, in a press statement.

“Flu remains a significant public health challenge, and mFlusiva provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation.”

Both Moderna and its European competitor BioNTech shot to fame during the COVID-19 pandemic as the key developers of the two most widely used vaccines, developed in record time, to protect against severe SARS-CoV-2 infection.

Although both companies have been trying to develop flu vaccines with their partners since before the pandemic, protecting against flu has proved more of a challenge.

Seasonal influenza mutates quickly and vaccines have historically targeted two A and two B lineages depending on predictions of which would be most problematic each season. Packing multiple mRNAs into lipid nanoparticles while maintaining appropriate expression, reactogenicity, and balanced immunity has proved more demanding than building a single-antigen SARS-CoV-2 vaccine.

Another challenge was that flu already has safe, inexpensive, licensed vaccines and very large studies are required to prove efficacy for a flu vaccine.

The main scientific bottleneck was achieving sufficiently strong, balanced responses to influenza B as well as influenza A. Moderna’s original formulation, like other early mRNA flu candidates, struggled on B strains.


Moderna also has a joint flu and COVID vaccine, mCombiavax, approved by the European Medicines Agency earlier this year. The company also submitted this vaccine for approval by the FDA but withdrew its U.S. filing in 2025 after the FDA requested standalone-flu efficacy data. This triggered a public dispute between the company and the regulator with Moderna publishing the Refusal to File letter it received early this year online.

This week’s approval is a positive note in a period that has been a difficult one for mRNA vaccines in the U.S. with loss of research funding and pushback against the COVID-19 vaccines that are already on the market.

The mRNA flu vaccine has an advantage over the standard flu vaccine in that it is quicker to make so can respond quickly to changes in dominant flu strains. Whether the Centers for Disease Control and Prevention (CDC) advisory committee recommends mFlusiva going forward remains to be seen, however.

A recommendation by the CDC committee guides clinicians, payer coverage, and pharmacy use. If the committee declines to recommend the vaccine, or places it behind the high dose, adjuvanted and recombinant flu vaccines the CDC already prefers, coverage and demand could be lower than ideal.

Fuente: INSIDE PRECISIÓN MEDICINE. Disponible en <https://n9.cl/2okf3x>



The global vaccine market is shifting towards the elderly

Aug 8. Medical staff administer COVID-19 vaccines to residents in Tel Aviv, Israel. Photo: THX/VNA

According to the newspaper economy According to Les Echos, the declining birth rate in many countries, particularly China, is profoundly altering the global vaccine market, forcing major pharmaceutical companies to adjust their development strategies as demand for childhood vaccines declines, while the adult and elderly segments are becoming new growth drivers.

“The global vaccine market is shifting toward adults and the elderly due to declining birth rates and an aging population, impacting pharmaceutical companies' strategies.”

This trend is clearly reflected in the business results of many leading pharmaceutical companies worldwide during the first six months of 2026.

Sanofi has just lowered its revenue target for its vaccine business in 2030 from over 10 billion euros (11.5 billion USD) to 9 billion euros.

According to the French pharmaceutical company, about half of the adjustment stemmed from exchange rate fluctuations, but the fundamental reason was the shrinking market for pediatric vaccines due to the decreasing number of births.

In the first half of this year, Sanofi's vaccine revenue fell by 1.1%, to approximately 2.4 billion euros.

In China alone – the company's second-largest market after the US – revenue fell nearly 5% in the second quarter, mainly due to a decline in demand for its combination polio, pertussis, and Hib meningitis vaccine as the number of newborns decreased.

Previously, global sales of Sanofi's combination vaccines for children and booster shots had also declined by 4.4% in 2025.

According to Sanofi, the declining birth rate is no longer a localized phenomenon but is occurring in many economies, causing the focus of the company's vaccine research and development to gradually shift from children to adolescents, adults, and especially the elderly.

The head of Sanofi's vaccine division stated that the current research portfolio focuses on vaccines for adults against conditions such as acne and Chlamydia, next-generation respiratory vaccines, and combined vaccines against influenza and COVID-19. This direction also governs the group's investment decisions.

In late 2025, Sanofi spent \$2.2 billion to acquire the American biotechnology company Dynavax to expand its portfolio of vaccines for adults, including a hepatitis B vaccine and a vaccine candidate for shingles – a disease commonly found in people over 50.

According to Sanofi, this population group will continue to grow in most countries for the next several decades.

This shift is also occurring at other pharmaceutical companies.



Pfizer is developing a new generation of pneumococcal vaccines for children that will protect against a wider range of bacteria strains.

This technology will also be applied to develop a pneumococcal vaccine for the elderly – a group, along with young children, at high risk of pneumococcal infections.

Meanwhile, the British company GSK continues to reap success with its Shingrix shingles vaccine, with sales of the product increasing by 12% in the first half of the year, reaching nearly £1.9 billion and becoming a major growth driver for the vaccine segment.

Not only is the target audience shifting, but the vaccine market is also entering a phase of technological innovation. The US Food and Drug Administration (FDA) has just approved Moderna's mRNA-based flu vaccine, paving the way for the commercialization of a combined flu and COVID-19 vaccine in the US in the near future.

Previously, the European Union became the first region in the world to approve this combination vaccine.

According to experts, changes in population structure are not reducing the demand for vaccinations but are changing the structure of the vaccine market.

Against a backdrop of declining child births and increasing life expectancy, pharmaceutical companies are shifting their focus to diseases prevalent in adults and the elderly, and developing multivalent and combination vaccines to meet the healthcare needs of an aging society.

Fuente: VIETNAM.VN. Disponible en <https://n9.cl/ycqp0>

Pfizer and BioNTech Advance Next-Season Pediatric COVID-19 Booster Strategy With New Phase 3 Update

Aug 8. Pfizer Inc. (PFE) and BioNTech SE (BNTX) have completed a Phase 3 study of an updated BNT162b2 (2025/2026) COVID-19 vaccine in higher-risk children aged 5–11. The trial, titled “A Phase 3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of a BNT162b2 (LP.8.1)-Adapted Vaccine in Children 5 Through 11 Years of Age Considered at High Risk for Severe COVID-19,” aims to confirm safety and immune response in a key pediatric group.

The intervention is a single intramuscular dose of the BNT162b2 2025/2026 formulation, a biological vaccine tailored to the SARS-CoV-2 strain expected to dominate the 2025–2026 season. It is designed to boost protection in children with underlying conditions who face higher odds of severe COVID-19 outcomes.

The study uses a simple design with one treatment group and no placebo arm, so all participants receive the vaccine. It is open-label, meaning doctors and families know what is given, and the main purpose is prevention, with a focus on safety and immune response rather than comparing multiple products.

According to the registry, the study was first submitted on 28 October 2025 and reached overall completion before the latest update. The most recent update was filed on 5 August 2026, signaling that follow-up, data cleaning, or analysis is still in progress even though primary study activities have wrapped up.

For investors, this update reinforces Pfizer and BioNTech’s position as key players in the evolving

COVID-19 booster market, particularly in high-risk pediatric segments. While revenue from COVID-19 vaccines has cooled from pandemic peaks, positive data here could support stable booster demand, defend share versus Moderna and other rivals, and modestly support sentiment toward PFE and BNTX as vaccine platforms with long-term relevance.

The study is now completed but recently updated, and further details are available on the ClinicalTrials.gov portal for NCT07222384.

Fuente: THE GLOBE AND MAIL. Disponible en <https://n9.cl/0atrm>

India's homegrown malaria vaccine still a couple of years away from potential rollout, says ICMR chief

Aug 11. India's indigenous malaria vaccine candidate could take "a couple of years" before it is known whether it will be "available" for use, Indian Council of Medical Research (ICMR) Director General Dr Rajiv Bahl said Tuesday.

While a global malaria vaccine is already available and licensed, the Indian candidate is still under evaluation, the ICMR DG added.

He was speaking at the inauguration of the ICMR-SHINE initiative, a two-day programme to create awareness among school students about Science and Health Innovation for Nextgen Explorers (SHINE).



AdFalcivax is a recombinant multi-stage malaria vaccine candidate developed by ICMR's Regional Medical Research Centre in Bhubaneswar. | Special arrangement

"It will still take a couple of years before we see whether that vaccine is available," he said.

ICMR's indigenous candidate, AdFalcivax, is a recombinant multi-stage malaria vaccine developed by ICMR's Regional Medical Research Centre in Bhubaneswar, with support from ICMR's National Institute of Malaria Research and the National Institute of Immunology.

The vaccine is designed to target multiple stages of *Plasmodium falciparum*, the parasite responsible for the most severe form of malaria.

The ICMR had initially invited companies to take up technology transfer for the candidate in 2025. It subsequently granted non-exclusive licences to five companies—Indian Immunologicals, Techinvention Lifecare, Panacea Biotec, Biological E and Zydus Lifesciences—for further development and commercialisation.

However, the vaccine is not yet available for clinical use. Earlier reports had indicated a considerably longer timeline for its development.

Dengue vaccine in Phase 3

Bahl said India's indigenous dengue vaccine is further ahead, with the candidate currently in a Phase 3 trial. Final results are expected by the end of next year, he said.

India is also evaluating two tuberculosis vaccine candidates, Bahl said.

One is MTBVAC, for which Hyderabad-based Bharat Biotech is involved in the Indian development programme.

The other candidate is M72/AS01E, which is currently in a global Phase 3 trial sponsored by the Gates Medical Research Institute.

In July this year, the Serum Institute of India entered into an agreement with THE Gates Medical Research Institute to manufacture the vaccine candidate if it successfully completes trials and receives regulatory approvals.

The Gates Foundation and Wellcome are supporting the Phase 3 programme, while British pharma company GSK supplies the AS01E adjuvant.

The M72/AS01E Phase 3 trial began in 2024 and has enrolled about 20,000 participants across several countries. If successful, it could become the first new TB vaccine introduced in more than a century.

Fuente: THE PRINT. Disponible en <https://n9.cl/bx57h>

Final UN pandemic declaration draft on the table

Aug 12. The final draft of the Political Declaration on Pandemic Prevention, Preparedness and Response (PPPR) was sent to United Nations members last week, but, writes Kerry Cullinan for Health Policy Watch, it has several weaknesses in its failure to address major problems linked to the world's pandemic preparedness.

Armenia and Rwanda, the co-facilitators of the declaration negotiations, put the “final” text of the declaration for the High-Level Meeting (HLM) on PPPR in September under the silence procedure on 28 July.

The silence procedure means member states have a certain period during which to object – or break the silence – otherwise the text is regarded as agreed on, despite any weaknesses.

For example, the text identifies climate change as one of the issues straining developing countries' pandemic prevention, preparedness and response. But at the HLM on Road Safety last month, the US was the lone vote against that – in part because it mentioned climate change.

The PPPR declaration also recognises that women and girls are among the groups disproportionately affected by pandemics, and calls for “gender equality” to be mainstreamed “into all policies and programmes”, and urging “universal access to sexual and reproductive healthcare services” by 2030, and the reaffirmation of “commitments to ensure universal access to sexual and reproductive health and rights (SRHR) in accordance with the Programme of Action of the International Conference on Population and Development (ICPD) and the Beijing Platform for Action”.

The ICPD, adopted by 179 member states in 1994, calls for universal access to a full range of reproductive health services, including family planning.

Meanwhile, the Beijing Platform, adopted a year later by 189 member states, establishes that all people have “the right to attain the highest standard of sexual and reproductive health” and that their right to make reproduction decisions should be “free of discrimination, coercion and violence”.

However, SRHR has become contested in the UN, with several countries claiming that, by linking sexual and reproductive health to rights, the UN and the WHO are trying to promote universal access to abortion.

Positive points

According to a group called The Friends of the HLM on PPPR, the final draft contains positive language on foundational elements that could lead to a stronger pandemic readiness system.

This group's co-convenors are The Elders, FOUR PAWS, The Independent Panel for Pandemic Preparedness and Response and Resilience Action Network International (rani).

The Friends add that positive aspects include that the text welcomes the adoption of the Pandemic Agreement and amendments to the International Health Regulations (2005) and calls for the timely conclusion of the pathogen access and benefit-sharing (PABS) negotiations. It also promotes geographically diversified research, development and manufacturing of health tools, and calls for "the need for financing preparedness".

The group also approves of "recognising a One Health approach to prevent spillover of pathogens from animals to humans" and "the importance of data, tools and assessments that facilitate action-oriented plans, and science and evidence-based monitoring".

And the real problems...^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100]}

But Helen Clark, co-chair of The Independent Panel and a member of The Elders, and on behalf of The Friends' co-convenors, notes: "At a time when the Ebola Bundibugyo emergency is now the second largest Ebola outbreak in history, we need measurable commitments which put effective multi-sectoral plans into action, serious money on the table, and ensure real accountability.

"The ultimate test of this declaration is simple: will its implementation make the world measurably safer?"

The Friends identify four key gaps in the draft.

The first is the lack of concrete commitments or timelines to fill the financing gap, including the \$15bn needed annually to prepare for pandemics.

Weakness Two is the failure to "strengthen the capacities of veterinary, animal, and environmental health services" given that more than 70% of emerging infectious diseases in humans are zoonotic.

The third weakness is its failure to recognise current gaps in monitoring, "including of equitable access to medical countermeasures, operational readiness, financing, and the social dimensions of resilience".

Finally, The Friends highlight that the Secretary General gets almost five years to report back on the implementation of the political declaration, "too late to follow up on commitments ... and which will take momentum from an already neglected agenda". They propose three years instead.

The HLM is set for 25 September.

Meanwhile, a recent study in The New England Journal of Medicine warns that the "dominant model of pandemic preparedness has focused on technical capacities: stronger laboratories and surveillance, more effective vaccines and medicines, faster emergency response".

Yet, argue the authors, including Nobel Prize-winning economist Joseph Stiglitz, some of the most "prepared" countries have mounted the most ineffectual responses in real time.

"Among the officials and experts charged with stopping pandemics, the current understanding of what drives pandemic risk for the world is proving to be insufficient. The missing element...is inequality," say Stiglitz and co-authors Matthew Kavanagh, Monica Geingos, Winnie Byanyima and Michael Marmot, for the Global Council on Inequality, Aids, and Pandemics.

They propose four approaches.

The first involves addressing the social determinants that drive outbreaks to become pandemics, for example, ensuring social protection including expanded unemployment insurance and paid sick leave “so people can follow public health guidance without impossible trade-offs”.

The second involves “strengthening visibility, governance, and trust” by establishing multisectoral governance bodies that include government officials, community organisations, and scientific leadership.

The third involves reforming the international financial architecture to enable “sovereign debt-suspension mechanism for distressed nations during pandemic emergencies”, International Monetary Fund special drawing rights during pandemics and expanded pandemic lending facilities.

The fourth measure involves equitable access to pandemic science and technologies, including “open licensing for publicly funded biomedical research with pandemic relevance” and expanded regional manufacturing capacity for cutting-edge medicines and vaccines.

Fuente: Medical Brief. Disponible en <https://n9.cl/uriihe>

Computationally Designed Nanoparticle Platform Enhances Influenza Vaccine Immunity

Aug 12. Researchers have developed a new protein nanoparticle platform called I53cs. Designed using artificial intelligence (AI), I53cs demonstrated promising performance in animal studies and offers a versatile approach for developing next-generation vaccines.

The study was led by Prof. WANG Xiangxi from the Institute of Biophysics of the Chinese Academy of Sciences, in collaboration with Jiangsu Recbio Technology Co., Ltd. The findings were published in *Protein & Cell* on July 10.

Protein nanoparticles have emerged as a promising vaccine platform because they display antigens in a highly ordered, multivalent manner, thereby enhancing immunogenicity and the durability of protective immune responses. However, many existing nanoparticle scaffolds are limited by scaffold-directed immune responses, suboptimal manufacturability, and restricted structural flexibility, highlighting the need for improved and more versatile antigen-display platforms.

Through the integration of AI-guided protein design, structural characterization, and animal immunization studies, the researchers established a comprehensive validation framework that provides a new technological strategy for developing next-generation vaccines.

The researchers first established a library of protein nanoparticle scaffolds. Using symmetry as the central design principle, they generated higher-order symmetric nanoparticles with diverse geometries through high-dimensional symmetry matching and hierarchical docking based on a single symmetric scaffold.

They subsequently evaluated the candidate scaffolds using structure prediction models, including AlphaFold and RosettaFold, together with sequence-design algorithms such as ProteinMPNN and SCUBA for sequence optimization and assembly screening. This workflow yielded a series of mature immunopotentiating scaffolds with tunable particle size, symmetry, and antigen-display valency.


Using this strategy, the researchers successfully constructed multiple nanoparticle architectures, including octahedral, icosahedral, and double-layer symmetric assemblies. The designed

nanoparticles have diameters ranging from approximately 24 to 32 nm and can support 48 to 120 copies of displayed antigens. This provides a modular, customizable platform that can accommodate diverse antigens and immunization requirements.

Using this platform, the researchers generated monovalent, trivalent, and mosaic nanoparticle vaccines that display the hemagglutinin (HA) proteins of H1N1, H3N2, and influenza B/Victoria viruses.

Animal studies demonstrated that the I53cs platform rapidly elicits high levels of hemagglutination-inhibiting antibodies. Compared to soluble HA proteins and a licensed trivalent inactivated influenza vaccine, the nanoparticle vaccines generated stronger, more durable antibody responses and broad immunity against multiple influenza strains simultaneously.

These results suggest the potential of the I53cs platform as a versatile technology for developing next-generation influenza vaccines.



AI-designed protein nanoparticles enable multivalent display of influenza HA antigens, eliciting faster, stronger, more durable, and broader antibody responses. (Image by WANG Xiangxi's group)

Fuente: Chinese Academy of Sciences. Disponible en <https://n9.cl/zijke6>

Wantai BioPharm's Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Aug 13. Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand's Food and Drug Administration. The approval marks the vaccine's first clearance outside China and an important step in Wantai BioPharm's international expansion.

The vaccine was independently developed by Xiamen Innovax Biotech and is designed to protect against nine types of human papillomavirus associated with cervical cancer and other HPV-related diseases. Compared with the company's earlier bivalent vaccine, the nine-valent product provides broader protection and allows Wantai BioPharm to enter a higher-value segment of the global HPV vaccine market.

Thailand represents an important entry point into Southeast Asia, where cervical cancer prevention remains a major public-health priority. Obtaining local authorization also provides Wantai BioPharm with its first overseas regulatory reference for the nine-valent vaccine, potentially supporting future applications in other regional markets, although each country maintains its own approval requirements.

Wantai BioPharm has previously expanded internationally through its bivalent HPV vaccine. The Thai approval indicates that its overseas portfolio is beginning to move from lower-valent products toward the more advanced nine-valent category. It also marks the first approval of a Chinese-developed nine-valent HPV vaccine in Southeast Asia, according to Chinese media reports.

For China's vaccine industry, the approval reflects a broader shift from supplying affordable alternatives toward competing in higher-value product categories traditionally dominated by multinational pharmaceutical companies. The next test for Wantai BioPharm will be whether regulatory approval can translate into local procurement, distribution and vaccination demand, turning its first overseas license into sustained commercial growth.

Fuente: EqualOcean News. Disponible en <https://n9.cl/50m4b>



Pfizer's Abrysvo wins Korean approval for maternal and adult RSV prevention

Aug 14. Pfizer Korea said Friday that its respiratory syncytial virus (RSV) vaccine Abrysvo received approval from the Ministry of Food and Drug Safety (MFDS) on Thursday, giving the company an RSV prevention option spanning infants through maternal vaccination, older adults and younger adults at high risk of severe disease.

Under the approval, Abrysvo can be administered to pregnant women at 28 to 36 weeks of gestation to protect infants against RSV-associated lower respiratory tract disease (LRTD) through 6 months of

age. It is also approved for adults aged 60 and older and adults aged 18 to 59 who are at increased risk of RSV-related LRTD.

Pfizer said Abrysvo is the only RSV vaccine approved in Korea for all three populations.

Abrysvo is a bivalent vaccine containing recombinant stabilized prefusion F antigens from RSV A and RSV B. In pregnant women, vaccination induces neutralizing antibodies that are transferred to the fetus through the placenta, providing passive immunity to the infant from birth without requiring direct vaccination of the newborn.

RSV usually causes cold-like symptoms but can progress to bronchiolitis or pneumonia, particularly in infants and older adults. Infants younger than 6 months are considered among those at greatest risk of severe RSV disease, with a substantial proportion of RSV-related hospitalizations occurring during the first months of life.

The maternal indication was supported by the global phase 3 MATISSE trial involving about 7,400 pregnant women.

Among infants born to women who received a single dose of Abrysvo, the vaccine reduced the risk of medically attended severe RSV-associated LRTD by 82.4 percent within the first 3 months after birth and by 70 percent within the first 6 months compared with placebo.

Safety findings were broadly similar between the vaccine and placebo groups. Adverse events reported within one month after vaccination or birth occurred in 13.8 percent of vaccinated pregnant women and 37.1 percent of their infants, compared with 13.1 percent and 34.5 percent, respectively, in the placebo group.

Real-world data have also supported the maternal vaccination strategy. In Argentina's BERNI multicenter study, maternal vaccination showed 71.3 percent effectiveness in preventing RSV-related LRTD hospitalization in infants through 6 months of age. Pfizer said studies in the U.K. have also shown reductions in RSV-related infant hospitalizations.

For adults aged 60 and older, the approval was supported by the phase 3 RENOIR trial involving about 37,000 participants.

During the first RSV season, Abrysvo reduced the risk of RSV-associated LRTD with three or more symptoms or signs by 88.9 percent and disease with two or more symptoms by 65.1 percent. Across two RSV seasons, cumulative efficacy was 81.5 percent and 58.8 percent, respectively.

Serious adverse events occurred in 6.2 percent of Abrysvo recipients and 6.1 percent of placebo recipients.

The indication for high-risk adults aged 18 to 59 was supported by a phase 3 MONEt substudy, in which immune responses against RSV A and B met predefined noninferiority criteria compared with an external control group of adults aged 60 and older from the RENOIR study.

"With the approval of Abrysvo, we can contribute to expanding RSV prevention across the life course, from protecting infants through maternal vaccination to preventing disease in high-risk adults and older people," said Song Chan-woo, vice president of Pfizer Korea's Primary Care Business Unit. "Pfizer Korea will continue working to address unmet needs in prevention and expand vaccination options in Korea to help improve infectious disease prevention and public health."

Fuente: KOREAN BIOMEDICAL REVIEW. Disponible en <https://n9.cl/ee7ad7>

Pfizer divulga estudios sobre miocarditis asociada a su vacuna contra la COVID-19

15 ago. La miocarditis, una inflamación del músculo cardíaco que puede provocar dolor en el pecho, fatiga y dificultad para respirar, es uno de los efectos adversos asociados a las vacunas de ARN mensajero contra la COVID-19 que ha sido objeto de mayor vigilancia desde el inicio de la vacunación. Pfizer reconoció este riesgo y divulgó resultados de múltiples estudios que evalúan su frecuencia, evolución y comparación con la miocarditis relacionada con la infección por SARS-CoV-2.

"La farmacéutica reconoce que la miocarditis es un riesgo asociado a Comirnaty, aunque sostiene que ocurre con muy poca frecuencia y presenta datos de investigaciones realizadas en varios países."

Un riesgo reconocido, pero poco frecuente

Pfizer señaló que la miocarditis está incluida entre las advertencias y reacciones adversas descritas para Comirnaty, su vacuna contra el COVID-19, pero enfatizó que el evento ocurre "muy raramente", de acuerdo con análisis farmacoepidemiológicos realizados en Estados Unidos, Francia, países nórdicos y Reino Unido, además de un metanálisis.

Los datos disponibles identifican el mayor riesgo en varones jóvenes, particularmente dentro de los 14 días posteriores a la vacunación y después de la segunda dosis de la serie primaria.

De acuerdo con los análisis del Sistema de Notificación de Eventos Adversos a las Vacunas (VAERS) de los Centros para el Control y la Prevención de Enfermedades (CDC) de Estados Unidos, la miocarditis también puede presentarse después de una dosis de refuerzo, aunque sería menos frecuente que después de la segunda dosis de la serie primaria.

La infección por COVID-19 presenta un riesgo mayor

Uno de los datos destacados por Pfizer corresponde a una revisión sistemática y un metanálisis que estimaron que el riesgo de desarrollar miocarditis después de una infección por COVID-19 es aproximadamente 42 veces mayor que el riesgo registrado después de la vacunación contra la COVID-19.

La compañía también citó investigaciones que compararon la evolución clínica de la miocarditis asociada a la vacuna con la provocada por otras causas. Según esos estudios, los pacientes con miocarditis relacionada con la vacunación presentaron resultados clínicos más favorables.

Estudios con millones de personas

Entre las investigaciones mencionadas se encuentra un análisis basado en el Sistema Nacional de Datos de Salud de Francia, que incluyó a personas de entre 12 y 49 años hospitalizadas por miocarditis. El estudio encontró que quienes desarrollaron miocarditis después de una vacuna de ARN mensajero presentaron una menor frecuencia de complicaciones cardiovasculares que quienes tuvieron miocarditis convencional.



Otro análisis, que examinó más de 42 millones de vacunaciones en Inglaterra, encontró que el riesgo de hospitalización o muerte por miocarditis era mayor después de una infección por COVID-19 que después de la vacunación. El riesgo asociado con la vacuna, según los datos citados, se mantuvo bajo incluso después de dosis posteriores de Comirnaty.

Seguimiento de pacientes con miocarditis

Pfizer también presentó resultados de investigaciones independientes que siguieron a personas que desarrollaron miocarditis después de recibir una vacuna contra la COVID-19.

Un estudio financiado por la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) siguió durante un promedio de 178 días a 333 personas con miocarditis asociada a la vacunación. Los resultados reportados no registraron muertes relacionadas con el corazón ni trasplantes cardíacos durante el seguimiento.

Por otra parte, una investigación realizada en Australia incluyó a 256 personas con miocarditis asociada a la vacuna y realizó un seguimiento de 18 meses. El estudio informó bajas tasas de hospitalización, ninguna muerte y una mejoría progresiva en la calidad de vida relacionada con la salud.

Fuente: Medicina y Salud Pública. Disponible en <https://n9.cl/a6eg3>



VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:



Síguenos en redes sociales



@vaccimonitor



@finlayediciones

EBSCO
Information Services



DOAJ
DIRECTORY OF
OPEN ACCESS
JOURNALS



reDalyC.org



HINARI
Research in Health

latindex
Sistema Regional de Información en Línea para
Revistas Científicas de América Latina, el Caribe,
España y Portugal

SeCiMed



Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/08/01"[Date - Publication] : "2026/08/16"[Date - Publication])) 948 records

[Cholera vaccine.](#)

Graf PJ, Decker CF. Dis Mon. 2026 Aug;72(8):102126. doi: 10.1016/j.disamonth.2026.102126. Epub 2026 Apr 22. PMID: 42025463

[Typhoid vaccine.](#)

Ellis G, Decker CF. Dis Mon. 2026 Aug;72(8):102120. doi: 10.1016/j.disamonth.2026.102120. Epub 2026 Apr 21. PMID: 42020265

[Dengue vaccine.](#)

Causbie JM, Decker CF. Dis Mon. 2026 Aug;72(8):102128. doi: 10.1016/j.disamonth.2026.102128. Epub 2026 Apr 21. PMID: 42020264

[Rabies Vaccine.](#)

Reddy MP, Decker CF. Dis Mon. 2026 Aug;72(8):102122. doi: 10.1016/j.disamonth.2026.102122. Epub 2026 Apr 15. PMID: 41991421

[Meningococcal vaccine.](#)

Aceves-Hurtado A, Decker CF. Dis Mon. 2026 Aug;72(8):102124. doi: 10.1016/j.disamonth.2026.102124. Epub 2026 Apr 21. PMID: 42020266

[Chikungunya vaccine.](#)

Ellis G, Decker CF. Dis Mon. 2026 Aug;72(8):102129. doi: 10.1016/j.disamonth.2026.102129. Epub 2026 Apr 15. PMID: 41991419

[mRNA-based influenza vaccine expands the B cell response breadth in humans.](#)

Matz HC, Yu TG, Dixit K, Kikawa C, Zhou JQ, Pena Alzua G, Peyton L, Madsen A, Han F, Farrell AG, Hoelzl R, Schmitz AJ, Horvath SC, Keplinger HK, Strnad BS, Hoegger MJ, Middleton WD, Klebert MK, Lin NH, Nachbagauer R, Krammer F, Paris R, Bloom JD, Turner JS, Presti RM, Lee J, Ellebedy AH. Nat Immunol. 2026 Aug;27(8):1666-1677. doi: 10.1038/s41590-026-02569-5. Epub 2026 Jun 15. PMID: 42297975

[Monkeypox \(mpox\) vaccine.](#)

Graf PJ, Decker CF. Dis Mon. 2026 Aug;72(8):102130. doi: 10.1016/j.disamonth.2026.102130. Epub 2026 Apr 23. PMID: 42031607

[Yellow fever vaccine.](#)

Everson KA, Decker CF. Dis Mon. 2026 Aug;72(8):102121. doi: 10.1016/j.disamonth.2026.102121. Epub 2026 Apr 15. PMID: 41991420

[Tick-borne encephalitis **vaccine**.](#)

Everson KA, Decker CF. Dis Mon. 2026 Aug;72(8):102127. doi: 10.1016/j.disamonth.2026.102127. Epub 2026 Apr 15. PMID: 41991424

[Human **vaccine** responses regulated by parallel cytokine pathways.](#)

Chen G, Guo J, Heath J, Prestwood TR, Kwon WJ, Smith AR, Nguyen TT, Kathuria KR, Sola E, Sangare A, Mallajosyula V, Furuichi Fong R, Mohsin A, Chen L, Siva O, Padilla C, Tan M, Dekker CL, Grant P, Lu Y, Greenberg HB, Robinson WH, Blish C, Shen-Orr SS, Salehi A, Maecker HT, Khatri P, Utz PJ, Chien YH, Davis MM. Nat Immunol. 2026 Aug;27(8):1643-1652. doi: 10.1038/s41590-026-02547-x. Epub 2026 Jun 12. PMID: 42286357

[**Vaccine-Preventable Diseases in Older Adults.**](#)

Al-Jabri M, Rosero C, Saade EA. Clin Geriatr Med. 2026 Aug;42(3):509-527. doi: 10.1016/j.cger.2025.09.009. PMID: 42547175

[Japanese encephalitis **vaccine**.](#)

Causbie JM, Decker CF. Dis Mon. 2026 Aug;72(8):102125. doi: 10.1016/j.disamonth.2026.102125. Epub 2026 Apr 22. PMID: 42025462

[Underinvestment in diagnostic and **vaccine** research & development has put the world at greater risk from the Bundibugyo virus epidemic in 2026.](#)

Ly H. Virulence. 2026 Dec;17(1):2710544. doi: 10.1080/21505594.2026.2710544. Epub 2026 Aug 9. PMID: 42572249

[Highlights from JAAD Case Reports: August 2026.](#)

Voorhees ASV. J Am Acad Dermatol. 2026 Aug;95(2):386. doi: 10.1016/j.jaad.2026.05.083. Epub 2026 Jun 2. PMID: 42229811

[iEvac-Z, an Inactivated Ebola **Vaccine** - Phase 1 Study in Japan.](#)

Watanabe T, Koga M, Nojima M, Kono M, Tomita Y, Maemura T, Anzai I, Furusawa Y, Duong C, Kino Y, Halfmann PJ, Nagamura F, Yotsuyanagi H, Kawaoka Y. N Engl J Med. 2026 Aug 13;395(7):715-717. doi: 10.1056/NEJMc2518666. Epub 2026 Jul 29. PMID: 42526044

[Towards a universal malaria **vaccine**.](#)

Bernard NJ. Nat Immunol. 2026 Aug;27(8):1531. doi: 10.1038/s41590-026-02610-7. PMID: 42521847

[ChAdOx1 nCoV-19 coronavirus **vaccine**: Long-term safety and immunological responses.](#)

Ebrahimi N, de Whalley P, Kanji N, Ramasamy MN, Aley PK, Bibi S, Clutterbuck EA, Collins AM, Darton TC, Duncan CJA, Faust SN, Feng ES, Goodman AL, Green CA, Heath PT, Kwok J, Lazarus R, Libri V, Lillie PJ, McGregor A, Mujadidi YF, Owino N, Plested E, Pollock KM, Robinson H, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Williams CJ, Hirsch I, Villafana TL, Lambe T, Voysey M, Pollard AJ. Vaccine. 2026 Aug 13;88:128951. doi: 10.1016/j.vaccine.2026.128951. Epub 2026 Jul 18. PMID: 42472497

[Antibodies Cross-Reactive with Bundibugyo Virus in Ferrets Vaccinated with Ebola Virus Vaccine.](#)

Wight J, Schulz H, Banadyga L. Emerg Infect Dis. 2026 Aug;32(8):1360-1363. doi: 10.3201/eid3208.260948. Epub 2026 Jun 24. PMID: 42342600

[Erratum.](#)

[No authors listed] Int Arch Allergy Immunol. 2026 Aug 10;1. doi: 10.1159/000552632. Online ahead of print. PMID: 42574309

[Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study.](#)

Miles AC, Vojcic J, Peyrani P, Rosenstock S, Li H, Vietri JT, Yan Q, Randall AE, Zhao X, Zhu W, Zhao B, Zhou A, Jodar L, Gessner BD, Theilacker C, Moisi JC, Balmer P, Grant LR, Cane A. Lancet Infect Dis. 2026 Aug;26(8):807-818. doi: 10.1016/S1473-3099(26)00115-5. Epub 2026 Apr 30. PMID: 42070554

[DNA, Peptide Vaccines Advance Against GBM.](#)

[No authors listed] Cancer Discov. 2026 Aug 3;16(8):OF1. doi: 10.1158/2159-8290.CD-NW2026-0075. PMID: 42396601

[New chapter in rabies vaccine development.](#)

Visser LG. Lancet Infect Dis. 2026 Aug;26(8):753-755. doi: 10.1016/S1473-3099(26)00137-4. Epub 2026 Apr 28. PMID: 42066781

[Vaccine Preventable Diseases in the Emergency Department.](#)

Cohen D, Kporku E. Emerg Med Australas. 2026 Aug;38(4):e70317. doi: 10.1111/1742-6723.70317. PMID: 42538133

[Vaccines mimicking conformational epitopes on \$\alpha\$ -synuclein fibrils provide immunity to Parkinson's disease.](#)

Ma L, Reithofer S, Pesch V, Flores-Fernandez JM, Sriraman A, Duckering C, Amidian S, Özdüzenciler P, Müller L, Wille H, Tamgüney G. Brain. 2026 Aug 3;149(8):2689-2701. doi: 10.1093/brain/awag010. PMID: 41512110

[Measles disease outbreaks are surging again globally in 2026.](#)

Ly H. Virulence. 2026 Dec;17(1):2713277. doi: 10.1080/21505594.2026.2713277. Epub 2026 Aug 10. PMID: 42576343

[Revaccination after an Adverse Event: A Patient Uses Bayesian Reasoning to Weigh COVID and Vaccine Risks.](#)

Hansen J. Med Decis Making. 2026 Aug;46(6):675-677. doi: 10.1177/0272989X261446571. Epub 2026 May 7. PMID: 42093291

[Vaccine coverage and quarantine during a school-based measles outbreak, South Carolina, USA, 2025-2026.](#)

Chen S, Hupert N, Bento AI. *Vaccine*. 2026 Aug 13;88:128860. doi: 10.1016/j.vaccine.2026.128860. Epub 2026 Jun 23. PMID: 42330775

[Evidence for the multistage malaria **vaccine** gamble.](#)

Joyner CJ, Vivas AR, Cheng WT. *Trends Parasitol*. 2026 Aug 10:S1471-4922(26)00211-4. doi: 10.1016/j.pt.2026.07.014. Online ahead of print. PMID: 42575791

[In mRNA drug and **vaccine** immunogenicity, expression patterns matter.](#)

Siu S, Brown BD. *Mol Ther*. 2026 Aug 5;34(8):4382-4383. doi: 10.1016/j.ymthe.2026.07.018. Epub 2026 Jul 22. PMID: 42480531

[2024-2025 COVID-19 **Vaccine** and Major Adverse Cardiovascular Events Among US Veterans.](#)

Cai M, Xie Y, Al-Aly Z. *JAMA Intern Med*. 2026 Aug 1;186(8):988-999. doi: 10.1001/jamainternmed.2026.1929. PMID: 42295793

[Advancements in Syphilis **Vaccine** Development.](#)

Giacani L, Cameron CE, Zhao F, Caimano MJ, Radolf JD. *Sex Transm Dis*. 2026 Aug 1;53(8):546-550. doi: 10.1097/OLQ.0000000000002347. Epub 2026 May 6. PMID: 42383911

[Meningococcal B vaccination for gonorrhoea prevention in men who have sex with men - time to revisit the recommendation?](#)

Lee SS, Al-Abri S. *Int J Infect Dis*. 2026 Aug 4;171:109033. doi: 10.1016/j.ijid.2026.109033. Online ahead of print. PMID: 42551585

[Quantifying the impact of vaccination on pertussis dynamics in Sweden.](#)

Brett TS, Tredennick A, Briga M, Coudeville L, Macina D, Domenech de Cellès M, Rohani P. *PLoS Comput Biol*. 2026 Aug 4;22(8):e1014538. doi: 10.1371/journal.pcbi.1014538. eCollection 2026 Aug. PMID: 42550879

[Anti-PEG Antibodies From mRNA COVID-19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels.](#)

Svyatova EA, Liu Z, Becker RE, Sung JM, Fayomi AP, Florian JA, Weaver JL, Rouse R, Howard KE. *Clin Transl Sci*. 2026 Aug;19(8):e70667. doi: 10.1111/cts.70667. PMID: 42477513

[Engineered bacteriophage nanoassemblies in vivo stabilize DC-T cell immune synapse for high-performance influenza vaccination.](#)

Xia Y, Xu Z, Song R, Wang W, Li Y, Xu L, Huan C, Cao P, Chen G. *Biomaterials*. 2026 Aug;331:124113. doi: 10.1016/j.biomaterials.2026.124113. Epub 2026 Mar 4. PMID: 41795404

[Logical paradoxes and epidemiologic inconsistencies in **vaccine**-related vitiligo risk assessment.](#)

Rocchetti M. *J Allergy Clin Immunol*. 2026 Aug;158(2):614. doi: 10.1016/j.jaci.2026.02.023. Epub 2026 Mar 18. PMID: 41842858

[Rotavirus **vaccine** success and the challenge of **vaccine** equity.](#)

Hungerford D, Ndeketa L. Lancet Child Adolesc Health. 2026 Aug 12:S2352-4642(26)00215-4. doi: 10.1016/S2352-4642(26)00215-4. Online ahead of print. PMID: 42586105

[Maternal and infant immunizations for respiratory diseases, United States, may 2025.](#)

Razzaghi H, Garacci E, Kahn KE, Meghani M, Kriss JL, Lindley MC, Jones JM, Ellington S, Hughes M, Black CL. Vaccine. 2026 Aug 13;88:128823. doi: 10.1016/j.vaccine.2026.128823. Epub 2026 Jun 12. PMID: 42284808

[Social capital and vaccine decision-making: A scoping review.](#)

Monette E, Duval G. Soc Sci Med. 2026 Aug;403:119443. doi: 10.1016/j.socscimed.2026.119443. Epub 2026 May 25. PMID: 42190488

[US policies are making a resurgence of vaccine-preventable diseases inevitable.](#)

Correia T, McKee M, Gonsalves G. BMJ. 2026 Aug 13;394:e100562. doi: 10.1136/bmj-2026-100562. PMID: 42595392

[Retraction: Exploring the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk population: a systematic review and meta-analysis of randomized controlled trials.](#)

[No authors listed] Ther Adv Vaccines Immunother. 2026 Aug 14;14:25151355261476385. doi: 10.1177/25151355261476385. eCollection 2026. PMID: 42603985

[GC B Cells, Tfh Cells, and Influenza bnAbs: Insights for Improving Universal Vaccine Design.](#)

Inoue T, Ise W, Kurosaki T. Immunol Rev. 2026 Aug;341(1):e70153. doi: 10.1111/imr.70153. PMID: 42528006

[Distinct differences between COVID-19 vaccine refusers and vaccine hesitant in the United States: Results from a population-based survey and latent class analysis.](#)

Huang K, Taylor BG, Hotton AL, Brewer RA, Sheng Y, Motley DN, McNulty MC, Pollack HA, Schneider JA. Ann Epidemiol. 2026 Aug;120:110118. doi: 10.1016/j.annepidem.2026.110118. Epub 2026 May 16. PMID: 42144042

[Comment on: "Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine".](#)

Persson C. J Infect Dis. 2026 Aug 3;234(1):e211-e212. doi: 10.1093/infdis/jiag180. PMID: 41869879

[Recent advances of anticancer nanomaterial vaccine platforms.](#)

Jia H, Fu Q, Wang D, Wang Z, Zhao X, Liu J. Biomater Sci. 2026 Aug 11;14(16):4146-4163. doi: 10.1039/d6bm00657d. PMID: 42418183

[Bioreactor technologies for bacterial-based vaccine manufacturing and industrial scale-up: insights and future prospects.](#)

Esmailnejad-Ahranjani P. 3 Biotech. 2026 Aug;16(8):305. doi: 10.1007/s13205-026-04914-9. Epub 2026 Jul 4. PMID: 42404969

[Association between **vaccine**-induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?](#)

Petito E, Bury L, Heck LA, Di Paola J, Gresele P.Br J Haematol. 2026 Aug;209(2):849-850. doi: 10.1111/bjh.70605. Epub 2026 Jun 10.PMID: 42267856

[Efficacy and Safety of an mRNA Seasonal Influenza **Vaccine** in Adults.](#)

Locquet M, Dogné JM.N Engl J Med. 2026 Aug 13;395(7):724-725. doi: 10.1056/NEJMc2607826.PMID: 42585656

[Whole-genome sequencing of the hemorrhagic septicemia **vaccine** strain in Bangladesh.](#)

Basak P, Karim MR, Banu RA, Khanam S, Kamal MM, Samad MA.Microbiol Resour Announc. 2026 Aug 11;15(8):e0062526. doi: 10.1128/mra.00625-26. Epub 2026 Jul 10.PMID: 42429775

[Risk-aware artificial intelligence for translational **vaccine** design.](#)

Villanueva-Flores F, Garcia-Atutxa I.Vaccine. 2026 Aug 14;90:129047. doi: 10.1016/j.vaccine.2026.129047. Online ahead of print.PMID: 42600247

[Language, trust, and the polio endgame: words matter in **vaccine** communication.](#)

Tsiodras S, Gupta N, Hanscheid T, Jokelainen P, Drexler JF, Barac A, Gkrania-Klotsas E, Mora-Rillo M, Bulescu C, Paño-Pardo JR, Lescure FX, Grobusch MP.Clin Microbiol Infect. 2026 Aug;32(8):1286-1292. doi: 10.1016/j.cmi.2026.02.023. Epub 2026 Feb 27.PMID: 41765092

[In silico comparison of the differential proteome produced by the tuberculosis **vaccine** candidate BCGdeltaBCG1419c and its parental BCG strain cultured as biofilms or planktonic cells.](#)

Flores-Valdez MA, Velázquez-Fernández JB, Vallejo-Cardona AA, Aceves-Sánchez MJ, Rodríguez-Campos J.Vaccine. 2026 Aug 13;88:128855. doi: 10.1016/j.vaccine.2026.128855. Epub 2026 Jun 19.PMID: 42314311

[ZPY-CpG-Ch, a broad coverage **vaccine** against *Streptococcus pneumoniae*.](#)

Audhasai T, Panagiotou S, Crossman L, Xu R, Verheijen L, Chaguza C, O'Brien M, Kadioglu A.Sci Adv. 2026 Aug 7;12(32):eade7981. doi: 10.1126/sciadv.ade7981. Epub 2026 Aug 7.PMID: 42566513

[Highlights of 2025: Advances in the T-Cell Regulation of Germinal Center Response.](#)

Zhou X, Chen Z.Immunol Cell Biol. 2026 Aug;104(7):682-685. doi: 10.1111/imcb.70141. Epub 2026 Jun 16.PMID: 42304679

[Immunogenicity and safety of a SARS-CoV-2 recombinant **vaccine** S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.](#)

Nakano T, Iwata S, Oishi K, Iguchi E, Suganuma Y, Tada Y, Saiki S, Hashimoto K, Nakajima-Yoshida H, Omoto S, Yazaki T, Sonoyama T.Vaccine. 2026 Aug 13;88:128871. doi: 10.1016/j.vaccine.2026.128871. Epub 2026 Jul 3.PMID: 42398333

[id.DRIVE: a public-private partnership for infectious disease surveillance, **vaccine** research, and pandemic preparedness in Europe and beyond.](#)

Carmona A, Breugelmans JG, Beutels P, Sánchez BM, Miller E, Moyersoen J, Nair H, Nguyen JL, Sánchez AO, Rebry G, Smith PG, Sullivan SG, Torcel-Pagnon L, Van Aalst R, Praet N, Gomez JP, Rousculp M, Savic M, Wang C, Bollaerts K. Clin Microbiol Infect. 2026 Aug 8:S1198-743X(26)00429-5. doi: 10.1016/j.cmi.2026.08.001. Online ahead of print. PMID: 42570801

[Genome sequencing of fowl cholera **vaccine** strain Pasteurella multocida in Bangladesh.](#)

Mokta MB, Karim MR, Dey TR, Alam S, Mohiuddin ANMG, Hosain MZ, Kamal MM, Samad MA. Microbiol Resour Announc. 2026 Aug 11;15(8):e0061426. doi: 10.1128/mra.00614-26. Epub 2026 Jun 29. PMID: 42370839

[Maternal DTaP immunization and transplacental transfer of pertussis antibodies in Japan.](#)

Hiiragi K, Shindo R, Kojima T, Nakanishi S, Obata S, Miyagi E, Aoki S. Int J Infect Dis. 2026 Aug;169:108794. doi: 10.1016/j.ijid.2026.108794. Epub 2026 May 13. PMID: 42134724

[Live Respiratory Syncytial Virus **Vaccine** D46/cp/deltaM2-2 Is Overattenuated in RSV-Seronegative Children.](#)

Karron RA, Woods S, Wanionek K, Oliva J, Yang L, Luongo C, Collins PL, Buchholz UJ. Open Forum Infect Dis. 2026 Jul 29;13(8):ofag388. doi: 10.1093/ofid/ofag388. eCollection 2026 Aug. PMID: 42549136

[2024-2025 COVID-19 mRNA **Vaccine** Effectiveness Against Severe Disease.](#)

Jayawardena I, Dean NE, Witrick B, Litwin AH, Rennert L. J Infect Dis. 2026 Aug 3;234(1):85-92. doi: 10.1093/infdis/jiag137. PMID: 41766610

[Distinct Innate Immune Responses Following Inoculation With a Replicon mRNA COVID-19 **Vaccine**.](#)

Nakayama T, Ito T, Katayama K. Microbiol Immunol. 2026 Aug;70(8):388-391. doi: 10.1111/1348-0421.70068. Epub 2026 Jun 15. PMID: 42290597

[Co-Administration of Novel Oral Polio **Vaccine** Type 2 and Bivalent Oral Polio **Vaccine**: Current Evidence, Challenges, and Implications for the Polio Eradication Endgame.](#)

Bateyi Mustafa SH, Rodrigue TP, Raoul RZ, Dominique BB. Infect Drug Resist. 2026 Aug 11;19:625567. doi: 10.2147/IDR.S625567. eCollection 2026. PMID: 42604350

[Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 \(IXCHIQ®\).](#)

Sattler N, Scheiblaue S, Hochreiter R, Kosulin K, Buerger V. Vaccine. 2026 Aug 13;88:128787. doi: 10.1016/j.vaccine.2026.128787. Epub 2026 Jun 6. PMID: 42250475

[Erratum to "The cost of respiratory syncytial virus \(RSV\) across all ages to the Australian healthcare system" \[Vaccine 88 \(2026\) 128922\].](#)

Paull KK, Newall AT. Vaccine. 2026 Aug 10:129019. doi: 10.1016/j.vaccine.2026.129019. Online ahead of print. PMID: 42575816

[Why is there still no licensed **vaccine** for Bundibugyo ebolavirus? Lessons from the 2026 outbreaks in Uganda and the Democratic Republic of Congo.](#)

Abdi AM, Omar AM, Khalif IA, Adan AM, Bashir SG. *New Microbes New Infect.* 2026 Jun 12;72:101789. doi: 10.1016/j.nmni.2026.101789. eCollection 2026 Aug. PMID: 42338895

[Vaccination policies for healthcare personnel in Europe, 2026.](#)

Maltezou HC, Borg M, Botelho-Nevers E, Brantsæter AB, Caplinskas S, Chernyshova L, Cirstea O, Civljak R, Dokova K, Falup-Pecurariu O, Filippova I, Froes F, Vitek MG, Heininger U, Hübschen JM, Josefsdottir KS, Kassianos G, Koliou M, Kyncl J, Lapii F, Ljungman P, Medić S, Molnar Z, Nitsch-Osuch A, Nohynek H, Ortiz de Lejarazu R, Rath B, Tafuri S, Townsend L, Ulbrichtová R, Van Damme P, van Essen GA, von Linstow ML, Wiedermann U, Zavadská D, Poland GA. *Vaccine.* 2026 Aug 13;88:128839. doi: 10.1016/j.vaccine.2026.128839. Epub 2026 Jul 2. PMID: 42392011

[Identification of **vaccine** candidates by immunization with a complex pool of recombinant VLPs.](#)

Nepal Y, Wondra G, Jones DT, Francian A, Peabody J, Peabody DS, Chackerian B. *Vaccine.* 2026 Aug 13;90:129027. doi: 10.1016/j.vaccine.2026.129027. Online ahead of print. PMID: 42594642

[Effectiveness of inactivated and live-attenuated influenza vaccines in children during the 2025-2026 influenza season with genetically distinct influenza A and B viruses.](#)

Shinjo M, Furuichi M, Sugimoto R, Kawakami C, Abe K, Kusano C, Otsubo G, Tsumura Y, Tezuka M, Narabayashi A, Kamei A, Maeda N, Shibata A, Nishida M, Yoshida M, Tsunematsu K, Yamada G, Itaki R, Chiga M, Yamaguchi Y, Fukushima H, Yaginuma M, Tokita A, Iwatsuki-Horimoto K, Narumi S, Kawaoka Y, Sugaya N; Keio Pediatric Influenza Research Group. *Vaccine.* 2026 Aug 13;88:128869. doi: 10.1016/j.vaccine.2026.128869. Epub 2026 Jun 25. PMID: 42349133

[HELPinKids&Adults 2026 Guideline Update on Reducing Distress During **Vaccine** Injections: Overview of Methods and the Evidence Base.](#)

Taddio A. *Clin J Pain.* 2026 Aug 1;42(8S Suppl 1):e1375. doi: 10.1097/AJP.0000000000001375. PMID: 42444176

[ACAM2000 **vaccine** safety and immunogenicity considerations for smallpox and mpox.](#)

Komlenovic V, McCarty J, Cassie D, Anantha R, Yeo K, Rodriguez M, Drobic B. *Expert Rev Vaccines.* 2026 Dec;25(1):2708197. doi: 10.1080/14760584.2026.2708197. Epub 2026 Aug 10. PMID: 42576544

[Global Shigella epidemiology and **vaccine** coverage stratified by socioeconomic development levels, 1934-2025.](#)

Jiang J, Yang Y, Zeng X, Xu C, Li X, Li Y, Li Y, Dong N. *Microbiol Spectr.* 2026 Aug 4:e0239325. doi: 10.1128/spectrum.02393-25. Online ahead of print. PMID: 42549883

[Ebola: how soon could a Bundibugyo **vaccine** be ready?](#)

Lang K. *BMJ.* 2026 Aug 5;394:e100450. doi: 10.1136/bmj-2026-100450. PMID: 42556857

[Pan-pathogen **vaccine** approaches: Toward broad-spectrum immunity in a One Health era.](#)

Manzoor S.J Microbiol Methods. 2026 Aug;247:107563. doi: 10.1016/j.mimet.2026.107563. Epub 2026 Jun 2.PMID: 42235797

[Neutrophils induce effective antibody responses to the pneumococcal conjugate **vaccine** by inhibiting regulatory T cells.](#)

Tchalla EYI, Betadpur A, Khalil AY, Lopez E, Bhalla M, Chang M, Wohlfert EA, Bou Ghanem EN.J Leukoc Biol. 2026 Aug 7:qia112. doi: 10.1093/jleuko/qia112. Online ahead of print.PMID: 42565624

[Advancing human metapneumovirus **vaccine** development through fusion protein stabilization.](#)

Sabir AJ, Ross TM.Virology. 2026 Aug 4;624:111043. doi: 10.1016/j.virol.2026.111043. Online ahead of print.PMID: 42566836

[Parental risk preferences and children's vaccination coverage.](#)

Coda Moscarola F, Zaccagni S.Eur J Health Econ. 2026 Aug;27(6):1233-1249. doi: 10.1007/s10198-025-01880-6. Epub 2025 Dec 29.PMID: 41460268

[Corrigendum to "Multi-antigen transmission-blocking malaria **vaccine** elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi" \[**Vaccine** 84 \(2026\) 128683\].](#)

Pourhashem Z, Siasi S, Nourani L, Yousefi H, Sani JJ, Vand-Rajabpour H, Raz A, Pirahmadi S, Zargar M, Djadid ND, Zakeri S, Mehrizi AA.Vaccine. 2026 Aug 13;88:128784. doi: 10.1016/j.vaccine.2026.128784. Epub 2026 Jun 7.PMID: 42251843

[Hepatitis A Outbreak in Skilled Nursing Facility, Los Angeles County, California, USA, 2025.](#)

Yazdi MT, Chang AH, Wong A, Asuncion C, Dao B, Gounder PP.Emerg Infect Dis. 2026 Aug;32(8):1358-1360. doi: 10.3201/eid3208.260202.PMID: 42521635

[Correction: Trust and Trustworthiness: Considerations for COVID-19 **Vaccine** Receipt in the Chicago Metropolitan Area.](#)

Bishop-Royse J, Gutierrez-Kapheim M, Silva A, Lomahan S, Jindal M, Krogen M, Vu M, Martin M.J Community Health. 2026 Aug;51(4):707-710. doi: 10.1007/s10900-026-01574-x.PMID: 42215839

[Universal **vaccine** for pneumococcal disease moves closer to reality.](#)

[No authors listed]Nature. 2026 Aug 7. doi: 10.1038/d41586-026-02462-z. Online ahead of print.PMID: 42567904

[Concerns over withdrawal of cattle lungworm **vaccine**.](#)

[No authors listed]Vet Rec. 2026 Aug 1;199(3):127-128. doi: 10.1002/vetr.71048.PMID: 42535572

[Efficacy, Safety, and Immunogenicity of the MATISSE \(Maternal Immunization Study for Safety and Efficacy\) Maternal Respiratory Syncytial Virus Prefusion F Protein **Vaccine** Trial: Correction.](#)

Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC,

Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I; MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. *Obstet Gynecol.* 2026 Aug 1;148(2):e138. doi: 10.1097/AOG.0000000000006358.PMID: 42462254

[Mucosal immunity as a **vaccine**-induced correlate of protection against influenza.](#)

Dvorscek AR, Kushnir AS, Dibben O, Kijak GH, Thwaites RS. *Mucosal Immunol.* 2026 Aug;19(4):100381. doi: 10.1016/j.mucimm.2026.100381. Epub 2026 Jul 8.PMID: 42419427

[What's Old Is New Again: Varicella.](#)

Naureckas Li C, Edwards KM, Kaplan SL, Marshall GS, Parker S, Healy CM. *Pediatrics.* 2026 Aug 14:e2026076519. doi: 10.1542/peds.2026-076519. Online ahead of print.PMID: 42595342

[Antiviral strategies against human norovirus: Molecular targets, therapeutics, and **vaccine** development.](#)

Islam S, Zia SA, Mirza S, Rahman MM, Ali Shafi MA, Hasan MH, Al Mamun A. *Ther Adv Infect Dis.* 2026 Aug 13;13:20499361261473798. doi: 10.1177/20499361261473798. eCollection 2026 Jan-Dec.PMID: 42602140

[Lungworm **vaccine** withdrawal causes alarm.](#)

Loeb J. *Vet Rec.* 2026 Aug 1;199(3):98. doi: 10.1002/vetr.71029.PMID: 42535548

[Shigella Vaccines: A Light at the End of a Long Tunnel.](#)

Walker RI, Choy RKM. *J Infect Dis.* 2026 Aug 3;234(1):1-3. doi: 10.1093/infdis/jiag221.PMID: 42028744

[World Association for the Advancement of Veterinary Parasitology \(WAAVP\) concept paper on the efficacy evaluation of parasite vaccines.](#)

Claerebout E, Blake DP, Lightowlers MW, Spithill TW, Nava S, Tabor AE, Joachim A, Kaplan RM, Fernandez S, Junior LC, Geurden T. *Vet Parasitol.* 2026 Aug;346:110805. doi: 10.1016/j.vetpar.2026.110805. Epub 2026 May 22.PMID: 42217264

[The Slr protein of *Streptococcus pyogenes* is selectively expressed in vivo and is a target for protective antibodies.](#)

Rumpret M, Lannergård J, Kristensen BM, Lynskey NN, Bowen C, Johnsson E, Nilsson OR, Norrby-Teglund A, Stålhammar-Carlemalm M, Lindahl G, McCarthy AJ. *EMBO Mol Med.* 2026 Aug;18(8):3086-3108. doi: 10.1038/s44321-026-00470-0. Epub 2026 Jun 15.PMID: 42298213

[Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.](#)

Bertoletti A, Ambike SS, Le Bert N, Binayke AA. *Antiviral Res.* 2026 Aug;252:106441. doi: 10.1016/j.antiviral.2026.106441. Epub 2026 May 28.PMID: 42214471

[Influenza, COVID-19, and RSV Vaccinations for Immunocompromised Children and Household Contacts.](#)

Kao CM, Bahakel H, Heald-Sargent TA, Minniear TD, Statler VA, Thomas SJ, Weakley KE, Cao Q, Ardura MI, Danziger-Isakov L, Foca M, Herold BC. *Pediatrics.* 2026 Aug 1;158(2):e2026075971. doi: 10.1542/peds.2026-075971.PMID: 42486492

[Thirty years of hepatitis A epidemiology and **vaccine** studies: A narrative review of lessons learned in Alaska.](#)

Balta VA, McMahon BJ, Moore K, Stevenson T, Scobie HM. *Ann Epidemiol*. 2026 Aug;120:110108. doi: 10.1016/j.annepidem.2026.110108. Epub 2026 May 3. PMID: 42086110

[Erratum to "Partner awareness and support for maternal RSV vaccination: a paired survey of pregnant women and co-residing partners in Japan" \[**Vaccine** 88 \(2026\) 128946\].](#)

Saitoh A, Takaku M. *Vaccine*. 2026 Aug 13;88:128966. doi: 10.1016/j.vaccine.2026.128966. Epub 2026 Jul 27. PMID: 42509102

[Complete genome sequence of BLRI-developed inactivated avian influenza A/H9N2 **vaccine** strain in Bangladesh.](#)

Samad MA, Karim MR, Uddin ASMA, Hossen A, Ali MZ, Khan MMR. *Microbiol Resour Announc*. 2026 Aug 11;15(8):e0030426. doi: 10.1128/mra.00304-26. Epub 2026 Jun 25. PMID: 42377032

[Intersectional Influences and Global Expertise: **Vaccine** Views of Internationally Educated Healthcare Professionals.](#)

HakemZadeh F, Neiterman E, Subbiah K, Beggs B, Bedard M. *Healthc Manage Forum*. 2026 Aug 1;8404704261473248. doi: 10.1177/08404704261473248. Online ahead of print. PMID: 42541398

[Antibiotic resistance and first comprehensive genomic characteristics of *Salmonella* Gallinarum isolated from poultry in Morocco.](#)

Farhat M, Khayi S, Mouahid M, Ameur N, El-Adawy H, Fellahi S. *Avian Pathol*. 2026 Aug;55(4):405-420. doi: 10.1080/03079457.2025.2562221. Epub 2025 Oct 31. PMID: 41170694

[Vaccines for the Prevention of COVID-19 in Older Adults.](#)

Olagunju OJ, Oyeboji OA, Mylonakis E, Canaday DH. *Clin Geriatr Med*. 2026 Aug;42(3):427-448. doi: 10.1016/j.cger.2025.09.003. PMID: 42547171

[\[The Royal Philanthropic **Vaccine** Expedition: interview with Susana Ramirez Martin\].](#)

Martín SMR, Brizola JH, Pimenta TS, Santos GGD. *Hist Cienc Saude Manguinhos*. 2026 Aug 7;33(suppl 1):e2026025. doi: 10.1590/S0104-59702026000100025. eCollection 2026. PMID: 42585443

[Advances in clinical immunogenicity evaluation of influenza vaccines.](#)

Xu N, Wang L, Zhao C, Shen Y, Zhao Z, Nie J. *Vaccine*. 2026 Aug 3;89:128989. doi: 10.1016/j.vaccine.2026.128989. Online ahead of print. PMID: 42546636

[Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza **vaccine** manufactured in Iran \(FluGuard\) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" \[**Vaccine** 42\(9\) \(2024\) 2254-2259\].](#)

Yadegarynia D, Keyvanfar A, Keyvani H, Tehrani S, Sali S, Abolghasemi S. *Vaccine*. 2026 Aug 13;88:128881. doi: 10.1016/j.vaccine.2026.128881. Epub 2026 Jun 28. PMID: 42365746 N

[Mucosal boosting of chimpanzee adenovirus-vectored **vaccine** encoding SARS-CoV-2 RBD-heterodimer provides robust protection in mice.](#)

Liu X, An Y, Duan H, Shao F, Xu K, Yang C, Xu S, Zhou X, Duan M, Zheng T, Sun S, Yang M, Cai K, Liu WJ, Zhou D, Xu K, Dai L, Wang S, Liu P, Ma W, Gao GF. *mBio*. 2026 Aug 12;17(8):e0146426. doi: 10.1128/mbio.01464-26. Epub 2026 Jul 21. PMID: 42478837

[Diagnostic Gaps as a Hidden Barrier to Hantavirus **Vaccine** Development.](#)

Shaikh R. *Ann Lab Med*. 2026 Aug 4. doi: 10.3343/alm.2026.0292. Online ahead of print. PMID: 42548184

[Patient and provider knowledge and attitudes regarding vaccination with the 9-valent HPV **vaccine** during pregnancy.](#)

Boudova S, Gannon M, Zhan J, Frusone V, Haidara A, Arce A, McGuigan K, Schwartz B, Chambers C, Boelig RC. *Am J Perinatol*. 2026 Aug 14. doi: 10.1055/a-2936-5812. Online ahead of print. PMID: 42601048

[Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and **Vaccine** Hesitancy.](#)

Munblit D, Buonsenso D, Oliaro PL, Semple MG, Greenhawt MJ, Genuneit J, Ashkenazi-Hoffnung L, Wilder-Smith A, Warner JO, Chang AY, Sultan F, Putri ND, Poland GA, Bush A, Boaventura V, Apfelbacher C, Ulloa-Gutierrez R, Watson HR, Oliveira CR, Reyes LF. *Clin Infect Dis*. 2026 Aug 5:ciag403. doi: 10.1093/cid/ciag403. Online ahead of print. PMID: 42554662

[Exploring the Clinical Landscape of Long Non-coding RNAs in Cancer Diagnosis and Therapy.](#)

Bhattacharyya R, Basu S, Gupta S, Sur S. *Biochem Genet*. 2026 Aug;64(4):4697-4772. doi: 10.1007/s10528-026-11334-0. Epub 2026 Feb 18. PMID: 41706367

[A Systematic Review and Meta-Analysis of Pharmacological and Physical Interventions Directed at the Injection Site for Reducing Distress During **Vaccine** Injections.](#)

Taddio A, Shah V, McMurtry CM, Lang E, MacDonald NE, Constantin K, Logeman C, Uleryk E; HELPinKids&Adults##. *Clin J Pain*. 2026 Aug 1;42(8S Suppl 1):e1374. doi: 10.1097/AJP.0000000000001374. PMID: 41821515

[Evaluation of immunogenicity and efficacy of a Plasmodium vivax nanoparticle **vaccine** in mice.](#)

Ntumngia FB, Kolli SK, Howard GP, Subramani PA, Barnes SJ, Ogbondah MM, Mahdavi P, Lu J, Nicholas J, De SL, Barnes BB, Dinglasan RR, Janse CJ, Mao HQ, Adams JH. *Vaccine*. 2026 Aug 13;88:128857. doi: 10.1016/j.vaccine.2026.128857. Epub 2026 Jun 20. PMID: 42322682

[**Vaccine**-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.](#)

Onozawa M, Kusumoto S, Kuwatsuka Y, Miyazono T, Tanaka M, Najima Y, Okada K, Shiratori S, Sato T, Kanda J, Inagaki Y, Murayama T, Hatano K, Onodera K, Sakurai M, Endo S, Kumode T, Itonaga H, Moriuchi Y, Kanemura N, Imi T, Edahiro T, Fukushima N, Oura M, Yui S, Watanabe M, Toubai T, Ando T, Nakamura D, Tamaki M, Kakinoki Y, Okada T, Nakano N, Tachibana T, Shimizu H, Ota S, Iida S, Sugiyama M, Atsuta

Y, Teshima T, Yoshizumi T, Mizokami M. Transplant Cell Ther. 2026 Aug;32(8):994.e1-994.e11. doi: 10.1016/j.jtct.2026.05.015. Epub 2026 May 17. PMID: 42150672

[The institutional roots of **vaccine** uptake and hesitancy: evidence from Africa.](#)

Barasa L, Onyango G. Vaccine. 2026 Aug 13;88:128980. doi: 10.1016/j.vaccine.2026.128980. Epub 2026 Jul 27. PMID: 42508328

[Up to Date Status and Acceptance of the Influenza **Vaccine** among a National Sample of Emergency Department Patients.](#)

Dhama S, Gulati R, Ge S, Torres J, Chinnock B, Gottlieb M, Kumar VA, Rising KL, Eucker S, Molina MF, Kean ER, Rodriguez RM. J Emerg Med. 2026 Aug;87:131-138. doi: 10.1016/j.jemermed.2026.05.011. Epub 2026 May 16. PMID: 42296645

[Neoantigen cancer vaccines in the mRNA Era: antigen selection, platform engineering, and clinical translation.](#)

Ge M, Wu N. Cancer Treat Res Commun. 2026 Aug 10;48:101358. doi: 10.1016/j.ctarc.2026.101358. Online ahead of print. PMID: 42574874

[Bivalent foot-and-mouth disease virus mRNA **vaccine** induces well-balanced humoral and cellular immune responses.](#)

Wang L, Li Z, Zhu H, Jia X, Su Z, Zhang S. Vaccine. 2026 Aug 13;88:128840. doi: 10.1016/j.vaccine.2026.128840. Epub 2026 Jun 19. PMID: 42320384

[Effectiveness of recombinant zoster **vaccine** against herpes zoster and postherpetic neuralgia: a systematic review and meta-analysis of post-licensure observational studies.](#)

Mbinta JF, Awuni PMA, Muhammed Basheer ST, Generao HK, Su'a-Tavila A, Bowe S, Harrison A, Sporle A, French N, Simpson CR. Vaccine. 2026 Aug 13;88:128842. doi: 10.1016/j.vaccine.2026.128842. Epub 2026 Jun 17. PMID: 42308980

[Trust in federal statistical agencies and **vaccine** uptake among U.S. adults.](#)

Maxey NJ, Bather JR, Griffin TS, Powla PP, Pabon-Rodriguez FM. Vaccine X. 2026 Aug;31:100847. doi: 10.1016/j.jvaxx.2026.100847. Epub 2026 May 30. PMID: 42592594

[Perspectives on chikungunya vaccinology: from traditional platforms to epitope-driven rational design.](#)

Sagheer U, Deng L. Int J Pharm. 2026 Aug 10;701:127088. doi: 10.1016/j.ijpharm.2026.127088. Epub 2026 Jun 17. PMID: 42309198

[Elected officials' online anti-vaccination statements respond to online engagement.](#)

Kim T, Wang X, Rajtmajer S, Harden JJ, Boehmke FJ, Desmarais BA. Vaccine. 2026 Aug 13;88:128901. doi: 10.1016/j.vaccine.2026.128901. Epub 2026 Jul 28. PMID: 42520644

[From policy to practice: Systemic solutions to strengthen maternal immunization in sub-Saharan Africa.](#)

Nazareth AK, Purandare CN, Kihara AB, Sekharan S, Al-Qedra A, Abdosh AA, Purandare NC. *Int J Gynaecol Obstet.* 2026 Aug 5. doi: 10.1002/ijgo.71286. Online ahead of print. PMID: 42555152

[Downward Trends in Neonatal Hepatitis B Vaccine Uptake: 2021 to 2025.](#)

Handel AS, Brill P, Rochlin I, Foy C. *Hosp Pediatr.* 2026 Aug 1;16(8):e646-e648. doi: 10.1542/hpeds.2025-009138. PMID: 42386201

[mRNA-LNP hepatitis C vaccine encoding p7 elicits improved humoral immunogenicity.](#)

Reagan EK, Wright DA, Clark KE, Mercado-Lopez X, Atochina-Vasserman EN, Ni H, Mui BL, Hu F, Bailey JR, Bar KJ, Weissman D. *Vaccine.* 2026 Aug 13;88:128938. doi: 10.1016/j.vaccine.2026.128938. Epub 2026 Jul 22. PMID: 42486050

[Understanding Vaccine Information Needs and Message Preferences for a Tailored mHealth Intervention.](#)

Peterson JC, Denny M, Kerns EK, Clarke MA, Reisher E, Stowers S, Newcomer SR. *Acad Pediatr.* 2026 Aug 1:103414. doi: 10.1016/j.acap.2026.103414. Online ahead of print. PMID: 42542296

[The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial.](#)

Lu-Lu P, Hong-Ze M, Zhao G, Min-Jie L, Wen-Jian F, Ya-Nan L, Wang B, Shao-Xin W, Shi G, Li-Na G, Li B, Ying Z, Lin D, Qi L. *Hum Vaccin Immunother.* 2026 Dec;22(1):2654914. doi: 10.1080/21645515.2026.2654914. Epub 2026 Aug 3. PMID: 42546220

[Navigating the future: An updated review and prospects for breast cancer vaccines.](#)

Roslei ASM, Huri HZ, Fisol FA, Nawaz A, Pratama DAOA, Sofian ZM, Jalil MFA, Nordin AH, Haron DEM, Norpi ASM, Azemi AK, Nordin ML. *Int Immunopharmacol.* 2026 Aug 1;182:116803. doi: 10.1016/j.intimp.2026.116803. Epub 2026 May 15. PMID: 42140162

[The English-Only Nature of Vaccine Deservedness and Harms of Racialized Administrative Burdens.](#)

Camacho S, Heinrich CJ, Sanders M, McGowan MM. *J Racial Ethn Health Disparities.* 2026 Aug;13(4):3391-3407. doi: 10.1007/s40615-025-02507-5. Epub 2025 Jun 27. PMID: 40579633

[Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.](#)

Tartof SY, Aliabadi N, Zasowski E, Goodwin G, Slezak JM, Hong V, Frankland TB, Ackerson B, Liu Q, Shaw S, Welsh S, Kapadia B, Spence BC, Davis GS, Lewnard JA, Chowdhry H, Dutro M, Chilson E, Jodar L, Gessner BD, Begier E. *Lancet Reg Health Am.* 2026 May 27;60:101520. doi: 10.1016/j.lana.2026.101520. eCollection 2026 Aug. PMID: 42256620

[HPV Vaccination Predictors Among College Students.](#)

Lee A, Kirby KB, Werthmann D, Daniel CL. *J Community Health.* 2026 Aug 7. doi: 10.1007/s10900-026-01620-8. Online ahead of print. PMID: 42566153

[Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Technical Report.](#)

Committee on Infectious Diseases.Pediatrics. 2026 Aug 10. doi: 10.1542/peds.2026-078779. Online ahead of print.PMID: 42572139

[Behavioural and social drivers of HPV **vaccine** uptake in Tonga: a mixed-methods study using the WHO BeSD framework and Talanoa in a Pacific Island setting.](#)

Alamgir M, Randimbivololona J, Patelisio PN, Tukia O, Fifita ST, Kafoa ST, Manoncourt E.Vaccine. 2026 Aug 13;88:128843. doi: 10.1016/j.vaccine.2026.128843. Epub 2026 Jun 17.PMID: 42308978

[Diversifying the antibody response to influenza virus with an mRNA-based **vaccine**.](#)

[No authors listed]Nat Immunol. 2026 Aug;27(8):1551-1552. doi: 10.1038/s41590-026-02565-9.PMID: 42337118

[Support for immunization-related child tax credit programs: A survey of parents in the United States.](#)

Boyce MR.Prev Med Rep. 2026 Jun 26;68:103552. doi: 10.1016/j.pmedr.2026.103552. eCollection 2026 Aug.PMID: 42441120

[State-Level Differences in Human Papillomavirus **Vaccine** Uptake Among 13- to 17-Year-Old Adolescents.](#)

Ejezie CL, Zhang C, Messiah SE.JAMA Pediatr. 2026 Aug 1;180(8):901-904. doi: 10.1001/jamapediatrics.2026.1338.PMID: 42113525

[Maternal RSV vaccination: A stress test for antenatal care systems.](#)

Ladomenou F, Matalliotakis M.Vaccine. 2026 Aug 13;88:128945. doi: 10.1016/j.vaccine.2026.128945. Epub 2026 Jul 15.PMID: 42456562

[Companion Animal **Vaccine** Hesitancy: Current Evidence and Practical Communication Strategies.](#)

Hartley AN, Ng Z, Ludwig CE, Pritchard JC.Vet Clin North Am Small Anim Pract. 2026 Aug 5:S0195-5616(26)00087-2. doi: 10.1016/j.cvsm.2026.06.006. Online ahead of print.PMID: 42557112

[The Relationship Between COVID-19 **Vaccine** Regret, Distrust of the Healthcare System, and Future **Vaccine** Intentions.](#)

Tayhan A, Azakli B.J Eval Clin Pract. 2026 Aug;32(5):e70532. doi: 10.1111/jep.70532.PMID: 42472384

[beta-glucan particles as oral carriers for a dual-antigen hepatitis B **vaccine**: Liver targeting and immune potentiation following subcutaneous priming.](#)

Panão-Costa J, Colaço M, Félix P, Melo AA, Gomes CMF, Borges O.Eur J Pharm Biopharm. 2026 Aug 6:115209. doi: 10.1016/j.ejpb.2026.115209. Online ahead of print.PMID: 42562079

[The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses.](#)

Fox A, Zhu Z, Sánchez-Ovando S.Immunol Rev. 2026 Aug;341(1):e70146. doi: 10.1111/imr.70146.PMID: 42499177

[Updated COVID-19 **Vaccine** Boosters-The Message From Data Is Consistent but Not Getting Through.](#)

Califf RM. JAMA Intern Med. 2026 Aug 1;186(8):986-987. doi: 10.1001/jamainternmed.2026.1945. PMID: 42295769

[Efficacy of a *Leptospira borgpetersenii* serovar Tarassovi **vaccine** against urinary shedding of *L. borgpetersenii* strain Pacifica in naturally exposed cattle.](#)

Little PR, Collins-Emerson JM, Hodge A, Notcovich S, Moutafis G, Littlejohn S, Clough WJ. N Z Vet J. 2026 Aug 16:1-12. doi: 10.1080/00480169.2026.2708016. Online ahead of print. PMID: 42604856

[On the implications of shifting Hepatitis B **vaccine** policy for surgical patients.](#)

Corpuz GS, Sidhu AS, Konig DJ, Waljee JF, Wooden WA. Vaccine. 2026 Aug 13;88:128791. doi: 10.1016/j.vaccine.2026.128791. Epub 2026 Jun 15. PMID: 42296832

[Global determinants of dengue **vaccine** acceptance: An updated systematic review and meta-analysis.](#)

Arriaga-Izabal D, Morales-Lazcano F, Angulo-Zamudio UA, Canizalez-Román A, León-Sicairos N. Public Health. 2026 Aug;257:106350. doi: 10.1016/j.puhe.2026.106350. Epub 2026 Jun 11. PMID: 42275853

[Augmented innate and humoral immune responses enhance early and durable rabies protection by a CD40L-overexpressing rabies **vaccine**.](#)

Xing X, Wang Y, Xiong Z, Liu D, Wang Y, Hu Y, Liu Y, Li Y. Vet Microbiol. 2026 Aug 1;321:111162. doi: 10.1016/j.vetmic.2026.111162. Online ahead of print. PMID: 42546450

[Maternal respiratory syncytial virus \(RSV\) **vaccine** perceptions amongst pregnant women and mothers of infants and toddlers in England: a qualitative study.](#)

Bell S, Chantler T, Passanante A, Pryce J, Bisset K, Letley L, Campbell H, Paterson P. Vaccine. 2026 Aug 13;88:128955. doi: 10.1016/j.vaccine.2026.128955. Epub 2026 Jul 24. PMID: 42497669

[Caregiver COVID-19 **vaccine** status and its influence on pediatric vaccination decisions in a US cohort.](#)

Ricke IJ, Ward C, Spaulding AB, Sherwood NE, Nguyen RHN. Vaccine. 2026 Aug 13;88:128847. doi: 10.1016/j.vaccine.2026.128847. Epub 2026 Jun 17. PMID: 42308977

[The use of the enzyme chitosanase to enable **vaccine** potency determination in a formulation containing the adjuvant chitosan.](#)

Fox N, Trausch JJ, Yarovoi H, Stiving AQ, Bowman A, Smith ML, Liu Y, Eddins MJ, Loughney JW, Mayhood T, Paduraru C, Grau B. J Pharm Sci. 2026 Aug 15:104461. doi: 10.1016/j.xphs.2026.104461. Online ahead of print. PMID: 42603690

[Immunogenicity and safety of co-administration of a recombinant shingles **vaccine** with an mRNA COVID-19 or adjuvanted influenza **vaccine**: a randomised controlled trial.](#)

Harris R, Thirard R, McBrien C, Middleditch A, Chadwick D, Jackson J, Moran E, Perry J, Payne RA, Goodman AL, Cosgrove C, Lillie P, Emmett S, Finn A, Pike K, Culliford L, Lazarus R; ZosterFluCov Trial team. J Infect. 2026 Aug;93(2):106784. doi: 10.1016/j.jinf.2026.106784. Epub 2026 Jun 4. PMID: 42248304

[Efficacy and Safety of an mRNA Seasonal Influenza **Vaccine** in Adults.](#)

Liu Z, Zhang L, Jiang M. *N Engl J Med*. 2026 Aug 13;395(7):724. doi: 10.1056/NEJMc2607826. PMID: 42585655

[Addressing HPV **vaccine** hesitancy and misinformation in India through public health communication strategies.](#)

Jindal R, R R, Ghanghas N, Gupta R, Arya R, Kanozia R, Sharma T. *Hum Vaccin Immunother*. 2026 Dec;22(1):2711551. doi: 10.1080/21645515.2026.2711551. Epub 2026 Aug 3. PMID: 42544634

[Weekly HIV pill moves closer but **vaccine** studies face new questions.](#)

Cohen J. *Science*. 2026 Aug 6;393(6811):549-550. doi: 10.1126/science.ael2155. Epub 2026 Aug 6. PMID: 42561052

[Design and synthesis of RNA vaccines encoding SAG1 antigen of toxoplasma gondii and evaluation of immunogenicity and its protective efficacy against acute toxoplasmosis in BALB/c mice.](#)

Zaki L, Ghaffarifar F, Sharifi Z, Horton J. *Vaccine*. 2026 Aug 13;88:128785. doi: 10.1016/j.vaccine.2026.128785. Epub 2026 Jun 11. PMID: 42275801

[Influenza and herpes zoster **vaccine** effectiveness in autoimmune or immune-mediated diseases.](#)

Denz R, van de Sand H, Basten J, Meiszl K, Tokic M, Oganowski T, Grüter T, Stock S, Simic D, Shukri A, Kiltz U, Zacharopoulou M, Vollmar HC, Otte IC, Giehl C, Lauer R, Stallmach A, Franz A, Marschall U, Saam J, Tiemann C, Reeb K, Meyer I, Hellwig K, Timmesfeld N; VAC-MAC Consortium. *J Infect Public Health*. 2026 Aug;19(8):103296. doi: 10.1016/j.jiph.2026.103296. Epub 2026 Jul 2. PMID: 42398453

[Improving COVID-19 **Vaccine** Uptake Among Ethnic Minority Communities in Wales: A Community-Based Approach.](#)

Talabani B, Hanif S, Ramzan K, Mohammed F, Naseem A, Alauddin E. *Immunol Cell Biol*. 2026 Aug;104(7):700-707. doi: 10.1111/imcb.70140. Epub 2026 Jun 30. PMID: 42374888

[Immunogenicity and safety of Papilloguard 4, the first quadrivalent HPV **vaccine** combined with adjuvant system 04, versus Gardasil in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.](#)

Mardani M, Darazam IA, Moini A, Ebrahimi A, Mirhassani R, Barati S, Shahpari R, Modiri G, Fallah N, Albooyeh S, Neyshaburinezhad N, Karimi-Zarchi M, Kashanian M, Sabzvari A, Kafi H. *Vaccine*. 2026 Aug 13;88:128886. doi: 10.1016/j.vaccine.2026.128886. Epub 2026 Jul 8. PMID: 42424856

[\[Emergence of revertant strains from the novel oral polio **vaccine**: what next?\].](#)

Bessaud M, Balière C, Doté J, Gouandjika-Vasilache I. *Virologie (Montrouge)*. 2026 Aug 1;30(4):251-255. doi: 10.1684/vir.2026.1147. PMID: 42565537 French.

[Does the Emergency Department Have a Role in Immunisation? Yes-But Not as a Routine **Vaccine** Clinic.](#)

Ricks TA, Bouchoucha SL. *Emerg Med Australas*. 2026 Aug;38(4):e70312. doi: 10.1111/1742-6723.70312. PMID: 42522206

[Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations.](#)

Lyth J, Spreco A, Hinkula J, Björnell O, Eriksson O, Nordvall D, Dahlström Ö, Gursky EA, Schön T, Timpka T. *Nat Commun.* 2026 Aug 8;17(1):8014. doi: 10.1038/s41467-026-76312-x.PMID: 42570961

[Cross-sectional analysis of chikungunya **vaccine** acceptability among residents of Ponce, Puerto Rico, 2024-2025.](#)

Guagliardo SAJ, Major CG, Rodriguez DM, Rivera-Amill V, Staples JE, Adams LE, Hills SL. *Vaccine.* 2026 Aug 13;88:128845. doi: 10.1016/j.vaccine.2026.128845. Epub 2026 Jun 19.PMID: 42320381

[Characteristics of successful and unsuccessful strategies to increase **vaccine** intention and improve **vaccine** uptake for U.S. adult populations in the Affordable Care Act era \(2010-2025\): a systematic review and meta-regression.](#)

Hensley AA, Jiles KA, Edwards S, Clinchard C, Hosig K. *Vaccine.* 2026 Aug 13;88:128910. doi: 10.1016/j.vaccine.2026.128910. Epub 2026 Jul 10.PMID: 42430872

[Efficacy and Safety of an mRNA Seasonal Influenza **Vaccine** in Adults. Reply.](#)

Huang G, Das R, Wilson E. *N Engl J Med.* 2026 Aug 13;395(7):725-726. doi: 10.1056/NEJMc2607826.PMID: 42585657

[Response Letter to the Editor Regarding "Adult RSV Vaccination: What Is the Role of RSV Subgroup in Disease Prevention?".](#)

Williams SE, Lisi GC, Luisi K, Ilangoan K, Hall-Murray C, Hayford K, Begier E. *Infect Dis Ther.* 2026 Aug 12. doi: 10.1007/s40121-026-01417-1. Online ahead of print.PMID: 42587243

[Irradiated Liver Cancer Cell **Vaccine** Transfected With GM-CSF Induces Specific and Long-Lasting Anti-tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM-CSF.](#)

Song Z, Jiang Y, Zhang Y, Ao D, Ye C, Huang X, Zhou Y, Yang H, Xia R, Ai J, Wan D, Tong A, Wei Y, He X, Alu A, Wei X. *Cell Prolif.* 2026 Aug;59(8):e70198. doi: 10.1111/cpr.70198. Epub 2026 Apr 8.PMID: 41947668

[Vaccinia virus and Monkeypox virus neutralizing and antigen-binding antibodies following subcutaneous and reduced intradermal doses of an MVA **vaccine**.](#)

Moss B, Cotter CA, Americo JL, Ignacio MA, Bassler JE, Frey SE, Beigel JH. *Vaccine.* 2026 Aug 13;88:128920. doi: 10.1016/j.vaccine.2026.128920. Epub 2026 Jul 11.PMID: 42435620

[HPV **vaccine**: Influencing peer recommendations through information provision at no-cost **vaccine** clinics.](#)

Ky SL, Coblenz EG, Swanson E, Shah R, Fritsch A, Rudd TM, Malcolm SD, Kasting ML. *Vaccine.* 2026 Aug 13;88:128807. doi: 10.1016/j.vaccine.2026.128807. Epub 2026 Jun 12.PMID: 42284811

[Clinical Effectiveness of the Recombinant Zoster **Vaccine** for Preventing Herpes Zoster in Individuals With Kidney Transplants: A Retrospective Cohort Study.](#)

Kwon K, Lim SY, Chang E, Bae S, Kwon H, Jung J, Kim MJ, Shin S, Chong YP, Kim YH, Choi SH, Lee SO, Kim SH. *Transpl Infect Dis*. 2026 Aug 12:e70300. doi: 10.1111/tid.70300. Online ahead of print. PMID: 42583900

[Protection against HPAI-H5N8 early challenge in commercial broilers with maternal immunity: prime-boost vs. single vaccination of a trivalent H5-inactivated **vaccine**.](#)

Elfeil WMK, Safwat M, Abaza MA, Elbestawy AR, Arafa E, Afify M, Elkady MF, Kilany WH. *Avian Pathol*. 2026 Aug;55(4):450-457. doi: 10.1080/03079457.2025.2603919. Epub 2026 Mar 10. PMID: 41392899

[Herpes Zoster vaccination coverage and its determinants in older adults: A Meta-analysis.](#)

Guillermou H, De Choudens C, Bourgeois A, Launay O, Diallo A, Galtier F. *Clin Microbiol Infect*. 2026 Aug 13:S1198-743X(26)00454-4. doi: 10.1016/j.cmi.2026.08.008. Online ahead of print. PMID: 42595092 Review.

[Fatty acid-binding protein is essential for molting and male mating in *Dermanyssus gallinae* and confers protection as a **vaccine** antigen.](#)

Liu B, Liu Y, Wang B, Deng Y, Liu Q, Sun W, Pan B. *Pest Manag Sci*. 2026 Aug;82(8):7758-7767. doi: 10.1002/ps.70838. Epub 2026 Apr 21. PMID: 42014963

[The role of interferon-gamma release assays in tuberculosis **vaccine** trials: strengths, limitations, and implications beyond trial design.](#)

Dagnew AF, Schmidt AC, Cinar A, Garcia-Basteiro AL, Noble R, Pelzer PT, Churchyard GJ, Hatherill M, White RG, Cobelens F. *Vaccine*. 2026 Aug 13;88:128822. doi: 10.1016/j.vaccine.2026.128822. Epub 2026 Jun 10. PMID: 42269281

[Characterization of **vaccine** viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue **vaccine** clinical development program.](#)

Tricou V, Saez-Llorens X, Kosalaraksa P, Reynales H, Sirivichayakul C, Borja-Tabora C, Low JG, Messer WB, Moss KJ, Mandaric S, Roubinis N, Sharma M, Livengood J, Pang H, Rauscher M, Biswal S. *Vaccine*. 2026 Aug 13;88:128917. doi: 10.1016/j.vaccine.2026.128917. Epub 2026 Jul 24. PMID: 42497670

[A salivary histamine-binding protein from *Rhipicephalus microplus* and its evaluation as an anti-tick **vaccine** antigen.](#)

Paes JA, Win SY, Gandini AM, Nogueira CL, Okagawa T, Parizi LF, Driemeier D, Konnai S, da Silva Vaz I Jr. *Vet Parasitol*. 2026 Aug;346:110808. doi: 10.1016/j.vetpar.2026.110808. Epub 2026 May 23. PMID: 42184500

[Reactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients.](#)

Hannaford A, Chamberlin E, Swank Z, van Haren SD, Han S, Thomas S, Ryff K, Connolly EM, Woehl EN, Regan DJ, Valentine GC, Morreale N, Li X, Eustace A, Tong A, Lan Z, Walt DR, Levy O, Issa NC, Sharma NS, Mehra MR, Givertz MM, Tullius SG, Azzi JR, Coppolino A, Baden LR, Sherman AC, Woolley AE. *Transplant Direct*. 2026 Jul 20;12(8):e1977. doi: 10.1097/TXD.0000000000001977. eCollection 2026 Aug. PMID: 42482841

[Rotavirus **vaccine** coverage and urban-rural equity in India: Evidence from the sixth National Family Health Survey \(NFHS-6\).](#)

Chowdhury M. *Vaccine*. 2026 Aug 12;90:129031. doi: 10.1016/j.vaccine.2026.129031. Online ahead of print. PMID: 42585807

[Structure-guided design of a PCSK9 epitope **vaccine** with efficacy against hyperlipidemia and atherosclerosis.](#)

Sun H, Li Z, Hu X, Zhang X, Ma K, Zhang J, Liu C, Xiao R. *Life Metab*. 2026 May 26;5(4):loag013. doi: 10.1093/lifemeta/loag013. eCollection 2026 Aug. PMID: 42395836

[Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026.](#)

McConeghy KW, Wilker EH, DeVone F, Skov B, Sun T, Patry E, Newbern EC, Araujo AB, Ghaswalla P, Clarke C, Tufts JR, Abul Y, Gravenstein S. *Vaccine*. 2026 Aug 13;88:128882. doi: 10.1016/j.vaccine.2026.128882. Epub 2026 Jul 9. PMID: 42424857

[Differential immune responses to SFTSV Gn and Gc mRNA vaccines in mice and dogs.](#)

Jiang Z, Tian L, Zhao Z, Wu X, Liu L, Li M, Qian H, Gao C, Lei X, Zheng W, Yu X, Zheng X. *Microbiol Spectr*. 2026 Aug 4;14(8):e0360325. doi: 10.1128/spectrum.03603-25. Epub 2026 Jul 13. PMID: 42439549

["Fridge-free" **vaccine** for tetanus-diphtheria shows promise in first human trial.](#)

Wise J. *BMJ*. 2026 Aug 6;394:e100517. doi: 10.1136/bmj-2026-100517. PMID: 42562412

[Efficient Sensing of a 4-Segmented Rift Valley Fever Virus **Vaccine** Candidate by Human Monocytes.](#)

Nair N, Friese J, Wichgers Schreur PJ, Osterhaus ADME, Rimmelzwaan GF, Prajeeth CK. *J Infect Dis*. 2026 Aug 3;234(1):e3-e8. doi: 10.1093/infdis/jiag085. PMID: 41679332

[Antigen avidity potentiates the durability of the **vaccine** immune response.](#)

Weidner NG, Padilla MV, Pruitt L, Cottrell CA, Gonzales K, Kalyuzhnyi O, Lu D, Alavi N, Phelps N, Aniqua M, Waldrep KM, Keller EJ, Weglarz M, Schief WR, Abbott RK. *Sci Transl Med*. 2026 Aug 12;18(862):eae5273. doi: 10.1126/scitranslmed.aee5273. Epub 2026 Aug 12. PMID: 42585296

[New **vaccine** strategies targeting cellular and trained immunity against intracellular bacteria in fish.](#)

Valdebenito EA, Bueno SM, González PA, Kalergis AM. *Fish Shellfish Immunol*. 2026 Aug 10;178:111642. doi: 10.1016/j.fsi.2026.111642. Online ahead of print. PMID: 42575390

[Longitudinal and spatial declines in equine Hendra virus vaccination despite continued risk.](#)

Linnegar B, McCallum H, Peel AJ. *Vaccine*. 2026 Aug 13;88:128937. doi: 10.1016/j.vaccine.2026.128937. Epub 2026 Jul 22. PMID: 42492241

[A Multidesign Study of 4CMenB **Vaccine** Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People.](#)

McMillan M, Wang B, Krause V, Greenwood-Smith B, Webby R, Chen J, Baird R, Gerrell J, Prince K, Whop L, Giles L, Bednarz J, Kaldor J, D'Antoine H, Binks M, Andrews R, Richmond P, Macartney K, Whiley D, Lawrence A, Petousis-Harris H, Ward J, Marshall H. *Open Forum Infect Dis.* 2026 Aug 4;13(8):ofag409. doi: 10.1093/ofid/ofag409. eCollection 2026 Aug. PMID: 42553573

[Construction of a chimeric multi-antigen fusion vaccine, EimeriaBig, and evaluation of immune response and protective effect in Eimeria necatrix.](#)

Chen X, Cai H, Liao S, Qi N, Li J, Lv M, Lin X, Song Y, Zhu Y, Zhang J, Zhang X, Sun M. *Poult Sci.* 2026 Aug;105(8):107104. doi: 10.1016/j.psj.2026.107104. Epub 2026 May 9. PMID: 42214189

[The Role of Medical Mistrust in Vaccination Decisions in Rural, Indigenous Namibian Communities.](#)

Prall S, Scelza B, Davis HE. *J Racial Ethn Health Disparities.* 2026 Aug;13(4):2610-2621. doi: 10.1007/s40615-025-02442-5. Epub 2025 Apr 21. PMID: 40259187

[A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes.](#)

Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Giné-Vázquez I, Mallah N, Mirás-Carballal S, Piñeiro-Sotelo M, Cribeiro González M, Conde Pájaro M, González-Pérez JM, Rivero-Calle I, Bello X, Razzini JL, Salas A, Harris RC, Loiacono MM, van Aalst R, Farre M, Dufournet M, Dyrby Johansen N, Modin D, Biering-Sørensen T, Duran-Parrondo C, Martínón-Torres F. *Clin Infect Dis.* 2026 Aug 3:ciag466. doi: 10.1093/cid/ciag466. Online ahead of print. PMID: 42546169

[2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.](#)

Ahi T, Andersen KM, Mateus JS, Yu T, Zhou A, Nepal RM, Lopez SMC, Puzniak L. *Vaccine.* 2026 Aug 13;90:129009. doi: 10.1016/j.vaccine.2026.129009. Online ahead of print. PMID: 42594639

[Progress in Protein Nanoparticle Vaccines for Human Viral Diseases.](#)

He Y, Wang J, Li J, Shen D, Mao J, Zhang Y, Cao S, Deng Y, Gao X. *ACS Omega.* 2026 Jul 31;11(31):45595-45611. doi: 10.1021/acsomega.6c03523. eCollection 2026 Aug 11. PMID: 42598283

[Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.](#)

Wong JM, Acevedo PK, Whitehead S, Durbin A, DeSale H, Jones FK, Medina FA, Rovira-Diaz E, Prutzman K, Leao IC, Wang T, Desilva A, Harris E, Katzelnick L, Salje H, Weiskopf D, Adams LE, Paz-Bailey G. *Vaccine.* 2026 Aug 13;88:128599. doi: 10.1016/j.vaccine.2026.128599. Epub 2026 Jul 22. PMID: 42486049

[A systematic review of knowledge, attitudes, and behaviour towards Japanese encephalitis vaccination.](#)

Nepali R, King C, Leask J, Campbell E, Webb CE, Sabahelzain MM, Tinessia A, Brookes VJ, Wiley K. *Vaccine.* 2026 Aug 5;89:128999. doi: 10.1016/j.vaccine.2026.128999. Online ahead of print. PMID: 42556299

[First volunteer gets Ebola vaccine - three months after the outbreak began.](#)

Shenai D. *Nature*. 2026 Aug;656(8126):14-15. doi: 10.1038/d41586-026-02278-x. PMID: 42521726

[Factors Impacting Intention of Dental Hygienists to Administer Vaccines in Dental Settings.](#)

Chokey T, Boyd LD, Oh UY, Vineyard J. *Int J Dent Hyg*. 2026 Aug;24(3):411-428. doi: 10.1111/idh.70044. Epub 2026 Mar 16. PMID: 41839823

[Ginsenoside Rb2-based inactivation enables a Zika **vaccine** that maintains pregnancy and protects offspring against virus.](#)

Chen H, Wu T, Chen L, Miao Y, Yi W, Ding Q, Guan Z, Chen D, Xu W, Zhang N, Huang R, Zheng Z. *Antiviral Res*. 2026 Aug;252:106472. doi: 10.1016/j.antiviral.2026.106472. Epub 2026 Jun 25. PMID: 42349753

[Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysis.](#)

Du D, Zeng T, Qin J, Gao L, Xiong J, Luo F, Shen Y. *Rheumatology (Oxford)*. 2026 Aug 1;65(8):keag352. doi: 10.1093/rheumatology/keag352. PMID: 42397204

[A regional coalition for Lassa fever **vaccine** development and preparedness in West Africa: A practice-based perspective.](#)

Usman AB, Oyeibanji O, Lokossou VK, Ramsauer K, Aissi MA. *Int J Infect Dis*. 2026 Aug;169:108810. doi: 10.1016/j.ijid.2026.108810. Epub 2026 May 20. PMID: 42167538

[Decoding yellow fever virus immunogenicity: Targeting highly effective epitopes of YFV for next-generation **vaccine** design.](#)

Aquino VH, Gomez ML. *Vaccine*. 2026 Aug 13;88:128779. doi: 10.1016/j.vaccine.2026.128779. Epub 2026 Jun 6. PMID: 42250476

[Comment on "Effect of pneumococcal conjugate **vaccine** booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018".](#)

Tyagi B, Toppo L, Biradar A. *Vaccine*. 2026 Aug 13;88:128925. doi: 10.1016/j.vaccine.2026.128925. Epub 2026 Jul 13. PMID: 42442047

[The ethics and moral psychology of HPV vaccination: Evidence from a cross-cultural study.](#)

Petino Zappala MA, Quint A, Nguyen TNP, Schulz JV, Doerflinger JT, Heinzelmann NC. *Soc Sci Med*. 2026 Aug;403:119374. doi: 10.1016/j.socscimed.2026.119374. Epub 2026 May 8. PMID: 42134287

[Letters and lymph: Jean de Carro and the transnational circulation of Jennerian vaccination, 1799-1810.](#)

Tuells J. *Vaccine*. 2026 Aug 14;90:129050. doi: 10.1016/j.vaccine.2026.129050. Online ahead of print. PMID: 42600246

[HIV virion capturing liposomes for therapeutic vaccination.](#)

Kang TK, Ang CG, Canziani G, Elkateb H, Thomas D, Yang D, Smith Iii AB, Haddad EK, Chaiken I, Deak P. *Biomaterials*. 2026 Aug;331:124124. doi: 10.1016/j.biomaterials.2026.124124. Epub 2026 Mar 7. PMID: 41830767

[Identification of Clinical Factors Associated With the Immunogenicity of Homologous ChAdOx1-nCoV-19 Vaccine in Hemodialysis Patients.](#)

Chang CW, Wu PH, Chang LY, Huang YY, Huang TH, Lee SC, Chiu YW, Hwang SJ, Kuo TY, Kuo MC. Kaohsiung J Med Sci. 2026 Aug;42(8):e70173. doi: 10.1002/kjm2.70173. Epub 2026 Jan 19. PMID: 41552967

[More than 10 years of Australia's AusVaxSafety \(2014-2026\): an adaptable model of a participant-powered active vaccine safety surveillance system.](#)

Pillsbury A, Nguyen T, Dawes L, Young J, Carter N, Tapper K, Dymock M, Snelling T, Marsh J, Cashman P, Leeb A, Wood N, Durrheim DN, Macartney K, Deng L. Vaccine. 2026 Aug 13;88:128928. doi: 10.1016/j.vaccine.2026.128928. Epub 2026 Jul 29. PMID: 42526174

[Knowledge and Awareness of HPV, Its Link to Oral and Oropharyngeal Cancer and Vaccine Acceptance Among Dental Students, Professionals and Patients in Western Tamil Nadu: A Cross-sectional Questionnaire Study.](#)

Sri K, SaiNithes KS, Pavithran A. J Maxillofac Oral Surg. 2026 Aug;25(4):964-975. doi: 10.1007/s12663-026-02984-z. Epub 2026 Mar 14. PMID: 42528923

[Universal off-the-shelf TGF-beta1-knockout whole-tumor cell vaccine overcomes immunotherapy resistance in pMMR/MSS tumors.](#)

Yang W, Dong Z, Xiong Q, Ren Y, Zhang L, Liu Y, Han J, Tian T, Su X, Shi G, Deng H. Acta Pharm Sin B. 2026 Aug;16(8):5405-5423. doi: 10.1016/j.apsb.2026.06.001. Epub 2026 Jun 8. PMID: 42592303

[Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.](#)

Gebremariam AG, Genie M, Le H, Regan A, Beard F, Macartney K, Paolucci F, Moore H, Attwell K, Blyth CC. Vaccine. 2026 Aug 13;88:128825. doi: 10.1016/j.vaccine.2026.128825. Epub 2026 Jun 13. PMID: 42284807

[Convalescent plasma in the pre-vaccine era-Lessons from PC-COVID and COV-PLAS.](#)

Díaz FJ, Atiénzar PJE, Cuello IG, Sánchez ED. Enferm Infecc Microbiol Clin (Engl Ed). 2026 Aug 13:503261. doi: 10.1016/j.eimce.2026.503261. Online ahead of print. PMID: 42595665

["You're Not Dealing with What We're Dealing with": COVID-19 Hesitancies and Motivations Among Late Vaccinating Black Americans in the Deep South.](#)

Stone AJ Jr, Arriaza M, Brindley C, Meador E, James WL, Matthews K. J Racial Ethn Health Disparities. 2026 Aug;13(4):3050-3060. doi: 10.1007/s40615-025-02479-6. Epub 2025 May 29. PMID: 40439852

[Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP T vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy.](#)

De Weerd L, Boissard F, Maertens K. *Vaccine*. 2026 Aug 13;88:128915. doi: 10.1016/j.vaccine.2026.128915. Epub 2026 Jul 10. PMID: 42430876

[Immunogenicity and efficacy of an Australian whole-cell killed *Tritrichomonas foetus* vaccine in experimentally challenged young bulls.](#)

Santos JHM, McCosker KD, McGowan MR, Siddle HV, Raza A, Boe-Hansen GB, Tabor AE. *Vet J*. 2026 Aug;318:106770. doi: 10.1016/j.tvjl.2026.106770. Epub 2026 Jul 7. PMID: 42413859

[RpoE-Mediated Virulence Attenuation Elicits Protective Immunity in Hypervirulent *Klebsiella pneumoniae*.](#)

Zhai Y, Jin Q, Shi J, Zhang X, Qian Y, Wen Y, Zhu J, Zhu Z, Wang L, Gao Q, Wang T, Li W, Zhang H, Chen L, Du H. *Emerg Microbes Infect*. 2026 Aug 7:2716501. doi: 10.1080/22221751.2026.2716501. Online ahead of print. PMID: 42565535

[Primary Cutaneous Anaplastic Large Cell Lymphoma at the COVID-19 Vaccine Site Following the Seventh Dose: A Case Report.](#)

Kotake K, Ohshima Y, Watanabe D, Takami A, Adachi S. *J Cutan Pathol*. 2026 Aug;53(8):661-663. doi: 10.1111/cup.70056. Epub 2026 Jan 8. PMID: 41506792

[Perceptions of acceptability and preferences surrounding a hypothetical syphilis vaccine in Lima, Peru.](#)

Fulqui V, Hamasaki W, Perez J, Orta Portillo GA, Klausner JD, Konda KA. *Int J STD AIDS*. 2026 Aug;37(9):1026-1034. doi: 10.1177/09564624261459952. Epub 2026 Jun 12. PMID: 42284552

[Author Correction: Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.](#)

He L, Lee YZ, Zhang YN, Newby ML, Janus BM, Gonzalez FG, Ward G, DesRoberts C, Hung SH, Giang E, Allen JD, Kulakova L, Toth EA, Fuerst TR, Law M, Ofek G, Crispin M, Zhu J. *Nat Commun*. 2026 Aug 13;17(1):8335. doi: 10.1038/s41467-026-76171-6. PMID: 42595753

[Pregnant women's needs regarding the Tdap vaccine: Insights from Reddit discussions.](#)

Jo S, Ringenberg TR, Hurley JW. *PLOS Glob Public Health*. 2026 Aug 12;6(8):e0006924. doi: 10.1371/journal.pgph.0006924. eCollection 2026. PMID: 42585153

[Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022-2023 and 2023-2024 seasons.](#)

Imran M, Chastek B, Bancroft T, Webb N, Pelton SI, Haag MDM, McGovern I. *Int J Infect Dis*. 2026 Aug 3:109025. doi: 10.1016/j.ijid.2026.109025. Online ahead of print. PMID: 42546898

[Vaccine hesitancy against HPV: adolescents' perspectives.](#)

Souza LRJ, Mazzetto GL, Forlani CG, Silva CI, Ballesterio JGA, Carlos DM. *Rev Gaucha Enferm*. 2026 Aug 10;47:e20250367. doi: 10.1590/1983-1447.2026.20250367.en. eCollection 2026. PMID: 42585391

[Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands.](#)

Huiberts AJ, Eggink D, de Gier B, Karens T, de Melker HE, Hahné SJM, Grobbee DE, van de Wijgert JHHM, van den Hof S, Knol MJ. *Vaccine*. 2026 Aug 12;90:129030. doi: 10.1016/j.vaccine.2026.129030. Online ahead of print. PMID: 42585808

[Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus **vaccine** in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.](#)

Hisamoto K, Yamanaka M, Nomura M, Kanno N, Giuliano AR, Wan K, Fukao Y, Oshima N, Wakana A, Tanaka Y, Luxembourg A, Sawata M. *Lancet Infect Dis*. 2026 Aug 3:S1473-3099(26)00291-4. doi: 10.1016/S1473-3099(26)00291-4. Online ahead of print. PMID: 42546724

[Conference report: airway mucosal sampling and immune analysis.](#)

Rosenheim J, Bender B, Gilmour J, Jambo K, Jensen JUS, King D, Kløverpris H, Taylor S, Boaz M, Chiu C, Crotty S, Dahlke C, Dheda K, Fortune S, Higham SL, Holm M, Jochems SP, Krammer F, Lindestam Arlehamn CS, Mankouri HW, Marquart HV, McShane H, Mortensen R, Nemes E, Ordovas-Montanes J, Roberts PC, Ruhwald M, Schully KL, Thålin C, Thwaites RS, Wang TY, Juel HB. *Vaccine*. 2026 Aug 13;88:128944. doi: 10.1016/j.vaccine.2026.128944. Epub 2026 Jul 17. PMID: 42468226

[Development and protection evaluation of a nanoparticle **vaccine** against transferrin-binding protein TbpB\(Y167A\) of *Glaesserella parasuis*.](#)

Chao L, Zhang B, Cai Y, Zhu C, Li Y. *Vet Microbiol*. 2026 Aug 6;321:111172. doi: 10.1016/j.vetmic.2026.111172. Online ahead of print. PMID: 42567121

[What Is Old Is New Again: Tips and Tricks for Recognizing and Treating **Vaccine**-Preventable Diseases of Childhood Presenting to the Emergency Department.](#)

Seneviratne D, Semakula R. *Emerg Med Australas*. 2026 Aug;38(4):e70313. doi: 10.1111/1742-6723.70313. PMID: 42489016

[Efficacy of a *Leptospira borgpetersenii* serovar Tarassovi **vaccine** against urinary shedding of *L. borgpetersenii* strain Pacifica in naturally exposed cattle.](#)

Little PR, Collins-Emerson JM, Hodge A, Notcovich S, Moutafis G, Littlejohn S, Clough WJ. *N Z Vet J*. 2026 Aug 16:1-12. doi: 10.1080/00480169.2026.2708016. Online ahead of print. PMID: 42604856

[Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome.](#)

Wang E, Chakraborty AK. *PLoS Comput Biol*. 2026 Aug 14;22(8):e1014632. doi: 10.1371/journal.pcbi.1014632. Online ahead of print. PMID: 42599953

[Commentary: The Return of **Vaccine**-Preventable Diseases: Implications for Pediatric Surgical and Perioperative Care.](#)

Pasquariello CA, O'Brien E.J Pediatr Surg. 2026 Aug 14;163386. doi: 10.1016/j.jpedsurg.2026.163386. Online ahead of print.PMID: 42600736

[High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination.](#)

Tut G, Lancaster T, Sylla P, Bone D, Bentley C, Jadir A, Bruton R, Spencer K, Mallick S, Elzaidi A, Dowell A, Wu M, Harvey R, Carr E, Beale R, Krutikov M, Stirrup O, Azmi B, Hayward A, Copas A, Shallcross L, Moss P; Crick COVID Immunity Pipeline.PLoS One. 2026 Aug 14;21(8):e0354079. doi: 10.1371/journal.pone.0354079. eCollection 2026.PMID: 42599929

[Purified gamma-irradiated influenza A **vaccine** demonstrates high immunogenicity and protection against a drifted H1N1 strain.](#)

Couto Moniz M, Luo S, Krokhin A, Egorov A, Davies JB, Saint D, Comerford I, Alsharifi M.Vaccine. 2026 Aug 13;88:128872. doi: 10.1016/j.vaccine.2026.128872. Epub 2026 Jun 22.PMID: 42330776

[Optimising pneumonia **vaccine** programmes: a strategic opportunity for child survival and lifelong lung health.](#)

Greenslade L; Secure PCV and Stop RSV Collaborators.Lancet Glob Health. 2026 Aug 14:104064. doi: 10.1016/j.langlo.2026.104064. Online ahead of print.PMID: 42600626

[Global inequities in representation of low-income and middle-income countries in **vaccine** clinical trials: protocol for a systematic review and meta-epidemiological analysis.](#)

Ramalan M, Yusuf I, Mathew M, Bako I, Imam MU, Musa B.BMJ Open. 2026 Aug 10;16(8):e117946. doi: 10.1136/bmjopen-2026-117946.PMID: 42575549

[Tembusu virus-vectored chimeric **vaccine** induces potent neutralizing antibody response against West Nile virus in ducks.](#)

Li L, Liu X, Yan D, Shuo D, Shi X, Xu B, Pan X, Yan M, Yuan C, Teng Q, van Oers MM, Liu Q, Pijlman GP, Li Z.Vaccine. 2026 Aug 13;88:128933. doi: 10.1016/j.vaccine.2026.128933. Epub 2026 Jul 29.PMID: 42526177

[Parenteral **Vaccine**-Induced Antibody Levels in Children with Heavy Antibiotic Exposure in Dhaka, Bangladesh.](#)

Kohl SB, Dickson DM, Alam M, Colgate ER, Petri WA Jr, Haque R, van der Klis F, Kirkpatrick BD, Lee B.Am J Trop Med Hyg. 2026 Jun 4;115(2):340-347. doi: 10.4269/ajtmh.25-0511. Print 2026 Aug 5.PMID: 42242201

[Efficacy and safety of a non-adjuvanted Bordetella bronchiseptica extract **vaccine** with recombinant pertactin administered subcutaneously to dogs.](#)

Velineni S, Wappel S, Sobell N, King V, Houser C, Hoovers J, Klink H, Tague A, Knupp L, Ehlers JK, Lundy C, Scobey A, Ketteler D, Millership J.Vaccine. 2026 Aug 13;88:128941. doi: 10.1016/j.vaccine.2026.128941. Epub 2026 Jul 17.PMID: 42468227

[Cultural-Social-Economic Background and Community Engagement Impacting COVID-19 Vaccination Uptake Among Pregnant and Lactating Refugee Women.](#)

Patton T, Koskan A, Johnstun L, Nizigiyimana J, Sapkota S, Azugbene E, Williams E, Johnson-Agbakwu C, Liu L.J Immigr Minor Health. 2026 Aug;28(4):881-891. doi: 10.1007/s10903-025-01839-y. Epub 2026 Jan 16.PMID: 41543670

[HPV vaccine uptake among university students, 18-45 years old: Analysis of electronic health records data.](#)

Shimoni N, Btoush R, Corpuz K, O'Dowd ME.J Am Coll Health. 2026 Aug;74(7):1914-1919. doi: 10.1080/07448481.2026.2647036. Epub 2026 Apr 1.PMID: 41920713

[Political ideology, science literacy and future-oriented vaccine optimism in the European Union: a cross-national eurobarometer analysis.](#)

Wróblewski M, Mendes PT.Vaccine. 2026 Aug 13;88:128926. doi: 10.1016/j.vaccine.2026.128926. Epub 2026 Jul 13.PMID: 42442046

[A Robust Defense Against IPNV and VHSV by Designing Revolutionary Multi-Epitope Vaccine Utilizing Immunoinformatics Approaches.](#)

Khatrawi EM, Ali SY, Luqman Ali S, Althagafi H.Viral Immunol. 2026 Aug;39(6):205-222. doi: 10.1177/08828245261449701. Epub 2026 May 11.PMID: 42112768

[Corrigendum to "Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries" \[Vaccine 37 \(2019\) 5073-5088\].](#)

Bogler L, Jantos N, Bärnighausen T, Vollmer S.Vaccine. 2026 Aug 13;88:128813. doi: 10.1016/j.vaccine.2026.128813. Epub 2026 Jun 12.PMID: 42284806

[Perspectives on COVID-19 vaccine decision-making in women of reproductive age: A social approach.](#)

Hornbach A, Tessier KM, Westberg S, Larsen K.Patient Educ Couns. 2026 Aug;149:109635. doi: 10.1016/j.pec.2026.109635. Epub 2026 Apr 7.PMID: 41997091

[Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.](#)

Ostergaard L, Czajka H, Roque-Guerrero L, Maguire JD, Pregaldien JL, Zolotas L, Moughan B, Maansson R, O'Neil R, Balmer P, Jodar L, Gruber WC, Anderson AS, Scott DA, Beeslaar J.Lancet Child Adolesc Health. 2026 Aug;10(8):584-596. doi: 10.1016/S2352-4642(26)00095-7. Epub 2026 Jun 18.PMID: 42314722

[A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.](#)

Liu S, Zhu Y, Chen T, Liu X, Lai J, Hu M, Liu Y, Rao H, Zhang B, Xiao S, Peng H, Liang T, Xie L, Qiu G, Li S, Ma X.Mater Today Bio. 2026 Aug 3;40:103524. doi: 10.1016/j.mtbio.2026.103524. eCollection 2026 Oct.PMID: 42602399

[Spatiotemporal atlas of pro-inflammatory NF-κB and anti-inflammatory STAT6 signaling using reporter mice during mRNA vaccination.](#)

Brunialti E, Panzeri A, Rizzi N, Villa A, Meda C, Sfogliarini C, Persano S, Arlati F, Guevara Lopez ML, Martelli C, Cannavale G, Rebecchi M, Di Vito C, Venturini L, Ottobrini L, Mavilio D, Fagerholm S, Minucci S, Vegeto E, Ciana P. *Mol Ther*. 2026 Aug 5;34(8):4998-5014. doi: 10.1016/j.ymthe.2026.05.028. Epub 2026 Jun 2. PMID: 42231579

[Antibody kinetics against tetanus toxoid before and after primary vaccination of foals.](#)

Olbrich K, Venner M, Wagner B. *Equine Vet J*. 2026 Aug 9. doi: 10.1002/evj.70303. Online ahead of print. PMID: 42572177

[What to Know About the mRNA Flu **Vaccine**, Newly Approved by the FDA.](#)

Rubin R. *JAMA*. 2026 Aug 14. doi: 10.1001/jama.2026.17069. Online ahead of print. PMID: 42599792

[Design and techno-economic assessment of an industrial-scale polyvalent clostridial **vaccine** production process.](#)

Esmailnejad-Ahranjani P. *Toxicon*. 2026 Aug 1;278:109070. doi: 10.1016/j.toxicon.2026.109070. Epub 2026 Mar 13. PMID: 41833737

[Developing an Antenatal Intervention to Improve **Vaccine** Uptake Using Parent, Patient and Public Involvement and Engagement in Northern Ireland.](#)

McCarron SA, Patterson L, Hart N. *Health Expect*. 2026 Aug;29(4):e70795. doi: 10.1111/hex.70795. PMID: 42550057

[Checkpoint Blockade and Acquired Humoral Immune Dysregulation: Emerging Evidence for Antibody Deficiency During Long-Term PD-1/PD-L1 Inhibition.](#)

Shivarov V. *Cancers (Basel)*. 2026 Aug 1;18(15):2472. doi: 10.3390/cancers18152472. PMID: 42588689

[Application of an extended information-motivation-behavioral skills model to predict HPV **vaccine** acceptability among Chinese gay, bisexual, and other men who have sex with men.](#)

Liu Q, Wong LP, Lim SH. *Hum Vaccin Immunother*. 2026 Dec;22(1):2708426. doi: 10.1080/21645515.2026.2708426. Epub 2026 Aug 4. PMID: 42550689

[Immunogenicity and safety of serum-free rabies **vaccine** for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.](#)

Jing Y, Chang X, Jin Z, Yang F, Cai Y, Chen K, Liu S, Huang L, Li J. *Vaccine*. 2026 Aug 13;88:128914. doi: 10.1016/j.vaccine.2026.128914. Epub 2026 Jul 15. PMID: 42456561

[Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?](#)

Jamwal S, Omene B, Giri A, Rojas K, Mohanty S, Calhoun C, Krishnamurti L, Montgomery RR, Shaw AC, Andemariam B, Yildirim I. *Vaccine*. 2026 Aug 13;88:128866. doi: 10.1016/j.vaccine.2026.128866. Epub 2026 Jun 20. PMID: 42322679

[Immunoinformatics-driven multi-epitope **vaccine** design as a promising strategy against multidrug-resistant pathogens: a comprehensive review.](#)

Nasir R, Javaid MM, Rahman R, Abbasi R, Khalid M, Arslan M, Sajjad MA, Ibrahim A. *Folia Microbiol (Praha)*. 2026 Aug 1. doi: 10.1007/s12223-026-01565-4. Online ahead of print. PMID: 42541679

[Immunocastration with recombinant GnRH6-CRM197 fusion protein improves reproductive suppression and meat tenderness in roosters.](#)

Li M, Han K, Fu D, Zhang R, Jiang X, Lu J, Yan Y, Li J, Liu Y, Li Y, Yu T, Duan H, Fang F. *Poult Sci*. 2026 Aug;105(8):107046. doi: 10.1016/j.psj.2026.107046. Epub 2026 May 1. PMID: 42096907

[Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025.](#)

Payne AB, Battan-Wraith S, Reese SE, Hathaway CA, Tartof SY, Natarajan K, Irving SA, Grannis S, Chickery S, Vazquez-Benitez G, Dascomb K, Salas SB, Bezi C, Sy LS, Lewin B, Stockwell MS, Stephens AB, Han J, Naleway AL, Dixon BE, Rogerson C, Duszynski T, Fadel WF, Ball SW, Cao J, McEvoy C, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Godfrey M, Kautz A, Ciesla AA, Najdowski M, Mak J, DeCuir J, Wiegand RE, Link-Gelles R. *Pediatrics*. 2026 Aug 4:e2026076089. doi: 10.1542/peds.2026-076089. Online ahead of print. PMID: 42547085

[Vaccination in pediatric transplantation-General recommendations. A position paper by the European Reference Network TransplantChild.](#)

Casotti V, Saglio F, Balduzzi A, Barany P, Christensen VB, Buelli S, Donà D, Klaudel-Dreszler M, Mosca S, Pietrobbattista A, Pinon M, Ranucci G, Wennberg L, D'Antiga L; ERN TransplantChild Working Group. *J Pediatr Gastroenterol Nutr*. 2026 Aug 7. doi: 10.1002/jpn3.70523. Online ahead of print. PMID: 42563542

[Past achievements and future perspectives of personalized vaccines and the role of dendritic cells.](#)

Sadat Larijani M, Bavand A, Moradi L, Ramezani A. *Immunol Res*. 2026 Aug 1;74(1):77. doi: 10.1007/s12026-026-09812-z. PMID: 42541646

[Sociodemographic and parental health factors associated with initiation of human papillomavirus vaccination among boys in a national free-of-charge program in Denmark.](#)

Kjær AK, Kjær SK, Hertzum-Larsen R, Hansen T, Baandrup L. *Prev Med*. 2026 Aug;209:108612. doi: 10.1016/j.ypmed.2026.108612. Epub 2026 May 27. PMID: 42208672

[Evaluation of the immunological efficacy of EsxA subunit **vaccine** and DNA **vaccine** against *Streptococcus iniae* in golden pompano \(*Trachinotus anak*\).](#)

Huang Z, Sun H, Wang H, Jia X, Li H, Rejoice Abba D, Li W, Wang L, Lu Y, Huang Y. *Fish Shellfish Immunol*. 2026 Aug;175:111446. doi: 10.1016/j.fsi.2026.111446. Epub 2026 May 22. PMID: 42176785

[Leish-F1 Multi-epitope Lentiviral **Vaccine** as a Novel Candidate Against *Leishmania major* in Balb/c Mice.](#)

Daneshi R, Rabienia M, Roudbari Z, Ghasemian A, Moulazadeh A, Mortazavidehkordi N, Farjadfar A. *Biochem Genet*. 2026 Aug;64(4):6110-6124. doi: 10.1007/s10528-026-11336-y. Epub 2026 Feb 18. PMID: 41706369

[Impact of Removing the Universal Hepatitis B Birth-Dose Vaccination in the US.](#)

Lind ML, Hitchings MDT, Singh RP, Linas BP, Cummings DAT, Epstein RL. JAMA Pediatr. 2026 Aug 1;180(8):891-899. doi: 10.1001/jamapediatrics.2026.1226. PMID: 42043807

[Cost-effectiveness analysis of a hypothetical **vaccine** for schistosomiasis in Madagascar and Burkina Faso.](#)

Hwang Y, Cakpo GE, Rakotozandrindrainy N, Nana LRW, Razafimanantsoa R, Derandrainy L, Nyirenda G, Soura AB, Rakotozandrindrainy R, Marks F, Lee JS. Vaccine. 2026 Aug 13;88:128936. doi: 10.1016/j.vaccine.2026.128936. Epub 2026 Jul 14. PMID: 42447735

[Cross-serotype immunity elicited by a consensus dengue NS1 mRNA **vaccine** in mice.](#)

Tharakhet K, Prompetchara E, Khawsang C, Saithong S, Kaewpang P, Yostrerat N, Wangsoontorn P, Sontikun J, Tantratorn S, Khotprathum T, Lam K, Heyes J, Weissman D, Ruxrungtham K, Ketloy C. PLoS One. 2026 Aug 6;21(8):e0355389. doi: 10.1371/journal.pone.0355389. eCollection 2026. PMID: 42561029

[Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" \[**Vaccine** 82 \(2026\) 128588\].](#)

Zhang L, Lin T, Wang M, Ma X, Dong H, Song J, Li Y. Vaccine. 2026 Aug 13;88:128885. doi: 10.1016/j.vaccine.2026.128885. Epub 2026 Jul 6. PMID: 42409714

[Corrigendum to "Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy: A targeted literature review" \[**Vaccine** 79 \(2026\) 128408\].](#)

Lutz CS, Cox SN, Courtney LP, Paulenich A, Vichnin M, Deese J, Jodar L, Gessner BD, Atwell JE. Vaccine. 2026 Aug 13;88:128812. doi: 10.1016/j.vaccine.2026.128812. Epub 2026 Jun 13. PMID: 42287824

[Durability of Respiratory Syncytial Virus Antibodies After Vaccination in Immunosuppressed Persons.](#)

Nauroz Z, Balasubramanian P, Rodrigues M, Arondekar S, Sengsouk I, Hage C, Chahoud M, Green X, Gallo W, Eby Y, Tobian AAR, Werbel WA, Karaba AH. Open Forum Infect Dis. 2026 Jul 23;13(8):ofag453. doi: 10.1093/ofid/ofag453. eCollection 2026 Aug. PMID: 42597566

[Safety and immunogenicity of a single-dose adenovirus-vectored rabies **vaccine** over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.](#)

Ritchie AJ, Hassan O, Urasa N, Apanga PA, Kimathi R, Kalinga WF, Mtaka IM, Lyimo RG, Shabani MM, Orliacq F, Berg A, Xiang Z, Ahmed S, Athuman T, Ertl HCJ, Olotu A, Douglas AD; RAB002 study team. Lancet Infect Dis. 2026 Aug;26(8):843-857. doi: 10.1016/S1473-3099(26)00071-X. Epub 2026 Apr 28. PMID: 42066780

[Erratum to "In silico design of a citrullinated protein-based multi-epitope **vaccine** for rheumatoid arthritis using immunoinformatics" \[Int. Immunopharmacol. 179 \(2026\) 116615\].](#)

Brindhha R, Pathak N, Kohila V. Int Immunopharmacol. 2026 Aug 15;183:116856. doi: 10.1016/j.intimp.2026.116856. Epub 2026 May 22. PMID: 42173725

[Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines \(BEEHIVE trial\).](#)

Yoon SK, Phillips AL, Battan-Wraith S, Thiese MS, Rowley E, Ellsworth GL, Fink RV, Chen D, Yates A, Yan F, Ball SW, Zhang Y, Toback S, Dunkle LM, Rousculp MD, Zhao H. *Vaccine*. 2026 Aug 13;88:128954. doi: 10.1016/j.vaccine.2026.128954. Epub 2026 Jul 22. PMID: 42486052

[Simultaneous Administration of Human Papillomavirus \(HPV\) Vaccine With Other Recommended Vaccines Among Adolescents Aged 13-17 years, National Immunization Survey-Teen \(NIS-Teen\), United States, 2023.](#)

Pingali C, Yankey D, Chen M, Elam-Evans LD, Markowitz LE, DeSisto CL, Stefanos R, Singleton JA. *J Adolesc Health*. 2026 Aug 7:S1054-139X(26)00238-7. doi: 10.1016/j.jadohealth.2026.06.014. Online ahead of print. PMID: 42565767

[mRNA vaccines targeting HPV E6/E7: A new frontier in cervical cancer immunotherapy.](#)

Aftabsavad S, Arashkia A, Shokrgozar MA, Rahimi AA, Karimipoor M. *Crit Rev Oncol Hematol*. 2026 Aug 5;226:105520. doi: 10.1016/j.critrevonc.2026.105520. Online ahead of print. PMID: 42556594

[Towards scalable production of recombinant EIT as a protective antigen against EHEC.](#)

Basile LA, Nosedá DG, Milstein I, Roset MS, Briones G. *Bioprocess Biosyst Eng*. 2026 Aug;49(8):2291-2301. doi: 10.1007/s00449-026-03398-4. Epub 2026 Jul 22. PMID: 42484640

[Examining evidence use in vaccine policymaking in Kenya: A qualitative case study.](#)

Waithaka D, Lewin S, Nzinga J, Gopinathan U, Glenton C, Barasa E, Tsofa B. *Health Policy Plan*. 2026 Aug 10:czag100. doi: 10.1093/heapol/czag100. Online ahead of print. PMID: 42573154

[Strain-specific detection of *Mycoplasma gallisepticum*: A duplex qPCR assay for vaccine efficacy and infection surveillance.](#)

Fan P, Liu Z, Xu Y, Guo M, Zhang C, Bo Z, Wu Y, Zhang X. *Poult Sci*. 2026 Aug;105(8):107094. doi: 10.1016/j.psj.2026.107094. Epub 2026 May 7. PMID: 42139893

[Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.](#)

Kazi F, Shapland CY, Spiga F, Villanueva G, Cornish RP, Henschke N, Cogo E, Sebastiani M, Aarabi M, Bergman H, Buckley B, Clayton GL, French CE, Liu J, Madley-Dowd P, Pelone F, Petkovic J, Probyn K, Saulle R, Savović J, Wilson R, Beck CR, Higgins JPT. *Vaccine*. 2026 Aug 13;90:128993. doi: 10.1016/j.vaccine.2026.128993. Online ahead of print. PMID: 42594644

[Capsid inclusion in a CHIKV mRNA vaccine impairs adaptive immune responses.](#)

Chen H, Yuan L, Yang H, Huang Q, Yang Y, Tang C, Wang J, Zhou Y, Yu W, Wang H, Quan W, Yuan Y, Wang Y, Lu S. *Cell Rep Med*. 2026 Aug 3:102965. doi: 10.1016/j.xcrm.2026.102965. Online ahead of print. PMID: 42546698

[Predicting parents' COVID-19 vaccination intentions and behavior for their children: application of an integrated social cognition model.](#)

Griffith ZM, Royer Z, Gaffney AM, Hagger MS. *Psychol Health*. 2026 Aug 2:1-34. doi: 10.1080/08870446.2026.2707302. Online ahead of print. PMID: 42543244

[Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study.](#)

Morio R, Takazono T, Morimoto S, Ashizawa N, Hirayama T, Yoshida M, Takeda K, Hirano K, Ide S, Iwanaga N, Hosogaya N, Funakoshi S, Yanagihara K, Mukae H. *Vaccine*. 2026 Aug 13;88:128861. doi: 10.1016/j.vaccine.2026.128861. Epub 2026 Jun 20. PMID: 42322683

[Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent **vaccine**, mRNA-1083, in adults aged 50 years in Japan.](#)

Kostanyan L, Fukase H, Rumyantsev A, Hashizume K, Osibajo S, Kogawara O. *Vaccine*. 2026 Aug 13;88:128961. doi: 10.1016/j.vaccine.2026.128961. Epub 2026 Jul 30. PMID: 42531981

[An assessment of Correctional Officers' health beliefs in relationship to COVID-19 **vaccine** uptake and hesitancy.](#)

Hedden-Clayton B, Roddy AL, Roddy JK, Ngassa Y, Pickard B, Tam RA, Wurcel AG. *SAGE Open Med*. 2026 Aug 10;14:20503121261476907. doi: 10.1177/20503121261476907. eCollection 2026. PMID: 42582729

[CD25\(+\) cell depletion enhances protective immunity of PR8 inactivated influenza **vaccine** in aged mice.](#)

Zhang Y, Liu L, Chen T, Li M, Shi X, Liu Y. *Virology*. 2026 Aug;621:110938. doi: 10.1016/j.virol.2026.110938. Epub 2026 May 2. PMID: 42107283

[Factors influencing COVID-19 **vaccine** hesitancy among pregnant women in Jos, Plateau State, Nigeria.](#)

Osawe S, Olasunkanmi YA, Salawu MM, Okedare OO, Okolo F, Adenekan TY, Babamale SM, Onyemata J, Israel-Isah S, Abdullahi A, Abimiku A. *Int Health*. 2026 Aug 7:ihag078. doi: 10.1093/inthealth/ihag078. Online ahead of print. PMID: 42565302

[Factors associated with COVID-19 **vaccine** acceptance among refugee women at Dzaleka refugee camp in Malawi.](#)

Gondwe KW, Hearst MO, Mbutuka HR, Khwepeya M, Abusbaitan H, Hoffman SJ, Nyondo-Mipando AL, Dressel AE, Eyadat A, Jaman PB, Lopez AA, Mkandawire-Valhmu L. *Vaccine*. 2026 Aug 13;88:128862. doi: 10.1016/j.vaccine.2026.128862. Epub 2026 Jun 23. PMID: 42335759

[The rotavirus cVLP\(VP8 \) **vaccine** candidate induces cross-genotype/heterotypic neutralizing antibody responses against human rotavirus G9P\[4\].](#)

Behnezhad F, Ataei-Pirkooh A, Kachooei A, Golsaz-Shirazi F, Arashkia A, Mir-Hosseini M, Hosseini-Fakhr SS, Mousavizadeh L, Jalilvand S, Roohvand F, Shoja Z. *Virology*. 2026 Aug;621:110957. doi: 10.1016/j.virol.2026.110957. Epub 2026 May 16. PMID: 42161115

[Evaluating knowledge and attitudes towards dengue fever and its vaccination in China: A questionnaire-based study in healthcare practitioners.](#)

Lam I, Yao Y, Sun Y, Xia Y, Lu Y. *PLoS Negl Trop Dis*. 2026 Aug 5;20(8):e0013530. doi: 10.1371/journal.pntd.0013530. eCollection 2026 Aug. PMID: 42555625

[A novel multiepitope peptide **vaccine** with intrinsic adjuvant confers protective immunity in mice against tuberculosis.](#)

Sharma M, Kumar D, Bedi AK, Yadav P, Bhatt P, Kathait S, Basil MV, Rani M, Kulshrestha R, Verma AK, Sharma M, Sharma S. *Microb Pathog.* 2026 Aug;217:108589. doi: 10.1016/j.micpath.2026.108589. Epub 2026 May 24. PMID: 42184873

[Live-attenuated *Toxoplasma gondii* RHΔddx6 mutant establishes comprehensive immunity against acute, chronic, and congenital toxoplasmosis.](#)

Yang Z, Wang J, Wu J, Fan Y, Ying T, Zhang H, Bai J, Wang Y, Liu P, Li G, Nie M, Tian X, Mei X, Zhang Z, Wang Q, Wang S. *Virulence.* 2026 Dec;17(1):2713823. doi: 10.1080/21505594.2026.2713823. Epub 2026 Aug 7. PMID: 42565651

[Infectious disease hospitalization rates before and after introduction of **vaccine** against human papillomavirus in Denmark, Norway, and Sweden: controlled interrupted time series analyses.](#)

Laake I, Feiring B, Sørup S, Englund H, Nieminen H, Cardél LG, Benn CS, Trogstad L. *Vaccine.* 2026 Aug 13;88:128851. doi: 10.1016/j.vaccine.2026.128851. Epub 2026 Jun 17. PMID: 42308975

[A Systematic Review and Meta-Analysis of the Effectiveness of Procedural Interventions for Reducing Distress During **Vaccine** Injections.](#)

Taddio A, Shah V, McMurtry CM, Lang E, MacDonald NE, Constantin K, Uleryk E; HELPinKids&Adults##. *Clin J Pain.* 2026 Aug 1;42(8S Suppl 1):e1373. doi: 10.1097/AJP.0000000000001373. PMID: 41880242

[Recent developments in typhoidal and non-typhoidal *Salmonella* vaccines.](#)

Blank M, Rydlova A, Gibani MM. *Curr Opin Infect Dis.* 2026 Aug 6. doi: 10.1097/QCO.0000000000001230. Online ahead of print. PMID: 42566676

[Enhancement of immune responses using a self-assembled lentinan nano-adjuvant.](#)

Zhu Y, Shen Y, Bao Y, Mei C, Zhou J, Chen J. *J Mater Chem B.* 2026 Aug 14. doi: 10.1039/d6tb00967k. Online ahead of print. PMID: 42598848

[Navigating stigma, faith, and fear: understanding HPV **vaccine** acceptance among adolescent girls in rural parts of Central Ethiopia.](#)

Dejene K. *Cult Health Sex.* 2026 Aug;28(8):978-989. doi: 10.1080/13691058.2025.2600046. Epub 2025 Dec 13. PMID: 41389081

[Protective immunity of lectin-adjuvanted intraperitoneal injection **vaccine** against *Aeromonas veronii* infection in *Oreochromis niloticus*.](#)

Guha R, Wangkahart E, Elumalai P. *Vaccine.* 2026 Aug 13;88:128948. doi: 10.1016/j.vaccine.2026.128948. Epub 2026 Jul 16. PMID: 42462678

[DTaP-IPV Vaccination-Induced Granuloma Diagnosed With Multi-Virus/Microbial Real-Time PCR.](#)

Hayashi H, Otsubo Y, Matsuoka K, Horikoshi Y, Katano H, Yuza Y. *Pediatr Dermatol*. 2026 Aug 6. doi: 10.1111/pde.70333. Online ahead of print. PMID: 42562641

[Immunogenicity and Safety of Two-dose Schedules With Different Intervals of an ORF7-deficient Live **Vaccine** Candidate for Varicella: A Randomized, Double-blind, Controlled, Phase 2b Trial.](#)

Qiu L, Pan H, Liang Q, Chen Z, Zhang M, Liu S, Liao M, Chen L, Liu X, Hu J, Li C, Li J, Xu J, Zhuang C, Huang S, Wang W, Han J, Jia J, Chu X, Zhu H, Cheng T, Su Y, Ye X, Quan Y, Wu T, Zhang J, Xia N. *Pediatr Infect Dis J*. 2026 Aug 1;45(8):733-741. doi: 10.1097/INF.0000000000005184. Epub 2026 Feb 18. PMID: 41703694

[Classification of the risk of transmission of **vaccine**-preventable diseases among children under 2 years of age in the municipality of Sao Paulo, Brazil.](#)

Araújo MS, Santana JES, Palmieri M, Nunes LU, Oliveira TM, Oliveira MEV, Veloso GA, Silva TPRD, Matozinhos FP. *Rev Bras Epidemiol*. 2026 Aug 7;29:e260035. doi: 10.1590/1980-549720260035. eCollection 2026. PMID: 42585533

[Batch-dependent safety signal: Nationwide analysis of suspected adverse events following COVID-19 vaccination in Germany.](#)

Manniche V, Karásek V, Schmeling M, Gilthorpe JD, Fürst T, Hansen PR. *Int J Risk Saf Med*. 2026 Aug;37(3):458-462. doi: 10.1177/09246479261453789. Epub 2026 May 19. PMID: 42155583

[Passive surveillance of infectious bursal disease virus circulating in Egyptian chicken flocks in 2025.](#)

Abd El-Fatah AH, Salama B, Elnahas MO, Abo Shama NM, Shehata M. *Sci Rep*. 2026 Aug 8;16(1):24540. doi: 10.1038/s41598-026-65194-0. PMID: 42570975

[Effectiveness, Safety, and Immunogenicity of a Second COVID-19 **Vaccine** Booster in the Elderly: A Systematic Review and Meta-Analysis Protocol.](#)

Garcia MTP, Valim V, Lopes-Júnior LC. *Health Sci Rep*. 2026 Jul 28;9(8):e72824. doi: 10.1002/hsr2.72824. eCollection 2026 Aug. PMID: 42524361

[Ebola virus disease in the modern era: pathogenesis, therapeutic advances, **vaccine** strategies, and global health preparedness.](#)

Sundeeep D, Umadevi K, Masood J, Tummala N. *Infection*. 2026 Aug 11. doi: 10.1007/s15010-026-02924-6. Online ahead of print. PMID: 42579070

[2024/25 end-of-season KP.2 **vaccine** effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.](#)

Carazo S, Skowronski DM, Sauvageau C, Talbot D, Racine E, Brousseau N. *Vaccine*. 2026 Aug 13;88:128786. doi: 10.1016/j.vaccine.2026.128786. Epub 2026 Jun 4. PMID: 42241837

[A nanoluciferase-expressing attenuated CHIKV **vaccine** strain enables rapid and visual drug screening in vitro and in vivo.](#)

Zheng M, Pan Z, Jiang Y, Guo Y, Chang W, Tang H, Chen X, Xiang Y, Wang X, Wang Z, Chang R, Liu L, Zhao P, Feng Y, Xia X. *J Virol.* 2026 Aug 11:e0046626. doi: 10.1128/jvi.00466-26. Online ahead of print. PMID: 42578665

[Development of a Trivalent Seasonal Influenza **Vaccine** Using Long alpha-Helix-Mediated Trimeric HA1 Proteins Produced in Baculovirus-Insect Cell System.](#)

Guo N, Xu Z, Chen X, Han X, Xue T, Yan J, Huang Q. *MedComm* (2020). 2026 Jul 19;7(8):e70880. doi: 10.1002/mco2.70880. eCollection 2026 Aug. PMID: 42518778

[An orthogonal transcription system enables high-efficiency rescue of measles virus-based **vaccine** vectors against multiple pathogens.](#)

Ma Z, Wang W, Lou Q, Jiang H, Xiang Y, Zhang W, Tian X, Fan Y, Yin W, Lou C. *Synth Syst Biotechnol.* 2026 Aug 3;17:41-50. doi: 10.1016/j.synbio.2026.06.012. eCollection 2027 Mar. PMID: 42572581

['Mismatched' Ebola **vaccine** may soon be rolled out widely.](#)

Kupferschmidt K. *Science.* 2026 Aug 13;393(6812):649-650. doi: 10.1126/science.ael4193. Epub 2026 Aug 13. PMID: 42594214

[Partner awareness and support for maternal RSV vaccination: a paired survey of pregnant women and co-residing partners in Japan.](#)

Saitoh A, Takaku M. *Vaccine.* 2026 Aug 13;88:128946. doi: 10.1016/j.vaccine.2026.128946. Epub 2026 Jul 16. PMID: 42462679

[Can We Compare Adverse Event's Attributable Risk Using a Self-Controlled Case Series Design for **Vaccine** Safety? A Guillain-Barre Syndrome Use Case.](#)

Liang C, Chilson EL, Wu J, Kelly SP, Liu Q, Dooling KL, Lino MM, Lewnard JA, Gessner BD, Begier E. *Infect Dis Ther.* 2026 Aug 6. doi: 10.1007/s40121-026-01365-w. Online ahead of print. PMID: 42562995

[Hesitancy and Perceptions Regarding Dengue Vaccination Among Educated Ecuadorians.](#)

Panchana-Lascano M, Veintemilla-Burgos F, Vela Velásquez C, Kronfle Cordovez R, Minchalo-Ochoa G, Balda S, Leone-Berry T, Diaz-Djevoich I, Cedillo Santos N. *Vector Borne Zoonotic Dis.* 2026 Aug 14:15303667261479462. doi: 10.1177/15303667261479462. Online ahead of print. PMID: 42599207

[Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.](#)

Olagunju OJ, Oyebanji OA, Keresztesy D, Wilk D, Dickerson E, Wallace T, Holland L, Payne M, See E, Li CJ, Lim E, Abul Y, Nugent C, Balazs AB, Bosch J, King CL, Wilson B, Gravenstein S, Canaday DH. *Hum Vaccin Immunother.* 2026 Dec;22(1):2705661. doi: 10.1080/21645515.2026.2705661. Epub 2026 Aug 4. PMID: 42551467

[Immunogenicity and post-challenge virological outcomes of a multivalent subunit **vaccine** in sheep challenged with cytopathic BVDV-1a.](#)

Shao Z, Yuan J, Li Y, Xiao L, Ni R, Li Y, Gao Y, Wang Z, Zhang Y, Wu A, Gu M, Li J, Fu Z, Zhang T, Sheng J, Yi J, Wang Y. *Vet Microbiol.* 2026 Aug 3;321:111174. doi: 10.1016/j.vetmic.2026.111174. Online ahead of print. PMID: 42561832

[Invasive pneumococcal disease in Latin America: serotype distribution and **vaccine** coverage among adults in Mexico, Brazil, and Argentina.](#)

Martino A, Urrego-Reyes J, Cervenka J, Paluru MK, Cossrow N. *Vaccine.* 2026 Aug 13;88:128947. doi: 10.1016/j.vaccine.2026.128947. Epub 2026 Jul 31. PMID: 42537290

[Clinical progress note: Hepatitis B.](#)

Vipulanandan Y, Poole C. *J Hosp Med.* 2026 Aug 15. doi: 10.1002/jhm.70424. Online ahead of print. PMID: 42603096

[Rubella immunity and vaccination coverage among medical students in Catalonia: a multicentre seroprevalence study.](#)

Benito P, Aldea M, Godoy P, Toledo D, Casas I, Soldevila N, Bartolomé R, Domínguez A; Working Group on vaccine preventable diseases in medical students. *Vaccine.* 2026 Aug 13;88:128968. doi: 10.1016/j.vaccine.2026.128968. Epub 2026 Jul 25. PMID: 42501718

[Prioritizing the introduction of new **vaccine** in Tanzania \(2026-2030\): a multi-criteria decision analysis by the Tanzania immunization technical advisory group.](#)

Kyesi F, Michael F, Kilonzo S, Misinzo G, Minzi O, Ntinginya NE, Kasonogo R, Bahati A, Hassan F, Chai JJ, Mahmoud S, Ali AS, Bugoye FC, Joachim G, Mdachi J, Nyamungumi Z, Mkhoi ML, Bukagile A, Mbwambo M, Mshana SE. *Vaccine.* 2026 Aug 13;88:128985. doi: 10.1016/j.vaccine.2026.128985. Epub 2026 Jul 31. PMID: 42537288

[Trends in pediatric and adult COVID-19, influenza, and routine vaccinations administered in retail pharmacies, 2015 through 2023, United States.](#)

Meador SA, Lamias MJ, Kroger A, Santibanez TA, Lu PJ, Singleton JA. *Am J Infect Control.* 2026 Aug;54(8):916-922. doi: 10.1016/j.ajic.2026.04.011. Epub 2026 Apr 17. PMID: 42001958

[Durable clinical and immunologic response to an off-the-shelf EWSR1-FLI1 peptide **vaccine** in metastatic Ewing sarcoma.](#)

Calukovic B, Benzler K, Zelba H, Seitz C, Kayser S, Feldhahn M, Shao B, Schulze M, Maksimovic O, Scheble V, Battke F, Zender L, Lauer UM, Biskup S, Deinzer CKW. *NPJ Precis Oncol.* 2026 Aug 8;10(1):305. doi: 10.1038/s41698-026-01642-4. PMID: 42570981

[Understanding parent motivation for participating in the Pfizer COVID-19 **vaccine** trial.](#)

Diarra M, Li S, Gaur S, Greenberg P, Mazzaferro N, Ramagopal M, Parmar S, Gubenko EE. *Vaccine.* 2026 Aug 13;88:128960. doi: 10.1016/j.vaccine.2026.128960. Epub 2026 Jul 23. PMID: 42492243

[In older adults, mRNA-1010 vs. a licensed standard-dose influenza **vaccine** reduced influenza A- or B-related ILI at a median 181 d.](#)

Chen V, Glatt AE; ACP Journal Club Editorial Team at McMaster University. *Ann Intern Med*. 2026 Aug 4. doi: 10.7326/ANNALS-26-02527-JC. Online ahead of print. PMID: 42546301

[In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.](#)

Ullah S, Parizi LF, Almutairi MM, Ali A, da Silva Vaz Junior I. *Vaccine*. 2026 Aug 13;88:128789. doi: 10.1016/j.vaccine.2026.128789. Epub 2026 Jun 30. PMID: 42378924

[Development and evaluation of a virus like particle based **vaccine** candidate against Indian Isolate of porcine circovirus 2d in pig.](#)

Deb R, Maity HK, Samanta K, Madhanmohan M, Sengar GS, Pegu SR, Kar I, Parthiban S, Khulape SA, Das PJ, Rajkhowa S, Gupta VK. *Microb Pathog*. 2026 Aug 3;219:108748. doi: 10.1016/j.micpath.2026.108748. Online ahead of print. PMID: 42546908

[SARS-CoV-2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History.](#)

Vizgirda G, Underwood AP, Fahnøe U, Sølund C, Villadsen SL, Galli A, Weis N, Bukh J. *J Med Virol*. 2026 Aug;98(8):e71054. doi: 10.1002/jmv.71054. PMID: 42592680

[Breakthrough varicella infection: a retrospective cohort study based on large-scale real-world data in Guangxi, China, 2014-2025.](#)

Wang J, Li S, Zhou W, Huang J, Huang Y, He W, Nong X, Ning C, Lan G, Zeng X. *Vaccine*. 2026 Aug 13;88:128838. doi: 10.1016/j.vaccine.2026.128838. Epub 2026 Jun 17. PMID: 42308974

[A novel inactivated **vaccine** for cross-protection against *Actinobacillus pleuropneumoniae* in pigs.](#)

Wei W, Yang R, Wang Z, Feng S, Jin Y, Liu H, Fu J, Wang Y, Chen H, Wang X. *Vaccine*. 2026 Aug 7;90:129010. doi: 10.1016/j.vaccine.2026.129010. Online ahead of print. PMID: 42566982

[Efficacy of a multi-clade inactivated recombinant **vaccine** against the circulating highly pathogenic influenza A/H5N1 of clade 2.3.4.4b in poultry.](#)

Elfeil WM, Safwat M, Sedeek A, Adel A, Hassan H, Zain El-Abideen MA, Ali I, Hisham I, Arafa A, Selim A, Afifi M, Shaheen MA, Elkady MF, Kilany WH. *Avian Pathol*. 2026 Aug;55(4):438-449. doi: 10.1080/03079457.2025.2582672. Epub 2025 Nov 24. PMID: 41277443

[Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.](#)

Shao S, Dong ZY, Kang ZY, Zhang H, Zheng X, Shen FJ, Jin YQ, Pan Z, Li X, Liu N, Li XG, Liu ZM, Zhang XF, Ren J, Han ZB, Liang Y, Zhang J, Su JG, Li QM. *Biochem Biophys Res Commun*. 2026 Aug 6;825:153958. doi: 10.1016/j.bbrc.2026.153958. Epub 2026 May 20. PMID: 42172905

[Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK.](#)

Bucholc M, Murphy S, O'Doherty MG, Wilton S, Dickson E, Bradley DT. *Influenza Other Respir Viruses*. 2026 Aug;20(8):e70303. doi: 10.1111/irv.70303. PMID: 42560010

[Sex differences in excess mortality during the COVID-19 pandemic: a longitudinal ecological analysis of 34 high-income countries.](#)

Doniec K, Schöley J, Kühn M, Dowd JB. *EClinicalMedicine*. 2026 Jul 23;98:104072. doi: 10.1016/j.eclinm.2026.104072. eCollection 2026 Aug. PMID: 42542596

[Regulatory fragmentation as the hidden barrier to regional **vaccine** sovereignty.](#)

Ngcobo M. *Nat Med*. 2026 Aug 13. doi: 10.1038/s41591-026-04580-7. Online ahead of print. PMID: 42595786

[Genetic diversity of the Chikungunya virus E2 gene may have implications for the design of vaccines and therapeutic antibodies.](#)

Mohamed NS, Ahmed A. *Virus Genes*. 2026 Aug;62(4):470-483. doi: 10.1007/s11262-026-02246-7. Epub 2026 Jun 4. PMID: 42236645

[Effects of dietary protein level on growth performance, intestinal morphology, and **vaccine**-induced antibody responses in Sakini chickens during the starter phase.](#)

Karki S, Barsila SR, Devkota NR, Toyomizu M. *Poult Sci*. 2026 Aug;105(8):107135. doi: 10.1016/j.psj.2026.107135. Epub 2026 May 15. PMID: 42214188

[Ferritin as a Nanoparticle Scaffold for Plant-Produced Next-Generation Subunit Vaccines.](#)

VanderBurg JT, Strasser R, Garnham CP, Menassa R. *Biotechnol Bioeng*. 2026 Aug 11. doi: 10.1002/bit.70330. Online ahead of print. PMID: 42581595

[Safety of Live and Live-Attenuated Vaccines in Patients Receiving Biologics and Small-Molecule Therapies for Dermatologic Diseases: A Systematic Review.](#)

Majri AL, Chan J. *Australas J Dermatol*. 2026 Aug;67(5):259-269. doi: 10.1111/ajd.70088. Epub 2026 Mar 17. PMID: 41845916

[Ferritin nanoparticle-based **vaccine** enhances mucosal immunity by promoting antigen uptake and activation of alveolar macrophages.](#)

Zhang X, Lin Y, Liu J, Wang D, Yuan J, Chen R, Zhang X, Zhang X, Zhou N, Zhang H, He X. *Virol Sin*. 2026 Aug 10:S1995-820X(26)00133-1. doi: 10.1016/j.virs.2026.08.004. Online ahead of print. PMID: 42575250

[Stability of *Chlamydia pecorum* MOMP at 37 C: suitability for use in delayed-release **vaccine** implants in koalas \(*Phascolarctos cinereus*\).](#)

Russell FA, Fisher MA, Leahy D, Harris J, Hutmacher D, Dargaville TR, Beagley KW. *Vaccine*. 2026 Aug 4;89:128991. doi: 10.1016/j.vaccine.2026.128991. Online ahead of print. PMID: 42551398

[Optimization and production of a GLP-grade recombinant Sm29 **vaccine** against schistosomiasis: From expression to preclinical assessment.](#)

Andrade JM, Mambelli F, Gomes DS, Souza MFS, Fahel JS, Sanches RCO, Marinho FV, Salazar N, Gomes IP, Martins VT, Carvalho EM, de Magalhaes MTQ, Teixeira SR, Oliveira SC. *PLoS Negl Trop Dis*. 2026 Aug 7;20(8):e0014617. doi: 10.1371/journal.pntd.0014617. eCollection 2026 Aug. PMID: 42566478

[Stabilization of prefusion hMPV F improves manufacturability and protective immunity across hMPV lineages.](#)

Qu C, Zou J, Niu D, Wu Q, Liu L, Yu M, Zhang Q, Zhang L, Wei S, Zhang W, Peng W. *Virol Sin.* 2026 Aug 6;S1995-820X(26)00131-8. doi: 10.1016/j.virs.2026.08.002. Online ahead of print. PMID: 42562214

[Adverse events following immunization with human papillomavirus **vaccine**: post-marketing surveillance in China, 2021-2024.](#)

Zhang L, Li K, Li Y, Fan C, Li Y, Ren M, Cao L, Yu W, Yin Z. *Vaccine.* 2026 Aug 13;88:128826. doi: 10.1016/j.vaccine.2026.128826. Epub 2026 Jun 15. PMID: 42296833

[Determinants and mitigation strategies of **vaccine** hesitancy toward routine immunisations recommended for older adults: a systematic review.](#)

Huang S, Zhang M, Ruan C, Song Y, Hu X, Liu N, Ye J, Chen D, Zhang Y, Zhou J, Li Q, Wang L, Shi X, Yu W, Luo S. *Age Ageing.* 2026 Aug 3;55(8):afag233. doi: 10.1093/ageing/afag233. PMID: 42585558

[Statistical misreasoning in online content about vaccines: Implications and recommendations for addressing disinformation.](#)

Ordak M. *PLoS One.* 2026 Aug 3;21(8):e0355341. doi: 10.1371/journal.pone.0355341. eCollection 2026. PMID: 42546032

[A Systematic Review and Meta-Analysis of the Effectiveness of Process Interventions for Reducing Distress During **Vaccine** Injections.](#)

Taddio A, Shah V, McMurtry CM, Lang E, MacDonald NE, Constantin K, Uleryk E; HELPinKids&Adults^{††}. *Clin J Pain.* 2026 Aug 1;42(8S Suppl 1):e1372. doi: 10.1097/AJP.0000000000001372. PMID: 41821507

[Protective effect of A\(H5N8\) stockpiled **vaccine** against a virus genetically identical to a human isolate of bovine A\(H5N1\) influenza virus.](#)

Uraki R, Kiso M, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Imai M, Kawaoka Y. *EBioMedicine.* 2026 Aug 11;131:106430. doi: 10.1016/j.ebiom.2026.106430. Online ahead of print. PMID: 42580038

[Entering into life-course immunization: Process, significance, and prospects of HPV **vaccine** inclusion into the national immunization program of China.](#)

Zundong Y, Xiaoxue L, Rodewald L, Fuzhen W, Hongbing S. *Vaccine.* 2026 Aug 4;89:129000. doi: 10.1016/j.vaccine.2026.129000. Online ahead of print. PMID: 42551399

[The Role of Pharmacists in Tackling Mpox: Challenges and Future Prospects: A Narrative Review.](#)

Degebo AS, Gebretsadik FA, Ambaye AS, Endalifer BL, Belachew TF. *Health Sci Rep.* 2026 Jul 27;9(8):e72916. doi: 10.1002/hsr.72916. eCollection 2026 Aug. PMID: 42517023

[Immunological effects of \$\beta\$ -glucan as a trained immunity-based adjuvant in vaccinated goats against anthrax.](#)

Angulo M, Angulo C. *Vet J.* 2026 Aug;318:106748. doi: 10.1016/j.tvjl.2026.106748. Epub 2026 Jun 18. PMID: 42309310

[Author Correction: IDH1-mutant **vaccine** in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.](#)

Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M. *Nat Cancer*. 2026 Aug 3. doi: 10.1038/s43018-026-01227-x. Online ahead of print. PMID: 42547583

[Efficacy of a novel lectin-conjugate platinum nanoparticle \(MdLec-PtNP\) to protect Nile tilapia \(*Oreochromis niloticus*\) from *Aeromonas hydrophila* infection by injection, immersion and oral routes of administration.](#)

Lakshmi S, Subramani PA, Horton D, Pirarat N, Monaghan SJ, Desbois AP, Thompson KD, Elumalai P. *Dev Comp Immunol*. 2026 Aug;181:105657. doi: 10.1016/j.dci.2026.105657. Epub 2026 Jun 25. PMID: 42349577

[Identification and protective efficacy characterization of novel immunogenic antigens for *Salmonella* Enteritidis vaccines.](#)

Zhao Y, Li G, Li YA, Li Q, Shi H. *Poult Sci*. 2026 Aug;105(8):107033. doi: 10.1016/j.psj.2026.107033. Epub 2026 May 1. PMID: 42105384

[A bivalent inactivated influenza **vaccine** incorporating epitope-optimized surface proteins confers cross-protective immunity against H9N2 influenza virus.](#)

Hao M, Guan Y, Xu M, Yang W, Wang Y, Zhang Y, Chen J. *Emerg Microbes Infect*. 2026 Aug 3:2713325. doi: 10.1080/22221751.2026.2713325. Online ahead of print. PMID: 42546126

[Development of an mRNA **vaccine** against the OprF of *Pseudomonas aeruginosa* and evaluation of antibody response in mouse.](#)

Fathi M, Lotfollahi L, Mehravar F, Nomanpour B. *Microbiol Spectr*. 2026 Aug 12:e0047325. doi: 10.1128/spectrum.00473-25. Online ahead of print. PMID: 42584156

[Additional Landmark and RMST Analyses Addressing Immortal Time Bias in the Evaluation of Autologous Formalin-Fixed Tumor **Vaccine** for Metastatic Breast Cancer.](#)

Miyazaki T, Kuranishi F, Ohno T. *Clin Breast Cancer*. 2026 Aug;26(8):80-81. doi: 10.1016/j.clbc.2026.06.007. Epub 2026 Jun 23. PMID: 42470724

[Persistent **vaccine**-type invasive pneumococcal disease in children despite high PCV13 coverage: the role of serotype 3.](#)

Ciruela P, Broner S, Moraga-Llop F, de Sevilla MF, Izquierdo C, Pérez-Argüello A, González-Peris S, Díaz-Conradi A, Soldevila N, Viñado B, Alcaraz-Soler C, Vila J, Esteva C, García-García JJ, Muñoz-Almagro C, Domínguez A. *Vaccine*. 2026 Aug 13;88:128940. doi: 10.1016/j.vaccine.2026.128940. Epub 2026 Jul 22. PMID: 42486053

[Timing and frequency of antenatal care visits in relation to maternal respiratory syncytial virus **vaccine** opportunities in four Latin American countries.](#)

Fleming JA, Colistro V, Knudson S, Colomar M. *Vaccine*. 2026 Aug 13;88:128854. doi: 10.1016/j.vaccine.2026.128854. Epub 2026 Jun 19. PMID: 42320380

[Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine.](#)

Van Twuijver E, Versage E, Jacobs RL, Hohenboken M. *Hum Vaccin Immunother*. 2026 Dec;22(1):2712791. doi: 10.1080/21645515.2026.2712791. Epub 2026 Aug 5. PMID: 42555510

[Intraperitoneal extracellular trap-derived proteins mediate the amplification of vaccine-induced immune responses in flounder \(*Paralichthys olivaceus*\).](#)

Zhang J, Li Q, Tang X, Ha C, Xing J, Sheng X, Zhan W, Chi H. *Fish Shellfish Immunol*. 2026 Aug;175:111399. doi: 10.1016/j.fsi.2026.111399. Epub 2026 May 7. PMID: 42103109

[Safety and immunogenicity of one or two doses of the rVSVdeltaG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.](#)

Tremblay C, Valea I, Ndiaye BP, Barry H, ElSherif M, Cooper C, Breeze JL, Cai Y, Ye L, Omole T, Halperin SA, Mboup S, Langley JM. *Lancet HIV*. 2026 Aug 7:S2352-3018(26)00118-9. doi: 10.1016/S2352-3018(26)00118-9. Online ahead of print. PMID: 42567171

[An Orthogonal Nanoadjuvant-Based RSV Subunit Vaccine Unlocks Potent Immunity through a High-Entropy-like Immunostimulatory Effect.](#)

Chen L, Sun Y, Dong Y, Jin Y, Han Z, Liu N, Zheng X, Shao S, Zhang J, Liang Y, Pu M, Du M, Li Q, Nie G, Ren J, Li F. *J Am Chem Soc*. 2026 Aug 5;148(30):32863-32880. doi: 10.1021/jacs.6c11987. PMID: 42485602

[Pre-Clinical Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine Formulated with Aluminum Hydroxide Adjuvant.](#)

Watts DM, Collier BG, Da Rosa Travassos AP, Newman P, Grant A, Martyak T, Jia J, Clements DE, Lieberman MM. *Am J Trop Med Hyg*. 2026 Jul 14;115(2):372-382. doi: 10.4269/ajtmh.26-0133. Print 2026 Aug 5. PMID: 42447858

[Global misinformation, local consequences: conspiracy theory endorsement and a graded association with COVID-19 vaccine refusal across Nigeria.](#)

Asaga PM, Kroeger A, Yako A, Makpo J. *Vaccine*. 2026 Aug 13;88:128827. doi: 10.1016/j.vaccine.2026.128827. Epub 2026 Jun 17. PMID: 42308979

[Differences in parental risk perception of vaccine-preventable diseases based on disease name and clinical description: Results from the United States.](#)

Boyce MR, Callaghan T. *Prev Med Rep*. 2026 Jul 9;68:103561. doi: 10.1016/j.pmedr.2026.103561. eCollection 2026 Aug. PMID: 42519659

[A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positive *Pseudomonas aeruginosa* but reveals immunological interference against ExlA-positive strains.](#)

Howlader DR, Das S, Biswas S, Dietz ZK, Ernst RK, Picking WD, Picking WL. *Infect Immun*. 2026 Aug 4:e0017526. doi: 10.1128/iai.00175-26. Online ahead of print. PMID: 42550059

[The 'Other' face of health security: Reimagining epistemic attachments in global health.](#)

López Toledano MD, Alhaffar M, Alshalah A, Saleh M, Durrance-Bagale A, Nunes C, Sharma E, Howard N. *PLOS Glob Public Health*. 2026 Aug 14;6(8):e0007105. doi: 10.1371/journal.pgph.0007105. eCollection 2026. PMID: 42599959

[Mathematical modelling highlights the crucial role of early childhood immunization in preventing congenital CMV in countries with high CMV seroprevalence.](#)

Gazeau S, Byrne C, Coombs D, Kunzweiler C, Calheiros RC, Diaz-Decaro J, Gantt S, Craig M. *Vaccine*. 2026 Aug 13;88:128788. doi: 10.1016/j.vaccine.2026.128788. Epub 2026 Jun 10. PMID: 42269282

[Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1-CRM197 malaria transmission-blocking vaccine.](#)

Scaria PV, Chen B, Muratova O, Kemanli P, Doritchamou JYA, Lambert LE, Barnafo EK, Rausch KM, Narum DL, Shaligram U, Smith G, Duffy PE. *Vaccine*. 2026 Aug 13;88:128913. doi: 10.1016/j.vaccine.2026.128913. Epub 2026 Jul 14. PMID: 42456560

[Trump wants MMR vaccine split up: the science behind why it's a bad idea.](#)

Glickman K, Kozlov M. *Nature*. 2026 Aug 12. doi: 10.1038/d41586-026-02515-3. Online ahead of print. PMID: 42595887

[A six-proline stabilized trimeric spike DNA vaccine induces robust immunity and protects against SARS-CoV-2 delta challenge in K18-hACE2 transgenic mice.](#)

Gül-Mete A, Gül C, Karakavuk T, Karakavuk M, Can H, Ülbeği-Polat H, Serhatlı M, Yazıcı H, Köm Ş, Ekiz AT, Abaci-Bayraktar İ, Aksoy Ö, Enül H, Adıay C, Uzar S, Saraç F, Değirmenci Döşkaya A, Gürüz AY, Döşkaya M, Hameş EE. *Biomed Pharmacother*. 2026 Aug;201:119679. doi: 10.1016/j.biopha.2026.119679. Epub 2026 Jun 17. PMID: 42308922

[Objectionable Solidarity and Fractures in the Ethics of Global Health Solidarity : The Curse of COVID 19 Vaccine Donations Gone Awry.](#)

Chingarande GR. *J Bioeth Inq*. 2026 Aug 6. doi: 10.1007/s11673-026-10602-3. Online ahead of print. PMID: 42560650

[Chitosan as a Vaccine Adjuvant: From Material Determinants to Innate Immune Activation and Formulation Optimization.](#)

Li Z, Zhang X, Liu N, Xia N, Gu Y, Li S. *Int J Nanomedicine*. 2026 Aug 7;21:617925. doi: 10.2147/IJN.S617925. eCollection 2026. PMID: 42597484

[Indirect comparison of mRNA-1010 versus enhanced influenza vaccines in adults aged 65 years and older during the 2024-2025 US influenza season.](#)

Joshi K, Situ A, Mehta D, Li L, Canan C, Youhanna J, Radin JM, Rudin D, Georgieva M, Van de Velde N.J Med Econ. 2026 Dec;29(1):2046-2062. doi: 10.1080/13696998.2026.2706361. Epub 2026 Aug 4.PMID: 42550058

[Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.](#)

Le MH, Tran ND, Nguyen TTT, Phan TTN, Pham TT, Tran ND.Vaccine. 2026 Aug 13;88:128852. doi: 10.1016/j.vaccine.2026.128852. Epub 2026 Jun 18.PMID: 42314310

[Single-dose dual-indication nanoparticle **vaccine** co-displaying Pseudomonas aeruginosa antigen and tetanus toxin fragment confers durable protection against mixed exposure.](#)

Zhu Z, Yan J, Wan J, Wu M, Liao Z, Peng X, Wang Y, Li Y, Wang Y, Liu X, Wang B, Zou Q, Zhu J, Gu J.Mater Today Bio. 2026 Jun 13;39:103354. doi: 10.1016/j.mtbio.2026.103354. eCollection 2026 Aug.PMID: 42382725

[Corrigendum to "A virus-like particle candidate **vaccine** based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" \[Antivir. Res. 225 \(2024\) 105854\].](#)

Wang W, Wang S, Meng X, Zhao Y, Li N, Wang T, Feng N, Yan F, Xia X.Antiviral Res. 2026 Aug;252:106465. doi: 10.1016/j.antiviral.2026.106465. Epub 2026 Jun 23.PMID: 42331636

[Lipid parameters but not inflammatory indices predict hepatitis B **vaccine** responses in hemodialysis patients.](#)

Ekici H, Mirza A, Baltacı S, Eren D, Çetinkaya Fİ, Ceylan M, Dağdelen C, Yeşildağ S, Koyuncu S.Clin Kidney J. 2026 Jul 1;19(8):sfag221. doi: 10.1093/ckj/sfag221. eCollection 2026 Aug.PMID: 42553896

[Safety of the Dengue **Vaccine** TAK-003 and Factors Associated with Adverse Events in Travellers from Non-Endemic Areas: A Real-World Prospective Multicentre Pharmacovigilance Cohort Study in Spain.](#)

Camprubí-Ferrer D, Bertran-Cobo C, Valerio L, Saloni M, González Nieto I, López López V, Garcia D, Jurado E, Machado ML, Pérez-León D, Cuevas Marín S, Subirà C, Villar-García J, Herena García D, Ayala Cortés SN, Sánchez Casado M, Gomila-Grange A, Flores C, Morales Llorente N, Górriz Hidalgo E, Morales Martínez RM, Vila F, Martín N, Muñoz J; CATdenga study groupm; CATdenga study group.Lancet Reg Health Eur. 2026 Jun 3;67:101727. doi: 10.1016/j.lanepe.2026.101727. eCollection 2026 Aug.PMID: 42577248

[COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high **vaccine** uptake for the next pandemic.](#)

Aung TN, Muyindike W, Hoepfner SS, Nanfuka V, Komukama N, Barigye IT, Tumusiime J, Omoding D, Johnson LS, Stuckwisch A, Pinkney JA, Hedt-Gauthier B, Marconi VC, Moosa MS, Pillay D, Gupta RK, Siedner MJ, McCluskey SM.Vaccine. 2026 Aug 13;88:128912. doi: 10.1016/j.vaccine.2026.128912. Epub 2026 Jul 10.PMID: 42430873

[Rotavirus **vaccine** effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of pooled case-control studies from the MNSSTER-V dataset.](#)

Moran MC, Burnett E, Groome MJ, Michael F, Breiman RF, Robinson AL, Iniguez V, Mujuru HA, Goldfarb DM, Lungayo CL, Mandomando I, Bonkougou IJO, Anwari P, Contreras-Roldán I, Enweronu-Laryea C, N'Zue K, Nalunkuma C, Trang NV, Gheorghita S, Sahakyan G, Nazurdinov A, Latipov R, Uwimana J, Rey-Benito G, Weldegebriel G, Mwenda JM, Parashar UD, Tate JE; Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) project working group. *Lancet Child Adolesc Health*. 2026 Aug 12:S2352-4642(26)00158-6. doi: 10.1016/S2352-4642(26)00158-6. Online ahead of print.PMID: 42586106

[Effectiveness and waning of the fourth dose mRNA COVID-19 vaccines for the prevention of SARS-CoV2 infection related hospitalisations and deaths.](#)

Li X, Mercadé-Besora N, Lam AS, Barboza C, Delmestri A, Duarte-Salles T, Man WY, Mosseveld M, Palomar-Cros A, Raventós B, Verhamme K, Català M, Jödicke AM. *J Infect*. 2026 Aug 5;93(3):106825. doi: 10.1016/j.jinf.2026.106825. Online ahead of print.PMID: 42556476

[Broad-Spectrum Multi-Epitope Design Targeting Conserved Hantavirus Glycoproteins \(Gn/Gc\): Chimeric Antigen Engineering and Structural Mapping.](#)

Fontes SDS, Conte FP, Fernandes J, Lemos ERS, Lima-Junior JDC, Oliveira RC, Rodrigues-da-Silva RN. *Int J Mol Sci*. 2026 Aug 5;27(15):7021. doi: 10.3390/ijms27157021.PMID: 42589673

[Experimental evaluation of a novel bivalent **vaccine** against porcine circovirus type 2d and *Mycoplasma hyopneumoniae*.](#)

Suh J, Na H, Ham S, Kang I, Chae C. *Vet Microbiol*. 2026 Aug 9;321:111190. doi: 10.1016/j.vetmic.2026.111190. Online ahead of print.PMID: 42585698

[High-quality genome assembly and annotation of inactivated animal **vaccine** bacteria strains in South Korea.](#)

Lee Y, Nah JJ, Go SM, Ku HO, Jang I. *BMC Genom Data*. 2026 Aug 5;27(1):65. doi: 10.1186/s12863-026-01475-x.PMID: 42576204

[Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.](#)

Torre L, Hadler SC, Hopkins KL, Sommers T, Best T, Ndiaye S. *Vaccine*. 2026 Aug 13;88:128856. doi: 10.1016/j.vaccine.2026.128856. Epub 2026 Jun 28.PMID: 42365745

[Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.](#)

Tharmaraj D, Naidu P, Baptista M, McBride S, Stuart R, Dendle C, Polkinghorne KR, Mulley WR. *Intern Med J*. 2026 Aug 5. doi: 10.1111/imj.70540. Online ahead of print.PMID: 42554002

[Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults.](#)

Hutton DW, Prosser LA, Ortega-Sanchez IR, Leidner AJ, Havers FP, Prill MM, Whitaker M, Roper LE, Pike J, Melgar M, Britton A. *Vaccine*. 2026 Aug 9;90:129023. doi: 10.1016/j.vaccine.2026.129023. Online ahead of print.PMID: 42571751

[Computational prediction and molecular simulation-based development of a multi-epitope mRNA **vaccine** targeting capsule polysaccharide proteins of *Enterobacter cloacae*.](#)

Singh S, Swaminathan P. *Comput Biol Chem.* 2026 Aug;123:108994. doi: 10.1016/j.compbiolchem.2026.108994. Epub 2026 Mar 2. PMID: 41791271

[A Phase 1, Open Label, Safety Study of HBV-002 \(West Nile Recombinant Subunit **Vaccine**\) in Healthy Adults.](#)

Coller BG, Clements DE, Yelmene M, Martyak T, Thorne M, Pai V, Henley R, O'Connell M, Weeks-Levy C, Parks DE. *Am J Trop Med Hyg.* 2026 May 21;115(2):366-371. doi: 10.4269/ajtmh.26-0124. Print 2026 Aug 5. PMID: 42167201

[Poly\(lactic-co-glycolic acid\) \(PLGA\)-based **vaccine** delivery systems for fish: physicochemical properties, immunological mechanisms, and applications.](#)

Chuang SC, Lin YC, Chou YS, Liu SP, Hung SW, Chang TC, Chen CH, Yang CD. *Fish Shellfish Immunol.* 2026 Aug;175:111458. doi: 10.1016/j.fsi.2026.111458. Epub 2026 May 26. PMID: 42203190

[Impact of confidence in scientific community, manufacturers, and regulatory authorities on acceptance of locally manufactured mRNA vaccines.](#)

Wong LP, Alias H, Lee HY. *Vaccine.* 2026 Aug 13;88:128792. doi: 10.1016/j.vaccine.2026.128792. Epub 2026 Jun 12. PMID: 42284810

[Designing a multi-epitope **vaccine** against *Leishmania major* with broad population coverage and innate immune activation through immunoinformatic approaches.](#)

Shaheen R, Bibi R, Aurongzeb M, Nazir MA, Rashid Y, Khan AA, Alwaili MA, Al-Hoshani N, Alzhrani K, Mansouri OA. *Transpl Immunol.* 2026 Aug;97:102411. doi: 10.1016/j.trim.2026.102411. Epub 2026 Jun 1. PMID: 42229593

[Beyond coverage: Timeliness of routine childhood vaccination and its determinants in rural northern Ghana.](#)

Konlan M, Bhandari R, Adjei MR, Owusu SA, Abiwu HAK, Nunifant A, Adongo SW, Mahama F, Robertson T, Kubio C. *Vaccine.* 2026 Aug 13;88:128981. doi: 10.1016/j.vaccine.2026.128981. Epub 2026 Jul 28. PMID: 42520646

[Coupled Information-Infection Dynamics Produce Information-Driven Shifts in Epidemic Regimes via Competing **Vaccine** Narratives.](#)

Azizi A, Kazanci C, Guo X. *Bull Math Biol.* 2026 Aug 9;88(9):151. doi: 10.1007/s11538-026-01719-y. PMID: 42571670

[Herpesvirus of Turkeys \(HVT\) **vaccine** confers limited protection against the cellular changes induced by very virulent plus Marek's disease virus \(vv + MDV\) strains in commercial meat-type chickens.](#)

Khaled N, Gaghan C, Fares AM, Goodell C, Stanley W, Kulkarni RR, Gimeno IM. *Vaccine.* 2026 Aug 13;88:128921. doi: 10.1016/j.vaccine.2026.128921. Epub 2026 Jul 14. PMID: 42447734

[The blood pressure-lowering effect of an anti-soluble epoxide hydrolase **vaccine** in angiotensin II-induced hypertension in mice.](#)

Shichida S, Takahashi Y, Shiraki A, Nakagami H, Node K. Hypertens Res. 2026 Aug;49(8):2399-2403. doi: 10.1038/s41440-026-02697-3. Epub 2026 Jun 9. PMID: 42265329

[Design and preclinical evaluation of a multi-epitope circular RNA **vaccine** targeting the spike protein of canine coronavirus genotype II.](#)

Zhang X, Wang L, He W, Ren Z, Zhang C, Zhou M, Wan J, Zhao J, Zhao L. Vet Microbiol. 2026 Aug 9;321:111188. doi: 10.1016/j.vetmic.2026.111188. Online ahead of print. PMID: 42579946

[Luciferase unleashed: Lighting the path to **vaccine** approval using a novel high-throughput chikungunya virus neutralization assay.](#)

Mendy J, Bedell L, Tindale LC, Richardson JS, Li N, Fontebasso Y, Pierson TC, Gottlieb K, Vang L. PLoS Negl Trop Dis. 2026 Aug 3;20(8):e0014610. doi: 10.1371/journal.pntd.0014610. Online ahead of print. PMID: 42546072

[Cross-reactive immunity against orthopoxviruses after monkeypox virus infection or smallpox vaccination.](#)

Trovato M, Accordini S, Giancesini N, Chesini LM, Cheri S, Cotugno G, Matucci A, Donini A, Mantovani RP, Cassaniti I, Rovida F, Ferrari A, Mazzi C, Tacconelli E, Baldanti F, Capobianchi MR, Caro AD, De Berardinis P, D'Apice L, Castilletti C. Int J Infect Dis. 2026 Aug 16;109047. doi: 10.1016/j.ijid.2026.109047. Online ahead of print. PMID: 42604648

[Lung-resident T-cell immunity dominates protection induced by an intranasal adenoviral nucleoprotein influenza **vaccine**.](#)

Wang WC, Alhashimi M, Gairola V, Murala MST, Dumka S, Sayedahmed EE, Sambhara S, Mittal SK. Vaccine. 2026 Aug 13;88:128962. doi: 10.1016/j.vaccine.2026.128962. Epub 2026 Jul 23. PMID: 42492242

[Construction of a Suckling Mouse Model Based on an EV-C96 Clinical Isolate and Its Application in Drug Screening and **Vaccine** Development.](#)

Wang J, Qu Y, He Y, Yang Q, Zhu H, Chen Y, Duan X, Zheng H, Xiao S, Liu Q, Liu H. Antiviral Res. 2026 Aug 13;106511. doi: 10.1016/j.antiviral.2026.106511. Online ahead of print. PMID: 42595093

[Perceptions of HPV vaccination among children aged 9-13 and parents: A qualitative study from Ankara, Türkiye.](#)

Ozeller E, Sarıca Çevik H, Peremans L. Public Health. 2026 Aug;257:106378. doi: 10.1016/j.puhe.2026.106378. Epub 2026 Jun 15. PMID: 42296926

[Protective antibody response following two doses of measles vaccination and factors for non-response among children from tribal Odisha, India.](#)

Dwibedi B, Patra G, Behera A, Kaur H, Tarai R. Indian J Med Res. 2026 Aug;164(2):311-315. doi: 10.25259/IJMR_3672_2025. PMID: 42555691

[Administrative Burden and Vaccination Uptake Disparities: Evidence from Medicaid Participation Among Low-Income Adults.](#)

Kochersperger EC. J Public Health Manag Pract. 2026 Aug 11. doi: 10.1097/PHH.0000000000002427. Online ahead of print. PMID: 42579887

[Incidence of outcomes relevant to **vaccine** safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.](#)

Bush C, Desai S, Wang H, Hsu WC, Newbern EC, Toyip A, Grace S, Mues KE, Arakaki B, Khamamkar V, Esposito DB, Zhou CK. Vaccine. 2026 Aug 13;88:128821. doi: 10.1016/j.vaccine.2026.128821. Epub 2026 Jun 15. PMID: 42296834

[The association of individual, interpersonal and social support factors with willingness to vaccinate against COVID-19 in rural South Africa.](#)

Mazibuko L, Hoór D, Nxumalo V, Nxumalo S, McGrath N, Seeley J, Shahmanesh M, Myburgh N, Harling G. Vaccine. 2026 Aug 5;89:128998. doi: 10.1016/j.vaccine.2026.128998. Online ahead of print. PMID: 42556300

[Differential immune responses elicited by two tetravalent epitope-based DNA vaccines differently designed for human hand-foot-and-mouth disease.](#)

Bello AM, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, Roshorm YM. Vaccine. 2026 Aug 13;88:128824. doi: 10.1016/j.vaccine.2026.128824. Epub 2026 Jun 13. PMID: 42287823

[Immunogenicity and Protective Efficacy of the First Autogenous Aeromonas hydrophila **Vaccine** for Piaractus brachypomus.](#)

Pereira LAB, do Nascimento Ferreira J, Dos Santos LPC, Sampaio LAF, de Barros IBA, Affonso EG, Yunis-Aguinaga J, da Silva Claudiano G. J Fish Dis. 2026 Aug 7:e70271. doi: 10.1111/jfd.70271. Online ahead of print. PMID: 42567699

[Global mapping of Streptococcus pneumoniae sequence types associated with multidrug resistance and capsular switching: A systematic review.](#)

Akwetey SA, Karikari AB, Ntim OK, Donkor ES. Infect Genet Evol. 2026 Aug;142:105957. doi: 10.1016/j.meegid.2026.105957. Epub 2026 May 16. PMID: 42144089

[Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, **Vaccine** Strain CVD 1208S-122.](#)

Chen WH, Barry EM, Toapanta FR, Pasetti MF, Sztein MB, Permala-Booth J, Tennant SM, Ortiz JR, Thomas C, McGilvray M, Roane L, Datar R, Liang Y, Levine MM. J Infect Dis. 2026 Aug 3;234(1):9-19. doi: 10.1093/infdis/jiag220. PMID: 41999631

[Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis **vaccine** as a booster to Australian adults: a randomized, controlled, non-inferiority trial.](#)

Ong MM, van den Biggelaar AHJ, Goh L, Hutton H, Fortuna L, Yuwaree V, Kerdsomboon C, Mansouri S, Thai PH, Richmond PC, Wadia U. *Vaccine*. 2026 Aug 13;88:128863. doi: 10.1016/j.vaccine.2026.128863. Epub 2026 Jun 24. PMID: 42349132

[A randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccination to accelerate immune recovery after sepsis.](#)

Shankar-Hari M, Smith P, Szakmany T, Summers C, McGuigan PJ, Brealey D, Hopkins P, Creagh Brown B, Pogson D, McKechnie S, Rostron A, Fish M, Jennings A, Hoekstra R, Rynne J, Ghnewa Y, Cape A, Rahman A, Palmer-Joyce J, Viola T, Ostermann M, Pearce E, Goldblatt D, Rubinfeld G, Rowan K, Walsh TS, Singer M, Spencer J, McAuley DF, Harrison DA. *Sci Transl Med*. 2026 Aug 12;18(862):eaeb4113. doi: 10.1126/scitranslmed.aeb4113. Epub 2026 Aug 12. PMID: 42585292

[STING-activating & ICD dual-response whole tumor cell **vaccine** amplifies TNBC immunotherapy.](#)

Lu Z, Gu W, Jiang F, Chen L, Chen S, Feng J, Hu Q, Jin Y. *Biomaterials*. 2026 Aug;331:124112. doi: 10.1016/j.biomaterials.2026.124112. Epub 2026 Mar 2. PMID: 41785630

[COVID-19 vaccination among people affected by sexually transmitted and bloodborne infections, methamphetamine use and their intersection in Manitoba, Canada: a retrospective matched cohort analysis using population-based administrative healthcare data \(2020-2022\).](#)

Shaw SY, Mahar A, Bailey K, Payne M, Kindrachuk J, Kelly C, Friesen KJ, Bernstein CN, Reimer JN, Becker ML, McClarty LM, Stein D, Nickel NC. *BMJ Open*. 2026 Aug 12;16(8):e122964. doi: 10.1136/bmjopen-2026-122964. PMID: 42586735

[Real-world analysis of depression-related adverse events associated with the adsorbed anthrax **vaccine**: integrating pharmacovigilance signals, machine learning risk prediction, and transcriptomic mechanisms.](#)

Qing G, Zhao Y, Yang J, Wang G. *Infect Dis Poverty*. 2026 Aug 10;15(1):86. doi: 10.1186/s40249-026-01483-0. PMID: 42576235

[High Levels of Protection Against Acute and Chronic Toxoplasmosis in Institute of Cancer Research Mice with a Novel Low-Temperature Inactivated *Toxoplasma gondii* Candidate **Vaccine** Adjuvanted with HA201/HA203.](#)

Bai SY, Zhou GQ, Li YY, Pan M, Fu L, Huang SY. *Foodborne Pathog Dis*. 2026 Aug;23(8):547-554. doi: 10.1089/fpd.2024.0159. Epub 2025 Jul 7. PMID: 40622279

[Clinicians' self-reported HPV vaccination recommendations for sexual and gender minority patients.](#)

Kasting ML, Sutton SK, Davish M, Quinn GP, Donahue KL, Christy SM. *Vaccine*. 2026 Aug 14;90:129037. doi: 10.1016/j.vaccine.2026.129037. Online ahead of print. PMID: 42600245

[Updates on the research on nanocarriers in fish **vaccine** oral, immersion and injection delivery: A major review.](#)

Wang WJ, Zhu Q, Zhi YX, Huang MM, Fei H, Yang S. *Vaccine*. 2026 Aug 13;88:128873. doi: 10.1016/j.vaccine.2026.128873. Epub 2026 Jun 25. PMID: 42349135

[Techno-economic evaluation of Islamic-compliant cell-based influenza **vaccine** production using AGE1.CR cell line in comparison to the current production using MDCK cell line.](#)

Zulkarnain NN, Anuar N, Abd Rahman N, Alias MN, Abdul PM, Ahmad Rodzli N, Sheikh Abdullah SR. *Bioprocess Biosyst Eng.* 2026 Aug;49(8):2101-2117. doi: 10.1007/s00449-026-03377-9. Epub 2026 Jul 9. PMID: 42423747

[Anchoring convenience survey samples to a baseline census for **vaccine** coverage monitoring in global health.](#)

Dyrkton N, Alam S, Shepherd S, Sana I, Phelan K, Park JJH. *Vaccine.* 2026 Aug 13;88:128820. doi: 10.1016/j.vaccine.2026.128820. Epub 2026 Jun 11. PMID: 42275800

[Efficacy evaluation of live attenuated vaccines against *Streptococcus agalactiae* Ia, administered to Nile tilapia \(*Oreochromis niloticus*\) by immersion or intraperitoneal injection.](#)

Fyrand K, Xu C, Evensen Ø. *Fish Shellfish Immunol.* 2026 Aug;175:111401. doi: 10.1016/j.fsi.2026.111401. Epub 2026 May 7. PMID: 42105831

[Prevalence and determinants of **vaccine** hesitancy in the City of Buenos Aires, Argentina: A probabilistic household survey.](#)

Angeleri P, Biscayart C, Ferrante D, Macchia A. *Vaccine.* 2026 Aug 15;90:129045. doi: 10.1016/j.vaccine.2026.129045. Online ahead of print. PMID: 42603507

[Multi-peptide subunit vaccination induced IFN- \$\gamma\$ but lacked efficacy against *Mycobacterium avium* subsp. paratuberculosis in a goat challenge trial.](#)

Erbs G, Lybeck K, Jakobsen JT, Nguyen LTM, Henriksen ES, Bull TJ, Aagaard C, Tollefsen S, Jungersen G. *Vaccine.* 2026 Aug 13;88:128971. doi: 10.1016/j.vaccine.2026.128971. Epub 2026 Jul 25. PMID: 42501714

[Evaluating the impact of immunization with the "pan-fungal" **vaccine**, NXT-2, on the gut mycobiome and microbiome in non-human primates \(NHPs\).](#)

Owora KO, Rabacal W, Hu A, Wychrij DA, Rayens E, Chapman TI, Bahl J, Norris KA. *Microbiol Spectr.* 2026 Aug 4;14(8):e0104726. doi: 10.1128/spectrum.01047-26. Epub 2026 Jul 15. PMID: 42454945

[Effectiveness of BNT162B2 and CoronaVac vaccines in reducing COVID-19 severity among children aged 3-4 years in Brazil.](#)

de Padua MC, Antunes MOB, Stein RT, Pinto LA, Jones MH, Friedrich F, Scotta MC. *Vaccine.* 2026 Aug 13;88:128974. doi: 10.1016/j.vaccine.2026.128974. Epub 2026 Jul 29. PMID: 42526176

[Adjuvant properties of baculovirus enhance the immunogenicity and protective efficacy of foot-and-mouth disease virus-like particles vaccines in mice.](#)

Lobo Gaitán FB, González-Mora RD, Tutti S, Igarza RC, Arneodo Larochette JD, Miraglia MC, Pérez Filgueira DM, Marrero Díaz de Villegas R, Taboga OA, Gismondi MI, Molinari MP. *Vaccine.* 2026 Aug 13;88:128958. doi: 10.1016/j.vaccine.2026.128958. Epub 2026 Jul 20. PMID: 42476038

[The marketing authorization of vaccines is not an exact science: the 20-valent pneumococcal conjugate **vaccine** \(PCV-20\) is an example.](#)

De Wals P. *Vaccine*. 2026 Aug 6;90:128984. doi: 10.1016/j.vaccine.2026.128984. Online ahead of print. PMID: 42561780

[The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis.](#)

Heinonen S, Vartiainen P. *Acta Paediatr*. 2026 Aug 14. doi: 10.1111/apa.70725. Online ahead of print. PMID: 42596794

[Investigating the role of baseline gut *Akkermansia muciniphila* and its co-metabolite palmitoleic acid in BCG **vaccine** efficacy: a preclinical study.](#)

Chen D, Chen L, Chen C, Yan Y, Wu X, Chen D, Yuan P, Long X, Zou Y, Lin J, Xu JF, Pi J, Zeng G, Lu Y, Ge Z. *EBioMedicine*. 2026 Aug;130:106404. doi: 10.1016/j.ebiom.2026.106404. Epub 2026 Jul 23. PMID: 42492179

[Routine early childhood vaccination uptake before and during the COVID-19 pandemic in Scotland: A population-based cohort study of administrative data.](#)

Smith CD, Hardie I, Auyeung B. *Public Health*. 2026 Aug 13;259:106460. doi: 10.1016/j.puhe.2026.106460. Online ahead of print. PMID: 42594547

[Signal peptide-mediated endoplasmic reticulum targeting enhances antigen expression and secretion to improve mRNA **vaccine** efficacy.](#)

Guo Z, Ran L, Fu J, Bao N, Hu H, Wu Z, Dong H, Mao Y, Jin Y. *Acta Biochim Biophys Sin (Shanghai)*. 2026 Aug 3. doi: 10.3724/abbs.2026115. Online ahead of print. PMID: 42550669

[Meningococcal B Vaccination Patterns Across 10 Integrated Health Systems within **Vaccine** Safety Datalink, 2015-2023.](#)

Groom HC, Brooks N, Dandamudi P, Smith N, Duffy J, Cocoros NM, Glanz JM, Jackson LA, Kadlecik P, Kharbanda EO, Lewin B, McNeil MM, Schmidt T, Sundaram ME, Weintraub ES, Williams JTB, Zerbo O, Naleway AL. *J Pediatr*. 2026 Aug 4;115274. doi: 10.1016/j.jpeds.2026.115274. Online ahead of print. PMID: 42551732

[AS01\(E\)-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein **Vaccine** \(Adjuvanted RSVPreF3\): Review of the First 2 Years of Post-Marketing Safety Surveillance.](#)

Tregunno C, Deraedt Q, Cuadripani S, Verheust C, Bryan P. *Drug Saf*. 2026 Aug 1. doi: 10.1007/s40264-026-01698-y. Online ahead of print. PMID: 42541670

[Influenza **vaccine** effectiveness in school outbreaks during a A\(H3N2\) subclade K \(J.2.4.1\)-dominated season in Beijing, China, 2025-26.](#)

Shen Y, Ma C, Zhang D, Shi W, Duan W, Li J, Zhang L, Wu D, Zhang J, Ma J, Wang Y, Hu X, Yan S, Di Y, Zhao J, Xu H, Lu G, Liu Y, Wang Q, Yang P, Feng Z. *Int J Infect Dis.* 2026 Aug;169:108777. doi: 10.1016/j.ijid.2026.108777. Epub 2026 May 9. PMID: 42114651

[Post-COVID-19 pandemic inequities in routine childhood immunization in Canada: racial disparities in uptake of polio, meningococcal conjugate, and varicella vaccines.](#)

Dalexis RD, Beogo I, Xu Y, Muray M, Kibret TC, Cénat JM. *Vaccine.* 2026 Aug 13;88:128931. doi: 10.1016/j.vaccine.2026.128931. Epub 2026 Jul 20. PMID: 42476039

[SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV.](#)

Frasca F, Maddaloni L, D'Auria A, Fracella M, Bugani G, Falvino C, Baccolini V, Migliara G, Aloisi F, Santinelli L, Palermo E, Bortolani L, Lazzaro A, Ceccarelli G, Turriziani O, Mastroianni CM, Antonelli G, d'Ettore G, Scagnolari C. *J Med Virol.* 2026 Aug;98(8):e71067. doi: 10.1002/jmv.71067. PMID: 42504161

[Maternal vaccination protects dams and prevents *in utero* transmission of Rift Valley fever virus in rats.](#)

Hertel AT, McMillen CM, Hoehl RM, Frey ZD, McElroy AK, Hartman AL. *mBio.* 2026 Aug 12;17(8):e0025326. doi: 10.1128/mbio.00253-26. Epub 2026 Jun 22. PMID: 42328864

[Immunogenicity and protective efficacy of an inactivated cluster 2.1 duck Tembusu virus vaccine in ducks: Evidence of cross-genotype immune responses.](#)

Rungprasert K, Areeraksakul P, Tunterak W, Prakairungnamthip D, Wannaratana S, Yurayart N, Charoenvisal N, Limpavithayakul K, Jansen CA, Nedumpun T, Banlunara W, Thontiravong A. *Vaccine.* 2026 Aug 13;88:128867. doi: 10.1016/j.vaccine.2026.128867. Epub 2026 Jun 19. PMID: 42320385

[Acute intraocular inflammation: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.](#)

Yeh S, Mathenge W, Mwanza JC, Shetty S, Taylor A, Kaftan T, Ali H, Law B. *Vaccine.* 2026 Aug 13;88:128919. doi: 10.1016/j.vaccine.2026.128919. Epub 2026 Jul 21. PMID: 42481266

[When coverage is high: rethinking the role of caregiver perceptions in childhood vaccination uptake in Uganda.](#)

Gunderson AK, Kwon T, Kumarasinghe Y, Yan Y, Choe J, Jiang Q, Baguma E, Bwambale S, Barber JR, Reyes R, Ntaro M, Delamater PL, Mulogo EM, Boyce RM. *Trans R Soc Trop Med Hyg.* 2026 Aug 5;120(8):862-872. doi: 10.1093/trstmh/trag045. PMID: 42037374

[Enhancing memory T cell responses through Soluble Leishmania antigen and natural adjuvants against Leishmania donovani in murine model.](#)

Saini I, Kaur S. *Microb Pathog.* 2026 Aug;217:108552. doi: 10.1016/j.micpath.2026.108552. Epub 2026 May 12. PMID: 42119954

[Parent-Reported Influenza Vaccination Uptake, Hesitancy and Willingness for In-School Children: Survey Findings From Shenzhen, China With Free Vaccination Services.](#)

Xu Y, Ren F, Zhang R, Fan J, Lin W. Trop Med Int Health. 2026 Aug;31(8):1115-1127. doi: 10.1111/tmi.70158. Epub 2026 May 3. PMID: 42070990

["Just the Best Ones" combination: a new strategy for multi-epitope **vaccine** candidate based on immunoinformatics analysis to induce protective immunity against MRSA infection.](#)

Chang Q, Niu L, Zhang C, Xue K, Yao X, Li H, Jia Z, Wang F, Ge J. Microbiol Spectr. 2026 Aug 4;14(8):e0308525. doi: 10.1128/spectrum.03085-25. Epub 2026 Jul 13. PMID: 42439548

[Strategies and lessons learned from a type 1 circulating **vaccine**-derived poliovirus \(cVDPV\) outbreak affecting adult population: Madagascar, 2020-2023.](#)

Djawa K, Aigbogun E, Zoumanigui JS, Berete A, Rimoyal R, Macaulay K, Sanou M, Fadeyi O, Sall DS, Oshokhai B, Thomas G, N'draman K, Coulibaly L, Randrianarijaona HME, Diaw M, Ranoharisoa H, Ratsarahajarizafy L, Rakotonavalona R, Nwaokorie C, Igbokwe U, Thompson A, Wiesen E, Ndoutabe M, Musango L. Vaccine. 2026 Aug 5;89:128987. doi: 10.1016/j.vaccine.2026.128987. Online ahead of print. PMID: 42556297

[Beyond Accuracy: A Mixed-Methods Audit of Chain-of-Thought Failures in LLM-Based COVID-19 **Vaccine** Stance Detection.](#)

Praschk A, Fischill-Neudeck V, Caspari T, Wiesinger HP. J Med Syst. 2026 Aug 8;50(1):123. doi: 10.1007/s10916-026-02449-3. PMID: 42570145

[Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design.](#)

Codi A, Rogawski McQuade E, Benkeser D. Vaccine. 2026 Aug 13;88:128908. doi: 10.1016/j.vaccine.2026.128908. Epub 2026 Jul 15. PMID: 42456559

[Letter to the Editor Regarding "Adult RSV Vaccination: What is the Role of RSV Subgroup in Disease Prevention?".](#)

Madhava H, Velthove K. Infect Dis Ther. 2026 Aug 12. doi: 10.1007/s40121-026-01418-0. Online ahead of print. PMID: 42587246

[Correction to: Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV **Vaccine** Administered 24 Months Following a Primary Dose in Adults 60 Years of Age.](#)

[No authors listed] J Infect Dis. 2026 Aug 14;jiag422. doi: 10.1093/infdis/jiag422. Online ahead of print. PMID: 42599736

[Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024.](#)

Businge GB, Mupere E, Gyasi SO, Le Doare K, van Hensbroek MB, Bijlsma MW, Voysey M. Open Forum Infect Dis. 2026 Jul 24;13(8):ofag459. doi: 10.1093/ofid/ofag459. eCollection 2026 Aug. PMID: 42549252

[Development and evaluation of recombinant Varicella-Zoster virus glycoprotein E protein microneedles for enhanced pediatric **vaccine** delivery.](#)

Lee DE, Cha HR, Lee YL, Chung HW, Park S, Oh YJ, Jung E, Baek SK, Ahn BC, Yum JS, Lee JM, Park JH. *Drug Deliv Transl Res*. 2026 Aug;16(8):2737-2750. doi: 10.1007/s13346-025-02012-6. Epub 2025 Nov 11. PMID: 41217681

[Unraveling the complexity of PRRSV-2 recombination: recombination frequency, replication efficiency, and backbone fitness define highly recombinogenic backbone and evolutionary bottlenecks.](#)

Wu W, Fang X, Gao X, Zhang J, Zhou Q, Gao P, Zhang Y, Ge X, Han J, Guo X, Zhou L, Yang H. *Microbiol Spectr*. 2026 Aug 4;14(8):e0118426. doi: 10.1128/spectrum.01184-26. Epub 2026 Jul 17. PMID: 42466896

[Immunogenicity of Human Papillomavirus Virus **Vaccine** in a High-risk and Understudied Group: Female Sex Workers.](#)

Van Trang N, Tuan LA, Mai CTN, Ly LTK, Lien THM, Chung NT, Huyen DTT, Uyen NTT, Thanh NTT, Nhung TTH, Quang C, Von Mollendorf C, Murray G, Garland SM, Bright K, Licciardi PV, Mulholland K, Toh ZQ. *J Infect Dis*. 2026 Aug 3;234(1):e60-e68. doi: 10.1093/infdis/jiag112. PMID: 41764658

[Booster **vaccine** reduces BCG-primed mice's protection against primary *Mycobacterium tuberculosis* infection by raising IL-10 levels.](#)

Lei Q, Lin X, Yao Z, Fu H, Wang Y, Yuan Y, Ouyang Q, Xu X, Cao J, Gan M, Fan X. *Vaccine*. 2026 Aug 13;88:128841. doi: 10.1016/j.vaccine.2026.128841. Epub 2026 Jun 17. PMID: 42308982

[A novel albumin-based nanoparticle **vaccine** including the globular knob domain of the egg drop syndrome virus fiber protein for egg drop syndrome: Immunogenicity and preliminary structural analyses.](#)

Bagheri A, Ghobadi S, Mostafaie A, Khodarahmi R, Askari S. *Int Immunopharmacol*. 2026 Aug 1;182:116852. doi: 10.1016/j.intimp.2026.116852. Epub 2026 May 16. PMID: 42143501

[Pre-clinical Immunogenicity and Safety Evaluation of H2 strain Hepatitis A Inactivated **Vaccine** in rhesus macaques.](#)

Ping L, Chu H, Li Z, Liang J, Cai L, Yang J, Jiang Q, Wang X, Li J, Hu W, Ma Y, Gu Q, Gao N, Ji Q, Wen J, Liao H, Ji G, Jiang H, Hou D, Fu Y, Fu Y, Kong W, Qin X, Zheng H, Zhao T, Fan S, Yang J. *Antiviral Res*. 2026 Aug 11:106498. doi: 10.1016/j.antiviral.2026.106498. Online ahead of print. PMID: 42580485

[Development of an oral *Lactobacillus casei*-based recombinant **vaccine** expressing GCRV-II multi-epitope fusion protein and its protective efficacy against grass carp hemorrhagic disease.](#)

Chen X, Chen Y, Wang D, Tang J, Zhang Z, Cai F, Zhao K, Yin Z, Chen R, Mao H, Tian F, Xu X, Hu C. *Fish Shellfish Immunol*. 2026 Aug 4;178:111616. doi: 10.1016/j.fsi.2026.111616. Online ahead of print. PMID: 42546999

[Expert Consensus on Influenza **Vaccine** and Pneumococcal Vaccination in Elderly People With Chronic Respiratory Diseases \(2024\).](#)

Wang L, Yu Q, Chen Q, Yu P; Expert Committee of Consensus Opinion on Influenza Vaccine and Pneumococcal Vaccine Vaccination for Elderly People with Chronic Respiratory Diseases, Respiratory Group of Chinese Geriatrics Society. *Aging Med (Milton)*. 2026 Aug 13:10.1002/agm2.70090. doi: 10.1002/agm2.70090. Online ahead of print. PMID: 42598701

[Comparative clinical, immunological, and pulmonary responses to virulent bovine respiratory syncytial virus infection in colostrum-fed, intranasally vaccinated calves.](#)

Ellis J, Gow S, Sniatynski M, Lacoste S. J Am Vet Med Assoc. 2026 Aug 12;1-7. doi: 10.2460/javma.26.04.0247. Online ahead of print. PMID: 42590789

[The protective efficacy of inactivated **vaccine** against hemorrhagic fever with renal syndrome: A meta-analysis: Erratum.](#)

Wu W, Liu J, Guo S, Zhao H, Yang X. Medicine (Baltimore). 2026 Aug 14;105(33):e50151. doi: 10.1097/MD.00000000000050151. PMID: 42601781

[Identification of a reassortant infectious bursal disease virus \(genotype A3B1\) in the United Kingdom: pathogenicity and immune complex **vaccine** efficacy.](#)

Bech G, Marzo E, Blake-Dyke C, Busquet M, Woodward M, Alech M, Solé M, Sánchez A, Sebastià E. Avian Pathol. 2026 Aug 3;1-13. doi: 10.1080/03079457.2026.2701308. Online ahead of print. PMID: 42544918

[Clinical features and outcomes of pediatric breakthrough invasive pneumococcal disease \(IPD\) in vaccinated children in Calgary, Alberta, Canada, 2003-2024.](#)

Doucette EJ, Ricketson LJ, Murguía-Favela L, Wright N, Kellner JD. Vaccine. 2026 Aug 6;90:128977. doi: 10.1016/j.vaccine.2026.128977. Online ahead of print. PMID: 42561781

[V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.](#)

Myers TR, Zauche LH, Marquez PL, McCullum I, Hause AM, Shay DK. Vaccine. 2026 Aug 13;88:128725. doi: 10.1016/j.vaccine.2026.128725. Epub 2026 Jun 30. PMID: 42378925

[**Vaccine** antibody responses in children with inborn errors of metabolism on protein-restricted diets: an overlooked silent risk?](#)

Yılmazbaş NP, Çakar NE, Yıldız S, Karamanlı G, İdrisoğlu MF. J Pediatr Endocrinol Metab. 2026 Aug 4. doi: 10.1515/jpem-2026-0219. Online ahead of print. PMID: 42544393

[Perceptions and practices among students, parents, and teachers of the Human Papillomavirus \(HPV\) Vaccination: A pilot feasibility study from Rural Kerala.](#)

John A, Rasheed R, Idikula MJ. PLoS One. 2026 Aug 10;21(8):e0340559. doi: 10.1371/journal.pone.0340559. eCollection 2026. PMID: 42574468

[Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA **Vaccine** Versus Placebo.](#)

McNeel DG, Eickhoff JC, Perez A, Liu G. Clin Genitourin Cancer. 2026 Aug;24(5):102589. doi: 10.1016/j.clgc.2026.102589. Epub 2026 May 30. PMID: 42303538

[Personalized Autologous Vaccines Activate Stimulator of Interferon Gene and Suppress Dendritic Cell Programmed Death Ligand 1 to Potentiate Antitumor Immunity.](#)

Yang Z, Han H, Zhao Z, Ding L, Xu X, Ma M, Luo M, Tang W. *ACS Nano*. 2026 Aug 11;20(31):21752-21766. doi: 10.1021/acsnano.6c03725. PMID: 42503762

[In arms and on slides: slavery-related interests in the dissemination of smallpox **vaccine** in Brazil and Angola, 1804-1810.](#)

Brizola JH, Santos GGD. *Hist Cienc Saude Manguinhos*. 2026 Aug 7;33(suppl 1):e2026027. doi: 10.1590/S0104-59702026000100027en. eCollection 2026. PMID: 42585445

[Rescuing Dendritic Cells from Adjuvant Toxicity: Liposomal Ginsenoside Rh2 as a Dual-Action Strategy for Enhanced **Vaccine** Potency.](#)

Nie Q, Chen L, Cao W, Chen Z, Wang X, Gong W, Yu X, Liu Y, Zhang S, Yang Y, Zou Y, Huang Y, Zhang J, Meng Z. *Mol Pharm*. 2026 Aug 3;23(8):4360-4376. doi: 10.1021/acs.molpharmaceut.6c00787. PMID: 42411873

[Autologous tumor lysate vaccines enhance anti-glioma immunity and prolong survival in a GL261 glioblastoma mouse model.](#)

Dong B, Zheng M, Feng S, Jiang X, Wang P, Zou B, Zhang Y, Huo Y, Feng X. *Vaccine*. 2026 Aug 13;88:128758. doi: 10.1016/j.vaccine.2026.128758. Epub 2026 Jun 10. PMID: 42269283

[Risk of major structural birth defects following repeat mRNA COVID-19 vaccination in the first trimester: a population-based cohort study.](#)

Wee LE, Bin Abdul Malek MI, Ho RW, Lim JT, Chiew C, Li RJ, Chong CY, Choolani M, Lye D, Tan KB. *Clin Microbiol Infect*. 2026 Aug;32(8):1302-1310. doi: 10.1016/j.cmi.2026.03.027. Epub 2026 Mar 27. PMID: 41905557

[IRO-203: a novel intranasal COVID-19 **vaccine** showing immunogenicity and viral suppression in African green monkey challenge study.](#)

Kusano K, Suzuki S, Washizawa K, Takizawa K, Hara I, Kawaguchi J, Mori T. *Sci Rep*. 2026 Aug 11;16(1):24723. doi: 10.1038/s41598-026-60421-0. PMID: 42581065

[Protective and immunostimulatory effects of a vitellogenin functional domain-based **vaccine** in Atlantic salmon against *Caligus rogercresseyi*.](#)

Casuso A, Rodríguez-Gabilondo A, Leal Y, Gallardo-Escárate C, Valenzuela-Muñoz V. *Vaccine*. 2026 Aug 14;90:129025. doi: 10.1016/j.vaccine.2026.129025. Online ahead of print. PMID: 42600248

[Do the protein-based meningococcal group B vaccines, 4CMenB and MenB-fHbp, elicit serum bactericidal antibody against meningococcal serogroup X clonal complex 181?](#)

Townsend-Payne K, Hill E, Ali H, Mabey L, Clark SA, Basta NE, Linley E, Borrow R. *Int J Infect Dis*. 2026 Aug;169:108752. doi: 10.1016/j.ijid.2026.108752. Epub 2026 Apr 30. PMID: 42069330

[Immunoinformatics-driven design of a multiepitope **vaccine** against the EGFR extracellular domain for head and neck squamous cell carcinoma.](#)

Shah FH, Cho JS, Moon WW, Jo YR, Huh SJ, Chung HJ, Jung J, Jeong NY. Hum Immunol. 2026 Aug 14;87(10):112042. doi: 10.1016/j.humimm.2026.112042. Online ahead of print. PMID: 42600189

[\[Analysis of influencing factors on the second dose of varicella **vaccine** for children aged 1-12 years in 10 provinces of China\].](#)

Liu X, Hu RY, Yu WZ, Yu QS, Cao L, Song YF, Zhang ZN, Zhang S, Li L, Yin ZD, Ye JK. Zhonghua Yu Fang Yi Xue Za Zhi. 2026 Aug 6;60(8):1294-1299. doi: 10.3760/cma.j.cn112150-20250830-00844. PMID: 42595537

[Molecular cloning, mRNA expression analysis of immune-related genes and innate immune response of freshwater African catfish \(*Clarias gariepinus*\) vaccinated with heat-killed *Aeromonas hydrophila*.](#)

Adibe AC, Elsheshtawy A, Crumlish M, Payne C, MacKenzie S. Dev Comp Immunol. 2026 Aug 12;183:105706. doi: 10.1016/j.dci.2026.105706. Online ahead of print. PMID: 42586284

[Invasive pneumococcal disease by serotype 23B in an asplenic unvaccinated patient: A case report.](#)

Tanaka Y, Hayashi K, Abe Y, Uesaka S, Maeda H, Suzuki A, Nakaya Y, Takamura Y, Sato M, Kobayashi Y, Sakamaki I. IDCases. 2026 Aug 4;45:e02698. doi: 10.1016/j.idcr.2026.e02698. eCollection 2026. PMID: 42598152

[Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five *Shigella* serotypes.](#)

Boccadifuoco G, Fantoni G, Verdirosa F, Petri C, Lashchuk S, Mancini F, Piu P, Hogrefe W, Sunshine J, Micoli F, Rhyne PW, Alaimo C, Rossi O, Molesti E, Montomoli E, Manenti A. Vaccine. 2026 Aug 13;88:128965. doi: 10.1016/j.vaccine.2026.128965. Epub 2026 Jul 25. PMID: 42501717

[Systemic barriers to achieving yellow fever vaccination coverage targets among children aged 9-23 months in the Democratic Republic of the Congo.](#)

Nkodila AN, Luvande RO, Nsana AB, Wembonyama SO, Likwela JL, N'siala AK, Lukanu PN. Vaccine. 2026 Aug 13;88:128995. doi: 10.1016/j.vaccine.2026.128995. Epub 2026 Jul 31. PMID: 42542050

[Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue **vaccine**.](#)

Gottardo R, Dean H, Nascimento EJM, Tricou V, Sharma M. Vaccine. 2026 Aug 13;88:128929. doi: 10.1016/j.vaccine.2026.128929. Epub 2026 Jul 21. PMID: 42480195

[Vaccine hesitancy among healthcare professionals: factors associated with continuity of the COVID-19 vaccination schedule.](#)

Prado ACTD, Silva ALB, Amaral GG, Viegas SMDF, Machado RM, Oliveira VC, Guimarães EAA. Rev Bras Enferm. 2026 Aug 3;79:e20250477. doi: 10.1590/0034-7167-2025-0477. eCollection 2026. PMID: 42561254

[Experimental validation of a computationally designed mosquito midgut SGU protein-based epitope **vaccine** against malaria.](#)

Singh H, Dahiya N, Kirar M, Yadav M, Janjoter S, Sehrawat N. Dev Comp Immunol. 2026 Aug 15;105712. doi: 10.1016/j.dci.2026.105712. Online ahead of print. PMID: 42603668

[Why COVID-19 vaccination struggled in the Democratic Republic of Congo: a qualitative study exploring organizational and sociocultural barriers, 2025.](#)

Kazenza B, Masokolo B, Mbunga B, Egbende L, Elemo S, Lukusa J, Makindu D, NKamba D, Isosho D, Lusamba PS, Mafuta E. Vaccine. 2026 Aug 11;90:129033. doi: 10.1016/j.vaccine.2026.129033. Online ahead of print. PMID: 42585810

[DC vaccine loaded with Bacteroides fragilis elicits functional cross-reactivity and enhances anti-PD-1 immunotherapy.](#)

Hu S, Shi G, Zhao J, Long X, Tang L, Qi Z, Xu X, Cheng P, Liu J. Mol Ther. 2026 Aug 13:S1525-0016(26)00702-1. doi: 10.1016/j.ymthe.2026.08.021. Online ahead of print. PMID: 42596550

[Establishing humoral immunity to rabies in a person with multiple sclerosis through booster vaccination: A case report.](#)

Dinov D, Hardeman P, Tessier J, Sguigna PV. Mult Scler J Exp Transl Clin. 2026 Aug 13;12(3):20552173261474744. doi: 10.1177/20552173261474744. eCollection 2026 Jul-Sep. PMID: 42602172

[When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives.](#)

Kara V, Van Hunsel F, Younus M, Hauben M, Bate A, van Puijenbroek E. Drug Saf. 2026 Aug 14. doi: 10.1007/s40264-026-01691-5. Online ahead of print. PMID: 42599564

[Spore surface display of Chinook salmon bafinivirus \(CSBV\) nucleoprotein in Bacillus subtilis as an oral vaccine candidate for Japanese flounder Paralichthys olivaceus.](#)

Zhang Y, Wang G, Liu Y, He Z, He Z, Han T, Ren Y, Hou J. Fish Shellfish Immunol. 2026 Aug;175:111426. doi: 10.1016/j.fsi.2026.111426. Epub 2026 May 12. PMID: 42128078

[One health, one goal: Global imperatives for Nipah virus vaccine development.](#)

Thakur A. Diagn Microbiol Infect Dis. 2026 Aug 8;116(4):117609. doi: 10.1016/j.diagmicrobio.2026.117609. Online ahead of print. PMID: 42600205

[A novel self-amplified RNA vaccine co-expressing NA and HA1 delivered by Salmonella confers potent protection against H9N2 influenza in chickens.](#)

Wang M, Gao Y, Zhang Y, Zhang G, Xu Y, Wang T, Yang T, Zhang Y, Sun Y, Guo Q, Wang Z, Wang C, Jiang Y. Poult Sci. 2026 Aug;105(8):107072. doi: 10.1016/j.psj.2026.107072. Epub 2026 May 2. PMID: 42096905

[Expanding enhanced influenza vaccines programs for adults aged ≥65 in the Nordic region predicted to improve public health and health system resilience.](#)

Grootendorst A, Paludan-Müller AS, Madsen K, Støvring H, Nilsson A, Mould-Quevedo J. *Vaccine*. 2026 Aug 13;88:128934. doi: 10.1016/j.vaccine.2026.128934. Epub 2026 Jul 17. PMID: 42468224

[Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barre syndrome in the Vaccine Safety Datalink.](#)

Yih WK, Duffy J, Daley MF, Fireman B, Kim S, Klein N, McClure DL, Qian L, Smith N, Stein A, Vazquez-Benitez G, Weintraub E, Xu S, Zhu J, Maro JC. *Vaccine*. 2026 Aug 13;88:128949. doi: 10.1016/j.vaccine.2026.128949. Epub 2026 Jul 17. PMID: 42468225

[Molecular Surveillance and Genomic Characterization of Influenza A\(H3N2\) Viruses From a Secondary-Care Surveillance Site in Pakistan During the 2025-2026 Winter Season.](#)

Javed A, Hayat J, Haider SA, Jamal Z, Hakim R, Ali Q, Bullo MMH, Tahir M, Salman M, Javed Y, Waheed Y, Umair M. *J Med Virol*. 2026 Aug;98(8):e71075. doi: 10.1002/jmv.71075. PMID: 42485504

[Constructing a novel chimeric multiepitope vaccine against Simian immunodeficiency virus accessory proteins: Using hybrid deep learning algorithms and bioinformatics-driven tools.](#)

Karbalaee-Alinazari MM, Hashempour A, Hassanzadeh F, Hassanzadeh Z. *Comput Biol Chem*. 2026 Aug 9;125:109316. doi: 10.1016/j.compbiolchem.2026.109316. Online ahead of print. PMID: 42579895

[5-Year effectiveness of an oral cholera vaccine in a cholera outbreak in rural Haiti: a case-control study.](#)

Ivers LC, Guillaume Y, LaHood A, Augustin GC, Casseus A, Slater DM, Harris JB, Ternier R, Franke MF. *Lancet Reg Health Am*. 2026 May 30;60:101500. doi: 10.1016/j.lana.2026.101500. eCollection 2026 Aug. PMID: 42257677

[Enhanced cellular immunity against varicella-zoster virus by \$\beta\$ -sitosterol-substituted lipid nanoparticles in mRNA vaccines.](#)

Bian L, Cui J, Li G, Cao Y, Li D, Sun D, Gu J, Xing L, Zhou J, Yang Y, Su W, Chen Y, Zhang Y. *Int Immunopharmacol*. 2026 Aug 11;187:117252. doi: 10.1016/j.intimp.2026.117252. Online ahead of print. PMID: 42580145

[Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.](#)

Liu X, Cloughesy JN, Yu T, Ferranna M. *Vaccine*. 2026 Aug 13;90:129003. doi: 10.1016/j.vaccine.2026.129003. Online ahead of print. PMID: 42594641

[Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire.](#)

Chen H, Zhang Z, Wen Z, Yang Z, Li L, Wang S, Gao Q, Liu H, Liu L, Chen Y. *J Control Release*. 2026 Aug 13:115262. doi: 10.1016/j.jconrel.2026.115262. Online ahead of print. PMID: 42595179

[Balancing Act: Dual targeting of PhoPQ and QseBC two-component systems in *Edwardsiella tarda* enhances attenuation but diminishes protective immunity.](#)

Rehman MNU, Lin Y, Feng W, Wang M, Khan I, Fan L, Li X, Yang N, Guo G, Zheng J. *Microb Pathog*. 2026 Aug 12;219:108764. doi: 10.1016/j.micpath.2026.108764. Online ahead of print. PMID: 42586514

[PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.](#)

Liu P, Chen Q, Zhou Z, Xu Y, Li J. *Adv Sci (Weinh)*. 2026 Aug 11:e77089. doi: 10.1002/advs.77089. Online ahead of print. PMID: 42579297

[Protective efficacy of a PcrV-based **vaccine** formulated with chitosan nanoparticles against *Pseudomonas aeruginosa* infection in burn and sepsis mouse models.](#)

Jafarvand Atashgah H, Haghighat S, Abdolghaffari AH. *Burns*. 2026 Aug;52(6):108033. doi: 10.1016/j.burns.2026.108033. Epub 2026 Apr 29. PMID: 42114463

[Adapting in-cell ELISA to investigate the localization of hepatitis C virus envelope glycoproteins.](#)

Dimitriadis S, Edmans M, Frumento N, Hong Xiang N, Bailey J, Cox A, Klenerman P, Barnes E, Zurbia-Flores GM. *Microbiol Spectr*. 2026 Aug 11:e0289525. doi: 10.1128/spectrum.02895-25. Online ahead of print. PMID: 42578686

[Occupationally Exposed and General Population Antibody Profiles to Influenza A Viruses Circulating in Swine as Indication of Zoonotic Risk.](#)

Snyder CA, Janzen GM, Zanella GC, Moraes DCA, Silva GS, Santos JJS, Drapeau EM, Hensley SE, Anderson TK, Gauger PC, Baker AL. *Emerg Infect Dis*. 2026 Aug;32(8):1286-1296. doi: 10.3201/eid3208.251995. PMID: 42521455

[Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate **vaccine**.](#)

Launay O, Piat E, Bonduelle O, Bruhwylér J, Luong LB, Wokam M, Tourneur J, Moris P, Parfait B, Paques C, Téllez TG, Combadière C, Boissonnas A, Le Vert A, Groth N, Nicolas F. *J Infect Dis*. 2026 Aug 12:jiag409. doi: 10.1093/infdis/jiag409. Online ahead of print. PMID: 42583791

[Transcriptional analyses of peripheral blood lymphocytes obtained shortly after primary immunization discriminate vaccines against *Francisella tularensis*.](#)

De Pascalis R, Espich S, Khan H, Toney M, Chao-Kai C, Wells W, Elkins KL. *Infect Immun*. 2026 Aug 14:e0020826. doi: 10.1128/iai.00208-26. Online ahead of print. PMID: 42599158

[The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages.](#)

Chen F, Kim Nguyen YT, Lee YZ, Giang E, Lau SC, Koide Y, Hung SH, Ueno LA, He L, Toth EA, Fuerst TR, Lauer GM, Stanfield RL, Zhu J, Wilson IA, Law M. *Cell Rep*. 2026 Aug 4;45(8):117760. doi: 10.1016/j.celrep.2026.117760. Online ahead of print. PMID: 42550688

[Brucella abortus RB51 Persistent Infection and Milk Shedding in Vaccinated Dairy Cattle: A Public Health Risk.](#)

Hines ES, Margrey SF, Cox SW, Quance C, Thacker TC, Collins PL, Rollo S, Bulaga-Seraphin LL, Hunt A, Stevens G, Cadmus K, Negron M, Kharod G, Tiller R, Robbe-Austerman S, Lombard JE. *Zoonoses Public Health*. 2026 Aug 14. doi: 10.1111/zph.70079. Online ahead of print. PMID: 42598836

[Effectiveness of the recombinant zoster **vaccine** in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.](#)

Kluberg SA, Mayer SE, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahonill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh NJ, Bhattacharyya S, Ogdie A, George M. *Mult Scler*. 2026 Aug 13:13524585261468620. doi: 10.1177/13524585261468620. Online ahead of print. PMID: 42590996

[Optimising Pharmacovigilance Efficiency with MLIT \(Machine Learning for Intelligent Triage\): A Tool for Statistical Safety Alerts.](#)

Ciccarelli L, Mahaux O, Roshan C, Fofana A, Kawka A, Occhipinti E, Possidente M, Cenci S, Painter JL, Bate A. *Drug Saf*. 2026 Aug 10. doi: 10.1007/s40264-026-01696-0. Online ahead of print. PMID: 42573921

[Sadness, Risk Direction, and Correction of Health Misinformation: Effects on Beliefs and Sharing Intentions.](#)

Na K. *J Health Commun*. 2026 Aug 11:1-12. doi: 10.1080/10810730.2026.2716163. Online ahead of print. PMID: 42578915

[Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 **vaccine** over 5 years and its potential public health impact among older adults in Italy.](#)

Puggina A, Zarkadoulas E, Rumi F, Marijam A, Calabrò GE. *Eur J Health Econ*. 2026 Aug 7. doi: 10.1007/s10198-026-01968-7. Online ahead of print. PMID: 42565962

[Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025.](#)

Maeda H, Igarashi A, Mitsui S, Suzuki K, Kutomi T, Fujino H, Onoe T, Kimura T, Ichigi Y, Kozai H, Komazaki T, Kida S, Fujisawa A, Morimoto K. *Vaccine*. 2026 Aug 13;88:128964. doi: 10.1016/j.vaccine.2026.128964. Epub 2026 Jul 25. PMID: 42501715

[Adaptation of wild-type rabies virus on **vaccine** producing cell line and its quantification by peroxidase-based immunostaining.](#)

Riaz MR, Kamran Ullah SM, Rashid M, Ullah K, Ahmad H, Kaleem QM, Jamil F, Khan S. *Arch Virol*. 2026 Aug 14;171(9):254. doi: 10.1007/s00705-026-06717-y. PMID: 42601531

[Critical roles of CD4-1\(+\) T cells and their secreted IL-21 in **vaccine**-induced humoral immunity in grass carp.](#)

Zhang N, Liu X, Zhu R, Dong WJ, Huang YH, Zhang YA, Zhang XJ. *Fish Shellfish Immunol*. 2026 Aug;175:111421. doi: 10.1016/j.fsi.2026.111421. Epub 2026 May 12. PMID: 42119748

[A Systematic Review and Meta-Analysis of Psychological Interventions for Reducing Distress During **Vaccine** Injections.](#)

McMurtry CM, Taddio A, Shah V, Lang E, MacDonald NE, Constantin K, Logeman C, Uleryk E; HELPinKids&AdultsII||. Clin J Pain. 2026 Aug 1;42(8S Suppl 1):e1376. doi: 10.1097/AJP.0000000000001376.PMID: 41880234

[Computational formulation of a broad-spectrum multi-epitope **vaccine** against bacterial pathogens implicated in periodontal and systemic diseases.](#)

Khatrawi EM.3 Biotech. 2026 Aug;16(8):323. doi: 10.1007/s13205-026-04958-x. Epub 2026 Jul 15.PMID: 42459414

[Role of **Vaccine** Age Restrictions on Rotavirus **Vaccine** Coverage, **Vaccine** Safety Datalink 2018-2024.](#)

Cates JE, Haapala J, Baker JM, Vazquez-Benitez G, Daley MF, Lewin B, Klein NP, Naleway AL, Jackson LA, Williams JTB, Sundaram ME, Weintraub ES, Kharbanda EO, Parashar U, DeSilva M, Tate JE.J Pediatric Infect Dis Soc. 2026 Aug 4;15(8):piag056. doi: 10.1093/jpids/piag056.PMID: 42446961

[Dirty mice better recapitulate key features of mRNA **vaccine** immunogenicity observed in humans.](#)

Praena B, Shepherd FK, McDonald CA, Joshi D, Gupta SL, Ellis ML, Lai L, Moreno A, Roach SN, Pierson MJ, Gilbertsen AJ, Davis C, Suthar MS, Wrammert J, Langlois RA.mBio. 2026 Aug 12;17(8):e0098326. doi: 10.1128/mbio.00983-26. Epub 2026 Jul 6.PMID: 42405763

[Multidomain expert evaluation of leading large language models as providers of vaccination and preventive medicine information.](#)

Di Pumpo M, Villani L, Maio V, Gualano MR, Marziali E, De Maio L, Mancini R, Boccia S, Ricciardi W, Laurenti P.Public Health. 2026 Aug;257:106359. doi: 10.1016/j.puhe.2026.106359. Epub 2026 Jun 6.PMID: 42250396

[Comparative immunogenicity and cross-protection of wild-type and reverse genetics H5N8 \(clade 2.3.4.4b\) oil-adjuvanted vaccines against circulating H5N1 avian influenza viruses from clades 2.3.4.4b and 2.2.1.2.](#)

Abdelaal AM, Mahmoud SH, Shehata MR, Tarek AbdElSalam E, Abo Shama NM, Kandeil AM, Shehata M, Ali MA, Khalil AA.Avian Pathol. 2026 Aug;55(4):548-561. doi: 10.1080/03079457.2026.2671739. Epub 2026 Jun 3.PMID: 42231810

[Distinct cytotoxic cell subsets underlie protective and non-protective immunity to African swine fever virus.](#)

Marín-Moraleda D, Tort-Miró A, Ezcurra E, Montaner-Tarbes S, Muñoz-Basagoiti J, Coatu E, Navas MJ, Muñoz M, Monleon P, González-Oliver J, Pailler-García L, Pina-Pedrero S, Accensi F, Rodríguez F, Argilaguet J.Emerg Microbes Infect. 2026 Dec;15(1):2685920. doi: 10.1080/22221751.2026.2685920. Epub 2026 Aug 12.PMID: 42246494

[Immune responses triggered by oral administration of recombinant Bacillus subtilis expressing the E2 protein of classical swine fever virus.](#)

Zhao Y, Ma Z, Zhang Z, Lv J, Zhang L, Yu R, Lan X, Bai Y, Zhai K, Guo H, Pan L, Liu X.Virology. 2026 Aug;621:110924. doi: 10.1016/j.virol.2026.110924. Epub 2026 Apr 24.PMID: 42096829

[Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus-Like Particle Recovery.](#)

Samuelson N, Parker N, Wang S, Daley S, Cote A, Winters MA. *Biotechnol Bioeng*. 2026 Aug 16. doi: 10.1002/bit.70346. Online ahead of print. PMID: 42604587

[Keystone Epitope Theory: An Ecological Perspective on RNA Viruses, Tumor Immunoediting, and Vaccine Design.](#)

Mallal S, Asiaee A. *Pathog Immun*. 2026 Aug 7;11(2):39-65. doi: 10.20411/pai.v11i2.1011. eCollection 2026. PMID: 42598440

[Irradiation-based development of tumor vaccines: Mechanistic insights and translational exploration.](#)

Tian J, Feng X, Yu B, Zhang J, Jing J, Jin X. *Crit Rev Oncol Hematol*. 2026 Aug 6;227:105516. doi: 10.1016/j.critrevonc.2026.105516. Online ahead of print. PMID: 42562242

[Comparison of Immunogenicity of Cood-Cotd, CfaB-st-CfaE, and Cssa-Cssb-ltb Chimeric Proteins and Their Chitosan Nanoparticles Against ETEC in an Animal Model.](#)

Zarei B, Amani J, Haghighat S. *Protein J*. 2026 Aug;45(4):576-588. doi: 10.1007/s10930-026-10342-8. Epub 2026 Jun 9. PMID: 42262472

[The immunogenicity and safety of adenoviral-based vaccines.](#)

Gardner J. *Curr Opin Allergy Clin Immunol*. 2026 Aug 1;26(4):264-273. doi: 10.1097/ACI.0000000000001167. Epub 2026 May 14. PMID: 42138330

[Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.](#)

Cooper LV, Djedanem M, Nasser AA, Moussa K, Mamadou K, Ibrahima C, Douchi M, Baruch J, Fernandez K, Latt A, Lingani C, Bitá A, Berry I, Swarthout T, Guindo O, Pezzoli L, Tassiou EI, Coldiron M. *Vaccine*. 2026 Aug 12;90:128997. doi: 10.1016/j.vaccine.2026.128997. Online ahead of print. PMID: 42585809

[Construction of a subunit vaccine based on Mycobacterium tuberculosis EsxE and evaluation of its immunogenicity and ex vivo mycobacterial growth inhibitory activity.](#)

Wang R, Wang X, Wang B, Xu Y, Zhong Q, Zhou M, Wang S, Xiao R, Yang G. *Arch Microbiol*. 2026 Aug 7;208(11):546. doi: 10.1007/s00203-026-05076-1. PMID: 42566003

[High effectiveness of infant vaccination against pertussis in 1- and 2-year-olds, the Netherlands, 2013-2024.](#)

van Meijeren DL, van Roon AM, de Gier B, Huiberts AJ, Knol MJ, Hahné SJM, de Melker HE. *Vaccine*. 2026 Aug 13;88:128978. doi: 10.1016/j.vaccine.2026.128978. Epub 2026 Jul 29. PMID: 42526173

[ELISA-based quantification of neuraminidase in commercial influenza vaccines using virus-derived reference antigens.](#)

Kang H, Gao J, Giurgea L, Memoli MJ, Daniels R. *Microbiol Spectr*. 2026 Aug 4;14(8):e0122726. doi: 10.1128/spectrum.01227-26. Epub 2026 Jun 24. PMID: 42339829

[Four Decades of Stress, Depression, and Close Relationships: Lessons from Psychoneuroimmunology.](#)

Kiecolt-Glaser JK. *Annu Rev Psychol.* 2026 Aug 7. doi: 10.1146/annurev-psych-020226-033326. Online ahead of print. PMID: 42566682

[Human monoclonal antibodies from donors vaccinated with recombinant vaccinia **vaccine** targeting A35 and B6 effectively inhibit orthopoxvirus spread and infection.](#)

Zhang J, Hao Y, Li D, Shen X, Song H, Shi Y, Wang S, Wang S, Liu Y. *Antiviral Res.* 2026 Aug;252:106466. doi: 10.1016/j.antiviral.2026.106466. Epub 2026 Jun 21. PMID: 42323973

[Hepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort.](#)

Arima M, Yamamoto S, Adachi-Katayama M, Okamoto K, Ando M, Okugawa S, Ono M, Tsutsumi T. *J Artif Organs.* 2026 Aug 7;29(3):53. doi: 10.1007/s10047-026-01579-2. PMID: 42565867

[Expanding adult immunization in low- and middle-income countries through pharmacist-provided vaccination.](#)

Koonin LM, Velez SD, Bresee JS. *Vaccine.* 2026 Aug 12;90:129004. doi: 10.1016/j.vaccine.2026.129004. Online ahead of print. PMID: 42585811

[Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population.](#)

Amadi M, Vänskä S, Davidkin I, Haario H, Leino T, Melin M, Auranen K, Kontio M. *Infection.* 2026 Aug;54(4):2053-2063. doi: 10.1007/s15010-026-02832-9. Epub 2026 May 27. PMID: 42201515

[Emergence of an antigenically drifted and reassorted influenza B virus at the end of the 2024-25 influenza season.](#)

Akin E, Villafuerte DA, Werner AP, Pinsley M, Pierce CA, Fall A, Abdullah O, Norton JM, Rothman RE, Fenstermacher KZJ, Gong Y-N, Klein E, Mostafa HH, Pekosz A. *mBio.* 2026 Aug 12;17(8):e0119826. doi: 10.1128/mbio.01198-26. Epub 2026 Jun 22. PMID: 42328860

[Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.](#)

Favre G, Pfund A, Gerbier E, Anselem O, Balaya V, Ceccaldi PF, Chalouhi G, Ducarme G, Garabedian C, Guerby P, Mottet N, Picone O, Poncelet C, Quibel T, Sananes N, Sentilhes L, Simon J, Tran PL, Ville Y, Baud D, Blume C, Capoccia Brugger R, Farin A, Fougère Y, Fruscalzo A, Gallmann D, Haslinger C, Huber D, Martinez de Tejada B, Radan AP, Schäffer L, Todesco Bernasconi M, Vökt C, Miranda J, Nieto-Calvache AJ, Rivera-Torres LF, De Santis M, Kratochwila C, Paladini D, Tantari M, Ernst C, Mossong J, Murray J, Feuerschuette OHM, Luz AG, Surita F, Boucoiran I, Goncé A, Higgins M, Démolis R, Alexandre K, Pomar L. *Vaccine.* 2026 Aug 13;88:128783. doi: 10.1016/j.vaccine.2026.128783. Epub 2026 Jun 7. PMID: 42251842

[Parallel Declines in Human Papillomavirus 6/11-Related Disease Incidences: A National Study of Anogenital Warts and Recurrent Respiratory Papillomatosis in Norway.](#)

Orumaa M, Nygård S, Tota J, Mahale P, Hetland Falkenthal TE. *Open Forum Infect Dis.* 2026 Jul 29;13(8):ofag456. doi: 10.1093/ofid/ofag456. eCollection 2026 Aug. PMID: 42591918

[Defining Composition-Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed Immunogenicity.](#)

Walters AA, Hanafy BI, Lu CE, Marelli S, Zam A, Liu K, Foreman RE, Soundararajan R, Collin P, Lindfors L, Sabirsh A, Mazza M, Al-Jamal KT, Bates SM, Thom G, Rehwinkel J, Kapustin AN. *Small.* 2026 Aug;22(45):e74283. doi: 10.1002/smll.74283. Epub 2026 Jul 20. PMID: 42474084

[Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine.](#)

Henkes NC, Heien HC, Inselman JW, Farraye FA, Keaveny AP. *Vaccine.* 2026 Aug 13;88:128859. doi: 10.1016/j.vaccine.2026.128859. Epub 2026 Jun 20. PMID: 42322677

[From community mobilisation to school vaccination: experiences from Cameroon's first Expanded Programme on Immunisation-led school-based HPV campaign.](#)

Haddison E, Nebongo D, Amponsah-Dacosta E. *Vaccine.* 2026 Aug 13;88:128848. doi: 10.1016/j.vaccine.2026.128848. Epub 2026 Jun 17. PMID: 42308976

[Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-Elicited SARS-CoV-2 Immune Responses.](#)

Smith DM, Weir IR, Ramirez S, Coelho CH, Manne-Goehler J, Aziz M, Benson CA, Wu X, Hyer R, Dhillon PK, Faraji F, Bloom N, Myers A, Ramezani-Rad P, Lopez PG, Parikh UM, Heaps AL, Javan AC, Bender Ignacio RA, Li JZ, Greninger AL, Daar ES, Wohl DA, Crotty S, Sieg SF, Chew KW. *J Infect Dis.* 2026 Aug 3;234(1):e18-e28. doi: 10.1093/infdis/jiag091. PMID: 41700320

[The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity.](#)

Kubo M. *Immunol Rev.* 2026 Aug;341(1):e70148. doi: 10.1111/imr.70148. PMID: 42522246

[Prevalence, Serotype Distribution, and Risk Factors Associated With *Streptococcus pneumoniae* Carriage in Older Adults in Denmark, 2019-2022.](#)

Tinggaard M, Slotved HC, Petersen RF, Hovmand N, Benfield T. *Open Forum Infect Dis.* 2026 Jul 24;13(8):ofag452. doi: 10.1093/ofid/ofag452. eCollection 2026 Aug. PMID: 42553673

[Deletion of the N-terminal 400 amino acids of DPV pUL36 attenuated virulence and conferred effective protection against virulent challenge.](#)

Yang Q, Yu H, Ai L, Wang M, Wu Y, Tian B, Yang Y, Jia R, Zhu D, Chen S, Liu M, Zhao X, Zhang S, Huang J, Ou X, Sun D, He Y, Wu Z, Zhang L, Yu Y, Cheng A. *Poult Sci.* 2026 Aug;105(8):107100. doi: 10.1016/j.psj.2026.107100. Epub 2026 May 8. PMID: 42214186

[Parental preferences for immunization advisory clinic settings for children with special health care needs and associated factors in Shanghai: A cross-sectional study.](#)

Feng T, Xu Y, Li J, Ge Y, Wang Z, Zhao D, Huang Z, Zeng M. *Hum Vaccin Immunother.* 2026 Dec 31;22(1):2707857. doi: 10.1080/21645515.2026.2707857. Epub 2026 Aug 3. PMID: 42547995

[A Systematic Review and Meta-Analysis of the Effectiveness of Physical Interventions Administered Orally for Infants for Reducing Distress During **Vaccine** Injections.](#)

Shah V, Constantin K, Taddio A, McMurtry CM, Lang E, MacDonald NE, Logeman C, Uleryk E; HELPinKids&Adults##. Clin J Pain. 2026 Aug 1;42(8S Suppl 1):e1381. doi: 10.1097/AJP.0000000000001381.PMID: 42444178

[Development of an ion-pairing reagent-assisted LC-MS/MS method employing fragmentation with stepped collision energy for monophosphoryl lipid A containing 3-deoxy-D-manno-octulosonic acid and its derivatives.](#)

Hong J, Yoon J, Jin H, Oh H, Chung HS, Kim KH. J Chromatogr A. 2026 Aug 2;1780:467040. doi: 10.1016/j.chroma.2026.467040. Epub 2026 Apr 27. PMID: 42102636

[Live vaccines in solid organ transplant recipients.](#)

Sturgis R, Danziger-Isakov L, Feldman A. Curr Opin Infect Dis. 2026 Aug 1;39(4):327-333. doi: 10.1097/QCO.0000000000001196. Epub 2026 Apr 15. PMID: 42068586

[Vitamin B2 Derivative-Enabled Sonochemical Thioketal Cleavage for Ultrasound-Activated In Situ Tumor Vaccination.](#)

Ren X, Sun J, Cui L, Xu Y, Shen N, Tang Z, Chen X. Nano Lett. 2026 Aug 12;26(31):10413-10424. doi: 10.1021/acs.nanolett.6c02398. PMID: 42584258

[Engineered Bacterial Membranes as Next-Generation Platforms for Cancer Immunotherapy.](#)

Malik HA, Virk UY, Attia MS, Wilson J, Wei M. Small Sci. 2026 Jul 26;6(8):e70351. doi: 10.1002/smssc.70351. eCollection 2026 Aug. PMID: 42524337

[Reverse genetics strategies for coronaviruses: platform construction and applications in **vaccine** development.](#)

Jia Y, Han X, Ma Y, Wang X, Yang Y, Zhang A, Ding K, Chen S. Virus Genes. 2026 Aug;62(4):428-445. doi: 10.1007/s11262-026-02249-4. Epub 2026 Jun 12. PMID: 42286395

[Adaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction.](#)

Jamwal S, Mohanty S, Calhoun C, Krishnamurti L, Montgomery RR, Shaw AC, Yildirim I. Exp Hematol. 2026 Aug;160:105459. doi: 10.1016/j.exphem.2026.105459. Epub 2026 May 30. PMID: 42219144

[Science-policy translation for Lassa fever control in West Africa: a qualitative synthesis of regional evidence.](#)

Lokossou VK, Usman AB, Sombie I, Omeje O, Umeokonkwo CD, Sogbossi L, Johnson E, Adegbite BR, Tchamdja K, Mongbo Y, de Hardt-Kaffils H, Manigart O, Oyeibanji O, Ramsauer K, Anueyiagu C, Ndir A, Kaduru C, Ezenyi I, Ilori E, Ihekweazu V, Anyakora C, Agaboye K, Ndem A, Botton L, Keita N, Cardoso P, Hounkpe N, Ale F, Batonon A, Boya L, Adohinzin C, Agbla F, Janneh H, Aïssi MA. Trans R Soc Trop Med Hyg. 2026 Aug 5;120(8):879-885. doi: 10.1093/trstmh/trag048. PMID: 42065130

[Post-vaccination serological status predicts protection against heterologous SAT1 foot-and-mouth disease virus challenge in goats.](#)

Fosgate GT, Oerlemans DR, Seoke L, Opperman PA, Lazarus DD, Gobiye M, Heath L. *Prev Vet Med.* 2026 Aug;253:106893. doi: 10.1016/j.prevetmed.2026.106893. Epub 2026 Apr 21. PMID: 42030596

[Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.](#)

McCafferty K, Barratt J, Suzuki Y, Liew A, Rizk DV, Chacko B, Kooienga L, Lafayette R, Wong MG, Pasetti MF, Shriver MC, Follman K, Moc Willeford C, Sahay M, Honig G, Andrews L, Olinski LE, Mathur M, Oldach D. *Clin J Am Soc Nephrol.* 2026 Aug 1;21(8):1365-1375. doi: 10.2215/CJN.0000001089. Epub 2026 Jun 11. PMID: 42275148

[Partisan differences in childhood measles vaccination and general refusals: a retrospective cohort study of electronic health records in the United States, 1988-2024.](#)

Morton CM, Ouyang D, Schwartz D, Goldin J, Ho DE. *Lancet Reg Health Am.* 2026 May 14;60:101495. doi: 10.1016/j.lana.2026.101495. eCollection 2026 Aug. PMID: 42180007

[Lack of Rigour on COVID-19 Vaccines.](#)

Lataster R. *J Bioeth Inq.* 2026 Aug 11. doi: 10.1007/s11673-025-10548-y. Online ahead of print. PMID: 42579254

[Early challenge with LPAI-H9N2 followed by vNDV-VII.1.1 in vaccinated and unvaccinated broilers: a comprehensive study.](#)

Elbestawy A, Khalifa E, Saad AH, Elnagar AR, Ellakany HF, Abdel-Latif M, Noreldin AE, Geneedy A, Gado A. *Avian Pathol.* 2026 Aug;55(4):469-486. doi: 10.1080/03079457.2026.2674853. Epub 2026 Jun 24. PMID: 42339813

[Cost-effectiveness and budget impact analyses of introducing typhoid conjugate vaccine into Indonesia's national immunisation program.](#)

Haposan JH, Thobari JA, Watts E, Pitzer VE, Carvalho N, Tri Indarti H, Anjani A, Mulyadi AWE, Laksanawati IS, Bines JE. *Vaccine.* 2026 Aug 7;90:129008. doi: 10.1016/j.vaccine.2026.129008. Online ahead of print. PMID: 42570462

[Comparative immunogenicity of three meningococcal vaccines as the first booster dose in children primed with MPCV-AC in China.](#)

Chen Y, Su Y, Tang X, Pan F, Zheng H, Wang B, Zhou J, Song F, Cheng P, Wang Y, Zhang H, Ma B, Cai Q, Su Y, Qin W. *Vaccine.* 2026 Aug 13;88:128916. doi: 10.1016/j.vaccine.2026.128916. Epub 2026 Jul 10. PMID: 42430875

[Endocytosis-dependent and spleen-selective mRNA expression enabled by ionizable lipidoid linkers enhances therapeutic mRNA vaccination.](#)

Shi L, You F, Sun Z, Hu Z, Zhang Y, Zhang Q, Chen J, Wang H, Ye Y, Chen J, Sun Y, Deng W, Sun C, Deng G. *Acta Biomater.* 2026 Aug;219:590-603. doi: 10.1016/j.actbio.2026.06.031. Epub 2026 Jun 16. PMID: 42303148

[Elucidating the role of Toxoplasma gondii EF-hand containing protein 1 in parasite biology and its potential as a subunit **vaccine** antigen.](#)

Tian X, Ma H, Gao S, Li Y, Zhu B, Zhang J, Wang J, Hu Y, Li Y, Wang Q, Zhang Z, Yang Z, Mei X, Wang S. *Acta Trop.* 2026 Aug;280:108179. doi: 10.1016/j.actatropica.2026.108179. Epub 2026 Jun 11. PMID: 42276404

[Strengthening Adolescent Sexual Health Literacy through Targeted Educational Interventions in German Secondary Schools.](#)

Waldmann G, Neureiter M, Zippel S, Fuchs C. *J Cancer Educ.* 2026 Aug 3. doi: 10.1007/s13187-026-02962-6. Online ahead of print. PMID: 42545660

[Safety of BNT162b2 COVID-19 **Vaccine** in Pregnancy: A Systematic Review.](#)

Thoburn E, Giannakoulis VG, Hu T, Goebe H, Raina S, Moran MM, Perreault B, Val-Maranes L, Millar EB, Whittle I, Pearson F, Lopez SMC. *Infect Dis Ther.* 2026 Aug;15(8):2087-2101. doi: 10.1007/s40121-026-01378-5. Epub 2026 Jun 7. PMID: 42251625

[Barriers to Canine Rabies Vaccination in Nigeria: Implications for Rabies Elimination by 2030.](#)

Mshelbwala PP, Paul BT, Njoga EO, Audu SW, Mugodi M, Okezie PI, Wangdi K, Sabeta CT, Rupprecht CE. *Zoonoses Public Health.* 2026 Aug;73(5):467-479. doi: 10.1111/zph.70070. Epub 2026 May 21. PMID: 42169207

[Baseline adverse birth outcomes in a prospective pregnancy cohort in Uganda: Evidence to inform maternal **vaccine** readiness.](#)

Davies HG, Rukundo G, Komugisha C, Kipyeko S, Young A, Kisakye J, Voysey M, Mboizi R, Heath PT, Sekikubo M, Le Doare K. *Vaccine.* 2026 Aug 8;90:128952. doi: 10.1016/j.vaccine.2026.128952. Online ahead of print. PMID: 42570461

[Recombinant Fasciola gigantica Tegumental Calcium Binding Protein-4 Modulates Host Peripheral Blood Mononuclear Cell Immune Responses In Vitro.](#)

Yousaf A, Shahzad MI, Ehsan M, Hu RS, Shahid K, Rashid M, Malik MI, Khan MI. *Acta Trop.* 2026 Aug 12:108282. doi: 10.1016/j.actatropica.2026.108282. Online ahead of print. PMID: 42586466

[Perception about child vaccination and its determinants among caregivers in rural Northeastern Ethiopia.](#)

Beshir SA, Workineh MH, Workineh BD, Kahissay MH. *Res Health Serv Reg.* 2026 Aug 12;5(1):12. doi: 10.1007/s43999-026-00097-1. PMID: 42584777

[The Platform trial In COVID-19 priming and BOOsting \(PICOBOO\): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.](#)

C M, Dymock M, Flanagan KL, Plebanski M, Marshall H, Estcourt MJ, Tjiam MC, Blyth CC, Subbarao K, Mordant FL, Wilson K, Nicholson S, Karapanagiotidis T, Faust SN, Wadia U, Thornton RB, Tansil S, Tedja C,

Ellis Z, Williams PCM, McKenzie A, Marsh JA, McCallum C, Snelling TL, Richmond P. *Vaccine*. 2026 Aug 13;88:128970. doi: 10.1016/j.vaccine.2026.128970. Epub 2026 Jul 28. PMID: 42520645

[Francisella-primed T cells shift toward glycolysis during control of intramacrophage bacterial growth.](#)

Mittereder LR, Elkins KL. *mBio*. 2026 Aug 12;17(8):e0113326. doi: 10.1128/mbio.01133-26. Epub 2026 Jul 27. PMID: 42505133

[Effectiveness of emergency vaccination in controlling a foot-and-mouth disease epidemic in a previously FMD-free without vaccination country.](#)

Iriarte MV, de Jong MCM, Gil AD, Gonzáles JL. *Vet J*. 2026 Aug;318:106752. doi: 10.1016/j.tvjl.2026.106752. Epub 2026 Jun 24. PMID: 42342025

[Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus.](#)

Tu T, Tseng CY, Islam MD, Hsu WL, Ou SC, Yamazaki T, Huang CP, Hsu YC, Kuroda Y. *Vaccine*. 2026 Aug 13;88:128898. doi: 10.1016/j.vaccine.2026.128898. Epub 2026 Jul 11. PMID: 42435621

[Parental and Patients' Awareness, Knowledge, and Willingness for Human Papillomavirus Vaccination Among Survivors of Childhood Hematologic Malignancies.](#)

Seyhanlı D, Karadag-Oncel E, Cakil-Guzin A, Ozdem-Alatas Ş, Kasıkcı-Mermer E, İnce OT, Yılmaz Ş, Tufekci-Gurocak Ö, Oren H, Belet N. *Pediatr Hematol Oncol*. 2026 Aug;43(5):254-267. doi: 10.1080/08880018.2026.2685015. Epub 2026 Jun 20. PMID: 42322623

[Development of a novel competitive ELISA method for Typhoid Vi Polysaccharide Quantitation.](#)

Mandyal AK, Angannan R, Putcha BDK, David C, Sharma T. *Biologicals*. 2026 Aug 6;95:101906. doi: 10.1016/j.biologicals.2026.101906. Online ahead of print. PMID: 42561546

[The COVID-19 pandemic and access to vaccines in Latin America and the Caribbean: strategies adopted by the WHO and PAHO](#)
[Pandemia de COVID-19 e acesso a vacinas na América Latina e Caribe: estratégias da OMS e da OPAS.](#)

Bermudez L, Machado CV. *Cad Saude Publica*. 2026 Aug 3;42(suppl 1):e00016225. doi: 10.1590/0102-311XEN016225. eCollection 2026. PMID: 42561205

[The second Trump presidency: Health care themes, policies, and impacts in his first year back in office.](#)

Rice T, Unruh LY, Barnes AJ, Richardson E. *Health Policy*. 2026 Aug;170:105648. doi: 10.1016/j.healthpol.2026.105648. Epub 2026 May 7. PMID: 42096981

[Longitudinal predictors of vaccine conspiracy beliefs: findings from a five-wave panel study in Japan.](#)

Yamamoto H, Suzuki T, Ogawa Y, Umetani R. *Sci Rep*. 2026 Aug 3;16(1):23869. doi: 10.1038/s41598-026-57049-5. PMID: 42547780

[HPV vaccination and the risk of cancer in males.](#)

Hsu CH, Chen CF, Chu KA, Lin MH, Chang R. *Vaccine*. 2026 Aug 13;88:128923. doi: 10.1016/j.vaccine.2026.128923. Epub 2026 Jul 19. PMID: 42472496

[Analysis of monoclonal antibodies against the malaria invasion complex protein RIPP reveals the structural basis for synergistic antibody protection.](#)

Williams BG, Barrett JR, Scott JB, Rigby CA, Cagiada M, Quinkert D, McHugh K, Huhn A, Burnap SA, Gourjault C, Byrne F, Raghavan SSR, Rodrigues A, Bergamaschi L, Balzarotti B, Watson S, Miller N, King LDW, Donnellan FR, Gladstone CA, Paterson J, Scalabrino S, Silk SE, Salkeld J, Minassian AM, Skinner K, Struwe WB, Deane CM, Reece ST, Ward AB, Draper SJ. *Immunity*. 2026 Aug 11;59(8):2106-2121.e10. doi: 10.1016/j.immuni.2026.05.012. Epub 2026 Jun 12. PMID: 42285102

[Towards the development of a mucosal vectored vaccine against enterovirus D68.](#)

Zimina A, Viktorova EG, Kouliavskaia D, Chumakov K, Rosenfeld AB, Belov GA. *Virology*. 2026 Aug;621:110960. doi: 10.1016/j.virol.2026.110960. Epub 2026 May 19. PMID: 42172979

[Appearing where it matters: Ectopic Germinal centers in the respiratory Tract after influenza infection.](#)

Gailleton R, Angeletti D. *Immunol Lett*. 2026 Aug;280:107175. doi: 10.1016/j.imlet.2026.107175. Epub 2026 Apr 1. PMID: 41932401

['COVID kills, and it's not joking around': Perceptions and experiences of COVID-19 in Soweto, South Africa.](#)

Matina SS, Cohen E, Mokwena K, Mendenhall E. *Glob Public Health*. 2026 Dec 31;21(1):2717794. doi: 10.1080/17441692.2026.2717794. Epub 2026 Aug 13. PMID: 42594851

[Immunization with mosaic nanoparticles reveals that antigen avidity shapes the clonal hierarchy of the B cell response.](#)

Padilla MV, Weidner NG, Pruitt L, Cottrell CA, Gonzales K, Kalyuzhnyi O, Lu D, Alavi N, Phelps N, Aniqua M, Waldrep KM, Keller EJ, Weglarz M, Schief WR, Abbott RK. *Sci Transl Med*. 2026 Aug 12;18(862):eae5425. doi: 10.1126/scitranslmed.aee5425. Epub 2026 Aug 12. PMID: 42585293

[The forgotten foe returns: cholera's warning to a complacent world demanding urgent action.](#)

Cheema S, Sadia H, Talha M, Rafay-Ur-Rehman M, Sajjad W, Qamar I. *Ann Med Surg (Lond)*. 2026 Jul 8;88(8):5533-5536. doi: 10.1097/MS9.0000000000005361. eCollection 2026 Aug. PMID: 42583658

[RSV vaccination in immunocompromised adults.](#)

Loubet P, Fourati S, Launay O. *Int J Infect Dis*. 2026 Aug;169:108784. doi: 10.1016/j.ijid.2026.108784. Epub 2026 May 10. PMID: 42119657

[Rationally designed minimized TbpB confers broad protection against meningococcal infection.](#)

Islam EA, Fegan JE, Cole GB, Calmettes C, Ng D, Au NYT, Buckwalter CM, Ahn SK, Curran DM, Caruso LL, Schryvers AB, Moraes TF, Gray-Owen SD. *PLoS Pathog*. 2026 Aug 10;22(8):e1014493. doi: 10.1371/journal.ppat.1014493. Online ahead of print. PMID: 42574476

[Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes.](#)

Hickey JC, Roach T, Cassaidy B, Hergesheimer R, Franklin N, Morin J, Wagman S, Cohen J, Morrissey D, Chaparro-Riggers J, Lim Soo P. *Mol Pharm.* 2026 Aug 3;23(8):4190-4202. doi: 10.1021/acs.molpharmaceut.6c00239.PMID: 42473281

[Genetic analysis of inflammatory proteins following BCG vaccination in Danish children.](#)

Boahen CK, Nissen TN, Birk NM, Netea MG, Benn CS, Kumar V. *Biomed Pharmacother.* 2026 Aug 13;203:119848. doi: 10.1016/j.biopha.2026.119848. Online ahead of print.PMID: 42594746

[Reactivation of a Bacillus Calmette-Guérin Scar Following Routine Infant Vaccination.](#)

Demircioğlu F, Demircioğlu AS. *Clin Case Rep.* 2026 Aug 7;14(8):e73322. doi: 10.1002/ccr3.73322. eCollection 2026 Aug.PMID: 42571144

[\[Historical reflections on smallpox, science and health: an interview with Tania Fernandes\].](#)

Fernandes TMD, Pimenta TS, Santos GGD, Brizola JH. *Hist Cienc Saude Manguinhos.* 2026 Aug 7;33(suppl 1):e2026023. doi: 10.1590/S0104-59702026000100023. eCollection 2026.PMID: 42585442

[British Association of Sexual Health and HIV guidelines on the management of viral hepatitis 2026.](#)

Garvey L, Bhagani S, Kulasegaram R, Butler M, Hathorn E, Randell P, Smith S, Whyte R, Halford R, Grant A, Villa G, Dakshina S, Mandal S, Bradshaw D. *Int J STD AIDS.* 2026 Aug;37(9):939-968. doi: 10.1177/09564624261440830. Epub 2026 May 12.PMID: 42117446

[Evaluation of a Minigrant Program for Multilevel Interventions to Promote Human Papillomavirus Vaccination in Rural Communities in Georgia.](#)

Escoffery C, Petagna C, Chari R, Hsu E, Kadoo RV, Haardörfer R, Guan Y, Morshed AB, Wells J, Blake S, Hutchins R. *Prev Chronic Dis.* 2026 Aug 6;23:E30. doi: 10.5888/pcd23.250328.PMID: 42561963

[Integrated service delivery to improve adolescent health and human papillomavirus \(HPV\) vaccination in Lao PDR: a quasi-experimental mixed-methods study - study protocol.](#)

Lynn T, Sychareun V, Chaleunvong K, Vongxay V, Thongmixay S, Phimmavong C, Taikeophithoun C, Van Der Kooij J. *BMJ Open.* 2026 Aug 3;16(8):e098836. doi: 10.1136/bmjopen-2025-098836.PMID: 42547242

[Physicochemical characterization and immunostimulatory effects of mycogenic metal oxide nanoparticle-enriched feed-based bivalent vaccines in red hybrid tilapia \(*Oreochromis spp.*\).](#)

Anuar MSK, Ishaq SI, Ibrahim MZ, Chin YK, Zulkipli MAF, Nazarudin MF, Azmai MNA, Salleh A, Abdullah CAC, Yusof MT, Yasin ISM. *Dev Comp Immunol.* 2026 Sep;182:105701. doi: 10.1016/j.dci.2026.105701. Epub 2026 Aug 3.PMID: 42546891

[Design and Evaluation of Universal Multi-Epitope Vaccines Against Vibrio Infections Using a Single/Multi-Target Multi-Derived Epitope Strategy.](#)

Lun J, Zheng P, Li C, Hu Y, Li Y, Zhong M, Zhang Y, Hu Z. *J Fish Dis.* 2026 Aug;49(8):e70167. doi: 10.1111/jfd.70167. Epub 2026 Mar 23.PMID: 41872732

[Uptake of COVID-19 Vaccines and Intention to Vaccinate in the Democratic Republic of the Congo: A Cross-Sectional Survey.](#)

Bosonkie M, Egbende L, Chen N, Ndejjo R, Kabwama SN, Bondo B, Kashiya Y, Mubelo M, Tsai LL, Ali MM, Wanyenze RK. *Health Sci Rep.* 2026 Jul 31;9(8):e72934. doi: 10.1002/hsr2.72934. eCollection 2026 Aug. PMID: 42540484

[Burden of Shigella infection in children under five years living in a peri-urban area of Ouagadougou, Burkina Faso: A community-based cohort study.](#)

Héma A, Sawadogo J, Soulama BI, Hien D, Diarra A, Sermé SS, Ouédraogo AZ, Nébié I, Houard S, Ouédraogo A, Tiono AB, Sanou M, Sirima SB. *PLoS Negl Trop Dis.* 2026 Aug 14;20(8):e0014624. doi: 10.1371/journal.pntd.0014624. eCollection 2026 Aug. PMID: 42599952

[Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.](#)

Madhi SA, Snaggs H, Skogeby Z, Feng Y, Barnabas S, Baker J, Fairlie L, Beeslaar J, Radley D, Jiang HQ, Silmon de Monerri NC, Simon R, McLaughlin L, Gaylord M, Skinner J, Munjal I, Anderson AS, Gurtman A. *Nat Med.* 2026 Aug;32(8):3048-3059. doi: 10.1038/s41591-026-04558-5. Epub 2026 Jul 28. PMID: 42521820

[PFAS mixtures impair key T-cell-B-cell interactions essential for COVID-19 vaccine responses.](#)

Ayuk HS, Pierzchalski A, Myhre O, Smith NM, Zenclussen AC, Stojanovska V. *Environ Int.* 2026 Aug;214:110401. doi: 10.1016/j.envint.2026.110401. Epub 2026 Jul 5. PMID: 42419194

[Analysis of the genotyping of circulating strains and characteristics of Glycoprotein E of Varicella-Zoster Virus in Shanxi Province, China.](#)

Liu H, Lv P, Ma R, Guo S, Zhang P, Guo J, Gao R, Wang J. *PLoS One.* 2026 Aug 3;21(8):e0355368. doi: 10.1371/journal.pone.0355368. eCollection 2026. PMID: 42545991

[Linker-directed lipid-antigen conjugates co-enhance lymph node targeting and antigen presentation for potent T cell immunity.](#)

Zhu J, Bai L, Wang C, Liu J, Chen Y, Zhang W, Weng J, Wei L, Wei Z. *Mater Today Bio.* 2026 Jul 28;39:103505. doi: 10.1016/j.mtbio.2026.103505. eCollection 2026 Aug. PMID: 42571391

[A Modular T4 Phage-Based Nanoparticle Displaying Multiepitopes Provides Cross-Serotype Protection against Streptococcus suis in Mice and Swine.](#)

Chen G, Ni S, Guo J, Yang L, Li Y, Yuan Z, Zhang Y, Zhang Y, Chen H, Tao P, Tan C. *ACS Infect Dis.* 2026 Aug 14;12(8):2838-2852. doi: 10.1021/acsinfectdis.6c00464. PMID: 42599393

[Epidemic features and potential impact of vaccine campaigns on the 2025 chikungunya outbreak in southern China: a mathematical modelling study.](#)

Zheng Q, Ding Y, Wang X, Yang Y, Meng Q, Al-Tawfiq JA, Zhong Z, Wang W, Pan Q. *New Microbes New Infect.* 2026 Jun 11;72:101791. doi: 10.1016/j.nmni.2026.101791. eCollection 2026 Aug. PMID: 42327491

[Immunological Evaluation of mRNA-LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS-CoV-2.](#)

Begum F, Mallik MH, Ghora S, Ray U. *Biotechnol J*. 2026 Aug;21(8):e70294. doi: 10.1002/biot.70294.PMID: 42605164

[Antigen presentation requirements for effective cDC1-based cancer immunotherapy.](#)

Pineda JE, Minowa T, Shen L, Zhou Y, Dyevoich A, Patel B, Schneider SM, Keshari S, Saha A, Riba MN, Wang J, Watowich SS, Gubin MM. *J Immunol*. 2026 Aug 4;215(8):vkag198. doi: 10.1093/jimmun/vkag198.PMID: 42592936

[Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism.](#)

Wang Y, Chen Y. *Int J Mol Sci*. 2026 Aug 4;27(15):7007. doi: 10.3390/ijms27157007.PMID: 42589657

[Biomimetic Cancer Cell Membrane-Coated Polymeric Nanogels as a Therapeutic Vaccine for Synergistic Photothermo-Chemo-Immunotherapy of Nasopharyngeal Carcinoma.](#)

Wen S, Huang Y, Xiao X, Ni C, Ji R, Liu J, Shen M, Shi X. *ACS Appl Mater Interfaces*. 2026 Aug 11. doi: 10.1021/acsami.6c11261. Online ahead of print.PMID: 42578978

[Cellular immunity to *Streptococcus pneumoniae*: implications for vaccine-mediated prevention.](#)

VanSeggelen H, Ferreira DM, Malley R, Yuste J, Blohmke CJ, Srokowski C, Willer DO, Sebastian S. *Expert Rev Vaccines*. 2026 Dec;25(1):2708196. doi: 10.1080/14760584.2026.2708196. Epub 2026 Aug 10.PMID: 42576444

[Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study.](#)

Torkaman-Asadi F, Bakhtiari S, Safarzadeh M, Riahi-Rad Z, Riahi-Rad Z, Doosti Irani A, Ansari N. *Vaccine*. 2026 Aug 13;88:128868. doi: 10.1016/j.vaccine.2026.128868. Epub 2026 Jun 20.PMID: 42322678

[Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance.](#)

Liao R, Luo M, Yang F, Xu L, Zhang J, Zhang W, Guan S, Zhang Y, Luo P, Cheng P, Yang J, Li Y, Wang Q. *Drug Dev Res*. 2026 Aug;87(5):e70335. doi: 10.1002/ddr.70335.PMID: 42318873

[Affinity chromatography in vaccine manufacturing: from capture technology to quality-defining bioprocessing.](#)

Bülbül A, Kara A, Denizli A. *Trends Biotechnol*. 2026 Aug 1:S0167-7799(26)00282-9. doi: 10.1016/j.tibtech.2026.07.003. Online ahead of print.PMID: 42538160

[\[One hundred years of vaccination in Yucatán, Mexico, 1802-1902\].](#)

Moguel RMW. *Hist Cienc Saude Manguinhos*. 2026 Aug 7;33(suppl 1):e2026026. doi: 10.1590/S0104-59702026000100026. eCollection 2026.PMID: 42585444

[Excess mortality, statistical significance, and causation: Analyzing controversies in COVID-19 vaccine research.](#)

Lataster R. *Int J Risk Saf Med*. 2026 Aug;37(3):446-448. doi: 10.1177/09246479261446501. Epub 2026 Apr 24. PMID: 42029230

[Bordetella pertussis: emerging epidemiology, diagnosis and management.](#)

Baumgart SWL, Freeland I, Fong W, Chen SC, Sintchenko V, Basile K, Marriott D, Kok J. *Pathology*. 2026 Aug;58(5):525-538. doi: 10.1016/j.pathol.2026.03.016. Epub 2026 May 28. PMID: 42342467

[Benzothiazole derivatives target oligoadenylate synthetase and enhance RSV vaccine efficacy as adjuvants.](#)

Jin X, Zhang Z, Liu H, Tan Y, Luo P, Wen Z, Chen H, Liu L, Chen Y. *Bioact Mater*. 2026 Aug 4;67:80-94. doi: 10.1016/j.bioactmat.2026.07.049. eCollection 2027 Jan. PMID: 42592354

[Alignment-free prediction of cross-reactivity in influenza A \(H3N2\) anticipates antigenic drift.](#)

Forna A, Damodaran L, Gunning CE, Rahimi P, Venkat A, Kannan N, Kondor R, Bahl J, Rohani P, Drake JM. *PLoS Comput Biol*. 2026 Aug 11;22(8):e1014628. doi: 10.1371/journal.pcbi.1014628. Online ahead of print. PMID: 42579720

[Intersection of vaccination, health literacy, education, and communication in South America: A scientometric mapping.](#)

Augusto LV, de Araújo LP, Silva EN, Gutierrez JM, Amarante-Paffaro AM, de Almeida LA, Corsetti PP. *Vaccine*. 2026 Aug 4;89:128986. doi: 10.1016/j.vaccine.2026.128986. Online ahead of print. PMID: 42551401

[Factors affecting parental practices and attitudes toward influenza vaccination for children in China.](#)

Wei Z, Feng X, Sun Q, Chen D, Pan X, Hang G, Tang Z, Chen Y. *Vaccine*. 2026 Aug 13;88:128988. doi: 10.1016/j.vaccine.2026.128988. Epub 2026 Jul 31. PMID: 42537287

[Intact mass and peptide mapping approaches to characterize lipoprotein species of fHbp.](#)

Long Z, Li M, Zhu X, Luo X, Wang B. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2026 Aug 1;1280:125129. doi: 10.1016/j.jchromb.2026.125129. Epub 2026 May 14. PMID: 42143987

[Serological Benefit of SARS-CoV-2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia.](#)

Shapiro JR, Qi F, Colwill K, Dorogy AD, Liu Y, Science M, Gingras AC, Rini JM, Gupta S, Alexander S, Bolotin S, Watts TH. *Pediatr Blood Cancer*. 2026 Aug;73(8):e70395. doi: 10.1002/1545-5017.70395. Epub 2026 May 14. PMID: 42135995

[Fuimos olvidados y descuidados \[Forgotten and Neglected\]: Lessons Learned and Findings From On-Farm COVID-19 Education and Vaccine Clinics for Agricultural Workers and Their Multigenerational Families in Texas.](#)

Rodriguez A, Douphrate DI, Pineda Reyes AL, Zavala S, Chavez L, Lopez SN, Cabrera Cruz AV, Keeney AJ, Hernandez N, Berumen-Flucker B, Shipp EM, Nonnenmann MW, Guillot-Wright SP, Boggess Alcauter B, Lopez Ixta G, Cuccaro PM, Fernandez-Sanchez H, Gimeno Ruiz de Porras D. *Workplace Health Saf*. 2026 Aug;74(8):396-408. doi: 10.1177/21650799261430861. Epub 2026 Apr 16. PMID: 41989094

[A manganese-based nanoplatform leveraging chemodynamic and adjuvant effects for in situ vaccination against colorectal cancer.](#)

Yang Q, Shi X, Yang K, Gao Q, Cao Y, Huang Y, Chen L, Bao S, Xu L, Reis RL, Kundu SC, Xu H, Xiao B. *Biomaterials*. 2026 Aug;331:124085. doi: 10.1016/j.biomaterials.2026.124085. Epub 2026 Feb 18. PMID: 41723903

[Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Policy Statement.](#)

Committee on Infectious Diseases. *Pediatrics*. 2026 Aug 10. doi: 10.1542/peds.2026-078778. Online ahead of print. PMID: 42572140

[A model for the epidemiological impact of tuberculosis policy options.](#)

Mandal S, Satyanarayana S, McQuaid F, Dodd PJ, Menzies NA, White RG, Arinaminpathy N, Houben RM, Dowdy DW, Smit M, Sahu S, Pretorius C. *Bull World Health Organ*. 2026 Aug 1;104(8):540-550. doi: 10.2471/BLT.26.295896. Epub 2026 Jun 1. PMID: 42516122

[Malaria serology for surveillance, insights into immunity, and vaccine development.](#)

Lim PS, Bernal J, Karunaratne J, Longley RJ. *Infect Immun*. 2026 Aug 11;94(8):e0003126. doi: 10.1128/iai.00031-26. Epub 2026 Jul 13. PMID: 42439828

[Establishment of a circular polymerase extension reaction-based reverse genetics system for porcine reproductive and respiratory syndrome virus.](#)

Inoue A, Goda I, Kojima I, Esaki M, Okuya K, Ozawa M. *Vet Microbiol*. 2026 Aug;319:111053. doi: 10.1016/j.vetmic.2026.111053. Epub 2026 May 4. PMID: 42102597

[Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca.](#)

Nasraa MH, Abd-Elshafy DN, Nadeem R, Shalaby S, Amer K, Hassan WA, Bader AH, Elshehaby HA, Bahgat MM. *Viral Immunol*. 2026 Oct;39(8):293-304. doi: 10.1177/08828245261474281. Epub 2026 Aug 7. PMID: 42565654

[Identification and computational analysis of B-cell epitopes on the hemagglutinin protein of the H3N2 influenza virus.](#)

Guo M, Wang X, Zhou J, Chen Y, Liang C, Wang H, Wu S, Zhu X, Wang A. *Arch Microbiol*. 2026 Aug 5;208(11):539. doi: 10.1007/s00203-026-05048-5. PMID: 42554770

[Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016-2025.](#)

Leonard JS, Reinhart K, Lu PJ, Santibanez TA, Srivastav A, Hung MC, Jain A, Budd A, Huang S, Kniss K, Price AM, Burns E, Ellington S, Flannery B. *Pediatrics*. 2026 Aug 1;158(2):e2026076453. doi: 10.1542/peds.2026-076453. PMID: 42402353

[Relevance of circulating IgG levels as a marker of health in plasma donors.](#)

Laforce-Lavoie A, Deschênes J, Cloutier M, Lewin A, Bazin R. *Transfusion*. 2026 Aug 10. doi: 10.1111/trf.70373. Online ahead of print. PMID: 42574244

[A strain of high cell-adapted porcine deltacoronavirus: Isolation, genetic evolution, and pathogenicity analysis.](#)

Yang M, Ma Y, Liu M, Zhou H, Fan H, Lin H. *Microb Pathog*. 2026 Aug 4;219:108750. doi: 10.1016/j.micpath.2026.108750. Online ahead of print. PMID: 42551610

[Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.](#)

Uno N, Ross TM. *Virology*. 2026 Aug;621:110961. doi: 10.1016/j.virol.2026.110961. Epub 2026 May 20. PMID: 42202654

[Neuraltherapeutic Medicine in Post-Acute COVID-19 Vaccination Syndrome \(PACVS\): A Critical Review with a Case Report.](#)

Bustamante C, Pinilla-Bonilla LB, Patiño Soler M, Estravis M. *Restor Neurol Neurosci*. 2026 Aug;44(3):349-359. doi: 10.1177/09226028251412573. Epub 2026 Jan 21. PMID: 41564315

[Dual-expression-site fowl adenovirus 4 \(FAdV-4\) with high viral titer: a promising viral vector for multivalent poultry vaccines.](#)

Tang Z, Liu W, Xu B, Feng D, Liu S, Fan W, Song S, Yan L. *Vet Res*. 2026 Aug 13;57(1):149. doi: 10.1186/s13567-026-01820-z. PMID: 42596021

[Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01_E vaccination: an observational ancillary immunological study of a phase 3 clinical trial.](#)

Lara-Escandell M, Sánchez L, Macià D, Jairoce C, Mpina M, Sorgho H, Agnandji ST, Dosoo D, Gyan B, Vidal M, Jiménez A, Mitchell RA, Medina-Expósito D, Puyol L, Santano R, Dutta S, Owusu-Agyei S, Asante KP, Tinto H, Aide P, Nhabomba A, Mordmüller B, Daubenberger C, Aguilar R, Waitumbi J, Moncunill G, Dobaño C. *Lancet Infect Dis*. 2026 Aug;26(8):832-842. doi: 10.1016/S1473-3099(26)00081-2. Epub 2026 Apr 21. PMID: 42030969

[Phase I trial of a heat-conditioned tumor lysate vaccine \(TRIMELVax\) in anti-PD-1 refractory melanoma: safety and immunological aspects \(NCT06556004\).](#)

Estay R, Cortés A, Müller B, Tempio F, Merino C, Fuentes C, Rebolledo A, Ramírez N, Contalba P, Bustos K, Pereda C, Gleisner MA, Flores I, González FE, Tittarelli A, Achour A, Hidalgo S, Lladser Á, Becker MI, Salazar-Onfray F, López MN. *Br J Cancer*. 2026 Aug;135(3):436-444. doi: 10.1038/s41416-026-03459-1. Epub 2026 Apr 30. PMID: 42062531

[Synthesis of two trisaccharides related to the O-antigens from *Burkholderia cepacia* serotype E \(O2\) in the form of their 2-aminoethyl glycoside.](#)

Das S, Mukhopadhyay B. *Org Biomol Chem*. 2026 Aug 14. doi: 10.1039/d6ob00628k. Online ahead of print. PMID: 42599132

[BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.](#)

Tsai CY, Xie M, Cristaldo M, Peluso GR, Woo J, Nuritdinov F, Odjourian NM, Dougher M, Antilus-Sainte R, Kreutzfeldt KM, Ehrt S, Gengenbacher M. *J Infect Dis.* 2026 Aug 12;jiag416. doi: 10.1093/infdis/jiag416. Online ahead of print. PMID: 42585592

[Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors.](#)

Buzzard KA, Barnett M, Beadnall H, Forcadela M, Hall LA, Hall VG, Hardy T, Hsu D, Kinsella P, Monif M, Ramanathan S, Reddel SW, Riminton S, Johnson DF. *Intern Med J.* 2026 Aug 16. doi: 10.1111/imj.70610. Online ahead of print. PMID: 42604968

[Intranasal immunization with a P1 adhesin C-terminal-flagellin fusion protein elicits robust systemic and mucosal immunity and protects against Mycoplasma pneumoniae infection in a mouse model.](#)

Yang J, Lin T, Lin X, Wang Y, Wang F, Wang P, Jiang W. *Vaccine.* 2026 Aug 13;88:128996. doi: 10.1016/j.vaccine.2026.128996. Epub 2026 Aug 1. PMID: 42542051

[Over-induction of innate immune responses suppresses T cell response to mRNA SARS-CoV-2 vaccination.](#)

Tay CJX, Koh CWT, Ooi JSG, Li HE, Kang AYH, Roslan SNB, Osman NE, Ong SM, Ooi DSQ, Tham EH, Shek LP, Chan KR, Zhong Y. *Vaccine.* 2026 Aug 13;88:128983. doi: 10.1016/j.vaccine.2026.128983. Epub 2026 Jul 30. PMID: 42531983

[Impact of health education intervention on knowledge and attitude towards HPV vaccination in Africa: A systematic review.](#)

Gyamfi-Samakome A, Nimo FA, Odoom E, Nabe B, Koranteng HK, Ubeida S, Lanyo GS, Kagbo JE, Amodu M, Enyan NIE. *Vaccine.* 2026 Aug 13;88:128930. doi: 10.1016/j.vaccine.2026.128930. Epub 2026 Jul 17. PMID: 42468223

[Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.](#)

Spila-Alegiani S, Massari M, Cutillo M, Menniti-Ippolito F, Da Cas R, Mayer F, Marano G, Belleudi V, Addis A, Desiderio V, Mores N, Lopes S, Balducci M, Ejlli L, Del Zotto S, Clagnan E, Samez S, Zappetti C, Rossi P, Sapigni E, Puccini A, Villa M, Visigalli C, Trifirò G, Luxi N, Morciano C. *Vaccine.* 2026 Aug 13;88:128806. doi: 10.1016/j.vaccine.2026.128806. Epub 2026 Jun 12. PMID: 42284809

[Bacterial surface layer - Properties, role, applications and challenges - A review of the next-generation nanotechnological tool.](#)

Kumar A, Rana A, Kumar A, Tyagi A. *J Microbiol Methods.* 2026 Aug 1;249:107648. doi: 10.1016/j.mimet.2026.107648. Online ahead of print. PMID: 42542137

[Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.](#)

Christou-Ergos M, Sabahelzain MM, Bolsewicz KT, Kaufman J, Steffens M, Danchin M, Leask J. *Vaccine*. 2026 Aug 13;88:128846. doi: 10.1016/j.vaccine.2026.128846. Epub 2026 Jun 18. PMID: 42314308

[Preparation and application of IgM monoclonal antibodies in half-smooth tongue sole \(*Cynoglossus semilaevis*\).](#)

Qiu J, Zhang J, Qian X, Wu J, Li Y, Xu X, Chen S, Wang Y, Li Q. *Fish Shellfish Immunol*. 2026 Aug;175:111444. doi: 10.1016/j.fsi.2026.111444. Epub 2026 May 22. PMID: 42176789

[New concepts for glioblastoma **vaccine** immunotherapy.](#)

Shallak M, Shaik AKB, Gatta A, Volpi M, Accolla RS, Forlani G. *Biomed J*. 2026 Aug;49(4):100974. doi: 10.1016/j.bj.2026.100974. Epub 2026 Mar 28. PMID: 41912068

[Low Cord Blood Titers Are Associated with Prolonged Maternal RSV Antibody Half-Lives in Preterm Infants.](#)

Willemsen JE, Phijffer EWEM, Wildenbeest JG, Anderson LJ, Ha B, Sankaranarayanan R, Groenendaal F, Bloemenkamp KWM, Borghans JAM, Drylewicz J, Bont L. *J Infect Dis*. 2026 Aug 13;jiag417. doi: 10.1093/infdis/jiag417. Online ahead of print. PMID: 42594156

[Immunodominance hierarchy of influenza A haemagglutinin antigenic sites: an observational cohort study across distinct exposure histories.](#)

Martínez-Guevara JL, Lai TY, Mishra M, Hoang MT, Shea W, Page CK, Sinywimaanzi P, Simulundu E, Rothman RE, Pekosz A, Joan Fenstermacher KZ, Sutcliffe CG, Simon V, Palese P, Sun W, González-Domínguez I. *EBioMedicine*. 2026 Aug 6;131:106412. doi: 10.1016/j.ebiom.2026.106412. Online ahead of print. PMID: 42561813

[Immunomodulating treatments for bacterial meningitis and viral encephalitis.](#)

Brouwer MC, van de Beek D. *Clin Microbiol Infect*. 2026 Aug 14:S1198-743X(26)00460-X. doi: 10.1016/j.cmi.2026.08.013. Online ahead of print. PMID: 42601017

[Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.](#)

Bainbridge J, Mealing S, Graham C, Jenal M, von Dombrowski N, Dymond A. *Appl Health Econ Health Policy*. 2026 Aug 12. doi: 10.1007/s40258-026-01063-1. Online ahead of print. PMID: 42587205

[Polymorphisms in the Bordetella pertussis virulence factor SphB1 and altered antigen expression of clinical isolates before and after acellular pertussis vaccination in Finland.](#)

Niinikoski V, Myllylä A, Barkoff AM, He Q. *Vaccine*. 2026 Aug 13;88:128979. doi: 10.1016/j.vaccine.2026.128979. Epub 2026 Jul 29. PMID: 42531982

[Cholera vaccination readiness in six African countries: A psychological and ecological study.](#)

Geiger M, Korn L, Temme H, Betsch C. *Vaccine*. 2026 Aug 13;88:128932. doi: 10.1016/j.vaccine.2026.128932. Epub 2026 Jul 16. PMID: 42462676

[Genetic insights into circulating very virulent infectious bursal disease virus strains in Kenyan broiler flocks.](#)

Lizzi G, Quaglia G, Legnardi M, Graziosi G, Tomasoni R, Napolitano M, Messo W, Catelli E, Lupini C. *Acta Trop.* 2026 Aug;280:108194. doi: 10.1016/j.actatropica.2026.108194. Epub 2026 Jun 20. PMID: 42322998

[Prevention of respiratory syncytial virus bronchiolitis in infants with maternal immunization or monoclonal antibodies for the newborn: What do women choose?](#)

Azeroual S, Benvenuto D, Perrin A, Rey P, Launay O, Charlier C, Anselem O. *Int J Infect Dis.* 2026 Aug;169:108753. doi: 10.1016/j.ijid.2026.108753. Epub 2026 May 1. PMID: 42070628

[Perspectives on TLR2 agonist use in the road map to HBV cure.](#)

Pieterman RFA, Durantel D, Janssen HLA, Sprengers D, Buschow SI. *Antiviral Res.* 2026 Aug;252:106447. doi: 10.1016/j.antiviral.2026.106447. Epub 2026 May 27. PMID: 42208904

[Analysis of hepatitis B immunity in vaccinated medical students.](#)

Gentile N, Aghera C, Smith H, Mazzoleni S, Redden D, Tjiattas-Saleski L. *J Osteopath Med.* 2025 Dec 12;126(8):393-401. doi: 10.1515/jom-2025-0005. eCollection 2026 Aug 1. PMID: 41376563

[Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.](#)

El-Sehrawy AAMA, Al-Ameer HJ, Rizaev J, Jasim IK, Mahmood WB, Maharana L, Singhal D, Bainsal N. *Biotechnol Bioeng.* 2026 Aug 12. doi: 10.1002/bit.70344. Online ahead of print. PMID: 42590828

[Antimicrobial resistance and molecular epidemiology of *Streptococcus pneumoniae* in China: a 14-year serial surveillance study across age groups.](#)

Cui L, Zeng Y, Song Y, Xue F, Zhang J, Feng J, Zhang F, Li Y. *J Infect Public Health.* 2026 Aug;19(8):103308. doi: 10.1016/j.jiph.2026.103308. Epub 2026 Jul 11. PMID: 42435712

[Mesenchymal stem cells orchestrate a hypoxic niche that supports the generation of antigen-specific CD8⁺ tissue-resident memory T cells in bone marrow after vaccination.](#)

Wang S, Lin Z, Zhu J, Su R, Li J, Ruan X, Zhuang L, Qian Y, Wen J, Lai Y, Yang N, Zhang Z, Zhang H. *Int Immunopharmacol.* 2026 Aug 1;182:116810. doi: 10.1016/j.intimp.2026.116810. Epub 2026 May 9. PMID: 42107895

[The effect of short message reminders on seasonal influenza vaccination rates in the geriatric population.](#)

Özmen Sever S, Aksu SB, Zeren Öztürk G. *Hum Vaccin Immunother.* 2026 Dec;22(1):2710424. doi: 10.1080/21645515.2026.2710424. Epub 2026 Aug 4. PMID: 42550738

[Mi3 nanoparticles displaying the knob domains of Fiber1 and Fiber2 from fowl adenovirus serotype 4 induce robust humoral and cellular immune responses in chickens.](#)

Dong X, Ji J, Liu S, Zhu Z, Lu C, Zhang W, Lei B, Zhang Y, Yuan W, Li L, Lu Y, Zhao K. *Vet Microbiol.* 2026 Aug 4;321:111182. doi: 10.1016/j.vetmic.2026.111182. Online ahead of print. PMID: 42561831

[Outer membrane engineering through lipid A modification allows modulation of *Burkholderia pseudomallei* membrane permeability and innate immune responsivity.](#)

La THA, McMillan IA, Dahal P, McMillan JKP, Muszyński A, Heiss C, Fernando LD, Azadi P, Borlee BR, Norris MH. *Infect Immun*. 2026 Aug 11;94(8):e0060225. doi: 10.1128/iai.00602-25. Epub 2026 Jul 22. PMID: 42484648

[Assessment of Bacterial Pathogens in Young Children with Acute Otitis Media: A Prospective Cohort Study in Western Pennsylvania, 2019-2023.](#)

Martin JM, Hoberman A, Lee MC, Yahner KA, Kahambwe J, Tomazetto G, Lee S, Dohar JE, Kobayashi M, Andrejko K, Doxey AC, Lobb B, Shaikh N. *J Pediatric Infect Dis Soc*. 2026 Aug 4;15(8):piag059. doi: 10.1093/jpids/piag059. PMID: 42466881

[Seroefficacy of a 10-valent pneumococcal conjugate **vaccine** \(Pneumosil \) compared with other pneumococcal conjugate vaccines in children.](#)

Akeju O, Feng S, Clarke E, Bashorun AO, Adigweme I, Pidduck N, Voysey M. *Vaccine*. 2026 Aug 12;90:129029. doi: 10.1016/j.vaccine.2026.129029. Online ahead of print. PMID: 42585812

[Immunomodulatory effects of palm-derived tocotrienol-rich fraction in healthy volunteers following influenza vaccination: A randomised clinical trial.](#)

Chen S, Ahmad B, Palanisamy UD, Hafid SRA, Selvaduray KR, Radhakrishnan AK. *Nutr Res*. 2026 Aug 11;153:124-141. doi: 10.1016/j.nutres.2026.07.004. Online ahead of print. PMID: 42579941

[Attitudes and Behaviors of Canadians Towards COVID-19 Prevention Measures According to Vaccination Status: A Multi-phase, Cross-sectional Sequential Observational Cohort Study from May 2021 to June 2022.](#)

Coulombe Raymond F, Hébert-Augur L, Léger C, Deslauriers F, Gosselin Boucher V, Dialufuma MV, Tremblay N, Bacon SL, Lavoie KL. *Int J Behav Med*. 2026 Aug 10. doi: 10.1007/s12529-026-10474-2. Online ahead of print. PMID: 42573922

[Podcast: Immune Persistence After Primary Vaccination with MenQuadfi.](#)

Rämet M, Simon M. *Infect Dis Ther*. 2026 Aug;15(8):2017-2025. doi: 10.1007/s40121-026-01370-z. Epub 2026 Jun 8. PMID: 42252361

[Bacteriophage nanoparticles: an emerging modular delivery platform.](#)

Whiley L, Zhu HX, Garcia-Bennett AE, Jaschke PR. *Curr Opin Biotechnol*. 2026 Aug;100:103527. doi: 10.1016/j.copbio.2026.103527. Epub 2026 Jun 4. PMID: 42242179

[Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.](#)

Dong S, Li M, Huo D, Zhao H, Li R, Gao Z, Wang X, Zhang D, Tsang TK, Wang Q, Yang P. *J Infect*. 2026 Aug;93(2):106795. doi: 10.1016/j.jinf.2026.106795. Epub 2026 Jun 12. PMID: 42285524

[Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands.](#)

Huiberts AJ, Smits MMJ, Hoeve CE, de Melker HE, van den Hof S, Knol MJ. *Vaccine*. 2026 Aug 15;90:129043. doi: 10.1016/j.vaccine.2026.129043. Online ahead of print. PMID: 42603508

[The precarious state of community engagement in African clinical trials: A systematic review of funding, workforce gaps, and the path to institutionalization.](#)

Bain LE, Sangong S, Adewunmi O, Njei B. *PLOS Glob Public Health*. 2026 Aug 13;6(8):e0006484. doi: 10.1371/journal.pgph.0006484. eCollection 2026. PMID: 42594128

[In-depth monitoring of host cell proteins in influenza vaccines throughout multi-step purification processes.](#)

Liu B, Li F, Yang Y, Tu H, Hao P, Ma Q, Le Y, Zhang Q, Li X, Qiu R, Yu J, Zhang Z, Meng S, Yang Z, Yu L. *Vaccine*. 2026 Aug 13;88:128957. doi: 10.1016/j.vaccine.2026.128957. Epub 2026 Jul 25. PMID: 42501716

[Risk Factors for Coronavirus Disease 2019 Hospitalization and Vaccination Impact Among Pediatric Solid Organ Transplant Recipients in the United States.](#)

Thomas SJ, Almeida NEC, Bocchini C, Brammer C, Brock G, Calimaran A, Dallas R, Downes KJ, Ferrolino JA, Haque MR, Huppler AR, Kaur I, Kumar M, Landry M, Lerret S, Maron GM, Minniear TD, Muller WJ, Munoz FM, Otto WR, Perkins K, Ristagno EH, Sharova A, Siegel K, Song E, Valladares MJ, Wilson NA, Yoshida A, Shimamura M. *Transpl Infect Dis*. 2026 Aug 13:e70303. doi: 10.1111/tid.70303. Online ahead of print. PMID: 42596081

[Factors Associated With COVID-19 Primary and Booster Vaccine Uptake Among New York City Public School Students.](#)

Zhou EG, Day S, Argenio K, Schwartz AE, Elbel B. *Am J Public Health*. 2026 Aug 6:e1-e11. doi: 10.2105/AJPH.2026.308604. Online ahead of print. PMID: 42561175

[Recombinant BCG-Ag85A enhances antitumor immunity and controls melanoma progression through multimodal immune activation in mice.](#)

Lanius SL, Pacheco BS, Sousa FSS, Neto ACPS, Scholl NR, Cardozo SJF, Ehlert ME, Ferreira VG, Collares TV, Borsuk S, Dellagostin O, Bohn TLO, Seixas FK. *Arch Microbiol*. 2026 Aug 5;208(11):534. doi: 10.1007/s00203-026-05093-0. PMID: 42554758

[Chimeric virus-like particles of nodavirus displaying human and avian influenza A M2e induce conserved anamnestic protective immunity against human and avian influenza A viruses.](#)

Fatimah MNN, Thian BYZ, Ong HK, Wong CL, Ho KL, Mariatulqabtiah AR, Omar AR, Tan WS. *Vet Microbiol*. 2026 Aug;319:111054. doi: 10.1016/j.vetmic.2026.111054. Epub 2026 May 5. PMID: 42107208

[Efficacy of swine Influenza A virus vaccines on transmission, viral shedding and clinical signs: Systematic review and meta-analysis.](#)

Mtaallah O, Germeraad EA, Puspitarani GA, Bayle B, Nguyen UHP, Meester M, Stegeman A, Apolloni A, Hautefeuille C. *Prev Vet Med*. 2026 Aug;253:106877. doi: 10.1016/j.prevetmed.2026.106877. Epub 2026 Apr 1. PMID: 41946219

[Methods for 2026 HELPinKids&Adults Clinical Practice Guideline for Reducing Distress During Vaccination.](#)

Taddio A, Shah V, McMurtry CM, Lang E, MacDonald NE, Constantin K, Uleryk E; HELPinKids&Adults^{††}. Clin J Pain. 2026 Aug 1;42(8S Suppl 1):e1371. doi: 10.1097/AJP.0000000000001371. PMID: 41814946

[Immunization with PLGA-encapsulated recombinant staphylococcal enterotoxin C confers protection against intramammary Staphylococcus aureus challenge in a murine mastitis model.](#)

Deepak D, Prasanna P, Vaidya R, Ali SA, Bobby N, Pati BK, De UK, Verma MR, Sahoo M, Chaudhury P, Mukherjee R. Antonie Van Leeuwenhoek. 2026 Aug 14;119(9):196. doi: 10.1007/s10482-026-02400-z. PMID: 42599583

[Economic evaluation of alternative PCV13 vaccination strategies in Guangxi, China: a decision tree-Markov model study.](#)

He Q, Pang B, Su Z, Mo Y, Zhou W, Wei H, Peng Z, Zou X, Li H. Vaccine. 2026 Aug 13;88:128935. doi: 10.1016/j.vaccine.2026.128935. Epub 2026 Jul 15. PMID: 42456563

[Behavioural and social drivers of childhood immunisation uptake in sub-Saharan Africa: A rapid qualitative review.](#)

Christian E, Tinessia A, Zhu J, Chutiyami M, Mahimbo A, King C, Abdi I. Vaccine. 2026 Aug 13;88:128844. doi: 10.1016/j.vaccine.2026.128844. Epub 2026 Jun 16. PMID: 42302354

[Longitudinal dynamics of serum IL-33 and sST2 across age and sex in a healthy Finnish cohort before and after Tdap booster vaccinations.](#)

Anabe D, Teräsjarvi JT, Barkoff AM, Mertsola J, He Q. Cytokine. 2026 Aug 13;206:157197. doi: 10.1016/j.cyto.2026.157197. Online ahead of print. PMID: 42594457

[Expression and Immunogenicity of a Rabies Virus Glycoprotein-HSV-2 ICP35 Fusion Antigen Delivered by an mRNA-LNP Formulation.](#)

Li X, Niu Z, Mou T, Gao Y, Wang L, Zhang Y, Chen H, Tan S, Liu J, Li J, Li Q. Virus Res. 2026 Aug 12:199785. doi: 10.1016/j.virusres.2026.199785. Online ahead of print. PMID: 42586214

[Adaptive Immunity in Marsupials.](#)

Jol CL, Stannard HJ, Old JM. J Exp Zool A Ecol Integr Physiol. 2026 Aug 11:e70123. doi: 10.1002/jez.70123. Online ahead of print. PMID: 42581624

[Clinical and Economic Burden of Complicated Pneumonia and Invasive Disease due to Streptococcus pneumoniae Serotype 19A in an Ecuadorian Pediatric Reference Hospital.](#)

Salgado-Villalba ED, Costta-Michuy Á, Villalba-Valencia XDR, Carrasco-Ronquillo MI, Salas-Haas TA, Cifuentes-Carcelén AC, Bracero-Velasco KM, Aucapiña-Aucapiña IDPA, Palomeque-Velastegui P, Acosta-España JD. Pediatr Infect Dis J. 2026 Aug 7. doi: 10.1097/INF.0000000000005365. Online ahead of print. PMID: 42563214

[On the 50th year responding to Ebola: mapping diagnostic, vaccine, and therapeutic gaps across ebolavirus species.](#)

Si J, Cai J, Zhou J, Wang L, Gao GF, Liu J. *MedScience*. 2026 Aug 6. doi: 10.1007/s11684-026-1265-4. Online ahead of print. PMID: 42560595

[On or within: spatial determinants of antigen handling in the nasal turbinates.](#)

Bourgon C, Moseman EA. *Curr Opin Immunol*. 2026 Aug;101:102808. doi: 10.1016/j.coi.2026.102808. Epub 2026 Jun 26. PMID: 42361431

[Sensing the enemy within: Vy9Vδ2 T cells as metabolic sensors of intracellular parasites.](#)

Rodriguez F, Saeij JPJ. *Trends Parasitol*. 2026 Aug 1:S1471-4922(26)00203-5. doi: 10.1016/j.pt.2026.07.007. Online ahead of print. PMID: 42542392

[Subcutaneous immunization with kharon1-deficient leishmania infantum induces immunogenicity and protects hamsters against visceral leishmaniasis.](#)

Moreira GJL, Ostolin TLVDP, Moreira POL, Gonçalves LC, Barcelos ACA, da Silva FO, Celestino RMC, Aguiar-Soares RDO, Reis AB, do Monte-Neto RL, Roatt BM. *Vaccine*. 2026 Aug 13;88:128911. doi: 10.1016/j.vaccine.2026.128911. Epub 2026 Jul 13. PMID: 42442045

[Palm oil-adjuvanted feed-based vaccination enhances humoral and macrophage responses of marine tilapia \(*Oreochromis sp.*\) against *Vibrio harveyi* and *Vibrio alginolyticus*.](#)

Manchanayake T, Md Yasin IS, Amal MNA, Zamri-Saad M, Firdaus-Nawi M, Salleh A. *Microb Pathog*. 2026 Aug;217:108605. doi: 10.1016/j.micpath.2026.108605. Epub 2026 May 30. PMID: 42219064

[Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines.](#)

Ramponi N, Barda B, Barilaro G, Gallacchi Bouvier M, Mueller L, Giannini A, Raza ZA, Merlani G, Bernasconi E, Bongiovanni M. *Eur J Clin Microbiol Infect Dis*. 2026 Aug 4. doi: 10.1007/s10096-026-05602-5. Online ahead of print. PMID: 42550395

[A systematic meta-analytic comparative evaluation of seasonal influenza **vaccine** effectiveness from test-negative design studies in the Northern Hemisphere pre/post COVID-19 pandemic.](#)

Okoli GN, Sullivan SG, Harper DM, Tsang TK, Cowling BJ. *Vaccine*. 2026 Aug 13;88:128956. doi: 10.1016/j.vaccine.2026.128956. Epub 2026 Jul 22. PMID: 42486051

[Impact of ABO Blood System on Immunogenicity and **Vaccine** Efficacy of COVID-19 Booster Vaccination-A Population-Based Study of 3066 Individuals.](#)

Sieghart D, Jordakieva G, Dürschmid C, Hana CA, Tran LV, Heinz LX, Haslacher H, Zlesak M, Marzoner V, Nasztl P, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta CM, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. *Influenza Other Respir Viruses*. 2026 Aug;20(8):e70300. doi: 10.1111/irv.70300. PMID: 42524760

[Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.](#)

Bietz A, Sandow P, Hartmann C, Steffan L, Katzenberger B, Damm O, Dietzsch M, Hagemann C. *Vaccine*. 2026 Aug 13;88:128765. doi: 10.1016/j.vaccine.2026.128765. Epub 2026 Jun 8. PMID: 42247747

[Chemokine dynamics after mRNA vaccination.](#)

Marques Palma L, Schlaweck S, Flores C, Aslan H, Kurts C, Brossart P, Becker-Gotot J, Heine A. *Immunol Lett*. 2026 Aug;280:107183. doi: 10.1016/j.imlet.2026.107183. Epub 2026 May 5. PMID: 42097179

[Comprehensive Immunisation Among Children Aged 12-23 Months in India-A Multilevel Modelling Analysis From the National Family Health Survey \(2015-21\).](#)

Malik M, Basu S, Girotra S, Kundu S. *Public Health Chall*. 2026 Aug 11;5(3):e70329. doi: 10.1002/puh2.70329. eCollection 2026 Sep. PMID: 42583362

[Maternal RSVpreF Immunisation Against Infant RSV Hospitalisation: Nationwide Population-Based Effectiveness and Durability Study.](#)

Jabagi MJ, Bertrand M, Gabet A, Tréluyer L, Kolla E, Rachas A, Olié V, Zureik M. *Lancet Reg Health Eur*. 2026 Jun 20;67:101756. doi: 10.1016/j.lanepe.2026.101756. eCollection 2026 Aug. PMID: 42371532

[Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: An observational study.](#)

Zhang Y, Shrestha S, Feaheny F, Pant D, Shakya M, Bijukche S, Gehlhaar A, Shrestha S, Curtis B, Dongol S, Gurung M, Kelly S, Mujadidi YF, Haque N, Joshi M, Maharjan A, Karkey A, Basnyat B, Kim YC, Shrestha S, Pollard AJ, Liu X; TyVAC Nepal Study Team. *J Infect*. 2026 Aug 5;93(3):106823. doi: 10.1016/j.jinf.2026.106823. Online ahead of print. PMID: 42556475

[Measles outbreaks as signals of governance failure: Lessons from Bangladesh's 2026 immunisation collapse.](#)

Jahan Y, Aziz AB. *Vaccine*. 2026 Aug 13;88:128924. doi: 10.1016/j.vaccine.2026.128924. Epub 2026 Jul 15. PMID: 42456565

[Comparison of Respiratory Syncytial Virus \(RSV\)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.](#)

Kachikis A, Frivold C, Pike M, Reed JC, Stolarczuk JE, McVey K, Clark E, Mauer C, McAteer S, Saidac IM, Harteloo A, Carone M, Marshall G, Eckert LO, Greninger AL, Englund JA, Chu HY. *J Infect Dis*. 2026 Aug 3;234(1):e54-e59. doi: 10.1093/infdis/jiag111. PMID: 41885612

[Innovations in peptide-based targeted therapies for breast cancer: From conjugates to precision delivery.](#)

Ghazani ND, Shojaei A, Rahbarnia L, Safary A, Akbarzadeh-Khiavi M, Nabizadeh S. *Biomed Pharmacother*. 2026 Aug;201:119707. doi: 10.1016/j.biopha.2026.119707. Epub 2026 Jun 24. PMID: 42341587

[Genetic determinants of cell- and egg-preferred replication in H3N2 canine influenza virus.](#)

Wang R, Zhu Y, Zhu M, Li X, Zhou H, Peng L, Li S, Zhang H, Dong S, Qin Y, Ouyang K, Yin Y, Wei Z, Huang W, Chen Y. *Vet Microbiol.* 2026 Aug;319:111085. doi: 10.1016/j.vetmic.2026.111085. Epub 2026 May 26. PMID: 42208335

[Epidemiology and Clinical Presentation of COVID-19 in Older Adults.](#)

Abul Y, Leeder C, Gravenstein S. *Clin Geriatr Med.* 2026 Aug;42(3):399-425. doi: 10.1016/j.cger.2025.09.007. PMID: 42547170

[Adherence to COVID-19 vaccination in riverside populations of the municipality of Careiro/AM.](#)

Damasceno HA, Souza VCSE, Maciel LHG, Maciel MG. *Rev Bras Enferm.* 2026 Aug 7;79:e20250066. doi: 10.1590/0034-7167-2025-0066. eCollection 2026. PMID: 42585487

[Dynamics of an SEIRV endemic model: effects of reinfection.](#)

Khan A, Wang L, Liu J, Xiong M. *J Biol Dyn.* 2026 Dec 31;20(1):2713881. doi: 10.1080/17513758.2026.2713881. Epub 2026 Aug 8. PMID: 42570011

[Necrotizing Fasciitis Caused by Serotype 7C Streptococcus pneumoniae in Overwhelming Post-splenectomy Infection.](#)

Akazawa H, Fukushima S, Nakamoto K, Oguni K, Chang B, Akeda Y, Sugihara S, Takenaka M, Morizane S, Hagiya H. *Intern Med.* 2026 Aug 1;65(15):2160-2164. doi: 10.2169/internalmedicine.6637-25. Epub 2025 Dec 11. PMID: 41371658

[Finite-time stability of the West Nile Virus model with Brownian motion.](#)

Chang K. *PLoS One.* 2026 Aug 6;21(8):e0354331. doi: 10.1371/journal.pone.0354331. eCollection 2026. PMID: 42560975

[Lactylation in influenza a virus infection: Current evidence, knowledge gaps, and future perspectives.](#)

Yan YC, Li Z, He H, Wu M, Yang H, Wei F. *Virulence.* 2026 Dec;17(1):2712045. doi: 10.1080/21505594.2026.2712045. Epub 2026 Aug 2. PMID: 42543035

[Message Framing and Regulatory Focus: COVID-19 Vaccination Intentions for Young Children Among Vaccine-Hesitant Parents.](#)

Xu J. *Health Commun.* 2026 Aug 6:1-12. doi: 10.1080/10410236.2026.2715124. Online ahead of print. PMID: 42557950

[Supporting 3Rs approaches in biologicals testing: responses from a survey of Manufacturers, Contract Research Organisations, National Control Laboratories and National Regulatory Authorities.](#)

Lilley E, Goel S, Levis R, Shaid S, Sheridan S, Stickings P, Viviani L, Holmes A. *Biologicals.* 2026 Aug 15;96:101901. doi: 10.1016/j.biologicals.2026.101901. Online ahead of print. PMID: 42603454

[Assessment of dried blood spot and umbilical cord blood samples for the quantification of maternally transferred IgG against the group B streptococcal alpha-like surface proteins in neonates at Kolding Hospital, Denmark: a proof-of-concept, cross-sectional study.](#)

Murra M, Hall T, Henriksen TB, Khalil MR, Møller JK, Slotved HC, Doare KL, Nielsen SY. *Lancet Microbe*. 2026 Aug;7(8):101409. doi: 10.1016/j.lanmic.2026.101409. Epub 2026 Jun 23. PMID: 42335915

[Trends in vaccination in pharmacy and medical settings among Medicaid recipients in the United States, 2018-2023: a claims analysis.](#)

Eiden AL, Zheng Y, Bakker KM, Wang D, Fisher-Borne M. *Expert Rev Vaccines*. 2026 Dec;25(1):2715854. doi: 10.1080/14760584.2026.2715854. Epub 2026 Aug 14. PMID: 42596755

[Two-year durability of MVA-BN vaccine-induced antibodies and the risk of Mpox breakthrough infections among high-risk populations: a prospective, longitudinal study.](#)

Liu WD, Chan UM, Chao TL, Chen KH, Sun HY, Lin KY, Huang YS, Lin CY, Shih MC, Li GC, Liu WC, Wu CH, Su YC, Lin CY, Hung CH, Chen LY, Luo YZ, Chang HY, Wu PY, Chen YT, Wang TK, Sheng WH, Hsieh SM, Chang SC, Chang SY, Hung CC. *Clin Microbiol Infect*. 2026 Aug 3:S1198-743X(26)00415-5. doi: 10.1016/j.cmi.2026.07.048. Online ahead of print. PMID: 42546923

[Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors.](#)

Abdelgawad HAH, Hinkle K, Fodor B, Ritchey A, Ostdiek S, Ballan W, Walsh A. *J Pediatr Hematol Oncol*. 2026 Aug 1;48(6):e264-e272. doi: 10.1097/MPH.0000000000003230. Epub 2026 Jun 29. PMID: 42372247

[A clinical accuracy study protocol for a saliva-based point-of-care lateral flow test to assess protective immunity to tetanus \(TETANUS study\).](#)

Gokani K, Faustini SE, Tanner C, Kwok HF, Agarwal R, Takwoingi Y, H S, Umuhoza C, Richter A, Nyombayire J, Muvunyi CM, Heaney J, Green CA. *BMJ Open*. 2026 Aug 12;16(8):e119202. doi: 10.1136/bmjopen-2026-119202. PMID: 42586733

[Health Care Service Readiness and Quality of Care for Sexual Violence in Garissa, Kwale, Narok, and West Pokot Counties, Kenya: A Mixed-Methods Study.](#)

Njogu J, Ndung'u L, Momanyi H, Nthumbi M, Wambua A, Zaid H, Pahe C, Gwama F, Malmqvist A, Rothschild CW. *Glob Health Sci Pract*. 2026 Aug 10;14(1):e2400344. doi: 10.9745/GHSP-D-24-00344. Print 2026 Aug 10. PMID: 42342557

[Factors associated with severe health outcomes among community-dwelling older adults hospitalized with respiratory syncytial virus.](#)

Atukorale VN, Kwong JC, Hernandez A, Moineddin R, Lee N, Kopp A, Andrew MK, Bronskill SE, Brown KA, Daneman N, Deeks SL, Johnstone J, McGeer AJ, McNally JD, Mubareka S, Murti M, Smieja M, Wilson SE, Zahariadis G, Bolotin S, Buchan SA. *J Infect*. 2026 Aug;93(2):106797. doi: 10.1016/j.jinf.2026.106797. Epub 2026 Jun 16. PMID: 42302913

[Vaccine Handling Management in Korea, Japan, and Taiwan: A Comparative Study of Storage Standards, Implementation Practices, and Regulatory Approaches.](#)

Kang CR, Noh JY, Choi WS, Choe YJ, Kamiya H, Tomotaki S, Tomotaki H, Huang LM, Choe S, Lee YH, Choi NK, Won H, Jeong S, Lee JK. *J Korean Med Sci.* 2026 Aug 10;41(31):e200. doi: 10.3346/jkms.2026.41.e200. PMID: 42576716

[Update on the Pathophysiology of Yellow Fever Intoxication.](#)

Duarte-Neto AN, Ho YL, Kallas EG, Bailey AL. *Am J Trop Med Hyg.* 2026 Aug 11:tpmd260276. doi: 10.4269/ajtmh.26-0276. Online ahead of print. PMID: 42580329

[Full-length premembrane protein is not required for mature Zika virus particle assembly.](#)

Dowd KA, Schroeder M, Sanchez E, Brumbaugh B, Foreman BM, Burgomaster KE, Shi W, Wang L, Caputo N, Gordon DN, Schwartz CL, Hansen BT, Olia AS, Suleiman M, Guyette JL, Aleshnick M, Kong WP, Morabito KM, Tsybovsky Y, Hickman HD, Graham BS, Fischer ER, Zhou T, Pierson TC. *Sci Transl Med.* 2026 Aug 12;18(862):eads8464. doi: 10.1126/scitranslmed.ads8464. Epub 2026 Aug 12. PMID: 42585295

[Characterization of monoclonal antibody and identification of two novel linear epitopes on the hemagglutinin protein of H3N2 canine influenza virus.](#)

Wang R, Chen J, Zhang H, Qin Y, Peng L, Zhu M, Wei Y, Li X, Qin Y, Ouyang K, Yin Y, Wei Z, Huang W, Chen Y. *Virology.* 2026 Aug;621:110923. doi: 10.1016/j.virol.2026.110923. Epub 2026 May 1. PMID: 42102446

[Leveraging ligand density and multivalent binding for optimal mannose targeting of APCs in precision vaccines.](#)

Luo JR, Chai ZL, Li C, Shi J, Zhu YJ, Zhang FB. *Eur J Pharm Biopharm.* 2026 Aug 7:115210. doi: 10.1016/j.ejpb.2026.115210. Online ahead of print. PMID: 42567423

[From aid dependence to domestic ownership: Risks, challenges, and policy pathways for sustaining immunisation gains in lower-income countries.](#)

Adan AM, Omar AM, Abdi MS, Ali MA, Abdullahi YB. *Prev Med Rep.* 2026 Jul 8;68:103560. doi: 10.1016/j.pmedr.2026.103560. eCollection 2026 Aug. PMID: 42519657

[The Return of Diphtheria: Reflections From the Emergency Department.](#)

Mahant A. *Emerg Med Australas.* 2026 Aug;38(4):e70315. doi: 10.1111/1742-6723.70315. PMID: 42493416

[GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.](#)

Parladé E, Favaro MTP, Chellou-Bakkali S, Voltà-Durán E, López-Laguna H, Villaverde A, Vázquez E. *Biomater Adv.* 2026 Aug;185:214839. doi: 10.1016/j.bioadv.2026.214839. Epub 2026 Mar 25. PMID: 41915969

[Bovine lactoferrin confers antiviral effect against La Crosse virus by interfering with virus-heparan sulfate proteoglycan binding.](#)

Satoh M, Ebihara H, Takayama-Ito M. J Infect Chemother. 2026 Aug 6;32(9):103046. doi: 10.1016/j.jiac.2026.103046. Online ahead of print. PMID: 42562316

[Impact of the 2024 Council of State and Territorial Epidemiologists' Varicella Case Definition and Classification on Varicella Cases Reported in Minnesota.](#)

Gustavson G, Marin M, Nave S, Leung J, Kenyon C. Public Health Rep. 2026 Aug 3;333549261463482. doi: 10.1177/00333549261463482. Online ahead of print. PMID: 42548041

[Immunogenicity and immunoprotective potential of recombinant OmpC and TrxA-OmpC from *Vibrio parahaemolyticus*.](#)

Feng J, Li W, Zhu W, Yuan S, Wang Q, Feng H, Pan S, Wang W, Suryoprabowo S. Microb Pathog. 2026 Aug;217:108573. doi: 10.1016/j.micpath.2026.108573. Epub 2026 May 20. PMID: 42155904

[Progress of microneedle patches in analgesic management.](#)

Xu C, Li J, Qin F, Tu Y, Liu K. Chem Commun (Camb). 2026 Aug 6;62(61):15176-15193. doi: 10.1039/d6cc01847e. PMID: 42473869

[Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model.](#)

Dowall SD, Findlay-Wilson S, Graham VA, Yara DA, Warren A, Easterbrook L, Smith J, Kennedy E, Salguero FJ, Ruedas-Torres I, Crossley L, Kempster S, Almond N. Vaccine. 2026 Aug 13;88:128927. doi: 10.1016/j.vaccine.2026.128927. Epub 2026 Jul 10. PMID: 42430874

[mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.](#)

Agrawal N, Ates LS, Schille SA, Chaturvedi A, Vogt J, Vukovic N, Dulberger CL, Vogel AB, Diekmann J, Diken M, Şahin U. Nat Immunol. 2026 Aug;27(8):1653-1665. doi: 10.1038/s41590-026-02545-z. Epub 2026 Jun 12. PMID: 42286358

[Severe Guillain-Barré syndrome after mRNA COVID-19 vaccination with rapid deterioration and recovery: a case report.](#)

Samli R, Al-Diri B, Jamileh E, Hudaib T. Oxf Med Case Reports. 2026 Aug 11;2026(8):omag153. doi: 10.1093/omcr/omag153. eCollection 2026 Aug. PMID: 42582978

[Tetanus in Children: Clinical Insights and Management From a Multicenter Study in Turkey.](#)

Telefon AH, Lacineli Gurlevik S, Tural Kara T, Ozsurekci Y, Celik U. Pediatr Infect Dis J. 2026 Aug 12. doi: 10.1097/INF.0000000000005361. Online ahead of print. PMID: 42581395

[Lipid Nanoparticles Based Multi-Scale Systemic Immune Programming for Cancer Therapy.](#)

Lin X, Li Y, Shen X, Li B, Xu Y. Mol Ther. 2026 Aug 10;S1525-0016(26)00688-X. doi: 10.1016/j.ymthe.2026.08.007. Online ahead of print. PMID: 42576384

[A comprehensive look at Respiratory Syncytial Virus \(RSV\): from pathogenesis to prevention.](#)

Salahi Ardekani O, Hasannezhad P, Goudarzi Y, Letafati A, Taghiabadi Z, Bahari M, Nayerain Jazi N, Qaraee Najafabadi A, Shatizadeh Malekshahi S. *Trop Dis Travel Med Vaccines*. 2026 Aug 8;12(1):29. doi: 10.1186/s40794-026-00313-3.PMID: 42576256

[Site-specific and global glycan analysis of the human cytomegalovirus pentameric glycoprotein by high resolution mass spectrometry.](#)

Lembo A, Sardone GL, Aurilia M, Speciale I, De Castro C, Biagini M. *Glycobiology*. 2026 Aug 5:cwag062. doi: 10.1093/glycob/cwag062. Online ahead of print.PMID: 42555109

[Pertussis toxin as well as staphylococcal superantigen induce glycolysis as energy source during T cell activation in an adenoid organoid model.](#)

Neullens CT, Kühne C, de Jong R, Rajendiran A, Kessel C, Bennstein SB, Ilgner J, Goncalves M, Schraven SP, Hackenberg S, Baumjohann D, Ohl K, Tenbrock K. *Clin Sci (Lond)*. 2026 Aug 12;140(8):1725-1740. doi: 10.1042/CS20261341.PMID: 42417073

[The Plasmodium vivax high molecular weight \(HMW\) rhoptry 3 protein \(RhopH3\) is involved in human red blood cell binding.](#)

Gutiérrez-Ortegón D, Barreto-Santamaría A, Arévalo-Pinzón G, Patarroyo MA. *Acta Trop*. 2026 Aug;280:108192. doi: 10.1016/j.actatropica.2026.108192. Epub 2026 Jun 18.PMID: 42314857

[Therapeutic vaccines targeting solid tumors: A series of clinical trial analysis over the past decade.](#)

Qiu F, Sun Y, Lim DW. *Transl Oncol*. 2026 Aug;70:102831. doi: 10.1016/j.tranon.2026.102831. Epub 2026 May 28.PMID: 42208245

[mRNA-Based Vaccines and Immunomodulatory Strategies for Muscle Regeneration and Recovery: A Comprehensive Review.](#)

Yang Y, Cao X, Li Y, Kang X, Huang Y, Feng H, Li C. *Immunol Invest*. 2026 Aug;55(6):1247-1263. doi: 10.1080/08820139.2026.2667884. Epub 2026 May 7.PMID: 42095363

[Emergence and Genomic Characterisation of Influenza Virus A\(H3N2\) Subclade K in Saudi Arabia: Dominant Circulation With Fixed HA1 Substitutions and High-Frequency HA-NA Clade Association, 2025-2026.](#)

Naeem A, Hakami M, Alanazi KM, Alzahrani N, Bosaeed M. *J Med Virol*. 2026 Aug;98(8):e71102. doi: 10.1002/jmv.71102.PMID: 42592671

[Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotypic Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.](#)

Felizzia G, Segatori VI, Galluzzo L, Alonso DF, Pinto N, Sobrero V, Varela M, Verón D, Gulino CA, Eberle SE, Fernández D, Guthmann M, Tinelli M, Lombas C, Spitzer E, Demarco I, Montanari A, Basile C, Odella J, Posadas D, Viso M, Villar MV, Pires C, Bevilacqua G, Rubio P, Alonso C, Rossi J, Casanello AL, Rizzi A, Mascardi R, Salvador V, Ardiles N, Zubizarreta P, Cacciavillano W. *Pediatr Blood Cancer*. 2026 Aug;73(8):e70394. doi: 10.1002/1545-5017.70394. Epub 2026 May 14.PMID: 42136000

[Timeliness and dose-dependent protection of pertussis vaccination in children under 5 years: Evidence from a population-based cohort in Zhejiang Province, China.](#)

Zhu Y, Zhou Y, Qi X, Chi P, Gao K, He H. *Int J Infect Dis.* 2026 Aug;169:108793. doi: 10.1016/j.ijid.2026.108793. Epub 2026 May 12. PMID: 42128158

[Functional dissection of HCMV gB's autonomous fusion activity provides insights into how polymorphisms in clinical isolates confer distinct characteristics.](#)

Chen X, Kropff B, Li J, Sticht H, Mollik M, Sieger M, Ferrazzi F, Görzer I, Mach M, Thomas M. *mBio.* 2026 Aug 12;17(8):e0038826. doi: 10.1128/mbio.00388-26. Epub 2026 Jul 13. PMID: 42439560

[Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network.](#)

Wadia U, Richmond PC, Britton PN, Carr J, Clark JE, Crawford NW, Hung TY, Marshall HS, Macartney KK, Wood NJ, McMullan BJ, Moore HC, Effler PV, Cheng AC, Blyth CC; PAEDS-FluCAN Network. *Lancet Reg Health West Pac.* 2026 Jul 28;73:101938. doi: 10.1016/j.lanwpc.2026.101938. eCollection 2026 Aug. PMID: 42569662

[Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies.](#)

Adachi Y, Takahashi Y. *Immunol Rev.* 2026 Aug;341(1):e70147. doi: 10.1111/imr.70147. PMID: 42523047

[Correlation between multiple protective health behaviors can determine the outcome of disease spread.](#)

Mehta RS. *Theor Popul Biol.* 2026 Aug;170:11-25. doi: 10.1016/j.tpb.2026.04.003. Epub 2026 Jun 11. PMID: 42276297

[Distinct evolutionary patterns and structural insights into A33 and A34 glycoprotein in parapoxvirus.](#)

Wang Y, Liu X, Xiang H, Chen X, Li A, Guo X. *Microb Pathog.* 2026 Aug;217:108609. doi: 10.1016/j.micpath.2026.108609. Epub 2026 Jun 2. PMID: 42235709

[Expanding HPV Vaccination in the United States Through Policy Action: A Call for Legislative Support.](#)

Kyei GK, Kyei EK. *Policy Polit Nurs Pract.* 2026 Aug;27(3):165-170. doi: 10.1177/15271544251404015. Epub 2025 Dec 17. PMID: 41406054

[30 years in service, 1996-2026: Infectious Diseases Working Party \(AGIHO\) of the German Society of Hematology and Medical Oncology \(DGHO\).](#)

Cornely OA, Maschmeyer G, Hiddemann W, Bekaen N, Giesen N, Lass-Flörl C, Mellinghoff SC, Petzer V, Salmanton-García J, Sandherr M, Schalk E, Schiel X, Schmidt-Hieber M, Seidel D, Stemler J, Teschner D, Walti LN, Rieger CT. *Ann Hematol.* 2026 Aug 3;105(8):357. doi: 10.1007/s00277-026-07194-8. PMID: 42547600

[Development of an indirect competitive ELISA based on \$\sigma\$ C protein for detection of antibodies against avian reovirus.](#)

Wei F, Yang J, Yan Y, Zhang Y, He D, Diao Y. J Virol Methods. 2026 Aug 13;346:115450. doi: 10.1016/j.jviromet.2026.115450. Online ahead of print. PMID: 42595226

[Actinobacillus pleuropneumoniae - today's perspective on advances and challenges \(2017- 2026\).](#)

Hennig-Pauka I, Strutzberg-Minder K, Langford PR. BMC Vet Res. 2026 Aug 11;22(1):466. doi: 10.1186/s12917-026-05791-3. PMID: 42581360

[The CXCL10/CXCR3 axis drives actin remodeling to recruit CD4+ T cells to gut epithelium during transmissible gastroenteritis virus infection.](#)

Tan C, Chen J, Cai Y, Li Y, Wang G, Xie J, Liu G. J Immunol. 2026 Aug 4;215(8):vkag222. doi: 10.1093/jimmun/vkag222. PMID: 42571982

[BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer.](#)

Liu P, Liu K, Wang K, Guan H, Fan J, Li T, Hao J, Wang Z, Yan Y, Chen J, Ma Y, Yang Y, Niu Y. Adv Sci (Weinh). 2026 Aug 5:e76886. doi: 10.1002/advs.76886. Online ahead of print. PMID: 42555294

[An overview of the current animal models of Marburg virus disease for countermeasure development.](#)

Saito T, Maruyama J, Takada A. Expert Opin Drug Discov. 2026 Aug 3:1-14. doi: 10.1080/17460441.2026.2711720. Online ahead of print. PMID: 42548143

[A structural and mechanistic atlas of NTD antibody neutralization and immune escape across SARS-CoV-2 prototype and its \(sub-\)variants.](#)

Zhou J, Li W, Wang X, Sun J, Guo S, Rong X, Tong Z, Dai L, Liu WJ, Qi J, Gao GF, Wang Q. Proc Natl Acad Sci U S A. 2026 Aug 11;123(32):e2535385123. doi: 10.1073/pnas.2535385123. Epub 2026 Aug 5. PMID: 42555640

[S-layers as natural building blocks for nanobiotechnology and synthetic biology.](#)

Sleytr UB, Schuster B. Curr Opin Microbiol. 2026 Aug;92:102787. doi: 10.1016/j.mib.2026.102787. Epub 2026 Jul 3. PMID: 42398461

[The causes of Australian excess deaths in 2021, and beyond: An ecological study considering COVID-19, the lockdowns, and the vaccines.](#)

Lataster R. Int J Risk Saf Med. 2026 Aug;37(3):338-351. doi: 10.1177/09246479261426743. Epub 2026 Feb 14. PMID: 41689408

[Pre-existing hemagglutinin-specific antibody levels are associated with B-cell repertoire maturation and antibody breadth after influenza vaccination.](#)

Wang W, Sun Y, Liu Q, Xia Y, Wang J, Hu M, Kong M, He J, Gao R, Gao Y. Virol Sin. 2026 Aug 10:S1995-820X(26)00136-7. doi: 10.1016/j.virs.2026.08.007. Online ahead of print. PMID: 42575251

[Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue.](#)

Lay S, Auerswald H, Heng S, Sorn S, Ken S, Duran V, Rebellón Sanchez DE, Vinueza D, Villar Centeno LA, Rosso F, Einav S, Sakuntabhai A, Rey FA, Ariën KK, Ly S, Duong V, Barba-Spaeth G, Cantaert T. *EMBO Mol Med*. 2026 Aug 6. doi: 10.1038/s44321-026-00485-7. Online ahead of print. PMID: 42562883

[Development of ganciclovir as an anti-human cytomegalovirus drug: historical perspectives and future prospects.](#)

Garcia Del Valle N, Strang BL. *J Gen Virol*. 2026 Aug;107(8):002310. doi: 10.1099/jgv.0.002310. PMID: 42555156

[Research progress on plant polysaccharides in the prevention and treatment of tumors \(Review\).](#)

Wang J, Wang Y, Zhang X. *Oncol Rep*. 2026 Aug;56(2):152. doi: 10.3892/or.2026.9157. Epub 2026 Jun 26. PMID: 42438256

[Risk and Protective Factors Associated With HIV-Related Mortality in Children Receiving Antiretroviral Therapy: A Model-Based Meta-Regression.](#)

He J, Kassanjee R, Movo A, Walters MK, Brewer E, Sorensen RJD, Hay SI, Murray CJL, Flaxman A, Aravkin A, Zheng P, Kyu HH. *JAMA Pediatr*. 2026 Aug 1;180(8):829-837. doi: 10.1001/jamapediatrics.2026.1235. PMID: 42081240

[Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.](#)

Gosert R, Schmid S, Infanti L, Holbro A, Buser A, Passweg J, Halter J, Lötscher J, Walti CS, Tschudin-Sutter S, Khanna N, Heininger U, Leuzinger K. *Microbiol Spectr*. 2026 Aug 4;14(8):e0041726. doi: 10.1128/spectrum.00417-26. Epub 2026 Jun 26. PMID: 42360069

[A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old \(CoVacc trial\).](#)

Prat-Aymerich C, Yeghiazaryan L, Pathirana RD, Gautier V, Garcia Leon AA, Saini G, Loens K, Cox RJ, Formiconi E, O'Reilly S, van Hulst K, Nijland J, Cornely OA, Mallon P, Posch M, Bruijning-Verhagen P; CoVacc Study Group of the VACCCELERATE Consortium www.vaccelerate.eu; CoVacc Site investigators. *Vaccine*. 2026 Aug 13;88:128769. doi: 10.1016/j.vaccine.2026.128769. Epub 2026 Jun 27. PMID: 42364277

[Emerging Techniques of CRISPR/Cas System in Antiviral Therapy and Diagnostics: Applications, Limitations, and Translational Perspectives.](#)

Hasan MU, Azhar MW, Noor-Ul-Saba, Khurshid M, Riaz R. *J Virol Methods*. 2026 Aug 12:115447. doi: 10.1016/j.jviromet.2026.115447. Online ahead of print. PMID: 42586508

[Genotypic characterization of bovine rotavirus A from diagnostic submissions from 9 U.S. states, 2020-2025.](#)

Naveed A, Brewer C, Xie L, Lewin S, Loy JD, Loy DS. *J Vet Diagn Invest*. 2026 Aug 12:10406387261471139. doi: 10.1177/10406387261471139. Online ahead of print. PMID: 42584204

[Aerobactin: A Multifaceted Siderophore.](#)

Ghosh S. Indian J Microbiol. 2026 Aug;66(4):843-861. doi: 10.1007/s12088-025-01509-5. Epub 2025 Jun 25. PMID: 42568688

[Report of the international conference on animal testing replacement for vaccines: A one health view on global outlook and future strategy.](#)

Viviani L, Balbino E, Batolar M, Bolden J, Boonsuk S, Bouzya B, Buda M, Chapsal JM, Coppens E, Das P, Delvion F, Descampe B, Fauconnier A, Goel S, Gutierrez-Mazariegos J, Illes B, Iwaki M, Kalaivani M, Ketusing N, Lal M, Lei D, Little J, Mahmood K, Martin J, Martinez L, Milne C, Mvundura M, Olesen OF, Osetek-Müller K, Del Pace L, Pal S, Park IS, Philippe C, Pike C, Porfiri L, Premisri N, Pullirsch D, Sandy C, Sanyal G, Sato K, Schindl H, Sheridan S, Galvão J, Singh RP, Smith D, Stickings P, Tagle D, Tesolin L, Vandeputte J, Turner J. Biologicals. 2026 Aug 6;95:101903. doi: 10.1016/j.biologicals.2026.101903. Online ahead of print. PMID: 42561545

[The TG2/LRP1 Pathway for T Cell Activation by Post-Translationally Modified Antigens.](#)

Sewa AS, Yang FC, Khosla C. Immunol Rev. 2026 Aug;341(1):e70155. doi: 10.1111/imr.70155. PMID: 42552594

[One virus-many strategies: type-specific interactions between human adenoviruses and innate immunity.](#)

Hanrieder L, Schreiner S. J Virol. 2026 Aug 3:e0020426. doi: 10.1128/jvi.00204-26. Online ahead of print. PMID: 42545007

[Anatomical appropriateness of intramuscular injection at a new deltoid intramuscular injection site: comparison of nerve and arterial courses among three arm positions in healthy adult volunteers.](#)

Nakajima Y, Akashi Y, Ura A, Kawai K, Segi H, Nakada R, Hayakawa S, Matoba R, Murata K, Yamada A, Oe M, Mukai K. Vaccine. 2026 Aug 13;88:128975. doi: 10.1016/j.vaccine.2026.128975. Epub 2026 Jul 29. PMID: 42526175

[Hepatitis B in pregnancy and breastfeeding: current approaches to prophylaxis and treatment.](#)

Pan CQ, Pan BL, Li J, Wang FS. Expert Rev Anti Infect Ther. 2026 Aug;24(8):741-753. doi: 10.1080/14787210.2026.2690003. Epub 2026 Jul 7. PMID: 42298392

[Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation.](#)

González MAM, Rodríguez-Sainz C, Cardenas PP, Recio MJ, Gil-Herrera J. Clin Immunol. 2026 Aug;286:110732. doi: 10.1016/j.clim.2026.110732. Epub 2026 Jun 15. PMID: 42297123

[Expression profile of MHC class-II trans activator gene in pig immunized with recombinant virus like particles encoding porcine circovirus 2d.](#)

Wilson Varay L, Deb R, Maity HK, Sengar GS, Sandilya PB, Das PJ, Pegu SR, Rai V, Deka NJ, Das R, Rajkhowa S, Gupta VK. Microb Pathog. 2026 Aug;217:108620. doi: 10.1016/j.micpath.2026.108620. Epub 2026 Jun 6. PMID: 42251869

[Persistence of infectious bronchitis virus \(IBV\) in farms with chickens immunized with Massachusetts vaccines alone or combined with 793B serotype.](#)

Vagnozzi AE, Gerez Miranda RDC, Olivera V, Asenzo G, Cordara D, Di Giacomo S, Ferrufino C, Pozzobon E, Timo F. *Avian Pathol.* 2026 Aug;55(4):538-547. doi: 10.1080/03079457.2026.2663952. Epub 2026 Jun 3. PMID: 42013169

[Chikungunya virus: global epidemiology, transmission dynamics, and emerging challenges for public health.](#)

Rao D, Lu D, Yuan Z, Li X, Wu X, Li M, Du F, Zhao Y, Shen J, Cho CH, Yin W, He X, Xiao Z. *Infection.* 2026 Aug;54(4):1753-1768. doi: 10.1007/s15010-026-02780-4. Epub 2026 Apr 7. PMID: 41945227

[Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity.](#)

Zhao S, Shi T, Tian T, Zhang F, Zhang Z, Xu H, Zhou Y, Li Z, Qin Z, Xu P, Yang C, Zhang Z. *Proc Natl Acad Sci U S A.* 2026 Aug 11;123(32):e2604171123. doi: 10.1073/pnas.2604171123. Epub 2026 Aug 5. PMID: 42555643

[Theranostic innovation in infectious lung diseases: integrating biotechnology and nanotechnology for precision medicine.](#)

Jafari A, Manzari-Tavakoli A, Manzari Tavakoli M, Hashemian SM, Jamaati H, Akhtari M, Tabarsi P, Omrani M. *Expert Rev Mol Diagn.* 2026 Aug 11:1-24. doi: 10.1080/14737159.2026.2714060. Online ahead of print. PMID: 42549821

[Assessment of Neutralizing Antibodies Against COVID-19: The Impact of Vaccination in Western Rajasthan.](#)

Choudhary V, Khatri PK, Khinvasara P, Aseri GK, Jain N. *Indian J Clin Biochem.* 2026 Aug;41(4):533-542. doi: 10.1007/s12291-024-01258-0. Epub 2024 Sep 18. PMID: 42500335

[Recombinant subunit vaccines against invasive fungal infections: mechanisms, development progress, and therapeutic potential.](#)

Xu X, Jiang B, Xiong J, Jiang Y, Lu H. *Vaccine.* 2026 Aug 13;88:128864. doi: 10.1016/j.vaccine.2026.128864. Epub 2026 Jun 18. PMID: 42314309

[TRIM21 inhibited PRV infection and downregulated IFN- \$\alpha\$, IL-6, and TNF- \$\alpha\$ during the infection.](#)

Zhang G, Dong M, Li P, Huang J, Yin R, Lv X, Yang L, Ren L. *Microb Pathog.* 2026 Aug;217:108610. doi: 10.1016/j.micpath.2026.108610. Epub 2026 Jun 2. PMID: 42235710

[H5N1 avian influenza in dairy cattle: Molecular adaptation, transmission mechanisms, and control strategies.](#)

Ding K, Ding Y. *Virology.* 2026 Aug;621:110927. doi: 10.1016/j.virol.2026.110927. Epub 2026 May 6. PMID: 42107281

[Do vaccinated cases transmit measles? A systematic review and meta-analysis.](#)

Wright J, Crowcroft NS, Perry J, Poolsaar H, Gastañaduy PA, Durrheim DN, Moss WJ, Hahné S, Orenstein WA, Rota PA, Osman S, Pastor D, Severini A, Bolotin S. *Expert Rev Vaccines*. 2026 Dec;25(1):2708188. doi: 10.1080/14760584.2026.2708188. Epub 2026 Aug 14. PMID: 42599107

[A Robust Mitochondria-Targeted Photosensitizer Synergizes With Cisplatin Chemotherapy for Enhanced Antitumor Immunity.](#)

Cui W, Li M, Bai Q, He NSM, Yao S, An Y, Li E, Chen X, Meng Y, Wu X, Mao D, Wang J, Yu H. *Chemistry*. 2026 Aug 13:e71531. doi: 10.1002/chem.71531. Online ahead of print. PMID: 42593091

[Backbone-Ionized Polymers for Quantitatively Guided Extra-Hepatic mRNA Expression via Differential Local Structural Rearrangement.](#)

Geng Y, Zheng D, Yang J, Zhang X, An W, Shen J, Jiao X, Zhang Y, Cao D, Lu Z, Zhang X. *J Am Chem Soc*. 2026 Aug 12;148(31):33803-33817. doi: 10.1021/jacs.6c11271. PMID: 42584643

[Presumed Simultaneous Intraocular and Extraocular BCG-osis as a Complication of Intravesical Bacillus Calmette-Guérin Treatment for Non-Muscle-Invasive Bladder Cancer: A Case Report.](#)

Goh NS. *Cureus*. 2026 Aug 5;18(8):e114020. doi: 10.7759/cureus.114020. eCollection 2026 Aug. PMID: 42559380

[An orally administered biohybrid complex leveraging probiotic guidance to treat colorectal cancer via *in situ* vaccination.](#)

Fan W, Li S, Wang X, Xu J, Jiang S, Shen H, Yue Y, Dong Z, Wang X, Hu H, Xu W. *Mater Today Bio*. 2026 Jul 14;39:103445. doi: 10.1016/j.mtbio.2026.103445. eCollection 2026 Aug. PMID: 42502814

[Acacetin-incorporated lipid nanoparticles for inhaled mRNA vaccines.](#)

Huang X, Fan K, Zhang Y, Yang Y, Wang Y, Yang X, Meng Z, Guo Q, Li Y, Gong N, Wang S, Li J, Zhang Z. *Nanoscale Horiz*. 2026 Aug 3;11(8):2204-2214. doi: 10.1039/d5nh00794a. PMID: 42301134

[Intratracheal Delivery of mRNA Lipid Nanoparticles Reprograms Alveolar Macrophages for Pulmonary Cancer Immunotherapy.](#)

Zhou J, Li T, Zhang W, Qiao P, Zhang H, Ding Z, Lu Y, Yu J, Ding J, Chen H, Ji D, Wang Y, Chen B. *ACS Nano*. 2026 Aug 11;20(31):21798-21811. doi: 10.1021/acsnano.6c04529. PMID: 42579432

[A dual role for PGLYRP1 in host defense and immune regulation during *B. pertussis* infection.](#)

Rickert DM, Cardozo S, Carbonetti N, Goldman WE, Scanlon KM, Skerry C. *Elife*. 2026 Aug 11;15:RP108947. doi: 10.7554/eLife.108947. PMID: 42578462

[An investment too good to be true?: Reassessing the World Health Organization and World Bank return-on-investment estimates for pandemic preparedness.](#)

Brown GW, von Agris J, Tacheva B, Bell D. *Health Econ Policy Law*. 2026 Aug 6:1-10. doi: 10.1017/S174413312610067X. Online ahead of print. PMID: 42557899

[Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma.](#)

Zhao J, Li Q, Lin P, Yang Y, Yu H, Wen Y, Yu W, He H, Tao S, Zhang F, Li Y, Hu Z, Xie J, Chen Z, Huang S. *MedComm* (2020). 2026 Jul 30;7(8):e70890. doi: 10.1002/mco2.70890. eCollection 2026 Aug. PMID: 42534181

[Comparative Clinical and Molecular Epidemiology of Norovirus in Hospitalized Gastroenteritis Cases, Western India \(2013-2023\).](#)

Joshi MS, Gopalkrishna V, Chavan NA, Shinde MS, Dhembre VB, Sodnawar TV, Jadhav SM, Kalrao VR, Dhongade RK, Kulkarni RK, Bavdekar AR, Lavania M. *J Med Virol*. 2026 Aug;98(8):e71080. doi: 10.1002/jmv.71080. PMID: 42522423

[Alternative Developmental Toxicity Screening Methods Using Chick Embryo-Based Models.](#)

Kim JH, Park C, Kim D, Jeong W, Lee J. *J Appl Toxicol*. 2026 Aug;46(8):2640-2649. doi: 10.1002/jat.70193. Epub 2026 Apr 10. PMID: 41963253

[Enhancing Community Health Worker Communication: Evaluating Simulation-Based Training in Motivational Interviewing.](#)

Chance-Revels R, Phan Q, Crawford K, Steiger L, Swan BA. *J Community Health*. 2026 Aug;51(4):542-548. doi: 10.1007/s10900-025-01543-w. Epub 2026 Apr 5. PMID: 41936008

[Investigating the weak antibody response to vaccination with inactivated polio virus serotype 3 when delivered by microneedle patch.](#)

Gomaa Y, Kolluru C, Lee JW, Prausnitz MR. *J Control Release*. 2026 Aug 10;115251. doi: 10.1016/j.jconrel.2026.115251. Online ahead of print. PMID: 42575211

[Global, regional, and national burdens of human papillomavirus-associated cervical cancer attributable to sexually acquired human papillomavirus infections among individuals aged 10-54 years from 1990 to 2021: findings from the Global Burden of Disease study 2021.](#)

Nov P, Wang D, Tan M, Virak V, Zhou X, Liu K, Zhu Y, Zhou S, Zhu H. *Sex Med*. 2026 Jun 16;14(4):qfag045. doi: 10.1093/sexmed/qfag045. eCollection 2026 Aug. PMID: 42312021

[Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults.](#)

Wiegand RE, Payne AB, Mak J, Chickery S, Reese SE, Klein NP, Grannis SJ, Ong TC, Rowley EAK, DeSilva M, Dascomb K, Irving SA, Zerbo O, Hansen JR, Block L, Jacobson KB, Dixon BE, Rogerson CM, Duszynski TJ, Fadel WF, Barron MA, Mayer D, Chavez C, Yang DH, Ball SW, McEvoy CE, Akinsete OO, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Naleway AL, Natarajan K, Najdowski M, Ciesla AA, Kautz A, DeCuir J, Link-Gelles R. *JAMA Intern Med*. 2026 Aug 1;186(8):976-986. doi: 10.1001/jamainternmed.2026.1936. PMID: 42295789

[Prevalence, Antimicrobial Resistance, and Genetic Diversity of Non-Typeable *Streptococcus pneumoniae* Carriage: A Systematic Review and Meta-Analysis.](#)

Reeks RK, Ntim OK, Donkor ES. Health Sci Rep. 2026 Jul 25;9(8):e72890. doi: 10.1002/hsr.72890. eCollection 2026 Aug. PMID: 42504220

[Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial.](#)

Sullivan SG, Poh XY, Sanchez-Ovando S, Hadiprodjo AJ, Carolan L, Chin YQ, Rao S, Sutjipto S, Lim J, Anthony D, Sadarangani SP, Barr IG, Young B, Fox A. Lancet Infect Dis. 2026 Aug;26(8):778-792. doi: 10.1016/S1473-3099(26)00062-9. Epub 2026 Apr 2. PMID: 41936374

[CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting.](#)

Zhang M, Zhao L, Chen T, Ding L, He L, Guo Z. Int Immunopharmacol. 2026 Aug 6;187:117231. doi: 10.1016/j.intimp.2026.117231. Online ahead of print. PMID: 42561661

[Envelope protein residue E152 confers enhanced GAS6-dependent cell entry to the African Zika virus strain MR766.](#)

Kamiyama N, Saechue B, Watanabe K, Chalalai T, Dewayani A, Sachi N, Okamoto M, Ozaka S, Soga Y, Kagoshima Y, Ekronarongchai S, Umeki T, Khunsri T, Suzuki R, Kobayashi T. Antiviral Res. 2026 Aug;252:106462. doi: 10.1016/j.antiviral.2026.106462. Epub 2026 Jun 9. PMID: 42263867

[\[Expert consensus on key issues in Japanese encephalitis prevention and control \(2026 edition\)\].](#)

JE Prevention and Control Branch of China Association for Vaccines. Zhonghua Yu Fang Yi Xue Za Zhi. 2026 Aug 6;60(8):1207-1216. doi: 10.3760/cma.j.cn112150-20260422-00365. PMID: 42237845

[Candidate genomic regions associated with differential clinical response to lumpy skin disease in sahiwal cattle.](#)

Misal S, Patil A, Chhotaray S, Alex R, Gandham RK, Vohra V. Vet Res Commun. 2026 Aug 15;50(5):521. doi: 10.1007/s11259-026-11464-1. PMID: 42603235

[Bacterial Outer Membrane Vesicle-Based Versatile In Situ Nanovaccine Enhancer Synergized With Radiofrequency Ablation Against Hepatocellular Carcinoma.](#)

Li Y, Liu K, Guo J, Wang S, Sun Y, Liu J, Liu M, Cao J. Adv Healthc Mater. 2026 Aug 12:e71589. doi: 10.1002/adhm.71589. Online ahead of print. PMID: 42590861

[Integrated molecular, epidemiological, and bioinformatics perspectives on the Mpox virus: Implications for surveillance and Global Health preparedness.](#)

Detroja R, Chandra M. J Microbiol Methods. 2026 Aug 6;249:107656. doi: 10.1016/j.mimet.2026.107656. Online ahead of print. PMID: 42562267

[The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation.](#)

Ahmed MM, Joerger T, Wang Z, Li Y, Gerber JS. Clin Infect Dis. 2026 Aug 6:ciag406. doi: 10.1093/cid/ciag406. Online ahead of print. PMID: 42560328

[Progressive isolated lower-lip oedema after mRNA COVID-19 booster complicated by methicillin-resistant *Staphylococcus aureus* superinfection: a necrotizing fasciitis mimic.](#)

Ng TTW, Tillmann AM, Iacobelli JF, Delaney TA. Skin Health Dis. 2026 Jun 15;6(4):600-604. doi: 10.1093/skinhd/vzag074. eCollection 2026 Aug. PMID: 42539886

[Bacteremic Group A Streptococcal Co-Infection in Two Adults with H3N2 Influenza in Japan, 2025-2026: A Case Series.](#)

Seki M. Int Med Case Rep J. 2026 Aug 12;19:617504. doi: 10.2147/IMCRJ.S617504. eCollection 2026. PMID: 42605399

[Emerging and Re-Emerging Viral Infections in Poultry: Integrating Traditional and AI-Based Control Strategies.](#)

Mushtaq A, Gulzar M, Andrabi SA, Syal P. Curr Microbiol. 2026 Aug 14;83(10):513. doi: 10.1007/s00284-026-05118-3. PMID: 42599520

[A Self-Reinforcing Cuproptosis-Radiotherapy Loop by Copper Carbonate Nanoparticles for Enhanced Immunotherapy.](#)

Chen Y, Wang X, Li R, Zhang M, Song X, Han X, Dong X. ACS Appl Mater Interfaces. 2026 Aug 12;18(31):42357-42375. doi: 10.1021/acsami.6c10351. PMID: 42587511

[Shape-Memory Injectable Cryogels: From Minimally Invasive Delivery to Multifunctional Tissue Regeneration.](#)

Song Y, Lee SS. Macromol Biosci. 2026 Aug;26(8):e70241. doi: 10.1002/mabi.70241. PMID: 42587346

[Innate immunity: current understandings and future perspectives.](#)

Zou C, Ma T, Li J, Zhou X. Signal Transduct Target Ther. 2026 Aug 12;11(1):321. doi: 10.1038/s41392-026-02920-0. PMID: 42581325

[In-life Chemical Inactivation of Plasmodium Parasites by Cabamiquine Induces Long Lasting Immune Protection.](#)

Demarta-Gatsi C, Moita D, Fontinha D, Ventura R, Nunes-Cabaço H, Spangenberg T, Prudêncio M. J Infect Dis. 2026 Aug 11:jia402. doi: 10.1093/infdis/jia402. Online ahead of print. PMID: 42579294

[Unravelling the genomic epidemiology and antigenic evolution of Chandipura virus: A slow-evolving neurotropic threat.](#)

Kuri PR, Sharma A. PLoS Negl Trop Dis. 2026 Aug 3;20(8):e0014565. doi: 10.1371/journal.pntd.0014565. Online ahead of print. PMID: 42546036

[Highly Conserved Core Residues Define Old-World Alphaviruses and Trace Early Evolutionary Divergence.](#)

Piña-Ruiz WC, Jaime-Rocha LR, Castorena-Robles A, Castells-Graells R, Zandi R, Muñoz-Escalante JC, Comas-García M. J Mol Evol. 2026 Aug;94(4):668-685. doi: 10.1007/s00239-026-10331-6. Epub 2026 Jul 27. PMID: 42507035

[Unexplored Factors in Medication Wastage: Investigating Economic Impact in a Brazilian Teaching Hospital.](#)

Pessoa-Gonçalves YM, Flávio-Reis VHP, Costa JC, Tostes DR, Desidério CS, Gatto GC, Oliveira CJF. *J Eval Clin Pract.* 2026 Aug;32(5):e70530. doi: 10.1111/jep.70530.PMID: 42472378

[A unique dataset of immunological and bacteriological test results from experimental infection of European badgers \(*Meles meles*\) with *Mycobacterium bovis*.](#)

Belchior E, Birch CPD, Ashford R, Davé D, Middleton S, Anderson P, Palmer S, Williams GA, Powell S, Chambers MA, Gormley E, Balseiro A, Barral M, Durand B, Canini L, Lesellier S. *Data Brief.* 2026 Jul 2;67:113029. doi: 10.1016/j.dib.2026.113029. eCollection 2026 Aug.PMID: 42434499

[Community-Identified Barriers and Strategies for Improving HPV Vaccination in South Texas.](#)

Thompson EL, Cano M, Reyes C, Ravi T, Rodriguez J, Grimes A. *Health Promot Pract.* 2026 Aug 14:15248399261476034. doi: 10.1177/15248399261476034. Online ahead of print.PMID: 42598900

[Perspectives on an Intervention to Increase Confidence in Newborn RSV Immunoprophylaxis.](#)

Aronson PL, Loyal J, Del Valle C, Batti V, Mistry RD, Hong E, Aragona E. *Hosp Pediatr.* 2026 Aug 12:e2026009379. doi: 10.1542/hpeds.2026-009379. Online ahead of print.PMID: 42580725

[Vaccination Drives Alveolar Macrophages Pool Remodeling via Training Resident Cells and Recruiting Monocyte-Derived Cells to Defend Against Multidrug-Resistant *Acinetobacter baumannii*.](#)

Zhang X, Zhou Y, Xiang C, Wang N, Li Y, Chen K, Xie Y, Yang H, Sun X, Shi Y. *MedComm (2020).* 2026 Aug 3;7(8):e70887. doi: 10.1002/mco2.70887. eCollection 2026 Aug.PMID: 42549055

[Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.](#)

Zhou L, Hsieh CL, Leist SR, Happy Miller E, Horton AP, Shoemaker SR, Gardner EC, Powers JM, Boutz DR, Mallory ML, Mullins CM, Johnson NV, Tse AL, Wang A, Javanmardi K, Adams LE, Schisler J, Marqusee S, Chandran K, Baric RS, Gollihar JD, McLellan JS. *PLoS Pathog.* 2026 Aug 3;22(8):e1014391. doi: 10.1371/journal.ppat.1014391. eCollection 2026 Aug.PMID: 42546045

[The immune-stimulating particle adjuvant \(ISPA\) as a versatile adjuvant platform for recombinant vaccines against chronic *Toxoplasma gondii* infection.](#)

Arcon N, Pastor V, Palumbo A, Katán Piñeiro J, Fenoy IM, Sánchez VR, Marcipar I, Goldman A, Martin V. *Acta Trop.* 2026 Aug;280:108197. doi: 10.1016/j.actatropica.2026.108197. Epub 2026 Jun 23.PMID: 42336023

[COVID-19 vaccination in pregnancy and postpartum and human milk feeding non-initiation and discontinuation.](#)

Figueroa EB, Vazquez-Benitez G, Ehresmann K, Seburg EM, Daida YG, Vesco KK, Sidebottom A, Lipkind HS, DeSilva MB, Cao J, Kharbanda EO, Palmsten K. *Am J Epidemiol.* 2026 Aug 5;195(8):2121-2130. doi: 10.1093/aje/kwag105.PMID: 42127308

[Community awareness, perception, and preventive practices towards rabies in Ethiopia: A systematic review and meta-analysis.](#)

Abebe GK, Abebe W. Ther Adv Infect Dis. 2026 Aug 13;13:20499361261473789. doi: 10.1177/20499361261473789. eCollection 2026 Jan-Dec. PMID: 42602333

[Enhancing secretory expression of CSFV E2 glycoprotein via signal peptide engineering in a recombinant PRRSV vector platform.](#)

Guo Z, Zhao L, Li J, Luo M, Shuai W, Zhou Y, Jiang Y, Li L, Tong W, Tong G, Zeng Y, Wang J, Gao F. Vaccine. 2026 Aug 5;89:129005. doi: 10.1016/j.vaccine.2026.129005. Online ahead of print. PMID: 42556298

[Engineering Organoid Platforms for Pathogenesis Research.](#)

Han X, Zhang J, Bai J, Tian W, Zhou J, Ding L, Gao X. Research (Wash D C). 2026 Aug 4;9:1346. doi: 10.34133/research.1346. eCollection 2026. PMID: 42553490

[Infectious bovine keratoconjunctivitis in dairy herds: Presence of haemolytic Moraxella bovis and Moraxella bovoculi.](#)

Zbrun MV, Alvarado W, Peña A, Aliprandi D, Miotti C, Welschen N, Astesana DM, Cicottello J, Suarez Archilla G, Camussone CM, Molineri AI, Irazoqui M, Signorini ML. Res Vet Sci. 2026 Aug;207:106224. doi: 10.1016/j.rvsc.2026.106224. Epub 2026 Apr 29. PMID: 42070394

[The Role of Community Pharmacies in Seasonal Influenza Vaccination in Syracuse, Italy.](#)

Fiorilla C, Contarino F, Leonforte F, Nicosia V, Cucè GL, Caruso S, Nicolosi G, Mistretta A. J Community Health. 2026 Aug;51(4):629-636. doi: 10.1007/s10900-026-01566-x. Epub 2026 Apr 29. PMID: 42050235

[Toxic exposure and rates of suicidal thoughts and behaviors among U.S. military veterans.](#)

Bourassa KJ, Stephenson M, Dennis PA, Patel TA, Nugent SM, Patel P, Qin XJ, Chatzinakos C, Barr PB, Bigdeli TB, Hauser ER, Ashley-Koch AE, Program MV, Beckham JC, Kimbrel NA. Psychiatry Res. 2026 Aug;362:117172. doi: 10.1016/j.psychres.2026.117172. Epub 2026 Apr 15. PMID: 42033863

[Cost-effectiveness analyses of quadrivalent influenza vaccinations in the general European population - a systematic review.](#)

Van Sassenbroeck B, Piessens V, Roegies M, Vandijck D. Acta Clin Belg. 2026 Aug;81(4):316-329. doi: 10.1080/17843286.2026.2652263. Epub 2026 Apr 3. PMID: 41930417

[Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time.](#)

Yaksich L, Hartel G, Panizza BJ, Whiteman DC, Antonsson A. Int J Cancer. 2026 Aug 1;159(3):750-756. doi: 10.1002/ijc.70432. Epub 2026 Mar 7. PMID: 41795209

[Emergence of serotype 23F among levofloxacin-resistant invasive Streptococcus pneumoniae in the Republic of Korea: Association with the expansion of GPSC6.](#)

Lee J, Park J, La TM, Hyeon JY, Kim H, Ko SY, Kim DH, Kim J. J Infect Public Health. 2026 Aug 7;19(9):103333. doi: 10.1016/j.jiph.2026.103333. Online ahead of print. PMID: 42585898

[Multiple aspartic proteases process PE and PPE proteins on the mycobacterial surface of pathogenic mycobacteria.](#)

Meijers AS, Gallant JL, Speer A, Maaskant J, Hietamäki S, Ummels R, Paulußen FM, Grossmann TN, Pham TV, Piersma SR, Jiménez CR, Nejentsev S, Bitter W, Kuijl CP. *J Biol Chem.* 2026 Aug 13;113450. doi: 10.1016/j.jbc.2026.113450. Online ahead of print. PMID: 42595108

[A multimeric S1-nucleocapsid fusion antigen elicits cellular and humoral immune responses against porcine epidemic diarrhea virus in mice.](#)

Fragoso-Saavedra M, Thivierge B, Liu Q. *Microb Pathog.* 2026 Aug 4;219:108745. doi: 10.1016/j.micpath.2026.108745. Online ahead of print. PMID: 42551608

[Magnitude of human papillomavirus vaccination uptake and its determinants among adolescent girls in Lesotho: a cross-sectional study.](#)

Tebeje TM, Metkie KA, Asgedom YS, Gebrekidan AY, Sertsewold SG, Enyew EB, Abebe M. *BMJ Open.* 2026 Aug 3;16(8):e110615. doi: 10.1136/bmjopen-2025-110615. PMID: 42547243

[Identification of unvaccinated children, Madagascar.](#)

Muller N, Mahafeno AF, Rasolofondraibe AC, Andriantantsoa GT, Randrianirisoa AN, Ramarosaiiky E, Rakotoarisoa FR, Valitera FN, Rampanjato Z, Andriamanjany MM, Rajemison EN, Ramanantsoa RS, Emmrich JV, Press LM, Ravelomahafaly CH, Mananatitra M. *Bull World Health Organ.* 2026 Aug 1;104(8):560-565. doi: 10.2471/BLT.25.295299. Epub 2026 May 27. PMID: 42516117

[Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.](#)

Safari MS, Gicheru ET, Mburu MW, Makori TO, Nyawa O, Odoyo SO, Shee F, Ndungu F, Foley DJ, Nyagwange J, Chege T, Sande CJ. *Vaccine.* 2026 Aug 13;88:128837. doi: 10.1016/j.vaccine.2026.128837. Epub 2026 Jun 18. PMID: 42314312

[Continued High Levels of Invasive Streptococcus pyogenes Infections in Belgian Children Under 5 Years: Exploring Different Contributing Factors.](#)

Cornelissen L, De Keersmaecker F, De Koster S, van Kleef-van Koeveringe S, Matheeussen V, Smeesters PR. *Pediatr Infect Dis J.* 2026 Aug 1;45(8):677-683. doi: 10.1097/INF.0000000000005165. Epub 2026 Jan 28. PMID: 41593852

[Co-creating HPV Vaccination Messages for Rural Washington: Application of a Boot Camp Translation Approach.](#)

Thompson JH, Rivelli JS, Gautom P, Petrik AF, Najarian M, Edelmann AC, Villegas L, Slagle R, Christini K, Coronado GD, Kepka D. *Health Educ Behav.* 2026 Aug;53(4):367-376. doi: 10.1177/10901981251399649. Epub 2025 Dec 24. PMID: 41439412

[Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study.](#)

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whymys D, Terencio J, Piñol-Ripoll G, Boada M. *Alzheimers Dement*. 2026 Aug;22(8):e71746. doi: 10.1002/alz.71746.PMID: 42590850

[From decline to resurgence: current perspectives on *Mycoplasma pneumoniae*.](#)

Liu Y, Ye Q. *Clin Microbiol Rev*. 2026 Aug 6:e0005126. doi: 10.1128/cmr.00051-26. Online ahead of print.PMID: 42560049

[Innate immune response of lumpfish \(*Cyclopterus lumpus*\) to oil-based and water-soluble adjuvants.](#)

Joy CO, Valderrama K, Cao T, Vasquez I, Gnanagobal H, Boyce D, Hall JR, Rise ML, Santander J. *Dev Comp Immunol*. 2026 Sep;182:105700. doi: 10.1016/j.dci.2026.105700. Epub 2026 Aug 5.PMID: 42556659

[Impaired immune response to polysaccharide antigens and warning signs in children with recurrent respiratory infections.](#)

Pury S, Marini V, Lozano NA, Sasia LV, Córdoba EA, Saranz RJ, Visconti P, Alegre G, Monferini F, Lozano A. *Arch Argent Pediatr*. 2026 Aug 6:e202510978. doi: 10.5546/aap.2025-10978.eng. Online ahead of print.PMID: 42545920

[From Evidence to Practice: Implementing the 2026 Canadian Clinical Practice Guideline Update on Vaccination-Related Distress in the Dutch National Immunization Program.](#)

Huijten DCM, Widdershoven V, Leroy PLJM, Hoebe CJP, Reijds RP. *Clin J Pain*. 2026 Aug 1;42(8S Suppl 1):e1380. doi: 10.1097/AJP.0000000000001380.PMID: 42444177

[Codon optimization depletes stop codons in alternative reading frames of protein-coding nucleic acid therapeutics.](#)

Liu Z, Ying Z, Shen L, Ma W. *Proc Natl Acad Sci U S A*. 2026 Aug 18;123(33):e2606609123. doi: 10.1073/pnas.2606609123. Epub 2026 Aug 13.PMID: 42594282

[Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.](#)

Singh PK, Mehmood MS, Javaid F, Adnan H, Hassan MA, Kashif E, Saddique MN, Danaf N. *Ann Med Surg (Lond)*. 2026 Jul 15;88(8):5120-5129. doi: 10.1097/MS9.0000000000005260. eCollection 2026 Aug.PMID: 42583571

[The global demand and potential public health impact of oral antiviral treatment stockpile for influenza pandemics.](#)

Han AX, Hulme KD, Russell CA. *Proc Natl Acad Sci U S A*. 2026 Aug 4;123(31):e2524161123. doi: 10.1073/pnas.2524161123. Epub 2026 Jul 28.PMID: 42520120

[Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.](#)

Hansen CL, Shaikh N, Naeger S, Torcel-Pagnon L, Chaves SS, Viboud C. *J Infect*. 2026 Aug;93(2):106811. doi: 10.1016/j.jinf.2026.106811. Epub 2026 Jul 11.PMID: 42435861

[Repurposing RIPK3 inhibitor GSK840 as an enhancer of the safety and immunogenicity of lentogenic Newcastle disease virus La Sota used for in ovo and spray vaccination.](#)

Chai Y, Yu W, Liu X, Hu J, Hu Z. *Vet J.* 2026 Aug;318:106775. doi: 10.1016/j.tvjl.2026.106775. Epub 2026 Jul 10. PMID: 42431358

[Vaccination coverage among individuals receiving HIV pre-exposure prophylaxis \(PrEP\): A systematic review and meta-analysis.](#)

Pascucci D, Lontano A, Crovella S, Cosci S, Laurenti P. *Prev Med.* 2026 Aug;209:108611. doi: 10.1016/j.ypmed.2026.108611. Epub 2026 May 25. PMID: 42184839

[Decoding classical swine fever virus-swine protein interactions: a bioinformatics approach to targeted viral control.](#)

Ravikumar MJ, Velankar A, Krishnan P, Venkataramappa M, Naik N, Siddharthan N, Suresh KP, Hiremath J, Nayakvadi S, Patil SS. *Virus Genes.* 2026 Aug;62(4):505-520. doi: 10.1007/s11262-026-02245-8. Epub 2026 May 21. PMID: 42168735

[FcRn-targeted therapeutics: Neonatal fc receptor at the Interface of balancing immune modulation and persevering protective humoral immunity.](#)

Ghosh D, Wang J, Wen W, Saxena A, Kumar A. *Int Immunopharmacol.* 2026 Aug 1;182:116751. doi: 10.1016/j.intimp.2026.116751. Epub 2026 May 11. PMID: 42114305

[Incidence of Herpes Zoster Infection \(Shingles\) Among Adults Living With and Without HIV in British Columbia, Canada: A Population-based Study.](#)

Lima VD, Hussain SS, Yan J, Copp E, Hull M, Budu M, Duailibe F, Trigg J, Leung V, Phillips P, Guillemi S, Hogg RS, Montaner JSG. *J Infect Dis.* 2026 Aug 3;234(1):e69-e80. doi: 10.1093/infdis/jiag118. PMID: 41805836

[Economic Impact of the 2025 New Mexico Measles Outbreak: Highlighting the Cost of Efforts to Prevent Future Outbreaks.](#)

Pike J, Holzinger N, Xiao HT, Stanislawski E, Leung J, Romero A, Smelser C. *Ann Intern Med.* 2026 Aug 4. doi: 10.7326/ANNALS-26-00718. Online ahead of print. PMID: 42546299

[Meningococcal and pneumococcal carriage in children with HIV.](#)

Mete Atasever N, Dede E, Yilmaz S, Akkoç G, Öcal Demir S, Çakir D, Kahraman Çetin B, Devrim İ, Ekemen C, Şahbudak Bal Z, Somer A, Dinleyici EÇ, Hançerli Törün S. *AIDS.* 2026 Aug 1;40(8):1114-1123. doi: 10.1097/QAD.0000000000004500. Epub 2026 Mar 24. PMID: 41879086

[A retrospective analysis of COVID-19 vaccination uptake among patients admitted to psychiatric hospitals in southwest Bavaria.](#)

Aksar A, Amini Farsani Z, Hasan A, Röh A. *J Psychiatr Res.* 2026 Aug 12;202:87-94. doi: 10.1016/j.jpsychires.2026.08.005. Online ahead of print. PMID: 42603342

[Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.](#)

Cianciarullo AM, Sakauchi D, Sasaki EAK, Hosoda TM, Borelli P, Beçak W. *Int J Mol Sci.* 2026 Aug 3;27(15):6968. doi: 10.3390/ijms27156968. PMID: 42589622

[Expanding the role of pharmacists as vaccinators in New Zealand: a retrospective analysis of influenza vaccination trends following policy change.](#)

Larson A, Mitrovich R, Musse I, Lansdale AJ, Eiden AL. *Int J Pharm Pract.* 2026 Aug 6:riag102. doi: 10.1093/ijpp/riag102. Online ahead of print. PMID: 42560331

[Tricho-Hepato-Enteric Syndromic Immunodeficiency: Clinical Spectrum, Pathobiology, and Emerging Therapies.](#)

Mandola AB, Frizinsky S, Somekh I, Naor S, Somech R. *Isr Med Assoc J.* 2026 Aug;28(8):487-493. PMID: 42557665

[Mothers' intentions for adolescent sons' human papillomavirus vaccination in Japan: Psychosocial factors and relative influences across intention groups.](#)

Ueda M, Imai M, Yamamoto N, Kawai M, Kameda Y. *Hum Vaccin Immunother.* 2026 Dec;22(1):2686497. doi: 10.1080/21645515.2026.2686497. Epub 2026 Aug 3. PMID: 42546173

[Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024.](#)

Li J, Wang Z, Gong Y. *Vaccine.* 2026 Aug 13;88:128973. doi: 10.1016/j.vaccine.2026.128973. Epub 2026 Jul 28. PMID: 42520643

[Exploitation of cholesterol-dependent cytolysins for targeted biosensing and therapeutic systems.](#)

Abanum HO, Watt E, Ho EA. *Drug Deliv Transl Res.* 2026 Aug;16(8):2622-2639. doi: 10.1007/s13346-026-02128-3. Epub 2026 May 4. PMID: 42071090

[Discontinuation of prophylactic antimicrobial use in calves restores susceptibility in bovine respiratory pathogens.](#)

Okamura S, Fukuda A, Usui M. *J Glob Antimicrob Resist.* 2026 Aug 4:S2213-7165(26)00129-3. doi: 10.1016/j.jgar.2026.07.023. Online ahead of print. PMID: 42551527

[\[Interdisciplinary Management of Acute and Chronic Mastoiditis\].](#)

Lailach S, Neudert M, Zahnert T. *Laryngorhinootologie.* 2026 Aug;105(8):516-532. doi: 10.1055/a-2623-3015. Epub 2026 Aug 3. PMID: 42546716

[Multiomics Dissection Reveals Natural Killer Cell-CD8+ T-cell Cooperation in Shaping an Immunostimulatory Tumor Microenvironment.](#)

Shimizu K, Sanpei A, Liu Y, Ishibashi T, Yanagawa M, Nakazato H, Shinga J, Ueda S, Yamasaki S, Fujii SI. *Cancer Res.* 2026 Aug 3:OF1-OF18. doi: 10.1158/0008-5472.CAN-25-4957. Online ahead of print. PMID: 42545372

[A modular plug-and-play vaccine construction platform using bio-click chemistry and virus-like particles.](#)

Balbierer K, Kurze T, Herrmann FC, Jenzelewski V, Piontek M, Jose J.J Mater Chem B. 2026 Aug 12;14(31):9745-9763. doi: 10.1039/d6tb00809g.PMID: 42517409

[Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan.](#)

Hussain HS, Yousafzai MT, Iqbal J, Aslam ZM, Irum Fatima MS, Kehkashan Begum MS, Rabia Zuberi MS, Farheen Aftab MS, Mujahid W, Irfan Ghaffar MS, Afshan Piyarali MS, Miqdad Ali MS, Charu V, Hedlin H, Lu D, Zhang A, Gu Y, Rosser JI, Seidman JC, Carter AS, Luby SP, Croda J, Garrett DO, Qamar FN.Vaccine. 2026 Aug 13;88:128918. doi: 10.1016/j.vaccine.2026.128918. Epub 2026 Jul 21.PMID: 42480193

[Current trends and advances of microbial biosurfactants in the biomedical and pharmaceutical applications.](#)

Krishnamoorthi R, Mahalingam PU, Muthuramalingam K, Chang SH, Lin CY, Fang JY.Crit Rev Biotechnol. 2026 Aug 13:1-26. doi: 10.1080/07388551.2026.2711971. Online ahead of print.PMID: 42595699

[Understanding hesitancy and decision postponement toward digital therapeutics for Insomnia: Roles of objective ambivalence and digital health literacy.](#)

Choi S, Zo H.Int J Med Inform. 2026 Nov 1;220:106647. doi: 10.1016/j.ijmedinf.2026.106647. Epub 2026 Aug 5.PMID: 42580081

[EscaPRRS-ORF5: a structure-aware evolutionary framework for prioritizing immune escape-prone variants in porcine reproductive and respiratory syndrome virus.](#)

Chowdhury R, Sr V, Dey S, Ferdous S, Danurdoro R, Zeller MA.Bioinformatics. 2026 Aug 3;42(8):btag529. doi: 10.1093/bioinformatics/btag529.PMID: 42489519

[Autologous tumor-based vaccines in canine oncology: a systematic review of safety, immunogenicity, and therapeutic potential.](#)

Leitão JR, Tuani BRV, Vicente IST, Matera JM, de Oliveira Massoco C, Fonseca-Alves CE.Vaccine. 2026 Aug 13;88:128836. doi: 10.1016/j.vaccine.2026.128836. Epub 2026 Jun 12.PMID: 42284812

[Advances in research and application of therapeutic antibody strategies for porcine rotavirus prevention and control.](#)

Zheng S, Wang L, Xia X, Xin Z, Zhang J, Tian Y, Xing C, Wang Z, Yu X, Pan Y, Wen K.Vaccine. 2026 Aug 13;88:128777. doi: 10.1016/j.vaccine.2026.128777. Epub 2026 Jun 6.PMID: 42247746

[A recombinant baculovirus expressing multi-epitopes elicits protective immunity against ALV-J infection in chickens.](#)

Chen Y, Zheng Y, Chen R, Li X, Jiao W, Liao M, Feng M, Dai M.Vet Microbiol. 2026 Aug;319:111084. doi: 10.1016/j.vetmic.2026.111084. Epub 2026 May 26.PMID: 42208336

[Nationwide surveillance of antibacterial susceptibility patterns of bacterial pathogens isolated from otorhinolaryngological infectious diseases in Japan.](#)

Yano H, Suzuki K, Kamide Y, Hotomi M, Hayashi T, Sato J, Takahashi S, Matsumoto T, Yanagisawa H, Nakamura S, Takata M, Yamamoto K, Furuta Y, Nagano E, Katori Y, Kakuta R, Watanabe K, Kakehata S,

Suzuki Y, Chikamatsu K, Kuwabara M, Fujimaki Y, Sugita R, Okada H, Ikeda K, Matsumoto F, Furuki S, Sugano S, Baba H, Maruyama Y, Matsubara S, Yokota A, Fujisawa T, Kishimoto A, Miyamoto N, Iwasaki S, Kabaya K, Sakai M, Hidaka H, Iwai H, Maeda T, Hayashi Y, Sakamoto T, Horibe Y, Kunimoto M, Sugahara K, Hiyoshi M, Shimizu T, Sawada S, Hirano T, Watanabe T, Kumai Y, Kitaoka K, Uchizomo A. *J Infect Chemother*. 2026 Aug;32(8):102995. doi: 10.1016/j.jiac.2026.102995. Epub 2026 May 12. PMID: 42128293

[Immunomodulatory effect of traditional Chinese medicine in infectious diseases.](#)

Rao Z, Zhou H, Jing Q, Zhang X, Hou S, Liu X, Li Q, Wang Q. *J Ethnopharmacol*. 2026 Aug 10;367:121753. doi: 10.1016/j.jep.2026.121753. Epub 2026 Apr 21. PMID: 42025778

[Updating the evidence on brighton collaboration's GAIA maternal immunisation case definitions: a systematic review of performance and implementation challenges.](#)

Mboizi R, Maertens K, Le Doare K, Cutland CL, Muñoz FM, Davies HG. *Vaccine*. 2026 Aug 13:128899. doi: 10.1016/j.vaccine.2026.128899. Online ahead of print. PMID: 42595590

[Cholesterol Analogs and Vitamin-Conjugated Ionizable Lipids Enhance Lipid Nanoparticle Delivery for In Vitro and In Vivo Applications.](#)

Wang C, Gao Y, Zhou W, Wu F, Liu F, Xu Y, Liang Z, Pan X, Jia W, Wu T, Zhang Y. *ACS Appl Mater Interfaces*. 2026 Aug 12;18(31):42417-42427. doi: 10.1021/acsami.6c11233. PMID: 42587484

[Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review.](#)

Verma KK. *Crit Rev Oncol Hematol*. 2026 Aug 1;226:105512. doi: 10.1016/j.critrevonc.2026.105512. Online ahead of print. PMID: 42542196

[An updated systematic review on antimicrobial resistance among Salmonella Typhi worldwide.](#)

Murthy S, Hagedoorn NN, Adhy WP, Batool R, Rathan MD, Marchello CS, Crump JA. *Clin Microbiol Infect*. 2026 Aug 14:S1198-743X(26)00453-2. doi: 10.1016/j.cmi.2026.08.007. Online ahead of print. PMID: 42601018

[Fish cell lines in aquaculture and biomedical research: A global perspective on development, repositories, and multidisciplinary applications.](#)

Kumar A, Vimal B, Kumar V, Sarker S, Kumari P, Paul T, Rout AK, Saini VP, Pandey PK, Behera BK, Tyagi A. *Mol Biol Rep*. 2026 Aug 6;53(1):1348. doi: 10.1007/s11033-026-12550-y. PMID: 42560549

[Understanding the diagnostic tests and challenges in host genetic selection against Johne's disease in New Zealand dairy cattle.](#)

Km V, Dukkipati V, Gupta SK, Lopez-Villalobos N, Laven R, Udy GB. *N Z Vet J*. 2026 Aug 4:1-15. doi: 10.1080/00480169.2026.2704530. Online ahead of print. PMID: 42552635

[Rapid, precise and multi-excipient benchtop ¹H NMR method to monitor drug substance and drug product process consistency.](#)

Esposito K, Sutton AT, Rustandi RR, Schombs M. *J Pharm Biomed Anal*. 2026 Aug 15;276:117462. doi: 10.1016/j.jpba.2026.117462. Epub 2026 Mar 14. PMID: 41933981

[Oral or nasal immunization of piglets with porcine epidemic diarrhea virus \(PEDV\) S1 protein bacterial-like particles induces robust intestinal mucosal immune responses and provides reliable protection.](#)

Su K, Ren J, Wang Y, Yuan C, Zhang Y, Fan T, Liu Z, Sun T, Yang L, Wang X, Song Q. *Vet Microbiol*. 2026 Aug 12;321:111173. doi: 10.1016/j.vetmic.2026.111173. Online ahead of print. PMID: 42600389

[Structural Basis for the Immunological Paradox of a High-Affinity Yet Non-Immunogenic MHC-I Epitope from *Cryptosporidium parvum*.](#)

Fan S, Wang T, Ren S, Peng J, Li L, Zhao Y, Yang J, Zhang Y, Yan Y, Wang H, Wang Y. *Biology (Basel)*. 2026 Aug 4;15(15):1281. doi: 10.3390/biology15151281. PMID: 42589148

[Immunomodulatory Biomaterials: Principles, Immune Engineering Strategies, and Emerging Applications in Regenerative Medicine.](#)

Buran A, Durğun ME, Aydoğmuş E, Arslanoğlu H. *Biotechnol Bioeng*. 2026 Aug 10. doi: 10.1002/bit.70341. Online ahead of print. PMID: 42574546

[National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.](#)

Charatcharoenwittaya P, Tanwandee T, Tangkijvanich P, Piratvisuth T, Jullapetch C, Lertpiriyasuwat C, Chartpitak P. *Hepatol Int*. 2026 Aug 3. doi: 10.1007/s12072-026-11135-y. Online ahead of print. PMID: 42547747

[Molecular characterization and correlation with \$\beta\$ -lactam resistance of penicillin-binding protein 2x, 2b, and 1a of *Streptococcus pneumoniae* in clinical pneumococcal isolates.](#)

Zhang Y, Shen J, Hu F, Wang B, Liu C, Jiang F, Peng R, Liu X, Cheng J, Qian C, Shen K, Lu Y, Yi L, Wang M, He N, Zhang T, Zhao G. *Microbiol Spectr*. 2026 Aug 4;14(8):e0385025. doi: 10.1128/spectrum.03850-25. Epub 2026 Jul 2. PMID: 42390257

[Epidemiology of brucellosis in sheep and goats across different production systems in regions with high human brucellosis prevalence.](#)

Dadar M, Alamian S, Bahreinipour A, Amiry K. *Res Vet Sci*. 2026 Aug;208:106235. doi: 10.1016/j.rvsc.2026.106235. Epub 2026 May 1. PMID: 42085969

[Molecular detection and genotyping of *Orientia tsutsugamushi* in human serum samples from a scrub typhus outbreak in Vellore and adjacent districts, Tamil Nadu, India.](#)

Palavesam A, Selvaraj P, S P, E D, Ragavan GK, Lakshmipathy A, Gopalan TK, Parthiban ABR, Kp S, K K, Hegde NR, G TS. *Diagn Microbiol Infect Dis*. 2026 Aug 4;116(4):117597. doi: 10.1016/j.diagmicrobio.2026.117597. Online ahead of print. PMID: 42585943

[Durability and Breadth of Neutralizing Antibodies Against SARS-CoV-2 Variants Following XBB.1.5 Vaccination in a Multiply Exposed Cohort.](#)

Wang W, Goguet E, Lusvarghi S, Paz S, Shrestha L, Vassell R, Pollett S, Mitre E, Weiss CD. *Open Forum Infect Dis*. 2026 Jul 17;13(8):ofag446. doi: 10.1093/ofid/ofag446. eCollection 2026 Aug. PMID: 42549263

[Navigating ethical dilemmas during child and adolescent vaccinations: a scoping review.](#)

Sendekie AK, Chalmers L, Sim TF, Czarniak P. *Vaccine*. 2026 Aug 13;88:128943. doi: 10.1016/j.vaccine.2026.128943. Epub 2026 Jul 23. PMID: 42492244

[Seroprevalence and risk factors of Hepatitis A virus among Palestinian refugees in North Lebanon: A pilot study to inform vaccination and public health policy.](#)

Said N, Farhat N, El Safadi D, Khalife S. *New Microbes New Infect*. 2026 Jun 9;72:101784. doi: 10.1016/j.nmni.2026.101784. eCollection 2026 Aug. PMID: 42317722

[Effects of vaccines targeting interleukin-1 receptor, type I on atrial and ventricular function after myocardial infarction.](#)

Huang J, Yang Y, Qin P, Wang Y, Pu J, Wu J, Ma Q, Chen H, Wang Y, Liao Y, Wu H, Chen F, Hu X, Cheng X, Qiu Z, Zhou Z, Zhou Y. *Br J Pharmacol*. 2026 Aug;183(16):4628-4645. doi: 10.1111/bph.70436. Epub 2026 May 2. PMID: 42068142

[Identification and Molecular Characterization of 10 Novel Recombinant Variants of Hepatitis C Virus \(HCV\) in Cameroon Using Oxford Nanopore Sequencing and Phylogenomic Analysis.](#)

Mouchili-Njifon A, Heang V, Pum L, Messanga LLE, Modiyinji AF, Moumbeket-Yifomnjou MH, Nfombouot-Njitoyap HP, Lissack SF, Mbouyap PR, Assam JPA, Karlsson EA, Nouhin J, Njouom R. *J Med Virol*. 2026 Aug;98(8):e71105. doi: 10.1002/jmv.71105. PMID: 42605175

[Neutralizing and protective monoclonal antibodies identify antigenic sites in influenza H7 hemagglutinin and select for amino acid substitutions rarely observed at the global level.](#)

Parra GI, Odin M, Tohma K, Schmeisser F, Meseda CA, Wang W, Weiss CD, Vassell R, Woerner A, Pedro CL, Weir JP. *Microbiol Spectr*. 2026 Aug 6:e0109126. doi: 10.1128/spectrum.01091-26. Online ahead of print. PMID: 42560073

[Harmonization of Real-World Data for Vaccine-Preventable Infectious Diseases: Integration of SARS-CoV-2 Diagnostic and Serologic Data From Multiple Sources.](#)

Ziemba YC, Yoon S, Kaufman HW, Meyer WA 3rd, Gillim L, Okoye N, Schleicher CB, Islam S, Sison CP, Pinto LA, Penberthy L, Crawford JM. *Open Forum Infect Dis*. 2026 Jul 23;13(8):ofag454. doi: 10.1093/ofid/ofag454. eCollection 2026 Aug. PMID: 42558864

[Advanced statistical approaches in tuberculosis diagnosis and treatment outcomes in Africa: a systematic review.](#)

Okesanya OJ, Oso TA, Amisu BO, Abdullahi YB, Ahmed MM, Adebayo UO, Abdi YH, Ong CJN, Adigun OA, Ogaya JB, Lucero-Prisno DE 3rd. *Trop Med Health*. 2026 Aug 3;54(1):135. doi: 10.1186/s41182-026-01020-7. PMID: 42552557

[Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model.](#)

Freitas CS, Lage DP, Pimenta BL, Falcão KOM, Moreira GJL, Pereira IAG, Câmara RSB, Simão SLP, Silva AL, Oliveira-da-Silva JA, Abrão DM, Galdino AS, Chávez-Fumagalli MA, Roatt BM, Christodoulides M, Coelho EAF. *Vaccine*. 2026 Aug 3;89:128990. doi: 10.1016/j.vaccine.2026.128990. Online ahead of print. PMID: 42546635

[Protective effect of pneumococcal vaccination on pneumococcal pneumonia outcomes: analysis adjusted for severity and comorbidity.](#)

Moreno Salcedo JM, Malo Rico P, Alcalá Rivera G, Rueda Narváez MF. *Rev Clin Esp (Barc)*. 2026 Aug-Sep;226(7):502575. doi: 10.1016/j.rceng.2026.502575. Epub 2026 May 27. PMID: 42208937

[Phase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.](#)

Wolf AS, Gulati S, Dolasia K, Fitzgerald B, Gomez J, Yankelevitz D, Salazar A, Tsankov AM, Marron T, Flores R. *J Thorac Cardiovasc Surg*. 2026 Aug;172(2):467-475.e3. doi: 10.1016/j.jtcvs.2026.03.594. Epub 2026 Mar 24. PMID: 41881390

[Respiratory Viral Detection and Invasive Bacterial Infections in Infants ≤90 Days.](#)

Nicholson EG, Stopczynski T, Sahni LC, Avadhanula V, Amarin JZ, Chappell J, Klein EJ, Englund JA, Williams JV, Michaels MG, Weinberg GA, Szilagyi PG, Schuster JE, Selvarangan R, Staat MA, Schlaudecker EP, Toepfer AP, Moline HL, Halasa NB, Piedra PA, Boom JA. *Pediatr Infect Dis J*. 2026 Aug 10. doi: 10.1097/INF.0000000000005358. Online ahead of print. PMID: 42574253

[Association between pneumococcal vaccination and mortality risk in critically ill patients with acute myocardial infarction: A retrospective cohort study using a large clinical database.](#)

Yang M, Qiu J, Li X, Xu J, Kang F, Chen D. *Heart Lung*. 2026 Aug 7;80:102910. doi: 10.1016/j.hrtlng.2026.102910. Online ahead of print. PMID: 42567107

[Patient awareness of viral hepatitis infection in Al-Madinah, Saudi Arabia: a cross-sectional study.](#)

Elnawasany S, Afghani A, Alqahtani R, Almaimani R, AlKuhayli ST, AlShanqiti ZA, AlAhmadi SA, AlSharif FA, AlHarbi WA, AlOufi AA. *Sci Rep*. 2026 Aug 5;16(1):24159. doi: 10.1038/s41598-026-56296-w. PMID: 42557267

[Divergence in virus-host protein interactomes across species explains disparities in translational therapeutic success.](#)

Tang K, Zhuang K, Zhao Z, Zhang B, Liu X, Li S, Tang J, Chen Y, Du X. *mBio*. 2026 Aug 12;17(8):e0019526. doi: 10.1128/mbio.00195-26. Epub 2026 Jun 22. PMID: 42328988

[Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.](#)

Wu X, Tao Y, Sun Y, Chen J, Lv M, Yang T, Ye L. *Vaccine*. 2026 Aug 13;88:128782. doi: 10.1016/j.vaccine.2026.128782. Epub 2026 Jun 8. PMID: 42247748

[Administration of COVID-19 vaccination to adult caregivers in pediatric outpatient clinics: a vaccination cocooning project.](#)

Jensen LR, Posa M, Filipp S, Kelly M, Otero J. *Postgrad Med.* 2026 Aug;138(6):729-735. doi: 10.1080/00325481.2025.2482513. Epub 2025 Mar 28. PMID: 40133217

[In vivo imaging of lipid nanoparticle messenger RNA therapeutics: Current advances and emerging opportunities.](#)

Jugniot N. *Eur J Med Chem.* 2026 Aug 4;318:119213. doi: 10.1016/j.ejmech.2026.119213. Online ahead of print. PMID: 42574801

[The truncated major pilin subunit SBP2' contributes to *Streptococcus suis* meningitis by interacting with host plasminogen.](#)

Guo G, Li P, Zhou Y, Li Q, Yu Y, An J, Zhang W. *Appl Environ Microbiol.* 2026 Aug 10:e0126726. doi: 10.1128/aem.01267-26. Online ahead of print. PMID: 42573261

[mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model.](#)

Krueger J, Ruotsalainen JJ, Lutz J, Heidenreich R. *Sci Rep.* 2026 Aug 8;16(1):24539. doi: 10.1038/s41598-026-65120-4. PMID: 42570949

[Sero-epidemiological and functional evaluation of IgG specific for a cysteine protease inhibitor of *Plasmodium falciparum*, falstatin.](#)

Bhardwaj J, Gaskin EL, Holla P, De Los Santos O, Doumbo S, Kayentao K, Ongoiba A, Traore B, Crompton PD, Tran TM. *Infect Immun.* 2026 Aug 4:e0020226. doi: 10.1128/iai.00202-26. Online ahead of print. PMID: 42550035

[Municipal waste workers and hepatitis B and C virus and HTLV infection a cross-sectional study.](#)

Rafiei-Abatari F, Mohtasham-Amiri Z, Pourgholaminejad A, Jafari-Shakib R. *Virus Genes.* 2026 Aug;62(4):498-504. doi: 10.1007/s11262-026-02247-6. Epub 2026 Jun 2. PMID: 42230468

[Phylogeography and Molecular Evolution of Newcastle Disease Virus Across a Century of Global Surveillance.](#)

Ul-Rahman A, Shabbir MZ, Munir M. *Virus Res.* 2026 Aug 11:199783. doi: 10.1016/j.virusres.2026.199783. Online ahead of print. PMID: 42580484

[High Awareness, Poor Practice: The Cholera Prevention Knowledge-Attitude-Practice Gap in Ada Foah, Ghana-A Cross-Sectional Study.](#)

Dumevi CY, Dwomoh PAT, Aryee HNA, Asiamah JJ, Amenya GS, Aidoo GA, Teiko DA, Ennin IE, Amuah EE, Kretchy JP, Adjenti SK, Ayeh-Kumi PF. *Public Health Chall.* 2026 Aug 13;5(3):e70339. doi: 10.1002/puh.70339. eCollection 2026 Sep. PMID: 42598599

[iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy.](#)

Kumar A, Dwivedi D, Ghosh N, Gopalakrishnan K, Rahamathulla M, Ahmed MM, Nair C, Singh D, Singh R, Das U. *Mol Immunol*. 2026 Aug 13;198:98-120. doi: 10.1016/j.molimm.2026.08.008. Online ahead of print. PMID: 42594762

[Expanded prevalence of group 4 capsule expression and its genetic requirements in a broad array of *Shigella* strains.](#)

Brethour BW, Wu T, Guo B, Broussard MD, Rasko DA, Barry EM. *mSphere*. 2026 Aug 12:e0035426. doi: 10.1128/msphere.00354-26. Online ahead of print. PMID: 42584164

[Systematic review and meta-analysis of digital seasonal influenza vaccination promotion in people aged ≥50 years.](#)

Chen S, Fang Y, Yu FY, Ding L, Mo PKH, Wang Z. *Vaccine*. 2026 Aug 13;88:128865. doi: 10.1016/j.vaccine.2026.128865. Epub 2026 Jun 19. PMID: 42320382

[Rabies viral RNA and antibody response after post-exposure prophylaxis: Implications for blood donor deferral.](#)

Singh AD, Oberoi S, Singh K, Kaur S, Garg M, Bassi R, Kaur A, Attri K, Gajebasia S. *Trop Dis Travel Med Vaccines*. 2026 Aug 5;12(1):30. doi: 10.1186/s40794-026-00312-4. PMID: 42581393

[Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at Tertiary Hospital between 2010-2024.](#)

Choi SH, Huh JW, Hong SB, Sung H, Do KH, Lee SO, Lim CM, Koh Y. *Tuberc Respir Dis (Seoul)*. 2026 Aug 10. doi: 10.4046/trd.2026.0003. Online ahead of print. PMID: 42572802

[Bioinformatic analysis of the glutathione S-transferase gene family in *Sarcoptes scabiei* and protective immunity of Delta-class SsGSTd3 and SsGSTd5 in rabbits.](#)

Xu J, Wang H, Lei B, Bao X, Gu X, Tang H, Shi F, Huang X, Liang B. *Vet Parasitol*. 2026 Aug;346:110825. doi: 10.1016/j.vetpar.2026.110825. Epub 2026 Jun 2. PMID: 42241945

[The Impact of COVID-19 Infection and Vaccination on Myocarditis Incidence: A Comparative Analysis of Pre-, Peri-, and Post-Pandemic Eras.](#)

Waksman O, Abusnina W, Case BC, Cellamare M, Zhang C, Rappaport H, Sawant V, Thakkar Y, Waksman R. *Catheter Cardiovasc Interv*. 2026 Aug;108(2):388-394. doi: 10.1002/ccd.70659. Epub 2026 May 17. PMID: 42144794

[A Humoral Dilemma: Reassessing Monkeypox Virus Neutralizing Antibodies at More Than 2 Years From Mpox or Modified Vaccinia Ankara-Bavarian Nordic Vaccination.](#)

Moschetta N, Criscuolo E, Raccagni AR, Capra N, Lolatto R, Loi G, Canetti D, Castagna A, Nozza S, Clementi N. *J Infect Dis*. 2026 Aug 3;234(1):43-52. doi: 10.1093/infdis/jiag009. PMID: 41492703

[Prevalence and thrombotic risk of PF4-dependent platelet-activating antibodies.](#)

Scheuer L, Wesche J, Weitmann K, Thiele T, Greinacher A, Schönborn L. *J Thromb Haemost*. 2026 Aug 7:S1538-7836(26)00487-3. doi: 10.1016/j.jtha.2026.07.026. Online ahead of print. PMID: 42567363

[Rgg₁₄₄/SHP₁₄₄-controlled streptolancidin D mediates intra-species competition in *Streptococcus pneumoniae* with cumulative effect from other bacteriocins and fratricide.](#)

Valente C, Dias S, Gazioglu O, Cruz AR, Henriques AO, Yesilkaya H, Hiller NL, Sá-Leão R. *mBio*. 2026 Aug 7:e0159626. doi: 10.1128/mbio.01596-26. Online ahead of print. PMID: 42565612

[European Society of Gynaecological Oncology/European Network of Gynaecological Advocacy Groups Position on risk-based cervical cancer screening.](#)

Joura E, Chatzistamatiou K, Gultekin M, Sehoul J, Toth I, Toth R; European Society of Gynaecological Oncology (ESGO). *Int J Gynecol Cancer*. 2026 Aug;36(8):104794. doi: 10.1016/j.ijgc.2026.104794. Epub 2026 Jun 1. PMID: 42341405

[The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.](#)

Pakvisal N, Wongkongkathep P, Bunrasmee W, Sodsai P, Siriluksana J, Boonnak N, Sangcharoen T, Trakarnsanga B, Sukprakun S, Wantanasiri P, Chotirosniramit K, Phanichkrivalkosil M, Nanthawong S, Chanchaem P, Mankhong S, Kumpunya S, Supabphol S, Sirijun N, Kongtragulsub K, Pearngam P, Somparn P, Payne DM, Zhao B, Praphanphoj V, Pornputtapong N, Sriswasdi S, Wichadaku D, Uttamapinan S, Angspatt P, Wongchanapat P, Teeyapun N, Luangdilok S, Sitthideatphaiboon P, Susiriwatananont T, Zungsontiporn N, Parinyanitikul N, Tanasanvimon S, Vinayanuwattikun C, Salazar A, Hirankarn N, Sriuranpong V, Pisitkun T. *Clin Cancer Res*. 2026 Aug 3;32(15):3213-3227. doi: 10.1158/1078-0432.CCR-25-4271. PMID: 42095629

[Value of quantitative SARS-CoV-2 spike antibodies in assessing risk of severe COVID-19: A retrospective cohort study.](#)

Nyein CM, Sahib S, Lin Y, Yeo XE, Ooi ST. *J Microbiol Immunol Infect*. 2026 Aug;59(4):451-456. doi: 10.1016/j.jmii.2025.11.004. Epub 2025 Nov 17. PMID: 41276427

[Influenza vaccination uptake among people living with HIV in Melbourne, 2015-2025: a repeated cross-sectional study.](#)

Rafizadeh A, Wijekoon D, Aung ET, Aguirre I, Latt PM, Bissessor M, Krulic T, Murphy J, Chen MY, Soe NN, Chow EPF. *Vaccine*. 2026 Aug 13;90:129038. doi: 10.1016/j.vaccine.2026.129038. Online ahead of print. PMID: 42594643

[Humoral and cellular responses to SARS-CoV-2 variants after ancestral COVID-19 vaccines in people with HIV and lung transplant recipients.](#)

Griffin DW, Gill PA, Boo I, Sun S, Gugasyan R, Wang A, Bornheimer SJ, Turville S, Aggarwal A, Snell GI, Westall GP, Edwards ES, Coldham A, van Zelm MC, Drummer HE, McMahon JH. *Clin Transl Immunology*. 2026 Aug 3;15(8):e70117. doi: 10.1002/cti.2.70117. eCollection 2026. PMID: 42553076

[The emergence of novel H3N8 and H3N3 avian influenza viruses in chickens during multi-province surveillance in China and their potential public health risk.](#)

Wang X, Shi H, Li P, Zhu H, Zhang N, Song Q, Liu S, Lu Q, Khalique A, Saleemi MK, Li Z, Liu C, Li L. *Vet J*. 2026 Aug;318:106789. doi: 10.1016/j.tvjl.2026.106789. Epub 2026 Jul 22. PMID: 42486182

[The effectiveness of targeted therapy in the treatment of patients with neurofibromatosis type 2-related schwannomatosis and vestibular schwannomas: A systematic review.](#)

Rahman H, Senaratne M, Loueian MA, Madhusuthanan AK, Afzal M, Turuzhbaeva D, Yu AKD. *Neurooncol Pract*. 2026 Feb 25;13(4):649-660. doi: 10.1093/nop/npag017. eCollection 2026 Aug. PMID: 42453176

[Extracellular vesicles in osteosarcoma: bridging resistance, immunity, and clinical translation.](#)

Mao B, Zhang J, An L, Shao X. *J Bone Oncol*. 2026 Jun 19;59:100777. doi: 10.1016/j.jbo.2026.100777. eCollection 2026 Aug. PMID: 42382829

[Understanding the Second Year of the COVID-19 Pandemic From a Nursing Perspective: A Multi-Country Descriptive Study.](#)

Squires A, Dutton HJ, Casales-Hernandez MG, López JIR, Saldarriaga-Dixon P, Jimenez-Sanchez J, Lee SA, Lee T, Smichenko J, Lickiewicz J, Malinowska-Lipien I, Damiran D, Khatun S, Skela-Savič B, Anyorikeya M, Cheng HY, Rojas DM, Skipalska H, Yanjmaa E, Castillo TP, Zisberg A, Aborigo R, Burka L, Zhuo L, Engel P, Mobarki A, Jones S. *J Adv Nurs*. 2026 Aug;82(8):8006-8032. doi: 10.1111/jan.70380. Epub 2025 Nov 11. PMID: 41217107

[Technology-Themed Persecutory and Related Presentations of Delusions in the Digital Age: Narrative Review.](#)

Bokhari SA, Osman AA, Elnoor M, Alnor MA, Javaid SF. *JMIR Ment Health*. 2026 Aug 14;13:e102927. doi: 10.2196/102927. PMID: 42600140

[From fragmented records to living evidence: health system-governed, artificial intelligence-driven, continuously updated real-world clinical data from Truveta.](#)

Burkhardt HA, Blach SJ, Burugapalli SR, Cartwright BMG, Martin R, Simonov M, Stewart S, Turner G, Winegar AL, Stucky N. *JAMIA Open*. 2026 Jul 29;9(4):ooag142. doi: 10.1093/jamiaopen/ooag142. eCollection 2026 Aug. PMID: 42529767

[Identifying influencing factors and intervention targets for intention strength in tetanus booster vaccination: A cross-sectional study among Chinese adults.](#)

[The high-education paradox in hepatitis B vaccination: structural barriers, role conflict, and implications for infection control in a high-workload health system.](#)

Du G, Chen L, Cui X, Wei L, Zhang Y, Li N. *J Hosp Infect*. 2026 Aug;174:358-371. doi: 10.1016/j.jhin.2026.05.035. Epub 2026 Jun 1. PMID: 42229587

[Increase in serotypes 4 and 14 in invasive pneumococcal disease in adults aged 18 to 59 years. A retrospective population-based descriptive study during the period 2007-2025 in the Community of Madrid, Spain.](#)

Sanz-Moreno JC, Garrido-Esteba M, Íñigo-Martínez J, Martín-Martínez F, Humanes-Navarro AM, Garrido-Buenache A, Córdoba-Deorador E, Jiménez-Bueno S, Arce-Arnáez MA. *Eur J Clin Microbiol Infect Dis*. 2026 Aug 13. doi: 10.1007/s10096-026-05624-z. Online ahead of print. PMID: 42587238

[Genomic analysis of *Neisseria gonorrhoeae* strains from disseminated, urogenital, and rectal infections reveals differences in genes for iron acquisition and type IV secretion.](#)

Nunnally NS, Stoudenmire JL, Harrison OB, Unitt A, Kersh EN, Cornelissen CN. *Microbiol Spectr*. 2026 Aug 10:e0133826. doi: 10.1128/spectrum.01338-26. Online ahead of print. PMID: 42573258

[Italian regional data and oropharyngeal adverse events to drugs and vaccines: insights from a 3-year spontaneous reporting \(2022-2024\).](#)

Sportiello L, Gaio M, Zinzi A, La Mantia G, Panzarella V, Colella G, Marra PM, Sottosanti L, Potenza S, Oteri G, Coppini M, Seminara G, Mauceri R, Morreale I, Fusco V, Campisi G, Capuano A. *Pharmacol Rep*. 2026 Aug;78(4):1275-1291. doi: 10.1007/s43440-026-00873-3. Epub 2026 Jun 15. PMID: 42295693

[State-level progress in reducing cervical cancer incidence among US young women between the pre- and post-human papillomavirus vaccination eras.](#)

Jiang C, Rosenberg PS, Star J, Bandi P, Bednarczyk RA, Jemal A, Sung H. *J Natl Cancer Inst*. 2026 Aug 1;118(8):1395-1402. doi: 10.1093/jnci/djag051. PMID: 41730310

[HIV-1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption: a long-term follow-up study.](#)

Lungu C, Hossain T, Crespo R, Prins HAB, Hensley KS, Rokx C, Rao S, van Kampen JJA, van de Vijver DAMC, Mesplède T, Katsikis PD, Gruters RA, Mueller YM, Mahmoudi T. *EBioMedicine*. 2026 Aug 1;131:106411. doi: 10.1016/j.ebiom.2026.106411. Online ahead of print. PMID: 42541927

[Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.](#)

Thorn N, Danos Z, Andrews NJ, Sutton N, Cathie K, Owens D, Kelly D, Shackley F, Scorrer T, Lea C, Collinson A, Miah T, Lewis-Bridgeman J, Pearce J, Borrow R, Louth J, Bell A, Ladhani SN, Heath PT. *Lancet Infect Dis*. 2026 Aug;26(8):793-806. doi: 10.1016/S1473-3099(26)00119-2. Epub 2026 May 6. PMID: 42105778

[Effects of red osier dogwood extract on growth performance, protein digestibility, tibia breaking strength, immune response, and gut health of broiler chickens in a coccidiosis vaccine challenge model.](#)

Santos Reis Pereira I, I Adewole D. *Poult Sci*. 2026 Aug;105(8):107027. doi: 10.1016/j.psj.2026.107027. Epub 2026 Apr 29. PMID: 42105386

[Unveiling the genitourinary phenotype of long COVID: a systematic review and meta-analysis.](#)

Peñaherrera-Vásquez D, Reina A, Merlo F, Fajardo-Loaiza T, Zambrano-Sánchez G, Rivadeneira J, Fuenmayor-González L. *Int Urol Nephrol*. 2026 Aug;58(8):2849-2862. doi: 10.1007/s11255-026-05073-9. Epub 2026 Mar 8. PMID: 41796425

[Self-reported hepatitis B diagnoses and vaccination history in trans and non-binary communities in Germany, the TASG-study* 2022.](#)

Biallas R, Brandl M, Burdi S, Hamm JA, Spurgat C, Pöge K, Bremer V, Dudareva S, Koppe U; TASG-study group. BMC Public Health. 2026 Aug 11;26(1):2321. doi: 10.1186/s12889-026-28677-3. PMID: 42576212

[Pre-Infection COVID-19 Vaccination and Long-Term Cardiovascular Outcomes in Adults Without Preexisting Cardiovascular Disease: A Retrospective Cohort Study.](#)

Qadeer A, Khawar M, Fouad M, Jain S, Pathak P, Muhammad A, Twayana AR, Ikbariah K, Gohar N, Chaudhary M, Shenawa E, Khawar MMH. Health Sci Rep. 2026 Aug 6;9(8):e73014. doi: 10.1002/hsr2.73014. eCollection 2026 Aug. PMID: 42568866

[Vertical Vaccination Against Infant Influenza Hospitalization in a Tropical Setting.](#)

Wee LE, Goh NS, Ho RW, Lim JT, Ngiam JN, Lim SK, Chiew C, Li RJ, Li J, Yung CF, Chong CY, Choolani M, Lee V, Lye D, Tan KB. JAMA Netw Open. 2026 Aug 3;9(8):e2628389. doi: 10.1001/jamanetworkopen.2026.28389. PMID: 42579278

[Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran.](#)

Etemadifar M, Salari M, Kashefi M, Shams Y, Heydari Sichani M, Hojjatipour F. Neurodegener Dis Manag. 2026 Aug 14;1-8. doi: 10.1080/17582024.2026.2718409. Online ahead of print. PMID: 42599142

[Development and characterization of mouse-adapted recombinant SARS-CoV-2 expressing reporter genes.](#)

Mahmoud SH, Jackson N, Barre RS, Ma Y, Bayoumi M, Castro EM, Ezzatpour S, Plemper RK, Perlman S, Ye C, Martinez-Sobrido L. Microbiol Spectr. 2026 Aug 4;14(8):e0044426. doi: 10.1128/spectrum.00444-26. Epub 2026 Jul 14. PMID: 42446208

[Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.](#)

Margoni M, Preziosa P, Rocca MA, Filippi M. CNS Drugs. 2026 Aug;40(8):1051-1071. doi: 10.1007/s40263-026-01311-x. Epub 2026 Jun 23. PMID: 42334795

[Probe-based metagenomic sentinel surveillance of viral respiratory infections in primary care: a prospective, national, pilot study.](#)

Mourik K, Sidorov I, Meijers E, van den Brink S, Bos S, Aarts L, Veetil NK, Boers SA, Eggink D, Meijer A, de Vries JJC. Lancet Microbe. 2026 Aug 6;101473. doi: 10.1016/j.lanmic.2026.101473. Online ahead of print. PMID: 42561992

[Understanding malaria dynamics in Benin through time series, and environmental correlation: Implications for targeted interventions.](#)

Alohoutade SV, Hounsell R, Dandonougbo C, Aikpon R, Degila J, Silal S. PLOS Glob Public Health. 2026 Aug 6;6(8):e0006960. doi: 10.1371/journal.pgph.0006960. eCollection 2026. PMID: 42561007

[Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.](#)

Bedke J, Eccleston A, Unsworth M, Brinkmann J, Chang J, Koshy A, Manuel L, Skilling J, Biondi E, Brown E, Ford C, Steinberg G, Lotan Y, Liorot Y, Rodriguez Faba O. *Future Oncol.* 2026 Aug;22(18):2155-2168. doi: 10.1080/14796694.2026.2696928. Epub 2026 Jul 27. PMID: 42504607

[Causes of mortality and severe morbidity in young children in Sierra Leone: a prospective cohort study.](#)

Owusu-Kyei K, Cussó M, Fombah AE, Quintó L, Bofill A, Morató A, Fumadó V, Samai M, Menéndez C; ICARIA Safety Team. *Lancet Glob Health.* 2026 Aug 10:104025. doi: 10.1016/j.langlo.2026.104025. Online ahead of print. PMID: 42575116

[\[Comparison of antibody persistence after two-dose and three-dose hepatitis B vaccines for 20 years among people aged 15-40 years in Shandong Province\].](#)

Lyu JJ, Yan BY, Feng Y, Meng X, Xu AQ, Zhang L. *Zhonghua Yu Fang Yi Xue Za Zhi.* 2026 Aug 6;60(8):1287-1293. doi: 10.3760/cma.j.cn112150-20250819-00805. PMID: 42595536

Patentes registradas en Patentscope

Estrategia de búsqueda: (Vaccine) AND DP:([01.08.2026 TO 16.08.2026]) as the publication date 54 records.

1. [20260224690](#) TRIPLE MRNA VACCINE FOR PREVENTING FELINE RHINOTRACHEITIS, FELINE CALICIVIRAL DISEASE, AND FELINE PANLEUKOPENIA, AND PREPARATION METHOD THEREOF
US - 06.08.2026

Clasificación Internacional [A61K 39/245](#)Nº de solicitud 19147264 Solicitante ZHEJIANG UNIVERSITY Inventor/a JIANBIN TANG

The present invention discloses a triple mRNA vaccine for feline rhinotracheitis, feline caliciviral disease, and feline panleukopenia, and a preparation method thereof. The triple mRNA vaccine is prepared by combining an mRNA expressing a feline herpesvirus gB protein, an mRNA expressing a feline herpesvirus gD protein, an mRNA expressing a feline calicivirus VP1 protein, and an mRNA expressing a feline parvovirus VP2 protein with a liposome encapsulation protocol, followed by mixing to prepare the mRNA vaccine. In addition, the vaccine is applied for prophylactic immunization against the feline rhinotracheitis, the feline caliciviral disease, and the feline panleukopenia. The resulting triple mRNA vaccine can effectively activate a specific antibody, and simplifies a vaccination procedure, and can achieve a goal of simultaneously preventing and controlling the feline rhinotracheitis, the feline caliciviral disease, and the feline panleukopenia through a single immunization.

2. [20260232787](#) VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
US - 13.08.2026

Clasificación Internacional [A61K 39/12](#)Nº de solicitud 19153867 Solicitante WestVac Biopharma Co., Ltd. Inventor/a Xiawei WEI

The present invention relates to a vaccine against respiratory syncytial virus infection and pertains to the field of medicine. To address the unmet need for effective prevention and treatment drugs against respiratory

syncytial virus (RSV)-induced respiratory infection in the elderly, infants and immunocompromised persons, the present invention provides a **vaccine** against respiratory syncytial virus infection, and the **vaccine** uses adenovirus as the vector to express an engineered antigen gene specifically designed and optimized based on the fusion (F) protein sequence of RSV. The adenovirus vector **vaccine** can help the host to resist the respiratory syncytial virus infection, and has good prevention and treatment effect.

3. WO/2026/168617 MICRONEEDLE PATCH INCORPORATED WITH DRUG OR **VACCINE** AND METHOD FOR PRODUCING SAME

WO - 13.08.2026

Clasificación Internacional A61M 37/00Nº de solicitud PCT/JP2026/004859 Solicitante THE UNIVERSITY OF TOKYO Inventor/a KOHARA Michinori

[Problem] To provide a new method for producing a microneedle patch incorporated with a drug or a **vaccine** such as a live virus **vaccine**. [Solution] A method for producing a microneedle patch, the method comprising: (a) a step for injecting a solution containing a biosoluble material and a drug or **vaccine** into a female part of a mold; (b) a step for disposing, above the mold, a backing member in which a pillar part is provided on a backing layer; (c) a step for inserting the leading end portion of the pillar part into the solution injected into the mold; and (d) a step for drying the solution and the backing member and then removing the backing member to which a microneedle has adhered from the mold.

4. 20260232778 PERSONALIZED **VACCINE**

US - 13.08.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19652341 Solicitante Transgene Inventor/a Kaidre BENDJAMA

The present invention generally relates to a personalized cancer **vaccine** comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer **vaccine** for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a **vaccine** or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer **vaccine**. The invention is of very special interest in the field of personalized immunotherapy.

5. WO/2026/164283 ORAL **VACCINE** COMPOSITION FOR AQUATIC ORGANISMS

WO - 06.08.2026

Clasificación Internacional A61K 39/02Nº de solicitud PCT/JP2026/003417 Solicitante KYORITSU SEIYAKU CORPORATION Inventor/a MIYAZAKI Toh

[Problem] To provide a means with which it is possible to orally administer a **vaccine** with low effort, high efficiency, and effectiveness. [Solution] Provided is an oral **vaccine** composition for aquatic organisms that is spread on solid feed for aquatic organisms and contains an antigen and an enteric polymer compound. By spreading, on the solid feed for aquatic organisms, the oral **vaccine** composition for aquatic organisms that

contains the antigen, and then orally administering the same, it is possible to effectively prevent and treat aquatic organism infection as a result of an immune response to the antigen. Since the composition contains the antigen and the enteric polymer compound and is protected by the enteric polymer compound in a low-pH environment, the antigen can reliably and efficiently reach the intestine without being digested or decomposed in the stomach. Accordingly, it is possible to reliably and effectively immunize aquatic organisms and to reduce the number of immunizations.

6. WO/2026/169218 **VACCINE** COMPOSITION AND METHODS FOR INDUCING IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS

WO - 13.08.2026

Clasificación Internacional A61K 39/04Nº de solicitud PCT/TH2026/000001Solicitante MAHIDOL UNIVERSITYInventor/a PONPUAK, Marisa

The present invention is a development of a **vaccine** formulation or a **vaccine** composition for inducing antigen-specific cells to generate immunity for resistance against Mycobacterium tuberculosis, comprising Bacillus Calmette-Guérin (BCG), ESAT-6 protein (ESAT-6) encapsulated with a nanoparticle-type carrier, and a STING ligand, wherein the BCG, the ESAT- 6 protein encapsulated with the nanoparticle-type carrier, and the STING ligand are physically and/or chemically combined, with a mass ratio of ESAT-6 to the STING ligand being in a range of 4-10 : 1, and wherein the **vaccine** composition according to the present invention is administered by a prime-pool strategy for preventing pulmonary tuberculosis infection.

7. 20260232788 DENGUE VIRUS MRNA **VACCINE** AND METHOD AGAINST DENGUE VIRUS INFECTION USING THE SAME

US - 13.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19156524Solicitante ACADEMIA SINICAInventor/a Han-Chung WU

The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) **vaccine**. In particular, the **vaccine** includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA **vaccine** of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response.

8. 20260231916 SYSTEM AND METHOD FOR ORAL VACCINATION OF ANIMAL POPULATIONS VIA TRANSGENIC INSECTS

US - 13.08.2026

Clasificación Internacional A01K 67/68Nº de solicitud 19535460Solicitante Future Fields Cellular Agriculture and Research LTD.Inventor/a Matthew Anderson-Baron

One variation of a method includes: identifying a target pathogen associated with disease in a target aquatic species; accessing a **vaccine** antigen sequence encoding a target antigen for the target pathogen, the target antigen configured to trigger a target immune response in the target aquatic species responsive to exposure to the target pathogen; generating a transgenic *Drosophila* strain expressing the target antigen by inserting the **vaccine** antigen sequence into a genome of a base *Drosophila* species; cultivating a population of the

transgenic *Drosophila* strain to produce an amount of *Drosophila* biomass comprising the target antigen; processing the amount of *Drosophila* biomass into a vaccine feed configured for oral administration to a population of the target aquatic species; and administering the vaccine feed to the population of the target aquatic species via oral delivery to vaccinate the population of the target aquatic species against the target pathogen.

9. 20260232794 IMMUNE COMPOSITION PRODUCT FOR PREVENTING OR TREATING VARICELLA ZOSTER VIRUS-RELATED DISEASES AND PREPARATION METHOD THEREFOR

US - 13.08.2026

Clasificación Internacional A61K 39/25Nº de solicitud 19534319 Solicitante YANTAI PATRONUS BIOTECH CO., LTD. Inventor/a Jing JIN

Provided is a varicella-zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigenic component and a particle protein component. The particle protein component comprises a nanoparticle protein, and the antigenic component and the particle protein component covalently bind to each other by means of a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. Provided is a preparation method for the varicella-zoster vaccine.

10. 20260229308 TUMORIGENICITY SCORING FOR CANCER VACCINE DEVELOPMENT AND MEDICAL DECISION MAKING

US - 06.08.2026

Clasificación Internacional G16B 20/20Nº de solicitud 19463900 Solicitante NEC Laboratories America, Inc. Inventor/a Jonathan Warrell

Methods and systems for vaccine generation include determining genome sequence for target. A tumorigenicity score is determined for neoantigens of the target using a variance analysis in a linear random effects model. The neoantigens are ranked based on the tumorigenicity score. A vaccine is generated based on the ranked neoantigens.

11. WO/2026/165389 TUMORIGENICITY SCORING FOR CANCER VACCINE DEVELOPMENT AND MEDICAL DECISION MAKING

WO - 06.08.2026

Clasificación Internacional G16B 40/20Nº de solicitud PCT/US2026/013315 Solicitante NEC LABORATORIES AMERICA, INC. Inventor/a WARRELL, Jonathan

Methods and systems for vaccine generation include determining (200) genome sequence for target. A tumorigenicity score is determined (206) for neoantigens of the target using a variance analysis in a linear random effects model. The neoantigens are ranked (110) based on the tumorigenicity score. A vaccine is generated (112) based on the ranked neoantigens.

12. 20260226183 ANTI-TUBERCULOSIS VACCINE TARGETING SELECTED MYCOBACTERIUM TUBERCULOSIS PROTECTIVE ANTIGENS TO DENDRITIC CELLS

US - 06.08.2026

Clasificación Internacional C07K 16/28Nº de solicitud 19149612Solicitante INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor/a Yves LEVY

There is an urgent need for an efficient therapeutic **vaccine** against tuberculosis (TB), which remains a major public health issue. Current "classic" strategies under development failed or are not optimal, and to reach the World Health Organization's 2035 End TB Strategy, more efficacious vaccines are needed. The inventors have generated a post-exposure/therapeutic TB **vaccine** candidate (CD40.TB), consisting in an antibody directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated to 3 pertinent *Mycobacterium tuberculosis* (Mtb) antigens, and prone to induce strong anti-TB humoral and cellular immunity.

13.20260226425COLD-ADAPTED, LIVE ATTENUATED SARS-COV-2 **VACCINE**

US - 06.08.2026

Clasificación Internacional C12N 7/00Nº de solicitud 19147944Solicitante The University of TokyoInventor/a Yoshihiro Kawaoka

An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a **vaccine** comprising the recombinant genome and methods of using the **vaccine** are provided.

14.WO/2026/162707PISCINE MYOCARDITIS VIRUS **VACCINE**

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2026/052430Solicitante INTERVET INTERNATIONAL B.V.Inventor/a ROUXEL, Ronan

The present invention relates to the field of veterinary vaccines, more specifically to a DNA **vaccine** for fish against piscine myocarditis virus (PMCV). In particular, the invention relates to a nucleic acid comprising a nucleotide sequence encoding a PMCV ORF3 protein or a variant or fragment thereof, with modifications in a specific region, as well as to a DNA expression vector comprising the nucleic acid sequence encoding the modified ORF 3, and to medical uses of said DNA expression vector as a **vaccine** for fish against PMCV.

15.20260224693MRNA **VACCINE** FOR HERPES SIMPLEX VIRUS

US - 06.08.2026

Clasificación Internacional A61K 39/245Nº de solicitud 19152402Solicitante University of Houston SystemInventor/a Shaun ZHANG

This invention relates to an mRNA-based **vaccine** composition for strains of herpes simplex virus (HSV), such as herpes simplex virus-2 (HSV-2). The mRNA **vaccine** composition comprises a combination of herpesvirus glycoprotein D (gD) and gB-pf mRNA, either alone or in combination with gE and/or gC mRNA.

16.20260226112SYSTEMS AND METHODS FOR POST-**VACCINE** SPIKE NEUTRALIZATION MULTIVALENT PEPTIDE DETECTION AND ENGINEERING

US - 06.08.2026

Clasificación Internacional C07K 14/005Nº de solicitud 19463419Solicitante Neo7Bioscience, Inc.Inventor/a John A. Catanzaro

Systems, methods, and compositions involving post-vaccine spike neutralization multivalent peptide detection and engineering are described herein. In an embodiment, a system for post-vaccine spike neutralization multivalent peptide detection and engineering may include at least a processor and a memory communicatively connected to the at least a processor, wherein the memory contains instructions configuring the at least a processor to: receive transcriptomic data, analyze the transcriptomic data using bioinformatic surveillance, modeling, ranking, mapping, and confidence selection, and output a personalized spike neutralization multivalent peptide sequence as a function of the transcriptomic data.

17. 4786002 IMPFSTOFF MIT IMMUNOGENEN FUSIONSPROTEINEN

EP - 05.08.2026

Clasificación Internacional A61P 31/04Nº de solicitud 26186022 Solicitante MINERVAX
APS Inventor/a FISCHER PER

The present invention relates to a vaccine comprising: a) an immunogenic fusion protein consisting of amino acids 2-347 of SEQ ID NO. 21; and b) a further immunogenic fusion protein consisting of amino acids 2-347 of SEQ ID NO: 42. The invention further pertains to the vaccine for use as a medicament and in i) vaccination against group B Streptococcus infection or preventing a group B Streptococcus infection, or ii) treating a group B Streptococcus infection.

18. 20260232795 IMMUNOTHERAPEUTIC COMPOSITION FOR PREVENTION OF OBESITY, NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA, AND METHODS OF USE AND PREPARATION THEREOF

US - 13.08.2026

Clasificación Internacional A61K 39/385Nº de solicitud 19388616 Solicitante Utopia Therapeutics Pvt Ltd. Inventor/a Uday Saxena

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and/or an adjuvant.

19. WO/2026/163228 ENGINEERED DENV AND ZIKV DIMERIC ENVELOPE GLYCOPROTEINS BASED ON CONSENSUS SEQUENCES

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/IN2026/050139 Solicitante INTERNATIONAL CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (ICGEB) Inventor/a KUMAR, Sanjeev

The invention provides protein based, DNA-based, and protein nanoparticle vaccines useful in the prevention of Dengue and/or Zika virus infection. The vaccines comprise engineered dimeric envelope glycoproteins derived from consensus envelope sequences of dengue virus serotypes 1- 4 and Zika virus. The envelope glycoproteins are designed to form stable dimers that present native-like quaternary epitopes, including envelope dimer epitopes associated with broadly neutralizing antibody responses. The disclosed vaccine compositions elicit robust and cross- reactive humoral immune responses while minimizing the induction of non-neutralizing or infection-enhancing antibodies. The invention further provides methods of

inducing protective immunity against dengue and/or Zika virus in a subject by administering the disclosed [vaccine](#) compositions.

20. [20260234184](#) SIALOKININ IMMUNOGEN AND METHODS FOR USING SAME

US - 13.08.2026

Clasificación Internacional [C07K 7/06](#)Nº de solicitud 19156006Solicitante UNM RAINFOREST INNOVATIONSInventor/a Bryce CHACKERIAN

An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic *Aedes* spp. sialokinin peptide that includes amino acids of SEQ ID NO:1 linked to the immunogenic carrier. The immunogen can be formulated into a pharmaceutical composition such as [vaccine](#). The composition or [vaccine](#) may be used to treat a subject having, or at risk of having a mosquito-borne condition.

21. [20260224682](#) PLASMODIUM SPOROZOITE NPDP PEPTIDES AS [VACCINE](#) AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO

US - 06.08.2026

Clasificación Internacional [A61K 39/015](#)Nº de solicitud 19260006Solicitante INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor/a Antonio LANZAVECCHIA

The present invention provides a fragment of *plasmodium* circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria [vaccine](#). The present invention also provides nucleic acids encoding a fragment of *plasmodium* circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of *plasmodium* circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of *plasmodium* circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to *P. falciparum* sporozoites and May be used in the treatment and/or prevention of malaria.

22. [WO/2026/169800](#) SURFACE FUNCTIONALIZATION OF VIRUS-LIKE PARTICLES FOR BIO-CONJUGATION APPLICATIONS

WO - 13.08.2026

Clasificación Internacional [C07K 14/08](#)Nº de solicitud PCT/US2026/013984Solicitante TEXAS TECH UNIVERSITY SYSTEMInventor/a TUMBAN, Ebenezer

Embodiments of the present disclosure generally relate to a platform for [vaccine](#) delivery. Specifically, providing a virus-like particle (VLP) as a platform for [vaccine](#) delivery. The VLP platform includes a bacteriophage with a plurality of coat proteins, the plurality of coat proteins operable to assemble into a VLP, and a protein anchor system including a first portion inserted in at least one coat protein of the plurality of coat proteins and a second portion, wherein the first portion and the second portion are operable to link together.

23. [WO/2026/165435](#) METHODS, COMPOSITIONS, AND SYSTEMS TO TREAT CHRONIC DISEASE THROUGH CELLULAR REPROGRAMMING

WO - 06.08.2026

Clasificación Internacional C07K 16/46Nº de solicitud PCT/US2026/013392Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a SUTTON, Margie Nicole

The present disclosure concerns methods and compositions related to reprogramming cellular functions. Such compositions are cellular reprogramming proteins comprising two polypeptides and a human Fc domain. The cellular reprogramming protein can additionally comprise an appended domain. Embodiments include using the protein or a DNA/RNA encoding the protein in the therapy of immune diseases such as fibrosis and Castleman disease. Other example uses include, for example, suppressing irAEs associated with cancer immunotherapy including fibrosis, suppressing irAEs associated with cancer cell therapies (CAR-T, etc.), targeting immuno-senescence to improve cancer vaccine and general vaccine efficacy, treating inflammation-driven diseases (e.g., MASH, NASH, SLE, psoriasis, RA, etc.), treating GVHD in AML, treating or preventing radiation induced fibrosis, inflammatory cardiovascular, and inflammatory neurodegenerative diseases.

24. 20260226110RECOMBINANT CHIMERIC ANTIGEN FOR POXVIRUS, SUBUNIT VACCINE COMPRISING SAME AND USE THEREOF

US - 06.08.2026

Clasificación Internacional C07K 14/005Nº de solicitud 19149416Solicitante PEKING UNIVERSITYInventor/a Jianzhong Jeff XI

Provided are a recombinant chimeric antigen for a poxvirus, in particular for a Mpxvirus, a subunit vaccine comprising the recombinant chimeric antigen, and a use thereof. The recombinant chimeric antigen of the present application comprises two immunogens arranged in a specific manner: a Mpxvirus A35 protein or an antigenic fragment thereof or derivative peptides of same, and a Mpxvirus M1 protein or an antigenic fragment thereof or derivative peptides of same, and can excite an immune response to two infectious virus particles of intracellular mature virus (IMV) particles and extracellular enveloped virus (EEV) particles.

25. 20260232785VACCINES AGAINST CLOSTRIDIODES DIFFICILE AND METHODS OF USING THE SAME

US - 13.08.2026

Clasificación Internacional A61K 39/08Nº de solicitud 19330601Solicitante CLOSTRIDIAL DISEASE PREVENTION INC.Inventor/a Joseph M. Sasser

Disclosed are vaccine compositions comprising polypeptides selected from Clostridioides *difficile* binary toxin B, Clostridioides *difficile* binary toxin A, a High Molecular Weight portion of Clostridioides *difficile* Surface Layer Protein A, and a Low Molecular Weight portion of Clostridioides *difficile* Surface Layer Protein A. Methods of preparing the vaccine composition, methods of preventing or reducing attachment of *C. difficile* to an epithelial cell, and methods of preventing or treating a condition caused by infection of Clostridioides *difficile* are also provided.

26. 4639050KØLEOPBEVARINGSINDRETNING

DK - 03.08.2026

Clasificación Internacional F25D 3/08Nº de solicitud 24704780Solicitante B Medical Systems
S.à.r.l.Inventor/a PIRES, Daniel

An ice-lined cold storage device, notably a **vaccine** storage device, is provided with an indication of simulated autonomy indicating the duration during which a payload will be maintained below a pre-specified temperature without use of a cooling circuit to remove energy from the cold storage device. The simulated autonomy is provided using a temperature model which uses data which is specific to the ice-lined cold storage device and by: a) detecting an initial ambient temperature, an initial storage compartment temperature and an initial ice-lining temperature of the ice-lined cold storage device; b) running a first simulation using the temperature model and using the initial ambient temperature, the initial storage compartment temperature and the initial ice-lining temperature to determine a first simulated storage compartment temperature after a first simulation time step; c) running one or more subsequent simulations, each subsequent simulation being run using the temperature model and using data created in a previous simulation, to determine a subsequent simulated storage compartment temperature after a subsequent simulation time step; and d) determining the simulated autonomy of the ice-lined refrigerator using at least one of the subsequent simulated storage compartment temperature(s).

27.20260227114COLD STORAGE DEVICE

US - 06.08.2026

Clasificación Internacional F25D 3/06Nº de solicitud 19154903Solicitante B MEDICAL SYSTEMS
S.À.R.L.Inventor/a Daniel PIRES

An ice-lined cold storage device, notably a **vaccine** storage device, is provided with an indication of simulated autonomy indicating the duration during which a payload will be maintained below a pre-specified temperature without use of a cooling circuit to remove energy from the cold storage device. The simulated autonomy is provided using a temperature model which uses data which is specific to the ice-lined cold storage device and by: a) detecting an initial ambient temperature, an initial storage compartment temperature and an initial ice-lining temperature of the ice-lined cold storage device; b) running a first simulation using the temperature model and using the initial ambient temperature, the initial storage compartment temperature and the initial ice-lining temperature to determine a first simulated storage compartment temperature after a first simulation time step; c) running one or more subsequent simulations, each subsequent simulation being run using the temperature model and using data created in a previous simulation, to determine a subsequent simulated storage compartment temperature after a subsequent simulation time step; and d) determining the simulated autonomy of the ice-lined refrigerator using at least one of the subsequent simulated storage compartment temperature(s).

28.4784600IMMUNOGENE UND IMPFSTOFFZUSAMMENSETZUNGEN GEGEN HIV

EP - 05.08.2026

Clasificación Internacional C07K 14/005Nº de solicitud 24873743Solicitante HENRY M JACKSON FOUND
ADVANCEMENT MILITARY MEDICINE INCInventor/a ROLLAND MORGANE MARIE

29.20260224697MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE **VACCINE** FORMULATIONS

US - 06.08.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19636975Solicitante Massachusetts Institute of TechnologyInventor/a Ana JAKLENEC

Emulsion-based and micromolded ("MM") or three dimensional printed ("3DP") polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

30.20260232782HEMOLYSIN ANTIGENS AND **VACCINE** EMBODIMENTS FOR BACTERIAL INFECTION
US - 13.08.2026

Clasificación Internacional A61K 39/108Nº de solicitud 19156551Solicitante Baylor College of MedicineInventor/a Yikun Xing

Embodiments of the disclosure include methods of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection (including pathogenic) in an individual infected with a bacteria from the Gammaproteobacteria Class. In specific embodiments, the methods comprise the step of administering to the individual an effective amount of an immunogenic composition comprising a non-acylated/inactive form alphahemolysin (HlyA) and/or a non-acylated/inactive form, or functional fragment(s) of either. In specific embodiments, the individual is also provided a composition comprising SinH or a functional fragment thereof.

31.20260232791PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS GLYCOPROTEIN C, GLYCOPROTEIN D, AND GLYCOPROTEIN E ANTIGENS AND RELATED METHODS

US - 13.08.2026

Clasificación Internacional A61K 39/245Nº de solicitud 19151231Solicitante BioNTech SEInventor/a Alptekin Güler

The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV **vaccine**) and related technologies (e.g., components thereof and/or methods relating thereto).

32.WO/2026/162952PCV2 **VACCINE** COMPOSITION

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/GB2026/050134Solicitante ECO ANIMAL HEALTH LTD.Inventor/a MARTINSON, Brian

The present disclosure provides a composition for use in the prevention or treatment of porcine circovirus 2 (PCV2) infection or porcine circovirus-associated disease (PCVAD) in a porcine subject, said composition comprising a PCV2c ORF2 polypeptide comprising SEQ ID NO:1, or a sequence with at least 95% identity thereto, wherein said sequence with at least 95% identity contains one or more of the following: (i) R at position

14; (ii) H at position 21; (iii) N at position 232; and (iv) K at position 234. The present disclosure also provides a composition and a virus-like particle that comprises said PCV2c ORF2 polypeptide.

33.4788370IMPFSTOFFZUSAMMENSETZUNG MIT M2E-NANOPARTIKELN UND HA1-PROTEIN

EP - 12.08.2026

Clasificación Internacional A61K 39/145Nº de solicitud 24786072Solicitante INSTITUT NATIONAL DE LA RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENTInventor/a CHEVALIER CHRISTOPHE

34.20260235603HEMAGGLUTINATION INHIBITION ASSAYS FOR THE EVALUATION OF SEASONAL INFLUENZA VACCINES

US - 13.08.2026

Clasificación Internacional G01N 33/569Nº de solicitud 19533775Solicitante NOVAVAX, INC.Inventor/a Raj KALKERI

Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity. The method includes reducing or removing non-specific inhibitors of HA from the biological sample to produce a treated sample; exposing the treated sample to an influenza virus having an HA glycoprotein to produce a sample-virus mixture; incubating the sample-virus mixture with human red blood cells (RBCs), the human RBCs being at a concentration of about 0.5% to about 1%; and detecting agglutination of the human RBCs. Assay kits and methods for using the assay to select an immunogenic composition for use as a vaccine are also provided.

35.WO/2026/162747FMDV VIRUS-LIKE PARTICLE WITH STABILIZING MUTATIONS

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2026/052491Solicitante THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDInventor/a FRY, Elizabeth

The invention concerns a recombinant foot-and-mouth disease virus (FMDV) capsid precursor protein comprising at least the virus proteins VP1, VP2, VP3 and VP4, wherein the amino acid sequence of the capsid precursor protein is modified. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified capsid precursor protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein and a vaccine for use in the protection of a subject against an infection with FMDV produced from the VLP.

36.WO/2026/162694FMDV VIRUS-LIKE PARTICLE WITH STABILIZING MUTATIONS

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2026/052409Solicitante THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDInventor/a FRY, Elizabeth

The invention concerns a recombinant foot-and-mouth disease virus (FMDV) capsid precursor protein comprising at least the virus proteins VP1, VP3 and VP0 (VP0 may be cleaved to produce VP2 and VP4), wherein the amino acid sequence of the capsid precursor protein is modified. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified capsid precursor protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein and a vaccine produced from the VLP for use in the protection of a subject against an infection with FMDV.

37. 20260224685A NOVEL MRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS

US - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19146196Solicitante VIROGIN BIOTECH (SHANGHAI) LTD.Inventor/a Kuan Zhang

Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. In various embodiments, the immunogenic protein is derived (e.g., mutated) from an HPV strain such as HPV 16, 18, 31, 33,35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Also provided are compositions (e.g., mRNA compositions) encoding such immunogenic proteins, as well as method for treating and preventing HPV infections.

38. 20260232728METHODS FOR IDENTIFYING DISSEMINATED CANCER CELLS IN BREAST CANCER PATIENTS

US - 13.08.2026

Clasificación Internacional A61K 35/15Nº de solicitud 19150723Solicitante H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor/a Brian CZERNIECKI

Disclosed are methods for the detection and isolation of disseminated cancer cells and the used of tumor antigen pulsed type 1 dendritic cell vaccine for the treatment and prevention of metastasis and abscopal tumors.

39. 20260232790ADJUVANT FORMULATION INCLUDING LOW VISCOSITY CHITOSAN OR CHITOSAN DERIVATIVES

US - 13.08.2026

Clasificación Internacional A61K 39/155Nº de solicitud 19151645Solicitante Merck Sharp & Dohme LLCInventor/a Erica L. Strable

The invention relates generally to the use of chitosan and chitosan derivatives as an adjuvant in a vaccine composition. More specifically, the invention relates to pharmaceutical compositions and formulations that include a low viscosity chitosan or a trimethyl chitosan.

40. 20260224681VACCINE

US - 06.08.2026

Clasificación Internacional A61K 39/015Nº de solicitud 19150604Solicitante OXFORD UNIVERSITY INNOVATION LIMITEDInventor/a Simon J. DRAPER

The present invention relates to antigens, antibodies and vaccines for treatment or prevention of malaria.

41.WO/2026/162693A METHOD TO PRESERVE VIRUS LIKE PARTICLES OF FOOT AND MOUTH DISEASE VIRUS

WO - 06.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2026/052408Solicitante INTERVET INTERNATIONAL B.V.Inventor/a KAHL, Carina

The invention pertains to a method to preserve recombinant virus-like particles (VLPs) of Foot and mouth disease virus (FMDV), which VLPs include one or more stabilizing mutations, the method comprising formulating the recombinant VLPs in an aqueous solution that comprises 1-50% (v/v) glycerol and thereafter cooling the solution to a temperature of at least -20°C. The invention also pertains to an aqueous formulation comprising virus like particles of Foot and mouth disease virus, and to the use of this formulation as a vaccine to protect an animal against an infection with Foot and mouth disease virus.

42.20260224689MODIFIED IMMUNOGENIC PROTEINS

US - 06.08.2026

Clasificación Internacional A61K 39/21Nº de solicitud 19533655Solicitante International AIDS Vaccine Initiative, Inc.Inventor/a William SCHIEF

The invention relates to germline-targeting designs, stabilization designs, and/or combinations thereof, of proteins designed with modified surfaces helpful for immunization regimens, other protein modifications and/or development of nanoparticles, methods of making and using the same, and to (a) germline-targeting priming or boosting/shepherding immunogens to initiate or guide maturation of VRC01-class responses (b) PCT64/PG9-germline-targeting designs (c) BG18-germline-targeting designs or boosting/shepherding immunogens to initiate or guide maturation of BG18-like responses, and/or (d) trimer stabilization and presentation in a membrane-bound format.

43.4788368MANIPULIERTE MITTELÖSTLICHE ATEMWEGSSYNDROMPROTEINE UND ZUGEHÖRIGE VERFAHREN

EP - 12.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud 24795314Solicitante VACCINE CO INCInventor/a WEIDENBACHER PAYTON ANDERS-BENNER

44.4784159EIMERIA-IMPFSTOFF

EP - 05.08.2026

Clasificación Internacional A61K 39/012Nº de solicitud 25769054Solicitante EIMERIA PTY LTDInventor/a VRBA VLADIMIR

45.WO/2026/162741FMDV VIRUS-LIKE PARTICLE WITH STABILIZING MUTATIONS

WO - 06.08.2026

Clasificación Internacional A61K 39/135Nº de solicitud PCT/EP2026/052485Solicitante THE PIRBRIGHT INSTITUTEInventor/a FRY, Elizabeth

The invention concerns a recombinant foot-and-mouth disease virus (FMDV) capsid precursor protein comprising at least the virus proteins VP1, VP2, VP3 and VP4, wherein the amino acid sequence of the capsid precursor protein is modified. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified capsid precursor protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein and a **vaccine** for use in the protection of a subject against an infection with FMDV produced from the VLP.

46.4788367IMPfstoff zum Schutz eines Ferkels gegen afrikanische Schweinepest

EP - 12.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud 24786745Solicitante INTERVET INT BVInventor/a JOSHI JUI

47.20260226498ANTIBIOTIC-FREE MINIPLASMID, AND PREPARATION METHOD THEREFOR AND USE THEREOF

US - 06.08.2026

Clasificación Internacional C12N 15/85Nº de solicitud 19147957Solicitante MAXIRNA (SHANGHAI) PHARMACEUTICAL CO. LTD.Inventor/a Pingjing ZHANG

The present application provides an antibiotic resistance gene-free miniplasmid, comprising a nucleotide sequence encoding an antitoxin protein, and a replicon. A backbone of the antibiotic resistance gene-free miniplasmid of the present application is smaller and controlled within 1,000 bp, redundant useless fragments are reduced, and meanwhile, the miniplasmid does not comprise a resistance expression cassette, thereby improving the utilization rate of a sequence of interest in the plasmid and reducing the production burden. The miniplasmid has higher efficiency and safety in the plasmid DNA-mediated non-viral vector delivery, gene therapy, **vaccine** immunity, virus production, antibody production, and other genetic engineering. The present application further provides a system for producing a plasmid based on a toxin-antitoxin system, a bacterial host cell comprises a gene expression cassette for inducibly expressing a toxin protein, the antibiotic resistance gene-free miniplasmid comprises a gene expression cassette for expressing an antitoxin protein, and the system is used for efficiently maintaining replication and amplification of the antibiotic resistance gene-free miniplasmid.

48.4788365IMPfstofffreisetzungsverfahren und Zusammensetzung zur Verwendung davon

EP - 12.08.2026

Clasificación Internacional A61K 39/00Nº de solicitud 24873956Solicitante NANOVAION THERAPEUTICS INCInventor/a PAWAR GRISHMA

49.3075679CONCENTRATION OF INFLUENZA **VACCINE** ANTIGENS WITHOUT LYOPHILIZATION

ES - 06.08.2026

Clasificación Internacional A61K 39/145Nº de solicitud 20191093Solicitante Seqirus UK LimitedInventor/a KOMMAREDDY,, Sushma

50.WO/2026/165563/N OVO VACCINATION OF GENETICALLY MODIFIED *SALMONELLA* VECTORED VACCINES

WO - 06.08.2026

Clasificación Internacional C12N 1/36Nº de solicitud PCT/US2026/013708Solicitante UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor/a CURTISS, Roy

Disclosed are methods for inoculating embryonated avian eggs for conferring protective immune responses against diseases caused by a diversity of bacterial, viral and parasite pathogens. According to certain aspects methods are disclosed that involve administering, *in ovo*, a safe inoculating dose of a Protective Immunity Enhanced *Salmonella* Vaccine (PIESV) strain, or derivative thereof, and optionally co-administering a safe inoculating dose of a live self-destructing attenuated adjuvant *Salmonella* strain (SDAAS), or derivative thereof.

51.4788693CHLAMYDIA-IMPFFSTOFFZUSAMMENSETZUNGEN

EP - 12.08.2026

Clasificación Internacional C07K 14/295Nº de solicitud 24875373Solicitante VAXCYTE INCInventor/a ROZZELLE JAMES

52.4785951IMMUNOGENKOMBINATION DES AFRIKANISCHEN SCHWEINEPESTVIRUS UND VERWENDUNG DAVON

EP - 05.08.2026

Clasificación Internacional A61K 39/12Nº de solicitud 24870409Solicitante SHANGFUSHAFEI SHANGHAI BIOTECHNOLOGY CO LTDInventor/a XU JIANQING

Provided are an African swine fever virus immunogen combination and a use thereof. An immunogenic composition, comprising: (A) an antibody immunogen group containing immunogens derived from African swine fever virus structural proteins; and (B) a recombinant T cell immunogen group containing immunogens derived from non-structural proteins of African swine fever virus. Also provided are an encoding nucleic acid molecule of the immunogenic composition, a vector and a host cell thereof, a vaccine containing one or more of the foregoing, and a related product. The two immunogen combinations can effectively induce binding antibodies against p72, p54 and p30, as well as activate T cell responses against T antigens, p 17 and penton, thereby playing an effective preventive role against African swine fever virus.

53.20260232776COMBINATIONS OF DENDRITIC CELL-BASED VACCINES AND CHECKPOINT INHIBITORS

US - 13.08.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19154708Solicitante Mayo Foundation for Medical Education and ResearchInventor/a Keith L. Knutson

Methods and materials for treating cancer (e.g., ovarian cancer) using a combination of a Th 17 DC vaccine and an immune checkpoint inhibitor are provided herein.

54.WO/2026/165610PHARMACEUTICAL COMPOSITIONS FOR RESPIRATORY INFECTIONS AND USES THEREOF

WO - 13.08.2026

Clasificación Internacional A61K 39/39Nº de solicitud PCT/AU2026/050084Solicitante THE UNIVERSITY OF SYDNEYInventor/a ASHHURST, Anneliese Sophie

The present invention relates to a pharmaceutical composition comprising the lipopeptide adjuvant Cys-Dipalmitoyl-Ser-Lys-Lys-Lys-Lys-PEG2-NH2 (otherwise referred to as dipalmitoyl- S-glyceryl-cysteine or Pam2Cys), an antigen, and mannitol, for the treatment and/or prevention of respiratory infections. Disclosed herein, is NoVCoV, a nasal dry powder vaccine that provides a novel and stable alternative to traditional liquid vaccines. This formulation is not only effective for preventing and/or treating COVID-19 but is also adaptable for addressing other respiratory infections.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búsqueda: vaccine.ti. AND @PD>="20260801"<=20260816 28 records

Document ID	Title	Inventor	Applicant Name
US 20260232785 A1	VACCINES AGAINST CLOSTRIDIODES DIFFICILE AND METHODS OF USING THE SAME	Sasser; Joseph M.	CLOSTRIDIAL DISEASE PREVENTION INC.
US 20260235603 A1	HEMAGGLUTINATION INHIBITION ASSAYS FOR THE EVALUATION OF SEASONAL INFLUENZA VACCINES	KALKER; Raj et al.	NOVAVAX, INC.
US 20260232778 A1	PERSONALIZED VACCINE	BENDJAMA; Kaïdre et al.	Transgene

US 20260232780 A1	Individualized Vaccines for Cancer	Sahin; Ugur et al.	BioNTech SE,TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
US 20260232787 A1	VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION	WEI; Xiawei et al.	WestVac Biopharma Co., Ltd.
US 20260232776 A1	COMBINATIONS OF DENDRITIC CELL- BASED VACCINES AND CHECKPOINT INHIBITORS	Knutson; Keith L. et al.	Mayo Foundation for Medical Education and Research
US 20260232788 A1	DENGUE VIRUS MRNA VACCINE AND METHOD AGAINST DENGUE VIRUS INFECTION USING THE SAME	WU; Han-Chung et al.	ACADEMIA SINICA
US 20260232782 A1	HEMOLYSIN ANTIGENS AND VACCINE EMBODIMENTS FOR BACTERIAL INFECTION	Xing; Yikun et al.	Baylor College of Medicine
US 12702707 B2	Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof	Friedman; Harvey et al.	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
US 12702705 B2	Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines	Adamo; Roberto et al.	GLAXOSMITHKLINE BIOLOGICALS SA
US 12702704 B2	Klebsiella vaccine and methods of use	Bicalho; Rodrigo	Cornell University
US 20260229308 A1	TUMORIGENICITY SCORING FOR CANCER VACCINE DEVELOPMENT AND MEDICAL DECISION MAKING	Warrell; Jonathan et al.	NEC Laboratories America, Inc.

US 20260226112 A1	SYSTEMS AND METHODS FOR POST-VACCINE SPIKE NEUTRALIZATION MULTIVALENT PEPTIDE DETECTION AND ENGINEERING	Catanzaro; John A. et al.	Neo7Bioscience, Inc.
US 20260224697 A1	MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS	JAKLENEC; Ana et al.	Massachusetts Institute of Technology, Tokitae LLC
US 20260224682 A1	PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO	LANZAVECCHIA; Antonio et al.	INSTITUTE FOR RESEARCH IN BIOMEDICINE, SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE, SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT
US 20260224686 A1	VACCINES AND METHODS	HEENEY; Jonathan Luke et al.	CAMBRIDGE ENTERPRISE LIMITED, UNIVERSITY OF WESTMINSTER, UNIVERSITAT REGENSBURG
US 20260226183 A1	ANTI-TUBERCULOSIS VACCINE TARGETING SELECTED MYCOBACTERIUM TUBERCULOSIS PROTECTIVE ANTIGENS TO DENDRITIC CELLS	LEVY; Yves et al.	INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE, BAYLOR RESEARCH INSTITUTE
US 20260224681 A1	VACCINE	DRAPER; Simon J. et al.	OXFORD UNIVERSITY INNOVATION LIMITED

US 20260224690 A1	TRIPLE MRNA VACCINE FOR PREVENTING FELINE RHINOTRACHEITIS, FELINE CALICIVIRAL DISEASE, AND FELINE PANLEUKOPENIA, AND PREPARATION METHOD THEREOF	TANG; JIANBIN et al.	ZHEJIANG UNIVERSITY
US 20260226110 A1	RECOMBINANT CHIMERIC ANTIGEN FOR POXVIRUS, SUBUNIT VACCINE COMPRISING SAME AND USE THEREOF	XI; Jianzhong Jeff et al.	PEKING UNIVERSITY, INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES, SHANXI ACADEMY OF ADVANCED RESEARCH AND INNOVATION, BEIHANG UNIVERSITY
US 20260224691 A1	EPSTEIN-BARR VIRUS MRNA VACCINES	Bollman; Brooke et al.	ModernaTX, Inc.
US 20260224693 A1	mRNA VACCINE FOR HERPES SIMPLEX VIRUS	ZHANG; Shaun et al.	University of Houston System
US 20260226425 A1	COLD-ADAPTED, LIVE ATTENUATED SARS-COV-2 VACCINE	Kawaoka; Yoshihiro et al.	The University of Tokyo, Wisconsin Alumni Research Foundation
US 20260224685 A1	A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS	Zhang; Kuan et al.	VIROGIN BIOTECH (SHANGHAI) LTD.
US 20260224695 A1	Nucleic Acid Vaccines for Varicella-Zoster Virus (VZV)	MARTIN OROZCO; Natalia et al.	PROVIDENCE THERAPEUTICS HOLDINGS INC., EVEREST MEDICINES (SINGAPORE) PTE. LTD.

US 20260224692 A1	T CELL-DIRECTED ANTI-AGING AND ANTI-CANCER VACCINES AGAINST COMMENSAL CYTOMEGALOVIRUS	Demehri; Shadmehr et al.	The General Hospital Corporation
US 20260224678 A1	EXPEDITED NEOANTIGEN VACCINES	Homan; Jane et al.	IOGENETICS, LLC
US 12697377 B2	Therapeutic anticancer neoepitope vaccine	Granum; Stine et al.	Nykode Therapeutics ASA

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez

aramos@finlay.edu.cu

Randelys Molina Castro

rmolina@finlay.edu.cu

Claudia Camejo Salas

ccamejo@finlay.edu.cu

Yamira Puig Fernández

yamipuig@finlay.edu.cu

